assay_id,curated_by,assay_subcellular_fraction,assay_tissue,tissue_id,description,tid,assay_organism,doc_id,bao_format,assay_strain,assay_type,assay_test_type,assay_category,assay_tax_id,assay_cell_type,relationship_type
1,Autocuration,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,12052,,11087,BAO_0000019,,B,,,,,H
2,Autocuration,,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,22226,,684,BAO_0000219,,F,,,,,U
3,Autocuration,,,,,22226,,15453,BAO_0000019,,B,,,,,U
4,Autocuration,,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,104729,Bos taurus,17841,BAO_0000249,,B,,,9913.0,,H
5,Intermediate,,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,Homo sapiens,17430,BAO_0000219,,F,,,9606.0,143B,N
6,Intermediate,,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,Homo sapiens,17430,BAO_0000219,,F,,,9606.0,143B,N
7,Intermediate,,,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,80001,Mus musculus,13799,BAO_0000219,,F,,,10090.0,143B,N
8,Expert,,,,In vitro cell cytotoxicity was determined against 143B cell line,80001,Homo sapiens,17774,BAO_0000219,,F,,,9606.0,143B,N
9,Intermediate,,,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,80001,Homo sapiens,3801,BAO_0000219,,F,,,9606.0,143B,N
10,Intermediate,,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,Homo sapiens,17430,BAO_0000219,,F,,,9606.0,143B,N
11,Intermediate,,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,Homo sapiens,17430,BAO_0000219,,F,,,9606.0,143B,N
12,Expert,,,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,80001,Homo sapiens,17774,BAO_0000219,,F,,,9606.0,143B,N
13,Intermediate,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,Staphylococcus aureus,11324,BAO_0000218,,F,,,1280.0,,N
14,Intermediate,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,Staphylococcus aureus,11324,BAO_0000218,,F,,,1280.0,,N
15,Intermediate,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,Staphylococcus aureus,11324,BAO_0000218,,F,,,1280.0,,N
16,Intermediate,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,Staphylococcus aureus,11324,BAO_0000218,,F,,,1280.0,,N
17,Expert,,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,100122,Rattus norvegicus,11347,BAO_0000357,,A,,,10116.0,,D
18,Autocuration,,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),12054,,16474,BAO_0000357,,B,,,,,H
19,Autocuration,,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,12054,,10091,BAO_0000019,,B,,,,,H
20,Autocuration,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,,16474,BAO_0000357,,B,,,,,H
21,Autocuration,,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),12054,,16474,BAO_0000357,,B,,,,,H
22,Autocuration,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,,16474,BAO_0000357,,B,,,,,H
23,Autocuration,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,,16474,BAO_0000357,,B,,,,,H
24,Autocuration,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,,16474,BAO_0000357,,B,,,,,H
25,Autocuration,,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",22226,,14352,BAO_0000219,,B,,,,,U
26,Autocuration,,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,12054,Oryctolagus cuniculus,5646,BAO_0000357,,B,,,9986.0,,H
27,Autocuration,,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),12054,Oryctolagus cuniculus,5646,BAO_0000357,,B,,,9986.0,,H
28,Autocuration,,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,12426,,10997,BAO_0000219,,B,,,,,H
29,Autocuration,,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,12054,soya bean,6309,BAO_0000357,,B,,,3847.0,,H
30,Autocuration,,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,12054,Glycine max,167,BAO_0000357,,B,,,3847.0,,H
31,Autocuration,,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,12054,Glycine max,167,BAO_0000357,,B,,,3847.0,,H
32,Autocuration,,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,12054,Glycine max,11087,BAO_0000357,,B,,,3847.0,,H
33,Autocuration,,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,12054,Glycine max,11087,BAO_0000357,,B,,,3847.0,,H
34,Autocuration,,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,Glycine max,13622,BAO_0000357,,B,,,3847.0,,H
35,Autocuration,,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,Glycine max,13622,BAO_0000357,,B,,,3847.0,,H
36,Autocuration,,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,22226,Rattus norvegicus,11347,BAO_0000019,,A,,,10116.0,,U
37,Autocuration,,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,22226,Escherichia coli,5926,BAO_0000019,,B,,,562.0,,U
38,Autocuration,,,,Dissociation constant with dimeric 16S rRNA RNA construct B,22226,,4567,BAO_0000019,,B,,,,,U
39,Intermediate,,,,Dissociation constant towards 16S rRNA construct A,22222,,3782,BAO_0000225,,B,,,,,M
40,Intermediate,,,,Dissociation constant towards 16S rRNA construct B,22222,,3782,BAO_0000225,,B,,,,,M
41,Expert,,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,100263,Escherichia coli,4466,BAO_0000225,,B,,,562.0,,M
42,Expert,,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,100263,Escherichia coli,6592,BAO_0000225,,B,,,562.0,,M
43,Autocuration,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,898,BAO_0000019,,B,,,,,H
44,Autocuration,,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,898,BAO_0000019,,B,,,,,H
45,Autocuration,,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,Homo sapiens,13163,BAO_0000019,,B,,,9606.0,,H
46,Autocuration,,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,Homo sapiens,13163,BAO_0000019,,B,,,9606.0,,H
47,Expert,,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,Rattus norvegicus,10691,BAO_0000019,,B,,,10116.0,,D
48,Expert,,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,Rattus norvegicus,10691,BAO_0000019,,B,,,10116.0,,D
49,Expert,,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,Rattus norvegicus,10691,BAO_0000019,,B,,,10116.0,,D
50,Expert,,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,Rattus norvegicus,10691,BAO_0000019,,B,,,10116.0,,D
51,Autocuration,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,898,BAO_0000019,,B,,,,,H
52,Autocuration,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),11512,,912,BAO_0000357,,B,,,,,H
53,Autocuration,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,11512,,912,BAO_0000357,,B,,,,,H
54,Autocuration,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,11512,,912,BAO_0000357,,B,,,,,H
55,Autocuration,Membranes,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,104740,Rattus norvegicus,15103,BAO_0000249,,B,,,10116.0,,D
56,Intermediate,,,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,80002,Homo sapiens,5116,BAO_0000219,,F,,,9606.0,1A9,N
57,Autocuration,,,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,104835,Rattus norvegicus,14578,BAO_0000219,,F,,,10116.0,Oocytes,D
58,Autocuration,,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,104821,Rattus norvegicus,14578,BAO_0000219,,F,,,10116.0,Oocytes,D
59,Autocuration,,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,104848,Rattus norvegicus,14578,BAO_0000219,,F,,,10116.0,Oocytes,D
60,Expert,,,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,80002,Homo sapiens,4787,BAO_0000219,,F,,,9606.0,1A9,N
61,Intermediate,,,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,80002,Homo sapiens,4787,BAO_0000219,,F,,,9606.0,1A9,N
62,Intermediate,,,,Cytotoxic activity against human ovarian cancer (1A9) cell line,80002,Homo sapiens,3547,BAO_0000219,,F,,,9606.0,1A9,N
63,Intermediate,,,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,80002,Homo sapiens,3547,BAO_0000219,,F,,,9606.0,1A9,N
64,Intermediate,,,,Effective dose of compound against replication of 1A9 cell line was evaluated,80002,Homo sapiens,6726,BAO_0000219,,F,,,9606.0,1A9,N
65,Expert,,,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,80002,Homo sapiens,3455,BAO_0000219,,F,,,9606.0,1A9,N
66,Intermediate,,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),80002,Homo sapiens,5726,BAO_0000219,,F,,,9606.0,1A9,N
67,Intermediate,,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,80002,Homo sapiens,5726,BAO_0000219,,F,,,9606.0,1A9,N
68,Intermediate,,,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,80002,Homo sapiens,5726,BAO_0000219,,F,,,9606.0,1A9,N
69,Intermediate,,,,Inhibitory activity against Taxol resistant 1A9 cell lines,80002,Homo sapiens,3395,BAO_0000219,,F,,,9606.0,1A9,N
70,Expert,,,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,80002,Homo sapiens,3415,BAO_0000219,,F,,,9606.0,1A9,N
71,Expert,,,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,80002,Homo sapiens,3415,BAO_0000219,,F,,,9606.0,1A9,N
72,Expert,,,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,80002,Homo sapiens,17099,BAO_0000219,,F,,,9606.0,1A9,N
73,Intermediate,,,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,80002,Homo sapiens,17099,BAO_0000219,,F,,,9606.0,1A9,N
74,Intermediate,,,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,80002,Homo sapiens,17099,BAO_0000219,,F,,,9606.0,1A9,N
75,Intermediate,,,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,80002,Homo sapiens,17099,BAO_0000219,,F,,,9606.0,1A9,N
76,Intermediate,,,,Inhibitory concentration against Jurkat cells,81072,Homo sapiens,17721,BAO_0000219,,F,,,9606.0,Jurkat,N
77,Intermediate,,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,22226,,1229,BAO_0000019,,F,,,,,U
78,Expert,,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,100121,Rattus norvegicus,11347,BAO_0000357,,A,,,10116.0,,D
79,Expert,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,,17117,BAO_0000357,,B,,,,,H
80,Expert,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,,17117,BAO_0000357,,B,,,,,H
81,Expert,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",11231,,17117,BAO_0000357,,B,,,,,H
82,Autocuration,Microsomes,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",11231,Candida albicans,11375,BAO_0000251,,B,,,5476.0,,H
83,Autocuration,Microsomes,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",11231,Candida albicans,11375,BAO_0000251,,B,,,5476.0,,H
84,Autocuration,Microsomes,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",11231,Saccharomyces cerevisiae,11375,BAO_0000251,,B,,,4932.0,,H
85,Autocuration,Microsomes,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",11231,Saccharomyces cerevisiae,11375,BAO_0000251,,B,,,4932.0,,H
86,Autocuration,Microsomes,Liver,2107.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",12083,Sus scrofa,11375,BAO_0000251,,B,,,9823.0,,H
87,Autocuration,,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",11231,Rattus norvegicus,791,BAO_0000019,,B,,,10116.0,,H
88,Autocuration,,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",11231,Rattus norvegicus,791,BAO_0000019,,B,,,10116.0,,H
89,Autocuration,,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",11231,Rattus norvegicus,791,BAO_0000019,,B,,,10116.0,,H
90,Autocuration,Microsomes,Liver,2107.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",12083,Rattus norvegicus,11375,BAO_0000251,,B,,,10116.0,,D
91,Autocuration,Microsomes,Liver,2107.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,Rattus norvegicus,11375,BAO_0000251,,B,,,10116.0,,D
92,Autocuration,Microsomes,Liver,2107.0,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,Rattus norvegicus,153,BAO_0000251,,B,,,10116.0,,D
93,Expert,,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),11377,,8269,BAO_0000357,,B,,,,,H
94,Expert,,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,11377,,8269,BAO_0000357,,B,,,,,H
95,Expert,,,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,81020,Homo sapiens,17653,BAO_0000219,,F,,,9606.0,HepG2,N
96,Intermediate,,,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,81020,Homo sapiens,14277,BAO_0000219,,F,,,9606.0,HepG2,N
97,Intermediate,,,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,81020,Homo sapiens,1717,BAO_0000219,,F,,,9606.0,HepG2,N
98,Intermediate,,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,81020,Homo sapiens,14091,BAO_0000219,,F,,,9606.0,HepG2,N
99,Intermediate,,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,81020,Homo sapiens,14091,BAO_0000219,,F,,,9606.0,HepG2,N
100,Expert,,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,50606,Hepatitis B virus,17653,BAO_0000218,,F,,,10407.0,,N
101,Intermediate,,,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,81020,Homo sapiens,13105,BAO_0000219,,F,,,9606.0,HepG2,N
102,Intermediate,,,,Concentration required to inhibit 50% of 2.2.15 cell line,81020,Homo sapiens,1717,BAO_0000219,,F,,,9606.0,HepG2,N
103,Intermediate,,,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,81020,Homo sapiens,13105,BAO_0000219,,A,,,9606.0,HepG2,N
104,Intermediate,,,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,50587,Homo sapiens,13600,BAO_0000218,,F,,,9606.0,2.2.15,N
105,Intermediate,,,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,50587,Homo sapiens,13467,BAO_0000218,,F,,,9606.0,2.2.15,N
106,Expert,,,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",50606,Hepatitis B virus,17477,BAO_0000218,,F,,,10407.0,2.2.15,N
107,Intermediate,,,,In vitro anti-HBV activity in 2.2.15 cells,50587,Homo sapiens,1593,BAO_0000218,,F,,,9606.0,2.2.15,N
108,Intermediate,,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,50587,Homo sapiens,1593,BAO_0000218,,F,,,9606.0,2.2.15,N
109,Intermediate,,,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,50587,Homo sapiens,15089,BAO_0000218,,F,,,9606.0,2.2.15,N
110,Intermediate,,,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,50587,Homo sapiens,15089,BAO_0000218,,F,,,9606.0,2.2.15,N
111,Intermediate,,,,Cytotoxicity in 2.2.15 cells,50587,Homo sapiens,1593,BAO_0000218,,F,,,9606.0,2.2.15,N
112,Intermediate,,,,Cytotoxicity in 2.2.15 cells; Not determined,50587,Homo sapiens,1593,BAO_0000218,,F,,,9606.0,2.2.15,N
113,Intermediate,,,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,50587,Homo sapiens,13600,BAO_0000218,,F,,,9606.0,2.2.15,N
114,Intermediate,,,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,50587,Homo sapiens,13467,BAO_0000218,,F,,,9606.0,2.2.15,N
115,Intermediate,,,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,50587,Homo sapiens,13467,BAO_0000218,,F,,,9606.0,2.2.15,N
116,Intermediate,,,,Antiviral activity against HBV was determined in 2.215 cell line,81020,Homo sapiens,14764,BAO_0000219,,F,,,9606.0,HepG2,N
117,Autocuration,Microsomes,,,Inhibition of 20-HETE synthesis in human renal microsomes,22226,Homo sapiens,6531,BAO_0000251,,B,,,9606.0,,U
118,Autocuration,,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,22226,,17322,BAO_0000019,,B,,,,,U
119,Intermediate,,,,Inhibitory concentration against 2008 (ovarian) cells,80612,Homo sapiens,17072,BAO_0000219,,F,,,9606.0,2008,N
120,Intermediate,,,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,80612,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,2008,N
121,Intermediate,,,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),80612,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,2008,N
122,Intermediate,,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,80612,Homo sapiens,17146,BAO_0000219,,F,,,9606.0,2008,N
123,Intermediate,,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,80612,Homo sapiens,17146,BAO_0000219,,F,,,9606.0,2008,N
124,Intermediate,,,,In vitro inhibition of 2008/R ovarian cancer cell line,80613,Homo sapiens,10797,BAO_0000219,,F,,,9606.0,2008/R,N
125,Intermediate,,,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,80613,Homo sapiens,10797,BAO_0000219,,F,,,9606.0,2008/R,N
126,Intermediate,,,,In vitro inhibition of 2008/S ovarian cancer cell line,80614,Homo sapiens,10797,BAO_0000219,,F,,,9606.0,2008/S,N
127,Intermediate,,,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,80614,Homo sapiens,10797,BAO_0000219,,F,,,9606.0,2008/S,N
128,Expert,,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,100256,Homo sapiens,4823,BAO_0000220,,B,,,9606.0,,S
129,Intermediate,,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,100256,Homo sapiens,12912,BAO_0000220,,B,,,9606.0,,S
130,Expert,,,,Inhibition of chymotrypsin-like activity of 20S proteasome,100256,,2957,BAO_0000220,,B,,,,,S
131,Expert,,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,100256,,2957,BAO_0000220,,B,,,,,S
132,Intermediate,,,,Inhibitory activity against 20S proteosome,100256,,3260,BAO_0000220,,B,,,,,S
133,Autocuration,,,,Compound was tested for inhibitory activity against tryptase,22226,Homo sapiens,3451,BAO_0000019,,B,,,9606.0,,U
134,Intermediate,,,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,81020,Homo sapiens,13885,BAO_0000219,,F,,,9606.0,HepG2,N
135,Intermediate,,,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,81020,Homo sapiens,13885,BAO_0000219,,F,,,9606.0,HepG2,N
136,Autocuration,,,,Compound was tested for the inhibition of Alpha-glucosidase,22226,,3676,BAO_0000019,,B,,,,,U
137,Autocuration,,,,Inhibitory concentration against human neutrophil elastase (HNE),235,,6043,BAO_0000357,,B,,,,,H
138,Autocuration,,Heart,948.0,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,22226,Rattus norvegicus,11140,BAO_0000218,,F,,,10116.0,,U
139,Autocuration,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,10543,BAO_0000019,,F,,,,,H
140,Expert,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,10543,BAO_0000019,,F,,,,,H
141,Autocuration,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,10543,BAO_0000357,,B,,,,,H
142,Expert,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,10543,BAO_0000019,,F,,,,,H
143,Intermediate,,,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,80360,Mus musculus,11365,BAO_0000219,,F,,,10090.0,P338,N
144,Intermediate,,,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,80360,Mus musculus,11365,BAO_0000219,,F,,,10090.0,P338,N
145,Intermediate,,,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,80384,Homo sapiens,11803,BAO_0000219,,F,,,9606.0,PBL,N
146,Autocuration,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,22226,Ovis aries,11803,BAO_0000019,,F,,,9940.0,,U
147,Autocuration,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,22226,Ovis aries,11803,BAO_0000019,,F,,,9940.0,,U
148,Autocuration,,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),191,,12278,BAO_0000357,,B,,,,,H
149,Autocuration,,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,22226,Homo sapiens,8249,BAO_0000019,,F,,,9606.0,,U
150,Autocuration,,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,22226,Homo sapiens,8249,BAO_0000019,,F,,,9606.0,,U
151,Autocuration,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,22226,Homo sapiens,8249,BAO_0000219,,F,,,9606.0,CCRF-CEM,U
152,Autocuration,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,22226,Homo sapiens,8249,BAO_0000219,,F,,,9606.0,CCRF-CEM,U
153,Autocuration,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,22226,Homo sapiens,8249,BAO_0000219,,F,,,9606.0,CCRF-CEM,U
154,Autocuration,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,22226,Homo sapiens,8249,BAO_0000219,,F,,,9606.0,CCRF-CEM,U
155,Autocuration,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,22226,Homo sapiens,8249,BAO_0000019,,F,,,9606.0,,U
156,Autocuration,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,22226,Homo sapiens,8249,BAO_0000019,,F,,,9606.0,,U
157,Autocuration,,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,104290,,16992,BAO_0000249,,B,,,,,H
158,Intermediate,,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,50264,Streptococcus pyogenes,10543,BAO_0000218,,F,,,1314.0,,N
159,Intermediate,,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),50527,Human herpesvirus 3,17833,BAO_0000218,,F,,,10335.0,,N
160,Expert,,,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,50527,vericilla zoster virus,17290,BAO_0000218,,F,,,10335.0,HEL,N
161,Intermediate,,,,Antiviral activity against 07/1 strain of VZV; ND: No data,50527,vericilla zoster virus,17290,BAO_0000218,,F,,,10335.0,,N
162,Intermediate,,,,Antiviral activity against 07/1 strain of VZV; ND=No data,50527,vericilla zoster virus,17290,BAO_0000218,,F,,,10335.0,,N
163,Intermediate,,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",50145,escherichia cloac,10932,BAO_0000218,,F,,,561.0,,N
164,Autocuration,,,,Ratio of Ki at A2 to Ki at A1 receptors,22226,,9707,BAO_0000019,,B,,,,,U
165,Expert,,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",11143,Candida albicans,2346,BAO_0000249,,B,,,5476.0,,H
166,Expert,,,,"Inhibition of 1,3-beta-glucan synthase",18077,Candida glabrata CBS 138,2205,BAO_0000357,,B,,,284593.0,,H
167,Intermediate,,,,Inhibition of growth of 1-87 human tumor cell line,80609,Homo sapiens,11900,BAO_0000219,,F,,,9606.0,1-87 tumor cell line,N
168,Expert,,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,12166,Rattus norvegicus,14864,BAO_0000219,,B,,,10116.0,,D
169,Autocuration,,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),100171,Glycine max,16474,BAO_0000357,,B,,,3847.0,,D
170,Autocuration,,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,100171,Glycine max,16474,BAO_0000357,,B,,,3847.0,,D
171,Autocuration,,,,% inhibition against soybean 1-lipoxygenase (SLO),100171,Glycine max,16474,BAO_0000357,,B,,,3847.0,,D
172,Autocuration,,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,100171,Glycine max,16474,BAO_0000357,,B,,,3847.0,,D
173,Autocuration,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,100171,Glycine max,3094,BAO_0000357,,B,,,3847.0,,D
174,Autocuration,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,100171,Glycine max,3094,BAO_0000357,,B,,,3847.0,,D
175,Autocuration,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,100171,Glycine max,3094,BAO_0000357,,B,,,3847.0,,D
176,Autocuration,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,100171,Glycine max,3094,BAO_0000357,,B,,,3847.0,,D
177,Autocuration,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,100171,Glycine max,3094,BAO_0000357,,B,,,3847.0,,D
178,Autocuration,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,100171,Glycine max,3094,BAO_0000357,,B,,,3847.0,,D
179,Autocuration,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,100171,Glycine max,3094,BAO_0000357,,B,,,3847.0,,D
180,Autocuration,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,100171,Glycine max,3094,BAO_0000357,,B,,,3847.0,,D
181,Autocuration,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,100171,Glycine max,3094,BAO_0000357,,B,,,3847.0,,D
182,Autocuration,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,100171,Glycine max,3094,BAO_0000357,,B,,,3847.0,,D
183,Autocuration,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,100171,Glycine max,3094,BAO_0000357,,B,,,3847.0,,D
184,Autocuration,,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,22226,Mus musculus,10413,BAO_0000019,,B,,,10090.0,,U
185,Intermediate,,,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),80049,Mus musculus,16929,BAO_0000219,,F,,,10090.0,C3H 10T1/2,N
186,Intermediate,,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,22226,,1229,BAO_0000019,,F,,,,,U
187,Autocuration,,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11489,,16587,BAO_0000357,,B,,,,,H
188,Autocuration,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11862,,16587,BAO_0000357,,B,,,,,H
189,Autocuration,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,11862,,16587,BAO_0000357,,B,,,,,H
190,Autocuration,,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,11489,,16587,BAO_0000357,,B,,,,,H
191,Autocuration,,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,11862,,16587,BAO_0000357,,B,,,,,H
192,Expert,,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,12347,Bos taurus,8058,BAO_0000019,,F,,,9913.0,,D
193,Expert,,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,100120,Rattus norvegicus,9065,BAO_0000357,,B,,,10116.0,,D
194,Expert,,Adrenal gland,2369.0,Inhibition of 11 beta-hydroxylase from rat adrenal gland,100120,Rattus norvegicus,8865,BAO_0000357,,B,,,10116.0,,D
195,Expert,,,,Inhibition of rat adrenal 11-beta-hydroxylase,100120,Rattus norvegicus,9066,BAO_0000357,,B,,,10116.0,,D
196,Expert,,,,Inhibition of rat adrenal 11-beta-hydroxylase,100120,Rattus norvegicus,8394,BAO_0000357,,B,,,10116.0,,D
197,Expert,,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,100120,Rattus norvegicus,8394,BAO_0000357,,B,,,10116.0,,D
198,Autocuration,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,10328,,6431,BAO_0000019,,B,,,,,H
199,Autocuration,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,,6431,BAO_0000357,,B,,,,,H
200,Autocuration,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,,6431,BAO_0000357,,B,,,,,H
201,Autocuration,,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,11134,,9295,BAO_0000019,,F,,,,,H
202,Autocuration,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,10193,BAO_0000019,,B,,,,,H
203,Autocuration,,,,Compound was tested in vitro for inhibition of 12-LO human platelet,11134,,13622,BAO_0000019,,B,,,,,H
204,Autocuration,,,,Inhibitory concentration against human platelet 12-lipoxygenase,11134,,12079,BAO_0000019,,F,,,,,H
205,Autocuration,,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,11134,,13622,BAO_0000019,,B,,,,,H
206,Autocuration,,,,Inhibitory concentration against human platelet 12-lipoxygenase,11134,Homo sapiens,12079,BAO_0000019,,F,,,9606.0,,D
207,Expert,,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,11835,,13500,BAO_0000019,,B,,,,,H
208,Expert,,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,11601,,13723,BAO_0000357,,B,,,,,H
209,Autocuration,,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),11134,,16474,BAO_0000019,,B,,,,,H
210,Autocuration,,,,Inhibitory activity against human platelet 12-lipoxygenase,11134,,1630,BAO_0000019,,B,,,,,H
211,Autocuration,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,11134,,167,BAO_0000019,,B,,,,,H
212,Autocuration,,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),11134,,16474,BAO_0000019,,B,,,,,H
213,Autocuration,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,11134,,167,BAO_0000019,,B,,,,,H
214,Autocuration,,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,11134,,16474,BAO_0000019,,B,,,,,H
215,Autocuration,,,,Inhibitory activity towards porcine 12-lipoxygenase,11601,,10091,BAO_0000357,,B,,,,,H
216,Autocuration,,,,Tested for inhibition against porcine 12-LO,11601,,11966,BAO_0000357,,B,,,,,H
217,Autocuration,,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,12052,,951,BAO_0000019,,B,,,,,H
218,Autocuration,,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,12052,,10997,BAO_0000019,,B,,,,,H
219,Expert,,,,In vitro inhibition of rat platelet 12-lipoxygenase,12052,,10193,BAO_0000019,,B,,,,,H
220,Autocuration,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,10193,BAO_0000019,,B,,,,,H
221,Autocuration,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,12052,,10193,BAO_0000019,,B,,,,,H
222,Autocuration,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,12052,,10193,BAO_0000019,,B,,,,,H
223,Autocuration,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,10193,BAO_0000019,,B,,,,,H
224,Autocuration,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,12052,,10193,BAO_0000019,,B,,,,,H
225,Autocuration,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,12052,,11087,BAO_0000019,,B,,,,,H
226,Intermediate,,,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,80007,Homo sapiens,15569,BAO_0000219,,F,,,9606.0,41M,N
227,Expert,,,,In vitro antitumor activity against 41M cell line.,80007,Homo sapiens,12989,BAO_0000219,,F,,,9606.0,41M,N
228,Intermediate,,,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,80007,Homo sapiens,16745,BAO_0000219,,F,,,9606.0,41M,N
229,Intermediate,,,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,80007,Homo sapiens,15569,BAO_0000219,,F,,,9606.0,41M,N
230,Expert,,,,In vitro antitumor activity against 41McisR cell line.,80007,Homo sapiens,12989,BAO_0000219,,F,,,9606.0,41M,N
231,Expert,,,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,80007,Homo sapiens,12989,BAO_0000219,,F,,,9606.0,41M,N
232,Intermediate,,,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,80007,Homo sapiens,16745,BAO_0000219,,F,,,9606.0,41M,N
233,Expert,,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),84,Homo sapiens,6210,BAO_0000357,,B,,,9606.0,,D
234,Expert,,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,Homo sapiens,6210,BAO_0000357,,B,,,9606.0,,D
235,Expert,,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,,6226,BAO_0000357,,B,,,,,H
236,Expert,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,,17855,BAO_0000357,,B,,,,,H
237,Expert,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,10201,,17855,BAO_0000357,,B,,,,,H
238,Expert,,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,,17855,BAO_0000357,,B,,,,,H
239,Autocuration,,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,,10413,BAO_0000357,,B,,,,,H
240,Autocuration,,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,Escherichia coli,10413,BAO_0000357,,B,,,562.0,,H
241,Autocuration,,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,Escherichia coli,10413,BAO_0000357,,B,,,562.0,,H
242,Autocuration,,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",11303,Escherichia coli,10413,BAO_0000357,,B,,,562.0,,H
243,Autocuration,,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,,10413,BAO_0000357,,B,,,,,H
244,Autocuration,,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",12220,,10413,BAO_0000357,,B,,,,,H
245,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,Sus scrofa,7587,BAO_0000357,,B,,,9823.0,,H
246,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",11303,Sus scrofa,7587,BAO_0000019,,B,,,9823.0,,H
247,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",11303,Sus scrofa,7587,BAO_0000357,,B,,,9823.0,,H
248,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",11303,Sus scrofa,7587,BAO_0000357,,B,,,9823.0,,H
249,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,Sus scrofa,7587,BAO_0000357,,B,,,9823.0,,H
250,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,Sus scrofa,7587,BAO_0000019,,B,,,9823.0,,H
251,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",11303,Sus scrofa,7587,BAO_0000019,,B,,,9823.0,,H
252,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",11303,Sus scrofa,7587,BAO_0000019,,B,,,9823.0,,H
253,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",11303,Sus scrofa,7587,BAO_0000019,,B,,,9823.0,,H
254,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",11303,Sus scrofa,7587,BAO_0000019,,B,,,9823.0,,H
255,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,Sus scrofa,7587,BAO_0000357,,B,,,9823.0,,H
256,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,Sus scrofa,7587,BAO_0000019,,B,,,9823.0,,H
257,Autocuration,,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",11303,,7323,BAO_0000357,,B,,,,,H
258,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",22226,Sus scrofa,7587,BAO_0000019,,B,,,9823.0,,U
259,Autocuration,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",22226,Sus scrofa,7587,BAO_0000019,,B,,,9823.0,,U
260,Expert,,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,100249,Saccharomyces cerevisiae,13750,BAO_0000357,,B,,,4932.0,,H
261,Autocuration,,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,Rattus norvegicus,7662,BAO_0000019,,B,,,10116.0,,U
262,Autocuration,,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,Rattus norvegicus,7662,BAO_0000019,,B,,,10116.0,,U
263,Autocuration,,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",22226,Rattus norvegicus,7662,BAO_0000019,,B,,,10116.0,,U
264,Autocuration,,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,,12211,BAO_0000019,,F,,,,,H
265,Autocuration,,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,,12211,BAO_0000019,,F,,,,,H
266,Intermediate,,Ileum,2116.0,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,20033,Cavia porcellus,12211,BAO_0000221,,F,,,10141.0,,D
267,Expert,,,,Stimulatory activity of intragastric pressure was tested in the rat,10623,,12211,BAO_0000019,,F,,,,,H
268,Autocuration,,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,121,,15453,BAO_0000357,,B,,,,,H
269,Autocuration,,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),22226,Rattus norvegicus,11884,BAO_0000218,,F,,,10116.0,,U
270,Autocuration,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,12688,,7185,BAO_0000019,,F,,,,,H
271,Expert,,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,121,Homo sapiens,6876,BAO_0000357,,B,,,9606.0,,D
272,Expert,,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,121,Homo sapiens,6876,BAO_0000357,,B,,,9606.0,,D
273,Autocuration,,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,12198,,11863,BAO_0000019,,F,,,,,H
274,Autocuration,,,,Inhibition constant of high-affinity 5-HT uptake,12198,,11863,BAO_0000357,,B,,,,,H
275,Autocuration,,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,12198,,11863,BAO_0000019,,F,,,,,H
276,Autocuration,,,,Maximum rate was determined for high affinity transport of 5-HT,12198,,11863,BAO_0000019,,F,,,,,H
277,Autocuration,,,,Compound was tested for agonistic activity against 5-HT uptake,104714,,4639,BAO_0000019,,F,,,,,H
278,Expert,,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,10577,,15796,BAO_0000019,,B,,,,,H
279,Expert,,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,105,Bos taurus,15796,BAO_0000357,,B,,,9913.0,,H
280,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,104744,Rattus norvegicus,12801,BAO_0000224,,B,,,10116.0,,D
281,Autocuration,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,104744,,12801,BAO_0000224,,B,,,,,H
282,Autocuration,Membranes,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,104744,,12120,BAO_0000249,,B,,,,,H
283,Autocuration,Membranes,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,104744,,12120,BAO_0000249,,B,,,,,H
284,Autocuration,,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,11963,BAO_0000019,,B,,,,,H
285,Autocuration,,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,51,,11701,BAO_0000019,,F,,,,,H
286,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
287,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
288,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
289,Autocuration,,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),10576,,16394,BAO_0000218,,F,In vivo,,,,H
290,Intermediate,,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,105570,Cavia porcellus,11574,BAO_0000019,,F,,,10141.0,,D
291,Autocuration,,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,,15779,BAO_0000219,,B,,,,CHO,H
292,Autocuration,,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,107,,15363,BAO_0000357,,B,,,,,H
293,Expert,,,,Efficacy against 5-hydroxytryptamine 2A receptor,12687,Rattus norvegicus,15363,BAO_0000019,,F,,,10116.0,,D
294,Expert,,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,12687,,15329,BAO_0000019,,F,,,,,H
295,Expert,,,,Relative potency towards 5-HT2A receptor of rat tail artery,12687,,15329,BAO_0000019,,F,,,,,H
296,Expert,,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,,15329,BAO_0000019,,F,,,,,H
297,Expert,,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,12687,,15329,BAO_0000019,,F,,,,,H
298,Autocuration,,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,12687,,15329,BAO_0000019,,F,,,,,H
299,Expert,,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,,15329,BAO_0000019,,F,,,,,H
300,Intermediate,,Ileum,2116.0,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,Cavia porcellus,273,BAO_0000221,,F,,,10141.0,,D
301,Intermediate,,Ileum,2116.0,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),20033,Cavia porcellus,273,BAO_0000221,,F,,,10141.0,,D
302,Intermediate,,Ileum,2116.0,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,Cavia porcellus,273,BAO_0000221,,F,,,10141.0,,D
303,Autocuration,,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,10623,,12092,BAO_0000357,,B,,,,,H
304,Expert,,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,Rattus norvegicus,1317,BAO_0000019,,F,,,10116.0,,D
305,Expert,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,168,,12409,BAO_0000357,,B,,,,,H
306,Autocuration,,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,22226,Gallus gallus,11126,BAO_0000019,,B,,,9031.0,,U
307,Autocuration,,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,22226,Homo sapiens,11126,BAO_0000019,,F,,,9606.0,,U
308,Autocuration,,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,Homo sapiens,11126,BAO_0000019,,F,,,9606.0,,U
309,Autocuration,,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,80156,Homo sapiens,11126,BAO_0000219,,B,,,9606.0,HL-60,N
310,Autocuration,,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,22226,Homo sapiens,11126,BAO_0000019,,B,,,9606.0,,U
311,Autocuration,,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,Homo sapiens,11126,BAO_0000019,,B,,,9606.0,,U
312,Autocuration,,,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,104703,Homo sapiens,17807,BAO_0000219,,B,,,9606.0,Oocytes,D
313,Intermediate,,,,Chymotryptic inhibitory activity against 26S proteasome,100256,,16575,BAO_0000220,,F,,,,,S
314,Intermediate,,,,Inhibitory activity against 26S proteasome degradation of IkB,100256,,15407,BAO_0000220,,B,,,,,S
315,Intermediate,,,,In vitro inhibition of 2780/DOX ovarian cancer cell line,81034,Homo sapiens,10797,BAO_0000219,,F,,,9606.0,A2780,N
316,Intermediate,,,,In vitro inhibition of 2780/S ovarian cancer cell line,81034,Homo sapiens,10797,BAO_0000219,,F,,,9606.0,A2780,N
317,Autocuration,,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,22226,Homo sapiens,3469,BAO_0000019,,F,,,9606.0,,U
318,Intermediate,,,,Association constant for binding to AATT 28-mer AATT hairpin,22222,,16037,BAO_0000225,,B,,,,,M
319,Intermediate,,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,22222,,16037,BAO_0000225,,B,,,,,M
320,Intermediate,,,,Reaction Rate Parameter for 28-mer AATT hairpin,22222,,16037,BAO_0000225,,B,,,,,M
321,Intermediate,,,,Reaction Rate Parameter for 28-mer AATT hairpin,22222,,16037,BAO_0000225,,B,,,,,M
322,Autocuration,,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),22226,Homo sapiens,16524,BAO_0000019,,F,,,9606.0,,U
323,Autocuration,,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),22226,Homo sapiens,16524,BAO_0000019,,F,,,9606.0,,U
324,Autocuration,,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,22226,Homo sapiens,16524,BAO_0000019,,F,,,9606.0,,U
325,Autocuration,,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,22226,Cricetulus griseus,16758,BAO_0000019,,F,,,10029.0,,U
326,Autocuration,,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,22226,Cricetulus griseus,16758,BAO_0000019,,F,,,10029.0,,U
327,Autocuration,,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,22226,Cricetulus griseus,16758,BAO_0000019,,F,,,10029.0,,U
328,Autocuration,,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,241,,14360,BAO_0000357,,B,,,,,H
329,Expert,,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,241,Homo sapiens,14360,BAO_0000357,,B,,,9606.0,,D
330,Autocuration,,,,Selectivity ratio of ID50 in liver and heart,22226,Rattus norvegicus,9964,BAO_0000019,,B,,,10116.0,,U
331,Autocuration,,,,"Selectivity, ratio of relative ID50 in liver and heart",12132,,9964,BAO_0000019,,B,,,,,H
332,Autocuration,,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,12132,,9964,BAO_0000019,,B,,,,,H
333,Autocuration,,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,9964,BAO_0000218,,B,,,,,H
334,Autocuration,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,9964,BAO_0000218,,B,,,,,H
335,Autocuration,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,9964,BAO_0000218,,B,In vivo,,,,H
336,Autocuration,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,9964,BAO_0000218,,F,In vivo,,,,H
337,Autocuration,,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",22226,,9964,BAO_0000019,,B,,,,,U
338,Autocuration,,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,12132,,9964,BAO_0000019,,B,,,,,H
339,Autocuration,,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",22226,Homo sapiens,9964,BAO_0000019,,B,,,9606.0,,U
340,Autocuration,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,,9964,BAO_0000019,,B,,,,,H
341,Autocuration,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,,9964,BAO_0000019,,F,,,,,H
342,Autocuration,,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",12132,,9964,BAO_0000019,,B,,,,,H
343,Autocuration,,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",22226,Rattus norvegicus,9964,BAO_0000218,,B,,,10116.0,,U
344,Autocuration,,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,12132,,9964,BAO_0000218,,B,In vivo,,,,H
345,Autocuration,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,9964,BAO_0000218,,B,,,,,H
346,Autocuration,,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",22226,Rattus norvegicus,9964,BAO_0000218,,B,,,10116.0,,U
347,Autocuration,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,,9964,BAO_0000019,,B,,,,,H
348,Autocuration,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,,9964,BAO_0000019,,F,,,,,H
349,Autocuration,,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",22226,Rattus norvegicus,3796,BAO_0000019,,B,,,10116.0,,U
350,Autocuration,,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,Escherichia coli,4251,BAO_0000357,,B,,,562.0,,H
351,Autocuration,,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,Escherichia coli,4251,BAO_0000357,,B,,,562.0,,H
352,Autocuration,,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,Escherichia coli,4251,BAO_0000357,,B,,,562.0,,H
353,Autocuration,,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,Escherichia coli,4251,BAO_0000357,,B,,,562.0,,H
354,Autocuration,,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,19690,,166,BAO_0000357,,B,,,,,H
355,Autocuration,,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,19690,,17861,BAO_0000357,,B,,,,,H
356,Autocuration,,,,Inhibition constant against 3-dehydroquinate synthase,19690,,166,BAO_0000357,,B,,,,,H
357,Autocuration,,,,Association rate constant against 3-dehydroquinate synthase,19690,,166,BAO_0000357,,B,,,,,H
358,Autocuration,,,,Rate constant against 3-dehydroquinate synthase,19690,,166,BAO_0000357,,B,,,,,H
359,Autocuration,,,,Inhibitory activity against fuc-TVII,22226,,3548,BAO_0000019,,B,,,,,U
360,Autocuration,Microsomes,Liver,2107.0,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,Rattus norvegicus,9877,BAO_0000251,,B,,,10116.0,,D
361,Autocuration,Microsomes,Liver,2107.0,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,Rattus norvegicus,9877,BAO_0000251,,B,,,10116.0,,D
362,Autocuration,Microsomes,Liver,2107.0,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,Rattus norvegicus,9877,BAO_0000251,,B,,,10116.0,,D
363,Autocuration,Microsomes,Liver,2107.0,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,Rattus norvegicus,9877,BAO_0000251,,B,,,10116.0,,D
364,Autocuration,Microsomes,Liver,2107.0,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,Rattus norvegicus,9877,BAO_0000251,,B,,,10116.0,,D
365,Autocuration,Microsomes,Liver,2107.0,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,12236,Rattus norvegicus,9877,BAO_0000251,,B,,,10116.0,,D
366,Autocuration,Microsomes,Liver,2107.0,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,12236,Rattus norvegicus,9877,BAO_0000251,,B,,,10116.0,,D
367,Autocuration,Microsomes,Liver,2107.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,12236,Rattus norvegicus,9877,BAO_0000251,,B,,,10116.0,,D
368,Autocuration,Microsomes,Liver,2107.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,12236,Rattus norvegicus,9877,BAO_0000251,,B,,,10116.0,,D
369,Autocuration,Microsomes,Liver,2107.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,12236,Rattus norvegicus,9877,BAO_0000251,,B,,,10116.0,,D
370,Autocuration,Microsomes,Liver,2107.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,12236,Rattus norvegicus,9877,BAO_0000251,,B,,,10116.0,,D
371,Autocuration,,,,Inhibitory activity against 3-phosphoglycerate kinase.,104832,,3003,BAO_0000224,,B,,,,,H
372,Autocuration,,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,104832,,3003,BAO_0000224,,B,,,,,H
373,Autocuration,,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",104832,,3003,BAO_0000224,,B,,,,,H
374,Expert,,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,10612,Homo sapiens,17185,BAO_0000357,,B,,,9606.0,,D
375,Intermediate,,,,Cytotoxicity on 3677 melanoma cells,80616,Homo sapiens,6072,BAO_0000219,,F,,,9606.0,3677 melanoma cell line,N
376,Intermediate,,,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,80616,Homo sapiens,6072,BAO_0000219,,F,,,9606.0,3677 melanoma cell line,N
377,Intermediate,,,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,80617,Mus musculus,5018,BAO_0000219,,F,,,10090.0,MC-38,N
378,Intermediate,,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,22226,Homo sapiens,2852,BAO_0000019,,F,,,9606.0,,U
379,Autocuration,,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,22226,,8663,BAO_0000218,,F,,,,B16,U
380,Autocuration,,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,22226,,8663,BAO_0000218,,F,,,,B16,U
381,Expert,,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,12464,Human rhinovirus 14,3245,BAO_0000019,,F,,,12131.0,,D
382,Intermediate,,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,50085,Human rhinovirus sp.,3245,BAO_0000218,,F,,,169066.0,,N
383,Intermediate,,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,50679,human rhinovirus type 14,3877,BAO_0000218,,F,,,169066.0,,N
384,Intermediate,,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,50679,human rhinovirus type 14,3877,BAO_0000218,,F,,,169066.0,,N
385,Expert,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,Human rhinovirus 14,5861,BAO_0000019,,F,,,12131.0,,D
386,Expert,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,Human rhinovirus 14,5861,BAO_0000019,,F,,,12131.0,,D
387,Expert,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,Human rhinovirus 14,5861,BAO_0000019,,F,,,12131.0,,D
388,Expert,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,12464,Human rhinovirus 14,5861,BAO_0000019,,F,,,12131.0,,D
389,Intermediate,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,50665,Enterovirus,13748,BAO_0000218,,F,,,12059.0,,N
390,Intermediate,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,50665,Enterovirus,13748,BAO_0000218,,F,,,12059.0,,N
391,Intermediate,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,50665,Enterovirus,13748,BAO_0000218,,F,,,12059.0,,N
392,Intermediate,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,50665,Enterovirus,13748,BAO_0000218,,F,,,12059.0,,N
393,Expert,,,,Inhibition of human rhinovirus 3C protease,12464,Human rhinovirus B,13748,BAO_0000357,,B,,,147712.0,,H
394,Autocuration,,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,22226,Homo sapiens,17699,BAO_0000019,,B,,,9606.0,,U
395,Intermediate,,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),80619,Mus musculus,7145,BAO_0000218,,F,,,10090.0,3EM 37,N
396,Intermediate,,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),80619,Mus musculus,7145,BAO_0000218,,F,,,10090.0,3EM 37,N
397,Intermediate,,,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),80619,Mus musculus,7145,BAO_0000218,,F,,,10090.0,3EM 37,N
398,Intermediate,,,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),80619,Mus musculus,7145,BAO_0000218,,F,,,10090.0,3EM 37,N
399,Intermediate,,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,80619,Mus musculus,7145,BAO_0000218,,F,,,10090.0,3EM 37,N
400,Intermediate,,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,80619,Mus musculus,7145,BAO_0000218,,F,,,10090.0,3EM 37,N
401,Intermediate,,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,Mus musculus,5325,BAO_0000218,,F,,,10090.0,3LL cell line,N
402,Intermediate,,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,Mus musculus,5325,BAO_0000218,,F,,,10090.0,3LL cell line,N
403,Expert,,,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,80620,Mus musculus,5325,BAO_0000218,,F,,,10090.0,3LL cell line,N
404,Intermediate,,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
405,Intermediate,,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
406,Intermediate,,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
407,Intermediate,,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
408,Intermediate,,,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
409,Intermediate,,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
410,Intermediate,,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
411,Intermediate,,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
412,Intermediate,,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
413,Intermediate,,,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
414,Intermediate,,,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
415,Intermediate,,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
416,Intermediate,,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
417,Intermediate,,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
418,Intermediate,,,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
419,Intermediate,,,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
420,Intermediate,,,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
421,Intermediate,,,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
422,Intermediate,,,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
423,Intermediate,,,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
424,Intermediate,,,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
425,Intermediate,,,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
426,Intermediate,,,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
427,Intermediate,,,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
428,Intermediate,,,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
429,Intermediate,,,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,80620,Mus musculus,16169,BAO_0000219,,F,,,10090.0,3LL cell line,N
430,Intermediate,,,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,80621,Homo sapiens,15547,BAO_0000219,,F,,,9606.0,3LLD122,N
431,Autocuration,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,22226,,8663,BAO_0000218,,F,,,,,U
432,Autocuration,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,22226,,8663,BAO_0000218,,F,,,,,U
433,Autocuration,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,22226,,8663,BAO_0000218,,F,,,,,U
434,Autocuration,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,22226,,8663,BAO_0000218,,F,,,,,U
435,Intermediate,,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,Mus musculus,4504,BAO_0000219,,F,,,10090.0,NIH3T3,N
436,Intermediate,,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,Mus musculus,4504,BAO_0000219,,F,,,10090.0,NIH3T3,N
437,Expert,,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,11169,,12695,BAO_0000219,,F,,,,NIH3T3,H
438,Intermediate,,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,80951,Mus musculus,12695,BAO_0000219,,F,,,10090.0,NIH3T3,N
439,Intermediate,,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,80951,Mus musculus,12695,BAO_0000219,,F,,,10090.0,NIH3T3,N
440,Expert,,,,Effective dose against murine 3T3 fibroblasts cells,80951,Mus musculus,17642,BAO_0000219,,F,,,10090.0,NIH3T3,N
441,Expert,,,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,80951,Mus musculus,17642,BAO_0000219,,F,,,10090.0,NIH3T3,N
442,Expert,,,,Cytotoxic effect on 3T3 cells,80951,Mus musculus,12340,BAO_0000219,,F,,,10090.0,NIH3T3,N
443,Expert,,,,Cytotoxic effect on 3T3 cells,80951,Mus musculus,12340,BAO_0000219,,F,,,10090.0,NIH3T3,N
444,Intermediate,,,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,80951,Mus musculus,12716,BAO_0000219,,F,,,10090.0,NIH3T3,N
445,Intermediate,,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,Mus musculus,6277,BAO_0000219,,F,,,10090.0,NIH3T3,N
446,Intermediate,,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,80951,Mus musculus,6277,BAO_0000219,,F,,,10090.0,NIH3T3,N
447,Expert,,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,80951,Mus musculus,6277,BAO_0000219,,F,,,10090.0,NIH3T3,N
448,Expert,,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,80951,Mus musculus,6277,BAO_0000219,,F,,,10090.0,NIH3T3,N
449,Intermediate,,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,80951,Mus musculus,6277,BAO_0000219,,F,,,10090.0,NIH3T3,N
450,Expert,,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,80951,Mus musculus,6277,BAO_0000219,,F,,,10090.0,NIH3T3,N
451,Expert,,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,80951,Mus musculus,6277,BAO_0000219,,F,,,10090.0,NIH3T3,N
452,Intermediate,,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,80951,Mus musculus,6277,BAO_0000219,,F,,,10090.0,NIH3T3,N
453,Expert,,,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,80951,Mus musculus,17780,BAO_0000218,,F,,,10090.0,NIH3T3,N
454,Autocuration,,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,104860,Mus musculus,12751,BAO_0000219,,F,,,10090.0,,D
455,Expert,,,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,80951,Mus musculus,12380,BAO_0000219,,F,,,10090.0,NIH3T3,N
456,Intermediate,,,,Inhibitory activity against 3T3 cell line,80951,Mus musculus,14892,BAO_0000219,,F,,,10090.0,NIH3T3,N
457,Intermediate,,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,80951,Mus musculus,12695,BAO_0000219,,F,,,10090.0,NIH3T3,N
458,Expert,,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,11169,,12695,BAO_0000019,,F,,,,,H
459,Intermediate,,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,80951,Mus musculus,12695,BAO_0000219,,F,,,10090.0,NIH3T3,N
460,Intermediate,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,80951,Mus musculus,12695,BAO_0000219,,F,,,10090.0,NIH3T3,N
461,Expert,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,11169,,12695,BAO_0000019,,F,,,,,H
462,Expert,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,11169,,12695,BAO_0000019,,F,,,,,H
463,Intermediate,,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,Mus musculus,6277,BAO_0000219,,F,,,10090.0,NIH3T3,N
464,Expert,,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,80951,Mus musculus,6277,BAO_0000219,,F,,,10090.0,NIH3T3,N
465,Expert,,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,9,Homo sapiens,4959,BAO_0000219,,F,,,9606.0,NIH3T3,D
466,Expert,,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),9,Homo sapiens,4959,BAO_0000219,,F,,,9606.0,NIH3T3,D
467,Expert,,,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,188,Homo sapiens,4959,BAO_0000219,,F,,,9606.0,NIH3T3,D
468,Expert,,,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),188,Homo sapiens,4959,BAO_0000219,,F,,,9606.0,NIH3T3,D
469,Intermediate,,,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,80951,Mus musculus,12082,BAO_0000219,,F,,,10090.0,NIH3T3,N
470,Intermediate,,,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,80951,Mus musculus,12082,BAO_0000219,,F,,,10090.0,NIH3T3,N
471,Intermediate,,,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,80951,Mus musculus,12082,BAO_0000219,,F,,,10090.0,NIH3T3,N
472,Intermediate,,,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,80951,Mus musculus,12082,BAO_0000219,,F,,,10090.0,NIH3T3,N
473,Intermediate,,,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,80951,Mus musculus,2643,BAO_0000219,,F,,,10090.0,NIH3T3,N
474,Expert,,,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,80951,Mus musculus,11926,BAO_0000219,,F,,,10090.0,NIH3T3,N
475,Intermediate,,,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,80951,Mus musculus,15204,BAO_0000219,,A,,,10090.0,NIH3T3,N
476,Expert,,,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,80951,Mus musculus,15992,BAO_0000219,,F,,,10090.0,NIH3T3,N
477,Intermediate,,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,80951,Mus musculus,16279,BAO_0000219,,F,,,10090.0,NIH3T3,N
478,Intermediate,,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,Mus musculus,16279,BAO_0000219,,F,,,10090.0,NIH3T3,N
479,Intermediate,,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,Mus musculus,16279,BAO_0000219,,F,,,10090.0,NIH3T3,N
480,Intermediate,,,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,Mus musculus,16279,BAO_0000219,,F,,,10090.0,NIH3T3,N
481,Intermediate,,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,Mus musculus,16279,BAO_0000219,,F,,,10090.0,NIH3T3,N
482,Intermediate,,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,Mus musculus,16279,BAO_0000219,,F,,,10090.0,NIH3T3,N
483,Expert,,,,Inhibition of swiss 3T3 mouse fibroblast proliferation,80951,Mus musculus,12831,BAO_0000219,,F,,,10090.0,NIH3T3,N
484,Intermediate,,,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,80951,Mus musculus,13497,BAO_0000219,,F,,,10090.0,NIH3T3,N
485,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
486,Intermediate,,,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,80006,Mus musculus,13618,BAO_0000219,,F,,,10090.0,3T3-L1,N
487,Intermediate,,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,80006,Mus musculus,11902,BAO_0000219,,F,,,10090.0,3T3-L1,N
488,Intermediate,,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,80006,Mus musculus,11902,BAO_0000219,,F,,,10090.0,3T3-L1,N
489,Intermediate,,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,80006,Mus musculus,11902,BAO_0000219,,F,,,10090.0,3T3-L1,N
490,Intermediate,,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",80006,Mus musculus,14840,BAO_0000218,,F,,,10090.0,3T3-L1,N
491,Intermediate,,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",80006,Mus musculus,14840,BAO_0000218,,F,,,10090.0,3T3-L1,N
492,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,80006,,13715,BAO_0000219,,F,,,,3T3-L1,N
493,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,,13715,BAO_0000219,,F,,,,3T3-L1,N
494,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,13715,BAO_0000219,,F,,,,3T3-L1,N
495,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,,13715,BAO_0000219,,F,,,,3T3-L1,N
496,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,13715,BAO_0000219,,F,,,,3T3-L1,N
497,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
498,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
499,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
500,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
501,Expert,,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
502,Expert,,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
503,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
504,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
505,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
506,Expert,,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
507,Expert,,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
508,Expert,,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
509,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,,13715,BAO_0000219,,F,,,,3T3-L1,N
510,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,13715,BAO_0000219,,F,,,,3T3-L1,N
511,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,,13715,BAO_0000219,,F,,,,3T3-L1,N
512,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
513,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
514,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
515,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
516,Intermediate,,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,,13715,BAO_0000218,,F,,,,3T3-L1,N
517,Expert,,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,11214,,6411,BAO_0000219,,F,,,,3T3-L1,H
518,Intermediate,,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,80006,Mus musculus,6411,BAO_0000219,,F,,,10090.0,3T3-L1,N
519,Expert,,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,11214,,6411,BAO_0000219,,F,,,,3T3-L1,H
520,Expert,,,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,80006,Mus musculus,3966,BAO_0000219,,F,,,10090.0,3T3-L1,N
521,Intermediate,,,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,80006,Mus musculus,3966,BAO_0000219,,F,,,10090.0,3T3-L1,N
522,Expert,,,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,80006,Mus musculus,15556,BAO_0000219,,F,,,10090.0,3T3-L1,N
523,Expert,,,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,Mus musculus,5845,BAO_0000219,,F,,,10090.0,3T3-L1,N
524,Expert,,,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,Mus musculus,14422,BAO_0000219,,F,,,10090.0,3T3-L1,N
525,Expert,,,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,80006,Mus musculus,5845,BAO_0000219,,F,,,10090.0,3T3-L1,N
526,Expert,,,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,80006,Mus musculus,14508,BAO_0000219,,F,,,10090.0,3T3-L1,N
527,Expert,,,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,80006,Mus musculus,14508,BAO_0000219,,F,,,10090.0,3T3-L1,N
528,Expert,,,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,80006,Mus musculus,14508,BAO_0000219,,F,,,10090.0,3T3-L1,N
529,Intermediate,,,,Inhibitory activity against rat fibroblast (3Y1) cell line,80622,Rattus norvegicus,6349,BAO_0000219,,F,,,10116.0,3Y1 cell line,N
530,Expert,,,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,80622,Rattus norvegicus,15899,BAO_0000219,,F,,,10116.0,3Y1 cell line,N
531,Expert,,,,Cytotoxicity in 3Y1 cells.,80622,Rattus norvegicus,15899,BAO_0000219,,F,,,10116.0,3Y1 cell line,N
532,Expert,,,,Cytostatic effect in 3Y1 cells.,80622,Rattus norvegicus,15899,BAO_0000219,,F,,,10116.0,3Y1 cell line,N
533,Intermediate,,,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",80622,Rattus norvegicus,15899,BAO_0000219,,F,,,10116.0,3Y1 cell line,N
534,Expert,,,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,80622,Rattus norvegicus,17038,BAO_0000219,,F,,,10116.0,3Y1 cell line,N
535,Autocuration,,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,22226,,12421,BAO_0000019,,B,,,,,U
536,Autocuration,,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,,12947,BAO_0000019,,B,,,,,U
537,Autocuration,,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,,12947,BAO_0000019,,B,,,,,U
538,Expert,,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,11607,Sus scrofa,4896,BAO_0000019,,B,,,9823.0,,D
539,Autocuration,,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,11607,,6148,BAO_0000019,,B,,,,,H
540,Autocuration,,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,11607,,16432,BAO_0000019,,B,,,,,H
541,Expert,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,11607,,4978,BAO_0000019,,B,,,,,H
542,Expert,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),11607,,4978,BAO_0000019,,B,,,,,H
543,Autocuration,,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,11607,,3723,BAO_0000019,,B,,,,,H
544,Autocuration,,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),11607,,3518,BAO_0000357,,B,,,,,H
545,Autocuration,,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,11607,,4164,BAO_0000019,,B,,,,,H
546,Autocuration,,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,11607,,3518,BAO_0000019,,B,,,,,H
547,Expert,,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,11607,Sus scrofa,4164,BAO_0000019,,B,,,9823.0,,D
548,Autocuration,,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,11607,,3518,BAO_0000019,,B,,,,,H
549,Autocuration,,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),11607,,3518,BAO_0000357,,B,,,,,H
550,Autocuration,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,11607,,4978,BAO_0000019,,B,,,,,H
551,Autocuration,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),11607,,4978,BAO_0000019,,B,,,,,H
552,Autocuration,,,,Binding affinity against melatonin (MT1) receptor (pC1),104733,,6455,BAO_0000224,,B,,,,,H
553,Autocuration,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,22226,,2222,BAO_0000019,,B,,,,,U
554,Autocuration,,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,22226,,13020,BAO_0000019,,B,,,,,U
555,Autocuration,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,22226,,13021,BAO_0000019,,B,,,,,U
556,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,10619,,14532,BAO_0000357,,B,,,,,H
557,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,10619,,14118,BAO_0000357,,B,,,,,H
558,Autocuration,,Hippocampus,10000000.0,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,51,,11884,BAO_0000221,,B,,,,,H
559,Expert,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,51,,13969,BAO_0000357,,B,,,,,H
560,Expert,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,51,,13392,BAO_0000357,,B,,,,,H
561,Expert,,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,51,,14430,BAO_0000019,,B,,,,,H
562,Autocuration,,Hippocampus,10000000.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,12248,BAO_0000221,,B,,,,,H
563,Autocuration,,Hippocampus,10000000.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,12249,BAO_0000221,,B,,,,,H
564,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
565,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
566,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
567,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
568,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
569,Autocuration,,Hippocampus,10000000.0,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,12249,BAO_0000221,,B,,,,,H
570,Autocuration,,Hippocampus,10000000.0,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,,11799,BAO_0000221,,B,,,,,H
571,Expert,Membranes,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,10576,Rattus norvegicus,14331,BAO_0000249,,B,,,10116.0,,D
572,Expert,,Hippocampus,10000000.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,51,Bos taurus,11884,BAO_0000221,,B,,,9913.0,,H
573,Autocuration,,Hippocampus,10000000.0,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,51,,14331,BAO_0000221,,B,,,,,H
574,Autocuration,,Hippocampus,10000000.0,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,51,,11701,BAO_0000221,,B,,,,,H
575,Expert,,Hippocampus,10000000.0,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,51,,11701,BAO_0000221,,B,,,,,H
576,Autocuration,,Hippocampus,10000000.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,51,,12248,BAO_0000221,,B,,,,,H
577,Autocuration,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,51,,12248,BAO_0000219,,B,,,,CHO,H
578,Expert,,Hippocampus,10000000.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,12248,BAO_0000221,,B,,,,,H
579,Expert,,Hippocampus,10000000.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,12249,BAO_0000221,,B,,,,,H
580,Autocuration,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,12248,BAO_0000219,,B,,,,CHO,H
581,Expert,,Hippocampus,10000000.0,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,,11799,BAO_0000221,,B,,,,,H
582,Autocuration,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,,634,BAO_0000357,,B,,,,,H
583,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
584,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
585,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
586,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
587,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,9995,BAO_0000221,,B,,,,,H
588,Expert,,Hippocampus,10000000.0,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,51,,12210,BAO_0000218,,B,,,,,H
589,Expert,,Hippocampus,10000000.0,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,13311,BAO_0000221,,B,,,,,H
590,Expert,,,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",51,Homo sapiens,2331,BAO_0000219,,B,,,9606.0,CHO,D
591,Autocuration,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,51,Cavia porcellus,1375,BAO_0000019,,F,,,10141.0,,H
592,Autocuration,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,51,Cavia porcellus,1375,BAO_0000019,,F,,,10141.0,,H
593,Autocuration,,Hippocampus,10000000.0,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,51,Cavia porcellus,11574,BAO_0000221,,F,,,10141.0,,H
594,Autocuration,,Ileum,2116.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,Cavia porcellus,12867,BAO_0000221,,B,,,10141.0,,H
595,Autocuration,,Ileum,2116.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,Cavia porcellus,12867,BAO_0000221,,B,,,10141.0,,H
596,Autocuration,,Ileum,2116.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,Cavia porcellus,12867,BAO_0000221,,B,,,10141.0,,H
597,Autocuration,,Ileum,2116.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,Cavia porcellus,12867,BAO_0000221,,B,,,10141.0,,H
598,Autocuration,,Ileum,2116.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,Cavia porcellus,12867,BAO_0000221,,B,,,10141.0,,H
599,Autocuration,,Ileum,2116.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,51,Cavia porcellus,12867,BAO_0000221,,B,,,10141.0,,H
600,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,51,Cavia porcellus,11574,BAO_0000357,,B,,,10141.0,,H
601,Autocuration,,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,51,Cavia porcellus,13114,BAO_0000357,,B,,,10141.0,,H
602,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,51,Cavia porcellus,13181,BAO_0000357,,B,,,10141.0,,H
603,Autocuration,,Hippocampus,10000000.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,Cavia porcellus,10639,BAO_0000221,,B,,,10141.0,,H
604,Autocuration,,Hippocampus,10000000.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,Cavia porcellus,10639,BAO_0000221,,F,,,10141.0,,H
605,Autocuration,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),11863,Cricetulus griseus,11883,BAO_0000218,,B,,,10029.0,CHO,H
606,Autocuration,,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,51,,17785,BAO_0000357,,B,,,,,H
607,Autocuration,,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,51,,1558,BAO_0000219,,F,,,,HeLa,H
608,Autocuration,,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,51,,1558,BAO_0000219,,F,,,,HeLa,H
609,Autocuration,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,51,,15740,BAO_0000019,,F,,,,,H
610,Autocuration,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,,17624,BAO_0000219,,F,,,,CHO,H
611,Expert,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,,17624,BAO_0000219,,F,,,,CHO,H
612,Autocuration,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,51,,17624,BAO_0000219,,F,,,,CHO,H
613,Autocuration,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,51,,17624,BAO_0000219,,F,,,,CHO,H
614,Expert,,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,17624,BAO_0000219,,B,,,,CHO,H
615,Expert,,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,17624,BAO_0000219,,B,,,,CHO,H
616,Autocuration,,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,51,,17624,BAO_0000219,,B,,,,CHO,H
617,Autocuration,,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,51,,14256,BAO_0000219,,F,,,,,H
618,Expert,,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,Homo sapiens,3445,BAO_0000219,,B,,,9606.0,HeLa,D
619,Expert,,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,51,Homo sapiens,3445,BAO_0000219,,B,,,9606.0,HeLa,D
620,Expert,,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,51,Homo sapiens,17200,BAO_0000219,,B,,,9606.0,CHO,D
621,Expert,,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,Homo sapiens,17200,BAO_0000219,,B,,,9606.0,CHO,D
622,Autocuration,,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,,15180,BAO_0000019,,F,,,,,H
623,Autocuration,,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,,15180,BAO_0000019,,F,,,,,H
624,Autocuration,,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,16026,BAO_0000019,,F,,,,,H
625,Autocuration,,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,2759,BAO_0000219,,F,,,,CHO,H
626,Expert,,,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,Homo sapiens,2759,BAO_0000219,,F,,,9606.0,CHO,D
627,Autocuration,,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,,2759,BAO_0000219,,F,,,,CHO,H
628,Expert,,,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,Homo sapiens,2759,BAO_0000219,,F,,,9606.0,CHO,D
629,Autocuration,,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,2759,BAO_0000219,,F,,,,CHO,H
630,Autocuration,,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),51,,2759,BAO_0000219,,F,,,,CHO,H
631,Expert,,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,Homo sapiens,2759,BAO_0000219,,F,,,9606.0,CHO,D
632,Autocuration,,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,,2759,BAO_0000219,,F,,,,CHO,H
633,Expert,,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,Homo sapiens,2759,BAO_0000219,,F,,,9606.0,CHO,D
634,Expert,,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,51,Homo sapiens,3445,BAO_0000019,,F,,,9606.0,,D
635,Expert,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
636,Expert,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
637,Expert,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
638,Autocuration,,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,17624,BAO_0000219,,F,,,,CHO,H
639,Autocuration,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,17624,BAO_0000219,,F,,,,CHO,H
640,Autocuration,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,,17624,BAO_0000219,,F,,,,CHO,H
641,Expert,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,17624,BAO_0000219,,F,,,,CHO,H
642,Autocuration,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,,17624,BAO_0000219,,F,,,,CHO,H
643,Autocuration,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,51,,17624,BAO_0000219,,F,,,,CHO,H
644,Autocuration,,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,17624,BAO_0000219,,F,,,,CHO,H
645,Autocuration,,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,,17624,BAO_0000219,,F,,,,CHO,H
646,Expert,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,17624,BAO_0000219,,F,,,,CHO,H
647,Autocuration,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,51,,17624,BAO_0000219,,F,,,,CHO,H
648,Autocuration,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,17624,BAO_0000219,,F,,,,CHO,H
649,Autocuration,,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,,17624,BAO_0000219,,F,,,,CHO,H
650,Autocuration,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,6563,BAO_0000019,,F,,,,,H
651,Autocuration,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,6563,BAO_0000019,,F,,,,,H
652,Autocuration,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,,6563,BAO_0000019,,F,,,,,H
653,Autocuration,,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,17296,BAO_0000219,,F,,,,HEK293,H
654,Expert,,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",51,Homo sapiens,6876,BAO_0000019,,F,,,9606.0,,D
655,Expert,,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",51,,6876,BAO_0000019,,F,,,,,H
656,Expert,,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
657,Expert,,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
658,Autocuration,,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,5548,BAO_0000019,,F,,,,,H
659,Expert,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",51,,5548,BAO_0000019,,F,,,,,H
660,Autocuration,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,5548,BAO_0000019,,F,,,,,H
661,Autocuration,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,5548,BAO_0000019,,F,,,,,H
662,Expert,,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",51,,5929,BAO_0000019,,F,,,,,H
663,Expert,,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",51,Homo sapiens,5929,BAO_0000019,,F,,,9606.0,,D
664,Expert,,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",51,Homo sapiens,5929,BAO_0000019,,F,,,9606.0,,D
665,Autocuration,,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",51,,16245,BAO_0000019,,F,,,,,H
666,Expert,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,,5640,BAO_0000019,,F,,,,,H
667,Autocuration,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",51,,5640,BAO_0000019,,F,,,,,H
668,Autocuration,,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,51,,14509,BAO_0000219,,F,,,,CHO,H
669,Expert,,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,51,,14509,BAO_0000219,,F,,,,CHO,H
670,Autocuration,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,,15331,BAO_0000357,,B,,,,,H
671,Autocuration,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,,15331,BAO_0000357,,B,,,,,H
672,Autocuration,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,6563,BAO_0000019,,F,,,,,H
673,Autocuration,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",51,,6563,BAO_0000019,,F,,,,,H
674,Autocuration,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,,6563,BAO_0000019,,F,,,,,H
675,Expert,,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,51,Homo sapiens,6563,BAO_0000019,,F,,,9606.0,,D
676,Autocuration,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,6563,BAO_0000019,,F,,,,,H
677,Expert,,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
678,Expert,,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
679,Expert,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
680,Expert,,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
681,Expert,,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
682,Expert,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
683,Expert,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
684,Expert,,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,51,Homo sapiens,5272,BAO_0000019,,F,,,9606.0,,D
685,Expert,,,,Inhibition of human 5-hydroxytryptamine 1A receptor,51,Homo sapiens,16146,BAO_0000357,,B,,,9606.0,,D
686,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,17624,BAO_0000219,,B,,,,CHO,H
687,Expert,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,105,,13706,BAO_0000219,,B,,,,HEK293,D
688,Autocuration,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,51,,15250,BAO_0000219,,B,,,,CHO,H
689,Autocuration,,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,17624,BAO_0000219,,F,,,,CHO,H
690,Expert,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,51,,6861,BAO_0000357,,B,,,,,H
691,Expert,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,Homo sapiens,17200,BAO_0000357,,B,,,9606.0,,D
692,Autocuration,,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,51,,17624,BAO_0000219,,B,,,,CHO,H
693,Autocuration,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,17624,BAO_0000219,,B,,,,CHO,H
694,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
695,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
696,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
697,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
698,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
699,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
700,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
701,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
702,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
703,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
704,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
705,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
706,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
707,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
708,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
709,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
710,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
711,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
712,Autocuration,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,Rattus norvegicus,12058,BAO_0000218,,F,In vivo,,10116.0,,U
713,Autocuration,,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,105093,,11440,BAO_0000019,,B,,,,,H
714,Autocuration,,Hypothalamus,1898.0,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,11923,,6238,BAO_0000249,,B,,,,,H
715,Autocuration,,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,10577,,10046,BAO_0000019,,B,,,,,H
716,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,10577,,10046,BAO_0000019,,B,,,,,H
717,Expert,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,,10046,BAO_0000019,,B,,,,,H
718,Autocuration,,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",55,,167,BAO_0000357,,B,,,,,H
719,Autocuration,,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",55,,167,BAO_0000357,,B,,,,,H
720,Autocuration,,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),12166,,11520,BAO_0000019,,F,,,,,H
721,Autocuration,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,11520,BAO_0000019,,F,,,,,H
722,Autocuration,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,11520,BAO_0000019,,F,,,,,H
723,Autocuration,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,11520,BAO_0000019,,F,,,,,H
724,Autocuration,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,55,Cavia porcellus,135,BAO_0000019,,F,,,10141.0,,H
725,Autocuration,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,55,Cavia porcellus,135,BAO_0000019,,F,,,10141.0,,H
726,Autocuration,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,55,Cavia porcellus,11311,BAO_0000019,,B,,,10141.0,,H
727,Autocuration,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,Cavia porcellus,10193,BAO_0000357,,B,,,10141.0,,H
728,Expert,,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,55,Homo sapiens,12281,BAO_0000357,,B,,,9606.0,,D
729,Autocuration,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,,11311,BAO_0000219,,B,,,,,H
730,Autocuration,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,,12576,BAO_0000218,,F,,,,,H
731,Autocuration,,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,17087,,12281,BAO_0000357,,B,,,,,H
732,Autocuration,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,,12576,BAO_0000218,,F,,,,,H
733,Expert,,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,Sus scrofa,11089,BAO_0000019,,B,,,9823.0,,H
734,Expert,,,,In vitro inhibition of rat 5-Lipoxygenase,12166,,11006,BAO_0000357,,B,,,,,H
735,Expert,,,,Inhibitory activity against 5-Lipoxygenase,12166,Rattus norvegicus,11481,BAO_0000357,,B,,,10116.0,,D
736,Expert,,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,12166,,10864,BAO_0000219,,B,,,,RBL-1,H
737,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,3595,BAO_0000219,,B,,,,RBL-1,H
738,Autocuration,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,12166,,11311,BAO_0000219,,B,,,,RBL-1,H
739,Autocuration,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,12166,,11311,BAO_0000019,,B,,,,,H
740,Autocuration,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],12166,,11311,BAO_0000219,,B,,,,,H
741,Autocuration,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,,11006,BAO_0000357,,B,,,,,H
742,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,,3595,BAO_0000219,,B,,,,RBL-1,H
743,Autocuration,,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,12166,,11311,BAO_0000357,,B,,,,,H
744,Autocuration,,,,Ratio of IC50 against 5-LO and COX,22226,Rattus norvegicus,11481,BAO_0000019,,B,,,10116.0,,U
745,Autocuration,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,,11006,BAO_0000357,,B,,,,,H
746,Autocuration,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,12166,,11006,BAO_0000357,,B,,,,,H
747,Autocuration,,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,12166,,11311,BAO_0000219,,B,,,,,H
748,Autocuration,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,12166,,11006,BAO_0000019,,F,,,,,H
749,Autocuration,,Prostate gland,2367.0,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,120,,4288,BAO_0000357,,B,,,,,H
750,Autocuration,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,22226,Columba livia,7587,BAO_0000019,,B,,,8932.0,,U
751,Autocuration,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,22226,Columba livia,7587,BAO_0000019,,B,,,8932.0,,U
752,Autocuration,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,22226,Columba livia,7587,BAO_0000019,,B,,,8932.0,,U
753,Autocuration,,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,10732,,11249,BAO_0000357,,B,,,,,H
754,Expert,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,12198,Rattus norvegicus,8003,BAO_0000019,,F,,,10116.0,,D
755,Expert,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,Rattus norvegicus,8003,BAO_0000019,,F,,,10116.0,,D
756,Expert,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,Rattus norvegicus,8003,BAO_0000019,,F,,,10116.0,,D
757,Expert,,Hippocampus,10000000.0,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,,12416,BAO_0000221,,B,,,,,H
758,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,51,,16293,BAO_0000357,,B,,,,,H
759,Autocuration,,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,Oryctolagus cuniculus,13047,BAO_0000019,,B,,,9986.0,,U
760,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,Oryctolagus cuniculus,13047,BAO_0000019,,B,,,9986.0,,U
761,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,22226,Oryctolagus cuniculus,13047,BAO_0000019,,B,,,9986.0,,U
762,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,22226,Oryctolagus cuniculus,13047,BAO_0000019,,B,,,9986.0,,U
763,Autocuration,,Hippocampus,10000000.0,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,10085,BAO_0000221,,B,,,,,H
764,Autocuration,,Hippocampus,10000000.0,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,10085,BAO_0000221,,B,,,,,H
765,Autocuration,,Hippocampus,10000000.0,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,10085,BAO_0000221,,B,,,,,H
766,Autocuration,Membranes,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,104744,,9841,BAO_0000249,,B,,,,,H
767,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,104744,Rattus norvegicus,8822,BAO_0000249,,B,,,10116.0,,D
768,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,104744,Rattus norvegicus,9806,BAO_0000019,,B,,,10116.0,,D
769,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,104744,Rattus norvegicus,9806,BAO_0000019,,B,,,10116.0,,D
770,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,104744,,8868,BAO_0000224,,B,,,,,H
771,Autocuration,,Hippocampus,10000000.0,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,104744,,9036,BAO_0000221,,B,,,,,H
772,Autocuration,,Hippocampus,10000000.0,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,104744,,11374,BAO_0000221,,B,,,,,H
773,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,104744,,10881,BAO_0000224,,B,,,,,H
774,Autocuration,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,104744,,8822,BAO_0000019,,B,,,,,H
775,Autocuration,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,104744,Rattus norvegicus,9806,BAO_0000249,,B,,,10116.0,,D
776,Autocuration,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,15463,BAO_0000019,,B,,,,,H
777,Autocuration,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,15463,BAO_0000019,,B,,,,,H
778,Autocuration,,Brain,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,14542,BAO_0000221,,B,,,,,H
779,Autocuration,,Brain,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,14542,BAO_0000221,,B,,,,,H
780,Autocuration,,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,104744,,8569,BAO_0000019,,B,,,,,H
781,Autocuration,,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,104744,Rattus norvegicus,10062,BAO_0000224,,B,,,10116.0,,D
782,Autocuration,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,104744,,4771,BAO_0000224,,B,,,,,H
783,Autocuration,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,10062,BAO_0000224,,B,,,,,H
784,Autocuration,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,10062,BAO_0000224,,B,,,,,H
785,Autocuration,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,10062,BAO_0000224,,B,,,,,H
786,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,,15463,BAO_0000019,,B,,,,,H
787,Autocuration,,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,,15463,BAO_0000019,,B,,,,,H
788,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,104744,,9098,BAO_0000224,,B,,,,,H
789,Autocuration,,,,Affinity for 5-hydroxytryptamine 1 receptor,22226,Rattus norvegicus,3070,BAO_0000019,,B,,,10116.0,,U
790,Autocuration,,Brain,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,104744,,14542,BAO_0000221,,B,,,,,H
791,Autocuration,,Brain,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,14542,BAO_0000221,,B,,,,,H
792,Autocuration,,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,104744,,6398,BAO_0000224,,B,,,,,H
793,Autocuration,,Brain,955.0,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,104744,,1344,BAO_0000221,,B,,,,,H
794,Autocuration,,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,11963,BAO_0000019,,B,,,,,H
795,Autocuration,,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,22226,Rattus norvegicus,8908,BAO_0000019,,B,,,10116.0,,U
796,Autocuration,,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,104744,,9098,BAO_0000019,,B,,,,,H
797,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,104744,Rattus norvegicus,8841,BAO_0000019,,B,,,10116.0,,D
798,Autocuration,,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,22226,Rattus norvegicus,8814,BAO_0000019,,B,,,10116.0,,U
799,Autocuration,,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,104744,,11752,BAO_0000019,,B,,,,,H
800,Autocuration,,Brain,955.0,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,104744,,11642,BAO_0000221,,B,,,,,H
801,Autocuration,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,104744,,11642,BAO_0000019,,B,,,,,H
802,Autocuration,,Brain,955.0,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,104744,,9231,BAO_0000220,,B,,,,,H
803,Autocuration,,Brain,955.0,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,104744,,11351,BAO_0000221,,B,,,,,H
804,Autocuration,,,,Compound was tested for binding affinity against 5-HT1 receptor,22226,,4639,BAO_0000019,,B,,,,,U
805,Autocuration,,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,22226,,1205,BAO_0000019,,B,,,,,U
806,Expert,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,,10025,BAO_0000357,,B,,,,,H
807,Autocuration,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,,13241,BAO_0000249,,F,,,,,H
808,Autocuration,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,,16245,BAO_0000218,,F,In vivo,,,,H
809,Autocuration,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,,16245,BAO_0000218,,F,In vivo,,,,H
810,Autocuration,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,10576,,12438,BAO_0000019,,F,,,,,H
811,Autocuration,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,,16245,BAO_0000218,,F,In vivo,,,,H
812,Autocuration,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,,16245,BAO_0000218,,F,In vivo,,,,H
813,Autocuration,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,10576,,15740,BAO_0000019,,F,,,,,H
814,Autocuration,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,10576,,15535,BAO_0000219,,F,,,,,H
815,Expert,,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,51,,15535,BAO_0000219,,F,,,,,H
816,Autocuration,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,10576,,15535,BAO_0000219,,F,,,,,H
817,Expert,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,10576,,9888,BAO_0000249,,B,,,,,H
818,Autocuration,,Hippocampus,10000000.0,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,10576,,10085,BAO_0000221,,B,,,,,H
819,Autocuration,,Hippocampus,10000000.0,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,10576,,10085,BAO_0000221,,B,,,,,H
820,Expert,Membranes,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,10576,,17331,BAO_0000249,,B,,,,,H
821,Expert,,Hippocampus,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10576,Rattus norvegicus,10845,BAO_0000221,,B,,,10116.0,,D
822,Expert,,Hippocampus,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,Rattus norvegicus,10845,BAO_0000221,,B,,,10116.0,,D
823,Expert,,Hippocampus,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,10576,,10845,BAO_0000221,,B,,,,,H
824,Expert,,Hippocampus,10000000.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10576,Rattus norvegicus,10845,BAO_0000221,,B,,,10116.0,,D
825,Expert,,Hippocampus,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,Rattus norvegicus,10845,BAO_0000221,,B,,,10116.0,,D
826,Expert,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,10576,,13730,BAO_0000357,,B,,,,,H
827,Expert,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,10576,,13508,BAO_0000249,,B,,,,,H
828,Expert,,Hippocampus,10000000.0,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,10576,,13508,BAO_0000249,,B,,,,,H
829,Expert,,Hippocampus,10000000.0,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,12073,BAO_0000221,,B,,,,,H
830,Autocuration,,Hippocampus,10000000.0,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,10576,,4671,BAO_0000221,,B,,,,,H
831,Expert,,Hippocampus,10000000.0,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,10576,,13631,BAO_0000221,,B,,,,,H
832,Autocuration,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,10576,,12438,BAO_0000357,,B,,,,,H
833,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,10576,,10483,BAO_0000019,,B,,,,,H
834,Autocuration,,Hippocampus,10000000.0,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,10576,,10483,BAO_0000221,,B,,,,,H
835,Intermediate,,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,10576,,12352,BAO_0000249,,B,,,,,H
836,Autocuration,,Hippocampus,10000000.0,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,10576,,14732,BAO_0000249,,B,,,,,H
837,Expert,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,10576,Rattus norvegicus,11049,BAO_0000019,,B,,,10116.0,,D
838,Expert,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,10576,Rattus norvegicus,11049,BAO_0000019,,B,,,10116.0,,D
839,Expert,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",10576,,13657,BAO_0000249,,B,,,,,H
840,Autocuration,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,10576,,11473,BAO_0000019,,B,,,,,H
841,Autocuration,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,,2014,BAO_0000249,,B,,,,,H
842,Expert,,Hippocampus,10000000.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,3086,BAO_0000221,,B,,,,,H
843,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10576,,15854,BAO_0000019,,B,,,,,H
844,Expert,,Hippocampus,10000000.0,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,,10922,BAO_0000221,,B,,,,,H
845,Expert,,Hippocampus,10000000.0,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,10576,,13346,BAO_0000221,,B,,,,,H
846,Expert,,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,10576,,15311,BAO_0000357,,B,,,,,H
847,Autocuration,,Hippocampus,10000000.0,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,,10922,BAO_0000221,,B,,,,,H
848,Autocuration,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,10576,,10025,BAO_0000357,,B,,,,,H
849,Expert,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,,10025,BAO_0000357,,B,,,,,H
850,Autocuration,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,9742,BAO_0000019,,B,,,,,H
851,Autocuration,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,9742,BAO_0000019,,F,,,,,H
852,Expert,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,12304,BAO_0000019,,B,,,,,H
853,Autocuration,,Hippocampus,10000000.0,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,10576,,15789,BAO_0000221,,B,,,,,H
854,Autocuration,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",10576,,9912,BAO_0000019,,B,,,,,H
855,Autocuration,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",10576,,9912,BAO_0000019,,B,,,,,H
856,Autocuration,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",10576,,9912,BAO_0000019,,B,,,,,H
857,Expert,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,,16693,BAO_0000019,,B,,,,,H
858,Expert,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,13276,BAO_0000357,,B,,,,,H
859,Autocuration,,Hippocampus,10000000.0,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,,12678,BAO_0000221,,B,,,,,H
860,Autocuration,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,10576,,11825,BAO_0000357,,B,,,,,H
861,Expert,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,10576,,12443,BAO_0000357,,B,,,,,H
862,Expert,,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,,13830,BAO_0000357,,B,,,,,H
863,Expert,,Hippocampus,10000000.0,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,10576,,14286,BAO_0000249,,B,,,,,H
864,Expert,,Hippocampus,10000000.0,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,Rattus norvegicus,14356,BAO_0000221,,B,,,10116.0,,D
865,Autocuration,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,10576,,15306,BAO_0000357,,B,,,,,H
866,Expert,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),10576,,15306,BAO_0000357,,B,,,,,H
867,Expert,,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,Rattus norvegicus,16616,BAO_0000249,,F,,,10116.0,,D
868,Autocuration,,Hippocampus,10000000.0,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",10576,,3651,BAO_0000221,,B,,,,,H
869,Autocuration,,Hippocampus,10000000.0,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,14331,BAO_0000221,,F,,,,,H
870,Autocuration,,Hippocampus,10000000.0,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,14331,BAO_0000221,,F,,,,,H
871,Expert,,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,10576,Rattus norvegicus,14178,BAO_0000357,,B,,,10116.0,,D
872,Expert,,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,10576,Rattus norvegicus,10639,BAO_0000019,,B,,,10116.0,,D
873,Autocuration,,Hippocampus,10000000.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,12306,BAO_0000221,,B,,,,,H
874,Expert,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,10576,Rattus norvegicus,1348,BAO_0000357,,B,,,10116.0,,D
875,Autocuration,,Hippocampus,10000000.0,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,10576,,13605,BAO_0000221,,B,,,,,H
876,Autocuration,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,17624,BAO_0000219,,B,,,,CHO,H
877,Autocuration,,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,17624,BAO_0000219,,F,,,,CHO,H
878,Autocuration,,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,17624,BAO_0000219,,F,,,,CHO,H
879,Autocuration,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,,15267,BAO_0000357,,B,,,,,H
880,Autocuration,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,51,,16532,BAO_0000357,,B,,,,,H
881,Autocuration,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,6563,BAO_0000019,,F,,,,,H
882,Autocuration,,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,51,,4751,BAO_0000219,,B,,,,CHO,H
883,Autocuration,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,51,,15463,BAO_0000357,,B,,,,,H
884,Autocuration,,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),51,,3805,BAO_0000357,,B,,,,,H
885,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,5640,BAO_0000357,,B,,,,,H
886,Autocuration,,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,51,,6563,BAO_0000357,,B,,,,,H
887,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,51,,5548,BAO_0000357,,B,,,,,H
888,Autocuration,,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,51,,6347,BAO_0000357,,B,,,,,H
889,Autocuration,,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,17296,BAO_0000219,,F,,,,HEK293,H
890,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,51,,13047,BAO_0000019,,B,,,,,H
891,Autocuration,,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,51,,15740,BAO_0000357,,B,,,,,H
892,Expert,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,,5640,BAO_0000019,,F,,,,,H
893,Autocuration,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",51,,5640,BAO_0000019,,F,,,,,H
894,Expert,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,51,,17211,BAO_0000219,,B,,,,HeLa,H
895,Autocuration,,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,51,,4751,BAO_0000219,,B,,,,CHO,H
896,Expert,,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,51,Homo sapiens,6491,BAO_0000357,,B,,,9606.0,,D
897,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,51,,4707,BAO_0000357,,B,,,,,H
898,Expert,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,51,Homo sapiens,13910,BAO_0000357,,B,,,9606.0,,D
899,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,51,,16190,BAO_0000219,,B,,,,HeLa,H
900,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,16633,BAO_0000357,,B,,,,,H
901,Autocuration,,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,51,,11898,BAO_0000219,,B,,,,CHO,H
902,Autocuration,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,11898,BAO_0000219,,B,,,,CHO,H
903,Autocuration,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,51,,14331,BAO_0000357,,B,,,,,H
904,Expert,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,51,,17624,BAO_0000219,,B,,,,CHO,H
905,Autocuration,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,51,,17624,BAO_0000219,,B,,,,CHO,H
906,Autocuration,,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,51,,3307,BAO_0000357,,B,,,,,H
907,Expert,,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,Homo sapiens,6563,BAO_0000219,,B,,,9606.0,CHO,D
908,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,51,,14165,BAO_0000019,,B,,,,,H
909,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,,5732,BAO_0000357,,B,,,,,H
910,Expert,,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,,13366,BAO_0000357,,B,,,,,H
911,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,51,,17626,BAO_0000357,,B,,,,,H
912,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,51,,6588,BAO_0000219,,B,,,,HeLa,H
913,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,51,,16209,BAO_0000357,,B,,,,,H
914,Autocuration,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,,15463,BAO_0000357,,B,,,,,H
915,Autocuration,,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,,15463,BAO_0000357,,B,,,,,H
916,Autocuration,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,51,,14770,BAO_0000357,,B,,,,,H
917,Autocuration,,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),51,,16245,BAO_0000219,,B,,,,Cell line,H
918,Autocuration,,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),51,,16245,BAO_0000019,,B,,,,,H
919,Autocuration,,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,51,,5548,BAO_0000357,,B,,,,,H
920,Expert,,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,5548,BAO_0000357,,B,,,,,H
921,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,5548,BAO_0000357,,B,,,,,H
922,Expert,,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,51,,6876,BAO_0000357,,B,,,,,H
923,Autocuration,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,2598,BAO_0000357,,B,,,,,H
924,Expert,,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,51,,17785,BAO_0000357,,B,,,,,H
925,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,6013,BAO_0000357,,B,,,,,H
926,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,,5929,BAO_0000357,,B,,,,,H
927,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,16633,BAO_0000357,,B,,,,,H
928,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,,1558,BAO_0000357,,B,,,,,H
929,Expert,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,16026,BAO_0000357,,B,,,,,H
930,Autocuration,,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,51,,12469,BAO_0000219,,B,,,,,H
931,Expert,,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,Homo sapiens,15874,BAO_0000357,,B,,,9606.0,,D
932,Autocuration,,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,,15874,BAO_0000357,,B,,,,,H
933,Autocuration,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,51,,3935,BAO_0000357,,B,,,,,H
934,Autocuration,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,51,,15818,BAO_0000357,,B,,,,,H
935,Autocuration,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,51,,13706,BAO_0000219,,B,,,,CHO-K1,H
936,Expert,,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,51,,13729,BAO_0000219,,F,,,,CHO-K1,H
937,Autocuration,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,51,,15413,BAO_0000019,,B,,,,,H
938,Autocuration,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),51,,15413,BAO_0000019,,B,,,,,H
939,Autocuration,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),51,,15413,BAO_0000019,,B,,,,,H
940,Autocuration,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,51,,15413,BAO_0000019,,B,,,,,H
941,Expert,,,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,Homo sapiens,3445,BAO_0000219,,B,,,9606.0,HeLa,D
942,Autocuration,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,,15740,BAO_0000357,,B,,,,,H
943,Autocuration,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,51,,15740,BAO_0000357,,B,,,,,H
944,Autocuration,,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,51,,17626,BAO_0000357,,B,,,,,H
945,Expert,,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,51,Homo sapiens,4234,BAO_0000357,,B,,,9606.0,,D
946,Expert,,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,,5640,BAO_0000357,,B,,,,,H
947,Expert,,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,51,Rattus norvegicus,5272,BAO_0000357,,B,,,10116.0,,H
948,Autocuration,,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,51,,4622,BAO_0000219,,B,,,,CHO,H
949,Expert,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,51,,17085,BAO_0000019,,B,,,,,H
950,Autocuration,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,,3025,BAO_0000357,,B,,,,,H
951,Expert,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,,15315,BAO_0000357,,B,,,,,H
952,Autocuration,,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,51,,15267,BAO_0000357,,B,,,,,H
953,Autocuration,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,51,,17158,BAO_0000219,,B,,,,HeLa,H
954,Expert,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,51,Homo sapiens,14214,BAO_0000219,,B,,,9606.0,HeLa,D
955,Autocuration,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,17133,BAO_0000357,,B,,,,,H
956,Autocuration,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,51,,16532,BAO_0000357,,B,,,,,H
957,Expert,,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,51,Homo sapiens,2391,BAO_0000357,,B,,,9606.0,,D
958,Autocuration,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,51,,14447,BAO_0000019,,B,,,,,H
959,Autocuration,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,51,,14447,BAO_0000019,,B,,,,,H
960,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,51,,15086,BAO_0000357,,B,,,,,H
961,Expert,,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,Homo sapiens,13051,BAO_0000357,,B,,,9606.0,,D
962,Autocuration,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",51,,16026,BAO_0000019,,F,,,,,H
963,Expert,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,51,,17085,BAO_0000019,,B,,,,,H
964,Autocuration,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,17133,BAO_0000357,,B,,,,,H
965,Autocuration,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,51,,17133,BAO_0000357,,B,,,,,H
966,Autocuration,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,17211,BAO_0000219,,B,,,,HeLa,H
967,Autocuration,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,51,,17211,BAO_0000219,,B,,,,HeLa,H
968,Autocuration,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,17211,BAO_0000219,,B,,,,HeLa,H
969,Autocuration,,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,17211,BAO_0000219,,B,,,,HeLa,H
970,Autocuration,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,16394,BAO_0000019,,F,,,,,H
971,Autocuration,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,16394,BAO_0000019,,F,,,,,H
972,Autocuration,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,16394,BAO_0000019,,F,,,,,H
973,Autocuration,,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,51,,16394,BAO_0000218,,F,In vivo,,,,H
974,Autocuration,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,51,,16394,BAO_0000019,,B,,,,,H
975,Autocuration,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,51,,15740,BAO_0000019,,F,,,,,H
976,Autocuration,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,51,,15740,BAO_0000019,,F,,,,,H
977,Autocuration,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,,15740,BAO_0000357,,B,,,,,H
978,Autocuration,,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,17296,BAO_0000219,,F,,,,HEK293,H
979,Expert,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",51,,5640,BAO_0000019,,F,,,,,H
980,Autocuration,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",51,,5640,BAO_0000019,,F,,,,,H
981,Autocuration,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",51,,5640,BAO_0000019,,F,,,,,H
982,Autocuration,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",51,,5640,BAO_0000019,,F,,,,,H
983,Autocuration,,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,2759,BAO_0000219,,F,,,,CHO,H
984,Autocuration,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",51,,16394,BAO_0000019,,F,,,,,H
985,Expert,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",51,Homo sapiens,16394,BAO_0000019,,F,,,9606.0,,D
986,Expert,,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,51,Homo sapiens,3445,BAO_0000019,,F,,,9606.0,,D
987,Expert,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,51,,4316,BAO_0000219,,B,,,,CHO,H
988,Expert,,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,51,,4316,BAO_0000019,,B,,,,,H
989,Expert,,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,Homo sapiens,15180,BAO_0000019,,F,,,9606.0,,D
990,Expert,,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,Homo sapiens,15180,BAO_0000019,,F,,,9606.0,,D
991,Autocuration,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,15042,BAO_0000019,,F,,,,,H
992,Autocuration,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,15042,BAO_0000019,,F,,,,,H
993,Autocuration,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,,15042,BAO_0000019,,F,,,,,H
994,Autocuration,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,15042,BAO_0000019,,F,,,,,H
995,Autocuration,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,15042,BAO_0000019,,F,,,,,H
996,Autocuration,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,15042,BAO_0000019,,F,,,,,H
997,Autocuration,,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,,15042,BAO_0000019,,F,,,,,H
998,Expert,,,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,Homo sapiens,15180,BAO_0000219,,F,,,9606.0,HeLa,D
999,Expert,,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,Homo sapiens,15180,BAO_0000219,,F,,,9606.0,HeLa,D
1000,Expert,,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,Homo sapiens,15180,BAO_0000219,,F,,,9606.0,HeLa,D
1001,Autocuration,,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",51,,16245,BAO_0000019,,F,,,,,H
1002,Autocuration,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,16026,BAO_0000019,,F,,,,,H
1003,Autocuration,,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,17296,BAO_0000219,,F,,,,HEK293,H
1004,Autocuration,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,,2759,BAO_0000219,,F,,,,CHO,H
1005,Autocuration,,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,,2759,BAO_0000219,,F,,,,CHO,H
1006,Expert,,,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),51,Homo sapiens,2759,BAO_0000219,,F,,,9606.0,CHO,D
1007,Autocuration,,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,,2759,BAO_0000219,,F,,,,CHO,H
1008,Expert,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,51,,15419,BAO_0000219,,F,,,,,H
1009,Autocuration,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,51,,15419,BAO_0000219,,F,,,,,H
1010,Autocuration,,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,16026,BAO_0000019,,F,,,,,H
1011,Expert,,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,51,,1414,BAO_0000219,,B,In vitro,,,,H
1012,Expert,,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,51,,1414,BAO_0000219,,B,In vitro,,,,H
1013,Autocuration,,,,Binding activity radioligand.,51,,12861,BAO_0000357,,B,,,,,H
1014,Autocuration,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,51,,12861,BAO_0000019,,B,,,,,H
1015,Autocuration,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,,5104,BAO_0000357,,B,,,,,H
1016,Autocuration,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,,5105,BAO_0000357,,B,,,,,H
1017,Autocuration,,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,51,,16312,BAO_0000357,,B,,,,,H
1018,Expert,,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,51,Homo sapiens,15180,BAO_0000357,,B,,,9606.0,,D
1019,Autocuration,,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,51,,5033,BAO_0000357,,B,,,,,H
1020,Expert,,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,Homo sapiens,16909,BAO_0000219,,B,,,9606.0,CHO,D
1021,Autocuration,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,51,,2590,BAO_0000019,,F,,,,,H
1022,Autocuration,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,,2590,BAO_0000019,,F,,,,,H
1023,Expert,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,51,,16394,BAO_0000019,,B,,,,,H
1024,Expert,,,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,51,Homo sapiens,4540,BAO_0000219,,B,,,9606.0,HEK293,D
1025,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,51,,17296,BAO_0000219,,B,,,,HEK293,H
1026,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,51,,17296,BAO_0000219,,B,,,,HEK293,H
1027,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,,15779,BAO_0000219,,B,,,,HEK293,H
1028,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,51,,15779,BAO_0000219,,B,,,,HEK293,H
1029,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,51,,15779,BAO_0000219,,B,,,,HEK293,H
1030,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,,6166,BAO_0000357,,B,,,,,H
1031,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,,15779,BAO_0000219,,B,,,,HEK293,H
1032,Autocuration,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,51,,4199,BAO_0000219,,B,,,,HEK293,H
1033,Autocuration,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,51,,15316,BAO_0000219,,B,,,,,H
1034,Autocuration,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,51,,14875,BAO_0000357,,B,,,,,H
1035,Expert,,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,,14727,BAO_0000219,,B,,,,HeLa,H
1036,Expert,,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,,14727,BAO_0000019,,B,,,,,H
1037,Autocuration,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,51,,15146,BAO_0000219,,B,,,,HEK293,H
1038,Autocuration,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,51,,5213,BAO_0000219,,B,,,,HEK293,H
1039,Autocuration,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,51,,16429,BAO_0000219,,B,,,,,H
1040,Expert,,,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,51,Homo sapiens,15042,BAO_0000219,,B,,,9606.0,HeLa,D
1041,Autocuration,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,51,,14818,BAO_0000219,,B,,,,HEK293,H
1042,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",51,,4829,BAO_0000219,,B,,,,HEK293,H
1043,Expert,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,,17200,BAO_0000357,,B,,,,,D
1044,Autocuration,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,51,Homo sapiens,13051,BAO_0000357,,B,,,9606.0,,D
1045,Autocuration,,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,106,,5486,BAO_0000357,,B,,,,,H
1046,Autocuration,,,,Binding affinity against 5-HT1D receptor,105,,5254,BAO_0000357,,B,,,,,H
1047,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,105,,5254,BAO_0000357,,B,,,,,H
1048,Autocuration,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,107,,15331,BAO_0000357,,B,,,,,H
1049,Autocuration,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,Homo sapiens,13506,BAO_0000357,,B,,,9606.0,,H
1050,Autocuration,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,,15267,BAO_0000357,,B,,,,,H
1051,Autocuration,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,11863,,16616,BAO_0000218,,F,In vivo,,,,H
1052,Autocuration,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,11863,,16616,BAO_0000218,,F,In vivo,,,,H
1053,Autocuration,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,11863,,16616,BAO_0000218,,F,In vivo,,,,H
1054,Expert,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,11863,Mus musculus,16616,BAO_0000218,,F,,,10090.0,,D
1055,Expert,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,11863,Mus musculus,16616,BAO_0000218,,F,,,10090.0,,D
1056,Expert,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,11863,Mus musculus,16616,BAO_0000218,,F,,,10090.0,,D
1057,Expert,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,11863,Mus musculus,16616,BAO_0000218,,F,,,10090.0,,D
1058,Expert,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,11863,Mus musculus,16616,BAO_0000218,,F,,,10090.0,,D
1059,Expert,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,11863,Mus musculus,16616,BAO_0000218,,F,,,10090.0,,D
1060,Autocuration,,Hippocampus,10000000.0,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,,10297,BAO_0000221,,B,,,,,H
1061,Expert,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,11863,,13704,BAO_0000357,,B,,,,,H
1062,Expert,,Hippocampus,10000000.0,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,Mus musculus,10297,BAO_0000221,,B,,,10090.0,,D
1063,Autocuration,,Hippocampus,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,,10297,BAO_0000221,,B,,,,,H
1064,Expert,,Hippocampus,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,Mus musculus,10297,BAO_0000221,,B,,,10090.0,,D
1065,Autocuration,,Hippocampus,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,,10297,BAO_0000221,,B,,,,,H
1066,Autocuration,,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,11863,,217,BAO_0000357,,B,,,,,H
1067,Expert,,Hippocampus,10000000.0,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,Mus musculus,10297,BAO_0000221,,B,,,10090.0,,D
1068,Autocuration,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,51,Sus scrofa,4921,BAO_0000357,,B,,,9823.0,,H
1069,Autocuration,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,51,Sus scrofa,4921,BAO_0000357,,B,,,9823.0,,H
1070,Autocuration,,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,51,Sus scrofa,4996,BAO_0000019,,B,,,9823.0,,H
1071,Autocuration,,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,51,Sus scrofa,12918,BAO_0000357,,B,,,9823.0,,H
1072,Autocuration,,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,Sus scrofa,5333,BAO_0000019,,B,,,9823.0,,H
1073,Autocuration,,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,Sus scrofa,4437,BAO_0000019,,B,,,9823.0,,H
1074,Autocuration,,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,51,Sus scrofa,1742,BAO_0000019,,B,,,9823.0,,H
1075,Expert,,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,51,Sus scrofa,16688,BAO_0000357,,B,,,9823.0,,H
1076,Autocuration,,,,Binding activity radioligand.,51,Sus scrofa,12861,BAO_0000357,,B,,,9823.0,,H
1077,Expert,,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,Sus scrofa,12861,BAO_0000019,,B,,,9823.0,,H
1078,Autocuration,,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,Sus scrofa,12861,BAO_0000019,,B,,,9823.0,,H
1079,Expert,,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,10624,,12490,BAO_0000019,,B,,,,,H
1080,Expert,,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,51,Sus scrofa,11828,BAO_0000019,,B,,,9823.0,,H
1081,Autocuration,,Hippocampus,10000000.0,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,51,Sus scrofa,11866,BAO_0000221,,B,,,9823.0,,H
1082,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,51,Sus scrofa,12827,BAO_0000249,,B,,,9823.0,,H
1083,Autocuration,,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,51,Sus scrofa,12918,BAO_0000019,,B,,,9823.0,,H
1084,Expert,,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,51,Sus scrofa,12919,BAO_0000019,,F,,,9823.0,,H
1085,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,51,Oryctolagus cuniculus,13047,BAO_0000019,,B,,,9986.0,,H
1086,Expert,,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,10576,Rattus norvegicus,15796,BAO_0000249,,B,,,10116.0,,D
1087,Expert,,Hippocampus,10000000.0,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",10576,Rattus norvegicus,3651,BAO_0000221,,B,,,10116.0,,D
1088,Autocuration,,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,10576,,188,BAO_0000357,,B,,,,,H
1089,Expert,Membranes,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,Rattus norvegicus,16616,BAO_0000249,,F,,,10116.0,,D
1090,Expert,Membranes,Hippocampus,10000000.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,Rattus norvegicus,16616,BAO_0000249,,F,,,10116.0,,D
1091,Autocuration,,Hippocampus,10000000.0,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,12306,BAO_0000221,,B,,,,,H
1092,Expert,,Hippocampus,10000000.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,10576,Rattus norvegicus,17167,BAO_0000221,,B,,,10116.0,,D
1093,Autocuration,,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,10576,,14776,BAO_0000019,,B,,,,,H
1094,Expert,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,10576,,12158,BAO_0000357,,B,,,,,H
1095,Autocuration,,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,10576,,13481,BAO_0000357,,B,,,,,H
1096,Autocuration,,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,10576,,13427,BAO_0000219,,B,In vitro,,,,H
1097,Autocuration,,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,10576,,10210,BAO_0000357,,B,,,,,H
1098,Autocuration,Membranes,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,,10205,BAO_0000249,,B,,,,,H
1099,Autocuration,Membranes,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,,10205,BAO_0000249,,B,,,,,H
1100,Expert,Membranes,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,10576,,10205,BAO_0000249,,B,,,,,H
1101,Expert,,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,10576,Rattus norvegicus,12280,BAO_0000357,,B,,,10116.0,,D
1102,Expert,,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,10576,,17386,BAO_0000357,,B,,,,,H
1103,Expert,,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,10576,,13654,BAO_0000357,,B,,,,,H
1104,Autocuration,,Hippocampus,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,10576,,14423,BAO_0000221,,B,,,,,H
1105,Autocuration,,Hippocampus,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,10576,,15412,BAO_0000221,,B,,,,,H
1106,Autocuration,,Hippocampus,10000000.0,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,12073,BAO_0000221,,B,,,,,H
1107,Expert,,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,10576,Rattus norvegicus,4101,BAO_0000357,,B,,,10116.0,,D
1108,Autocuration,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,10576,,10062,BAO_0000357,,B,,,,,H
1109,Autocuration,,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,10576,,6238,BAO_0000249,,B,,,,,H
1110,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,16273,BAO_0000357,,B,,,,,H
1111,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,10576,,11139,BAO_0000357,,B,,,,,H
1112,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,,16796,BAO_0000019,,B,,,,,H
1113,Expert,,Brain,955.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,Rattus norvegicus,9548,BAO_0000221,,B,,,10116.0,,D
1114,Autocuration,,Brain,955.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,10381,BAO_0000221,,B,,,,,H
1115,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,10576,,13408,BAO_0000249,,B,,,,,H
1116,Expert,,Hippocampus,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,10576,Rattus norvegicus,13825,BAO_0000221,,B,,,10116.0,,D
1117,Expert,,Hippocampus,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,10576,,11147,BAO_0000221,,B,,,,,H
1118,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,10576,,10552,BAO_0000249,,B,,,,,H
1119,Autocuration,,Striatum,2435.0,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,,10552,BAO_0000249,,B,,,,,H
1120,Expert,Membranes,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,10576,Rattus norvegicus,17136,BAO_0000249,,B,,,10116.0,,D
1121,Expert,Membranes,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,10576,Rattus norvegicus,5778,BAO_0000249,,B,,,10116.0,,D
1122,Autocuration,,Hippocampus,10000000.0,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,10576,,13481,BAO_0000221,,B,,,,,H
1123,Autocuration,,Hippocampus,10000000.0,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,10576,,13481,BAO_0000221,,B,,,,,H
1124,Intermediate,,Hippocampus,10000000.0,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,10576,,13630,BAO_0000221,,B,,,,,H
1125,Expert,,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,,16245,BAO_0000249,,B,,,,,H
1126,Autocuration,,Hippocampus,10000000.0,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,14509,BAO_0000221,,B,,,,,H
1127,Expert,,Hippocampus,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,,14509,BAO_0000221,,B,,,,,H
1128,Autocuration,,Hippocampus,10000000.0,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,10576,,14509,BAO_0000221,,B,,,,,H
1129,Autocuration,,Hippocampus,10000000.0,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,10576,,14509,BAO_0000221,,B,,,,,H
1130,Expert,,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,10576,,14256,BAO_0000019,,B,,,,,H
1131,Autocuration,,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,10576,,11139,BAO_0000357,,B,,,,,H
1132,Expert,,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,10576,Rattus norvegicus,11047,BAO_0000019,,B,,,10116.0,,D
1133,Expert,,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,10576,Rattus norvegicus,11047,BAO_0000019,,B,,,10116.0,,D
1134,Expert,,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,10576,Rattus norvegicus,11047,BAO_0000019,,B,,,10116.0,,D
1135,Expert,,,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,Rattus norvegicus,2395,BAO_0000219,,B,,,10116.0,CHO-K1,D
1136,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,9699,BAO_0000357,,B,,,,,H
1137,Expert,,Hippocampus,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,10576,Rattus norvegicus,12028,BAO_0000221,,B,,,10116.0,,D
1138,Autocuration,,Hippocampus,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,10576,,12028,BAO_0000221,,B,,,,,H
1139,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,5815,BAO_0000019,,B,,,,,H
1140,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,10576,,16616,BAO_0000019,,B,,,,,H
1141,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,10576,,5815,BAO_0000019,,B,,,,,H
1142,Autocuration,,Hippocampus,10000000.0,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",10576,,2761,BAO_0000221,,B,,,,,H
1143,Expert,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,10576,,13133,BAO_0000357,,B,,,,,H
1144,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,10576,,10444,BAO_0000019,,B,,,,,H
1145,Expert,,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,10576,Rattus norvegicus,13278,BAO_0000357,,B,,,10116.0,,D
1146,Autocuration,,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,10576,,15874,BAO_0000357,,B,,,,,H
1147,Autocuration,Membranes,Striatum,2435.0,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,,10552,BAO_0000249,,B,,,,,H
1148,Autocuration,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),10576,,11130,BAO_0000357,,B,,,,,H
1149,Autocuration,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),10576,,11130,BAO_0000218,,B,In vivo,,,,H
1150,Autocuration,,Brain,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,10576,,14542,BAO_0000221,,B,,,,,H
1151,Expert,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,Rattus norvegicus,13670,BAO_0000357,,B,,,10116.0,,D
1152,Expert,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,10576,,9888,BAO_0000249,,B,,,,,H
1153,Expert,Membranes,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,10576,Rattus norvegicus,3678,BAO_0000249,,B,,,10116.0,,D
1154,Autocuration,,Hippocampus,10000000.0,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,11332,BAO_0000221,,B,,,,,H
1155,Autocuration,,Hippocampus,10000000.0,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,11332,BAO_0000221,,B,,,,,H
1156,Expert,,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,,1185,BAO_0000357,,B,,,,,H
1157,Expert,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,10576,,2014,BAO_0000249,,B,,,,,H
1158,Autocuration,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,,1185,BAO_0000357,,B,,,,,H
1159,Expert,,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,10576,,14429,BAO_0000019,,B,,,,,H
1160,Expert,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",10576,,16288,BAO_0000019,,B,,,,,H
1161,Expert,,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,10576,Rattus norvegicus,5432,BAO_0000019,,B,,,10116.0,,D
1162,Autocuration,,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,10576,,14429,BAO_0000019,,B,,,,,H
1163,Expert,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,10576,,13672,BAO_0000357,,B,,,,,H
1164,Expert,,Hippocampus,10000000.0,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,11296,BAO_0000221,,B,,,,,H
1165,Autocuration,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,10576,,11296,BAO_0000357,,B,,,,,H
1166,Expert,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,10576,,14749,BAO_0000219,,B,,,,CHO,H
1167,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,10576,,15086,BAO_0000019,,B,,,,,H
1168,Autocuration,,Hippocampus,10000000.0,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,10576,,13462,BAO_0000221,,B,,,,,H
1169,Autocuration,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,,15363,BAO_0000019,,B,,,,,H
1170,Autocuration,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,,15363,BAO_0000019,,B,,,,,H
1171,Autocuration,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,10576,,10796,BAO_0000357,,B,,,,,H
1172,Expert,,Brain,955.0,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,10576,,12816,BAO_0000221,,B,,,,,H
1173,Expert,,Hippocampus,10000000.0,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,13542,BAO_0000221,,B,,,,,H
1174,Expert,,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,10576,,13308,BAO_0000019,,B,,,,,H
1175,Expert,,Hippocampus,10000000.0,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,10576,,13541,BAO_0000221,,B,,,,,H
1176,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,10576,,10058,BAO_0000221,,B,,,,,H
1177,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,,10058,BAO_0000221,,B,,,,,H
1178,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,10576,,10058,BAO_0000221,,B,,,,,H
1179,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,10576,,10058,BAO_0000221,,B,,,,,H
1180,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,10576,,10058,BAO_0000221,,B,,,,,H
1181,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,10576,,10058,BAO_0000221,,B,,,,,H
1182,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,10576,,10058,BAO_0000221,,B,,,,,H
1183,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,10576,,10058,BAO_0000221,,B,,,,,H
1184,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,10576,,10058,BAO_0000221,,B,,,,,H
1185,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,10576,,10058,BAO_0000221,,B,,,,,H
1186,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,10576,,10058,BAO_0000221,,B,,,,,H
1187,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,10576,,10058,BAO_0000221,,B,,,,,H
1188,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,10576,,10058,BAO_0000221,,B,,,,,H
1189,Expert,,Hippocampus,10000000.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,Rattus norvegicus,10058,BAO_0000221,,B,,,10116.0,,D
1190,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,10576,,10058,BAO_0000221,,B,,,,,H
1191,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,10576,,10058,BAO_0000221,,B,,,,,H
1192,Expert,,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,10576,,12879,BAO_0000019,,B,,,,,H
1193,Expert,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,10576,,11964,BAO_0000019,,B,,,,,H
1194,Autocuration,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),10576,,11964,BAO_0000019,,B,,,,,H
1195,Autocuration,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),10576,,11964,BAO_0000019,,B,,,,,H
1196,Expert,,Brain,955.0,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,9548,BAO_0000221,,B,,,,,H
1197,Expert,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,10576,,9098,BAO_0000019,,B,,,,,H
1198,Autocuration,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,10576,,9098,BAO_0000019,,B,,,,,H
1199,Autocuration,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,10576,,9098,BAO_0000019,,B,,,,,H
1200,Expert,,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,10576,,13248,BAO_0000219,,B,,,,CHO,H
1201,Expert,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,10576,,3147,BAO_0000249,,B,,,,,H
1202,Expert,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,,13949,BAO_0000019,,B,,,,,H
1203,Autocuration,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),10576,,11883,BAO_0000218,,B,,,,CHO,H
1204,Autocuration,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),10576,,11883,BAO_0000218,,B,,,,,H
1205,Expert,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,10576,Rattus norvegicus,11883,BAO_0000357,,B,,,10116.0,,D
1206,Expert,Membranes,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,,15535,BAO_0000249,,B,,,,,H
1207,Autocuration,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,10576,,15535,BAO_0000249,,B,,,,,H
1208,Autocuration,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,10576,,15535,BAO_0000249,,B,,,,,H
1209,Expert,,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,Homo sapiens,16372,BAO_0000219,,B,,,9606.0,CHO,D
1210,Expert,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,10576,,14608,BAO_0000249,,B,,,,,H
1211,Expert,,Hippocampus,10000000.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,Rattus norvegicus,4795,BAO_0000221,,B,,,10116.0,,D
1212,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,,13863,BAO_0000357,,B,,,,,H
1213,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,10576,,13863,BAO_0000357,,B,,,,,H
1214,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,10576,,13863,BAO_0000357,,B,,,,,H
1215,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,10576,,13863,BAO_0000357,,B,,,,,H
1216,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,10576,,13863,BAO_0000357,,B,,,,,H
1217,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,10576,,13863,BAO_0000357,,B,,,,,H
1218,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,10576,,13863,BAO_0000357,,B,,,,,H
1219,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,10576,,13863,BAO_0000357,,B,,,,,H
1220,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,10576,,13863,BAO_0000357,,B,,,,,H
1221,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,10576,,13863,BAO_0000357,,B,,,,,H
1222,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,10576,,13863,BAO_0000357,,B,,,,,H
1223,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,10576,,13863,BAO_0000357,,B,,,,,H
1224,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,10576,,13863,BAO_0000357,,B,,,,,H
1225,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,10576,,13863,BAO_0000357,,B,,,,,H
1226,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,10576,,13863,BAO_0000357,,B,,,,,H
1227,Autocuration,,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,9742,BAO_0000019,,B,,,,,H
1228,Autocuration,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,10576,,12073,BAO_0000357,,B,,,,,H
1229,Autocuration,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,10576,,4101,BAO_0000357,,B,,,,,H
1230,Autocuration,,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,10576,,15360,BAO_0000019,,B,,,,,H
1231,Autocuration,,Hippocampus,10000000.0,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,11576,BAO_0000221,,B,,,,,H
1232,Expert,,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,10576,,5834,BAO_0000019,,B,,,,,H
1233,Expert,,,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,Rattus norvegicus,2395,BAO_0000219,,B,,,10116.0,CHO-K1,D
1234,Autocuration,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,10576,,1375,BAO_0000019,,B,,,,,H
1235,Autocuration,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,10576,,1375,BAO_0000019,,B,,,,,H
1236,Autocuration,,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),10576,,3967,BAO_0000357,,B,,,,,H
1237,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,10576,,12884,BAO_0000357,,B,,,,,H
1238,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,10576,,2343,BAO_0000357,,B,,,,,H
1239,Autocuration,,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,,11511,BAO_0000019,,B,,,,,H
1240,Expert,,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,Rattus norvegicus,11511,BAO_0000019,,B,,,10116.0,,D
1241,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,10576,,16394,BAO_0000218,,F,In vivo,,,,H
1242,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1243,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1244,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1245,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1246,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1247,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1248,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1249,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1250,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1251,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1252,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1253,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1254,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),10576,,16394,BAO_0000218,,F,In vivo,,,,H
1255,Autocuration,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,10576,,16394,BAO_0000218,,F,In vivo,,,,H
1256,Expert,Membranes,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,Rattus norvegicus,16616,BAO_0000249,,F,,,10116.0,,D
1257,Autocuration,,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,10576,,16796,BAO_0000019,,B,,,,,H
1258,Autocuration,,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,,16796,BAO_0000019,,B,,,,,H
1259,Autocuration,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,10576,,15629,BAO_0000357,,B,,,,,H
1260,Autocuration,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,,13241,BAO_0000249,,F,,,,,H
1261,Expert,,Hippocampus,10000000.0,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,12073,BAO_0000221,,B,,,,,H
1262,Autocuration,,Hippocampus,10000000.0,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,10576,,14286,BAO_0000249,,B,,,,,H
1263,Autocuration,,Brain,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,10576,,14542,BAO_0000221,,B,,,,,H
1264,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1265,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1266,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1267,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,,13630,BAO_0000019,,F,,,,,H
1268,Expert,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,,13630,BAO_0000019,,F,,,,,H
1269,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1270,Expert,,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,10576,Rattus norvegicus,13630,BAO_0000019,,F,,,10116.0,,D
1271,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1272,Expert,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1273,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1274,Expert,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,10576,,13630,BAO_0000019,,F,,,,,H
1275,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1276,Expert,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,,13630,BAO_0000019,,F,,,,,H
1277,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1278,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1279,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1280,Expert,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1281,Expert,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1282,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,10576,,13630,BAO_0000019,,F,,,,,H
1283,Expert,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,10576,,13630,BAO_0000019,,F,,,,,H
1284,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1285,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,10576,,13630,BAO_0000019,,F,,,,,H
1286,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1287,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,,13630,BAO_0000019,,F,,,,,H
1288,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,10576,,9783,BAO_0000221,,B,,,,,H
1289,Expert,,Hippocampus,10000000.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,10576,,9783,BAO_0000221,,B,,,,,H
1290,Expert,Membranes,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,10576,Rattus norvegicus,14331,BAO_0000249,,B,,,10116.0,,D
1291,Expert,,Hippocampus,10000000.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,10576,,15260,BAO_0000221,,B,,,,,H
1292,Autocuration,,Hippocampus,10000000.0,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,10576,,15260,BAO_0000221,,B,,,,,H
1293,Autocuration,,Hippocampus,10000000.0,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,10576,,15260,BAO_0000221,,B,,,,,H
1294,Expert,,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,Rattus norvegicus,16616,BAO_0000249,,F,,,10116.0,,D
1295,Autocuration,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,10576,,15629,BAO_0000357,,B,,,,,H
1296,Autocuration,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,,15086,BAO_0000019,,B,,,,,H
1297,Expert,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,,5717,BAO_0000019,,F,,,,,H
1298,Autocuration,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,,12652,BAO_0000357,,B,,,,,H
1299,Autocuration,,Hippocampus,10000000.0,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,10576,,14608,BAO_0000221,,B,,,,,H
1300,Autocuration,,Hippocampus,10000000.0,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,12306,BAO_0000221,,B,,,,,H
1301,Autocuration,,Hippocampus,10000000.0,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,12306,BAO_0000221,,B,,,,,H
1302,Expert,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,Rattus norvegicus,15247,BAO_0000357,,B,,,10116.0,,D
1303,Expert,,Hippocampus,10000000.0,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,10576,,17529,BAO_0000221,,B,,,,,H
1304,Autocuration,,Hippocampus,10000000.0,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,14826,BAO_0000221,,B,,,,,H
1305,Autocuration,,Hippocampus,10000000.0,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,14826,BAO_0000221,,B,,,,,H
1306,Autocuration,,Hippocampus,10000000.0,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,13241,BAO_0000221,,B,,,,,H
1307,Autocuration,,Hippocampus,10000000.0,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,10576,,14093,BAO_0000221,,B,,,,,H
1308,Autocuration,,Hippocampus,10000000.0,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,10576,,14093,BAO_0000221,,B,,,,,H
1309,Autocuration,,Brain,955.0,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,10576,,14442,BAO_0000221,,B,,,,,H
1310,Autocuration,,,,Affinity for 5-hydroxytryptamine 1A receptor site,10576,,9919,BAO_0000357,,B,,,,,H
1311,Autocuration,,,,Affinity for 5-hydroxytryptamine 1A receptor site,10576,,9919,BAO_0000357,,B,,,,,H
1312,Autocuration,,Hippocampus,10000000.0,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,10576,,11440,BAO_0000221,,B,,,,,H
1313,Autocuration,,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,10576,,11257,BAO_0000357,,B,,,,,H
1314,Expert,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,10576,,10330,BAO_0000357,,B,,,,,H
1315,Expert,,Hippocampus,10000000.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,10576,Rattus norvegicus,17331,BAO_0000221,,B,,,10116.0,,D
1316,Expert,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,10576,,16567,BAO_0000249,,B,,,,,H
1317,Expert,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,Rattus norvegicus,12058,BAO_0000019,,B,,,10116.0,,D
1318,Autocuration,,Hippocampus,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,10576,,9699,BAO_0000221,,B,,,,,H
1319,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,10576,,9547,BAO_0000357,,B,,,,,H
1320,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,10576,,10330,BAO_0000357,,B,,,,,H
1321,Autocuration,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,,14331,BAO_0000357,,B,,,,,H
1322,Expert,,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,10576,Rattus norvegicus,14060,BAO_0000019,,B,,,10116.0,,D
1323,Autocuration,,Hippocampus,10000000.0,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,10576,,14744,BAO_0000221,,B,,,,,H
1324,Autocuration,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,,13506,BAO_0000357,,B,,,,,H
1325,Expert,,Brain,955.0,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,10862,BAO_0000221,,B,,,,,H
1326,Expert,,Brain,955.0,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,10862,BAO_0000221,,B,,,,,H
1327,Expert,,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,10576,,10062,BAO_0000357,,B,,,,,H
1328,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,10576,,12073,BAO_0000357,,B,,,,,H
1329,Autocuration,,,,GTPgammaS radioligand binding assay,106,,14875,BAO_0000357,,B,,,,,H
1330,Autocuration,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,,2391,BAO_0000357,,B,,,,,H
1331,Autocuration,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,106,,2391,BAO_0000019,,F,,,,,H
1332,Autocuration,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,106,,2391,BAO_0000019,,F,,,,,H
1333,Autocuration,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,,2391,BAO_0000357,,B,,,,,H
1334,Autocuration,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,,2391,BAO_0000357,,B,,,,,H
1335,Autocuration,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,106,,2391,BAO_0000019,,F,,,,,H
1336,Expert,,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,106,,17211,BAO_0000219,,B,,,,HeLa,H
1337,Autocuration,,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,106,,17211,BAO_0000219,,B,,,,HeLa,H
1338,Expert,,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,106,Homo sapiens,6491,BAO_0000357,,B,,,9606.0,,D
1339,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,,16190,BAO_0000219,,B,,,,CHO,H
1340,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,106,,14165,BAO_0000019,,B,,,,,H
1341,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,106,,14165,BAO_0000019,,B,,,,,H
1342,Expert,,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,106,Homo sapiens,4234,BAO_0000357,,B,,,9606.0,,D
1343,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,106,,6328,BAO_0000219,,B,,,,,H
1344,Autocuration,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,,14770,BAO_0000357,,B,,,,,H
1345,Autocuration,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,106,,2598,BAO_0000357,,B,,,,,H
1346,Expert,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,,6897,BAO_0000357,,B,,,,,H
1347,Autocuration,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,,6897,BAO_0000357,,B,,,,,H
1348,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,106,,6013,BAO_0000357,,B,,,,,H
1349,Expert,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,,5843,BAO_0000357,,B,,,,,H
1350,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,106,,14454,BAO_0000357,,B,,,,,H
1351,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,106,,16209,BAO_0000357,,B,,,,,H
1352,Autocuration,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,106,,3935,BAO_0000357,,B,,,,,H
1353,Expert,,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,106,,13729,BAO_0000219,,F,,,,CHO-K1,H
1354,Expert,,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,106,,14251,BAO_0000019,,F,,,,,H
1355,Expert,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,106,,17085,BAO_0000019,,B,,,,,H
1356,Autocuration,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,106,,3025,BAO_0000357,,B,,,,,H
1357,Expert,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,106,,15315,BAO_0000357,,B,,,,,H
1358,Expert,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,106,Homo sapiens,14214,BAO_0000219,,B,,,9606.0,,D
1359,Expert,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,Homo sapiens,3804,BAO_0000357,,B,,,9606.0,,D
1360,Expert,,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,106,Homo sapiens,2391,BAO_0000357,,B,,,9606.0,,D
1361,Expert,,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,Homo sapiens,4175,BAO_0000357,,B,,,9606.0,,D
1362,Autocuration,,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,106,,17296,BAO_0000219,,B,,,,CHO,H
1363,Expert,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,106,,17085,BAO_0000019,,B,,,,,H
1364,Autocuration,,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,,17211,BAO_0000219,,B,,,,HeLa,H
1365,Autocuration,,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,106,,17211,BAO_0000219,,B,,,,HeLa,H
1366,Autocuration,,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,,17211,BAO_0000219,,B,,,,HeLa,H
1367,Expert,,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,106,Homo sapiens,15926,BAO_0000357,,B,,,9606.0,,D
1368,Autocuration,,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,106,,16312,BAO_0000219,,B,,,,CHO-K1,H
1369,Expert,,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,106,,5843,BAO_0000357,,B,,,,,H
1370,Autocuration,,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,106,,5843,BAO_0000357,,B,,,,,H
1371,Expert,,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,106,,16312,BAO_0000219,,B,,,,CHO-K1,H
1372,Expert,,,,Binding activity against human 5-hydroxytryptamine 1B receptor,106,Homo sapiens,15926,BAO_0000357,,B,,,9606.0,,D
1373,Expert,,,,Binding activity against human 5-hydroxytryptamine 1B receptor,106,Homo sapiens,15926,BAO_0000357,,B,,,9606.0,,D
1374,Expert,,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,Homo sapiens,4540,BAO_0000219,,B,,,9606.0,CHO,D
1375,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,106,,6166,BAO_0000357,,B,,,,,H
1376,Autocuration,,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,106,,17296,BAO_0000219,,B,,,,CHO,H
1377,Autocuration,,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,106,,17296,BAO_0000219,,B,,,,CHO,H
1378,Autocuration,,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,106,,17296,BAO_0000219,,B,,,,CHO,H
1379,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,,15779,BAO_0000219,,B,,,,CHO,H
1380,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,,15779,BAO_0000219,,B,,,,CHO,H
1381,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,106,,15779,BAO_0000219,,B,,,,CHO,H
1382,Autocuration,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,106,,4199,BAO_0000219,,B,,,,CHO,H
1383,Expert,,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,Homo sapiens,14875,BAO_0000357,,B,,,9606.0,,D
1384,Autocuration,,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,,15146,BAO_0000219,,B,,,,CHO,H
1385,Autocuration,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,106,,5213,BAO_0000357,,B,,,,,H
1386,Autocuration,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,,14818,BAO_0000219,,B,,,,CHO,H
1387,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",106,,4829,BAO_0000219,,B,,,,CHO,H
1388,Expert,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,106,,14454,BAO_0000019,,F,,,,,H
1389,Expert,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,106,,14454,BAO_0000019,,F,,,,,H
1390,Autocuration,,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,,14875,BAO_0000219,,F,,,,CHO,H
1391,Autocuration,,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,,14875,BAO_0000219,,F,,,,CHO,H
1392,Autocuration,,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",105,,15250,BAO_0000019,,F,,,,,H
1393,Autocuration,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,105,,15250,BAO_0000219,,B,,,,CHO,H
1394,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,17105,,15086,BAO_0000357,,B,,,,,H
1395,Autocuration,,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,106,Oryctolagus cuniculus,3025,BAO_0000019,,F,,,9986.0,,H
1396,Autocuration,,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,106,Oryctolagus cuniculus,14998,BAO_0000019,,B,,,9986.0,,H
1397,Intermediate,,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",106,Oryctolagus cuniculus,14998,BAO_0000019,,B,,,9986.0,,H
1398,Autocuration,,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,106,Oryctolagus cuniculus,14998,BAO_0000019,,B,,,9986.0,,H
1399,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,10577,,13969,BAO_0000357,,B,,,,,H
1400,Intermediate,,,,Binding affinity for 5-hydroxytryptamine 1B receptor,10577,,13392,BAO_0000357,,B,,,,,D
1401,Expert,,Striatum,2435.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,10577,Rattus norvegicus,3651,BAO_0000019,,B,,,10116.0,,D
1402,Expert,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,,10025,BAO_0000357,,B,,,,,H
1403,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,10576,,13863,BAO_0000357,,B,,,,,H
1404,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,10576,,13863,BAO_0000357,,B,,,,,H
1405,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,10576,,13863,BAO_0000357,,B,,,,,H
1406,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,10576,,13863,BAO_0000357,,B,,,,,H
1407,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,10576,,13863,BAO_0000357,,B,,,,,H
1408,Autocuration,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,10576,,13863,BAO_0000357,,B,,,,,H
1409,Autocuration,,Hippocampus,10000000.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,10576,,4622,BAO_0000249,,B,,,,,H
1410,Intermediate,,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,,14911,BAO_0000019,,B,,,,,H
1411,Autocuration,,Hippocampus,10000000.0,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,,12678,BAO_0000221,,B,,,,,H
1412,Expert,,Hippocampus,10000000.0,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,10576,,12678,BAO_0000221,,B,,,,,H
1413,Expert,,Hippocampus,10000000.0,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,,14235,BAO_0000221,,B,,,,,H
1414,Expert,,Hippocampus,10000000.0,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,,14949,BAO_0000221,,B,,,,,H
1415,Expert,,Hippocampus,10000000.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,,14949,BAO_0000221,,B,,,,,H
1416,Expert,,Hippocampus,10000000.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,10576,,14949,BAO_0000221,,B,,,,,H
1417,Expert,,Hippocampus,10000000.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,10576,,14949,BAO_0000221,,B,,,,,H
1418,Expert,,Hippocampus,10000000.0,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,10576,,14949,BAO_0000221,,B,,,,,H
1419,Expert,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,,16118,BAO_0000249,,B,,,,,H
1420,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,10576,,3268,BAO_0000249,,B,,,,,H
1421,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,10576,,3268,BAO_0000249,,B,,,,,H
1422,Expert,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,10576,,16117,BAO_0000357,,B,,,,,H
1423,Expert,,Hippocampus,10000000.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,10576,,9783,BAO_0000221,,B,,,,,H
1424,Autocuration,,Hippocampus,10000000.0,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,10576,,9783,BAO_0000221,,B,,,,,H
1425,Expert,,Hippocampus,10000000.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,Rattus norvegicus,14356,BAO_0000221,,B,,,10116.0,,D
1426,Autocuration,,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,10576,,15740,BAO_0000019,,F,,,,,H
1427,Autocuration,,Hippocampus,10000000.0,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,12306,BAO_0000221,,B,,,,,H
1428,Expert,,Hippocampus,10000000.0,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,10576,Rattus norvegicus,13348,BAO_0000221,,B,,,10116.0,,D
1429,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,10576,,10394,BAO_0000249,,B,,,,,H
1430,Autocuration,,Hippocampus,10000000.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,10576,,15260,BAO_0000221,,B,,,,,H
1431,Expert,,Hippocampus,10000000.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,10046,BAO_0000221,,B,,,,,H
1432,Intermediate,,Hippocampus,10000000.0,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,10576,,15260,BAO_0000221,,F,,,,,H
1433,Autocuration,,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,10576,,12851,BAO_0000357,,B,,,,,H
1434,Expert,,Hippocampus,10000000.0,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,10576,Rattus norvegicus,2148,BAO_0000221,,B,,,10116.0,,D
1435,Expert,,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,10576,,13134,BAO_0000357,,B,,,,,H
1436,Autocuration,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,10576,,12462,BAO_0000019,,B,,,,,H
1437,Expert,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,10576,,12462,BAO_0000019,,B,,,,,H
1438,Autocuration,,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,10576,,12462,BAO_0000219,,B,,,,CHO,H
1439,Expert,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,10576,,11933,BAO_0000357,,B,,,,,H
1440,Autocuration,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,10576,,11933,BAO_0000357,,B,,,,,H
1441,Expert,,Hippocampus,10000000.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,Rattus norvegicus,403,BAO_0000221,,B,,,10116.0,,D
1442,Autocuration,,Hippocampus,10000000.0,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,15538,BAO_0000221,,B,,,,,H
1443,Autocuration,,Hippocampus,10000000.0,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,10576,,15538,BAO_0000221,,B,,,,,H
1444,Autocuration,,Hippocampus,10000000.0,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,10576,,15538,BAO_0000221,,B,,,,,H
1445,Intermediate,,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,10576,,12464,BAO_0000019,,B,,,,,H
1446,Expert,,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,10576,,1455,BAO_0000357,,B,,,,,H
1447,Autocuration,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,,12652,BAO_0000357,,B,,,,,H
1448,Autocuration,,Hippocampus,10000000.0,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,10576,,12639,BAO_0000221,,B,,,,,H
1449,Expert,,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,10576,,13949,BAO_0000249,,B,,,,,H
1450,Expert,,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,10576,Rattus norvegicus,12463,BAO_0000357,,B,,,10116.0,,D
1451,Expert,,Hippocampus,10000000.0,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,10576,,14829,BAO_0000221,,B,,,,,H
1452,Autocuration,,Hippocampus,10000000.0,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,10576,,14829,BAO_0000221,,B,,,,,H
1453,Autocuration,,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,10576,,12092,BAO_0000357,,B,,,,,H
1454,Autocuration,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,10576,,403,BAO_0000249,,B,,,,,H
1455,Autocuration,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,10576,,403,BAO_0000249,,B,,,,,H
1456,Expert,,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,10576,,3967,BAO_0000357,,B,,,,,H
1457,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,10576,Rattus norvegicus,12771,BAO_0000019,,B,,,10116.0,,D
1458,Autocuration,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,,15086,BAO_0000019,,B,,,,,H
1459,Autocuration,,Hippocampus,10000000.0,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,14909,BAO_0000221,,B,,,,,H
1460,Expert,,Hippocampus,10000000.0,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,14949,BAO_0000221,,B,,,,,H
1461,Expert,,Hippocampus,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,10576,Rattus norvegicus,2309,BAO_0000221,,B,,,10116.0,,D
1462,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,4170,BAO_0000357,,B,,,,,H
1463,Expert,,Hippocampus,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,10576,Rattus norvegicus,11642,BAO_0000221,,B,,,10116.0,,D
1464,Autocuration,,Hippocampus,10000000.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,10576,,11642,BAO_0000221,,B,,,,,H
1465,Autocuration,,Hippocampus,10000000.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,10576,,12953,BAO_0000221,,B,,,,,H
1466,Autocuration,,Hippocampus,10000000.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,,12953,BAO_0000221,,B,,,,,H
1467,Expert,,Hippocampus,10000000.0,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,12953,BAO_0000221,,B,,,,,H
1468,Expert,,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",10576,,12903,BAO_0000219,,B,,,,CHO,H
1469,Expert,,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,,12536,BAO_0000357,,B,,,,,H
1470,Autocuration,,,,The inhibition activity of 5-HT1A at 1 uM,10576,,10058,BAO_0000357,,B,,,,,H
1471,Expert,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",10576,,12902,BAO_0000219,,B,,,,CHO-K1,H
1472,Expert,,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,10576,,14057,BAO_0000249,,B,,,,,H
1473,Autocuration,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,10576,,11296,BAO_0000357,,B,,,,,H
1474,Autocuration,,Hippocampus,10000000.0,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,11296,BAO_0000221,,B,,,,,H
1475,Expert,,Hippocampus,10000000.0,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,11296,BAO_0000221,,B,,,,,H
1476,Expert,Membranes,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,10576,Rattus norvegicus,16616,BAO_0000249,,F,,,10116.0,,D
1477,Expert,Membranes,Hippocampus,10000000.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,Rattus norvegicus,16616,BAO_0000249,,F,,,10116.0,,D
1478,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,10576,,16567,BAO_0000019,,B,,,,,H
1479,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,10576,,16567,BAO_0000019,,B,,,,,H
1480,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,10576,,16567,BAO_0000019,,B,,,,,H
1481,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,10576,,16567,BAO_0000019,,B,,,,,H
1482,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,10576,,17136,BAO_0000249,,B,,,,,H
1483,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,10576,,17136,BAO_0000249,,B,,,,,H
1484,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,10576,Rattus norvegicus,16616,BAO_0000019,,B,,,10116.0,,D
1485,Autocuration,,Hippocampus,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,10576,,17331,BAO_0000221,,B,,,,,H
1486,Autocuration,,Hippocampus,10000000.0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,10576,,17331,BAO_0000221,,B,,,,,H
1487,Expert,,Hippocampus,10000000.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,10576,Rattus norvegicus,17167,BAO_0000221,,B,,,10116.0,,D
1488,Autocuration,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,,15740,BAO_0000019,,F,,,,,H
1489,Autocuration,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,10576,,15740,BAO_0000019,,F,,,,,H
1490,Autocuration,,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,10576,,4671,BAO_0000357,,B,,,,,H
1491,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,,10058,BAO_0000221,,B,,,,,H
1492,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,,10058,BAO_0000221,,B,,,,,H
1493,Autocuration,,Hippocampus,10000000.0,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,10576,,10058,BAO_0000221,,B,,,,,H
1494,Autocuration,,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,10576,,12073,BAO_0000357,,B,,,,,H
1495,Autocuration,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,,2759,BAO_0000249,,B,,,,,H
1496,Autocuration,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,,2759,BAO_0000249,,F,,,,,H
1497,Autocuration,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,,2759,BAO_0000249,,B,,,,,H
1498,Autocuration,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,,2759,BAO_0000249,,F,,,,,H
1499,Autocuration,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,,2759,BAO_0000249,,F,,,,,H
1500,Autocuration,,Brain,955.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10576,,9737,BAO_0000249,,B,,,,,H
1501,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,10576,,9737,BAO_0000019,,B,,,,,H
1502,Expert,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,10576,,5717,BAO_0000019,,F,,,,,H
1503,Autocuration,,Hippocampus,10000000.0,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,12253,BAO_0000221,,B,,,,,H
1504,Autocuration,,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,10576,,14025,BAO_0000019,,B,,,,,H
1505,Expert,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,10576,,10425,BAO_0000249,,B,,,,,H
1506,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,10576,,14998,BAO_0000019,,B,,,,,H
1507,Autocuration,,Hippocampus,10000000.0,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,10576,,13694,BAO_0000221,,B,,,,,H
1508,Autocuration,,Hippocampus,10000000.0,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,10576,,13694,BAO_0000221,,B,,,,,H
1509,Autocuration,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,10576,,4342,BAO_0000357,,B,,,,,H
1510,Expert,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,Rattus norvegicus,12936,BAO_0000357,,B,,,10116.0,,D
1511,Expert,,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,10576,Rattus norvegicus,13144,BAO_0000019,,B,,,10116.0,,D
1512,Expert,,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,10576,,13343,BAO_0000019,,B,,,,,H
1513,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,12132,BAO_0000357,,B,,,,,H
1514,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,10576,,15419,BAO_0000019,,B,,,,,H
1515,Autocuration,,Hippocampus,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,1479,BAO_0000221,,B,,,,,H
1516,Expert,,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,10576,,14287,BAO_0000019,,B,,,,,H
1517,Expert,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,10576,,13116,BAO_0000357,,B,,,,,H
1518,Expert,Membranes,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,10576,Rattus norvegicus,2759,BAO_0000249,,B,,,10116.0,,D
1519,Autocuration,,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,,2759,BAO_0000249,,B,,,,,H
1520,Expert,,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",10576,,14748,BAO_0000019,,B,,,,,H
1521,Autocuration,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,12304,BAO_0000019,,B,,,,,H
1522,Expert,,Hippocampus,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,10576,Rattus norvegicus,12409,BAO_0000221,,B,,,10116.0,,D
1523,Expert,,Hippocampus,10000000.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,10576,Rattus norvegicus,12409,BAO_0000221,,B,,,10116.0,,D
1524,Autocuration,,Hippocampus,10000000.0,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,10576,,13267,BAO_0000221,,B,,,,,H
1525,Autocuration,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,15194,BAO_0000357,,B,,,,,H
1526,Expert,,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,10576,,14256,BAO_0000357,,B,,,,,H
1527,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,10576,,16567,BAO_0000019,,B,,,,,H
1528,Autocuration,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,,15740,BAO_0000019,,F,,,,,H
1529,Expert,,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,Rattus norvegicus,13278,BAO_0000357,,B,,,10116.0,,D
1530,Expert,Membranes,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10626,,1970,BAO_0000249,,B,,,,,H
1531,Autocuration,,Brain,955.0,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,10576,,10034,BAO_0000221,,B,,,,,H
1532,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,51,Rattus norvegicus,13348,BAO_0000019,,B,,,10116.0,,H
1533,Autocuration,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,,13630,BAO_0000019,,F,,,,,H
1534,Autocuration,,Brain,955.0,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,10862,BAO_0000221,,B,,,,,H
1535,Autocuration,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,,12058,BAO_0000019,,B,,,,,H
1536,Autocuration,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,51,,4639,BAO_0000357,,B,,,,,H
1537,Expert,,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,51,,15453,BAO_0000357,,B,,,,,H
1538,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,4820,BAO_0000357,,B,,,,,H
1539,Autocuration,,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,51,,1089,BAO_0000357,,B,,,,,H
1540,Autocuration,Brain membranes,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,51,,386,BAO_0000249,,B,,,,,H
1541,Autocuration,,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,51,,6011,BAO_0000357,,B,,,,,H
1542,Autocuration,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,51,,5014,BAO_0000357,,B,,,,,H
1543,Expert,,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,51,,4402,BAO_0000357,,B,,,,,H
1544,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,17066,BAO_0000357,,B,,,,,H
1545,Autocuration,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,51,,17515,BAO_0000357,,B,,,,,H
1546,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,51,,2474,BAO_0000357,,B,,,,,H
1547,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,51,,4775,BAO_0000357,,B,,,,,H
1548,Expert,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,51,Homo sapiens,14294,BAO_0000357,,B,,,9606.0,,D
1549,Expert,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,51,Homo sapiens,14294,BAO_0000357,,B,,,9606.0,,D
1550,Autocuration,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,12249,BAO_0000219,,B,,,,CHO,H
1551,Expert,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,51,,11376,BAO_0000219,,B,,,,,H
1552,Autocuration,,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,2474,BAO_0000218,,B,In vivo,,,,H
1553,Autocuration,,Hippocampus,10000000.0,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,13311,BAO_0000221,,B,,,,,H
1554,Autocuration,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,51,,4373,BAO_0000357,,B,,,,,H
1555,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,51,,1633,BAO_0000357,,B,,,,,H
1556,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,,11866,BAO_0000357,,B,,,,,H
1557,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,,4373,BAO_0000357,,B,,,,,H
1558,Autocuration,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,51,,4687,BAO_0000357,,B,,,,,H
1559,Autocuration,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,11863,,16946,BAO_0000357,,B,,,,,H
1560,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,11863,,13291,BAO_0000357,,B,,,,,H
1561,Autocuration,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,11863,,14159,BAO_0000357,,B,,,,,H
1562,Autocuration,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,11863,,10812,BAO_0000357,,B,,,,,H
1563,Expert,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,11863,Mus musculus,3032,BAO_0000219,,B,,,10090.0,CHO,D
1564,Autocuration,,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,11863,,16655,BAO_0000357,,B,,,,,H
1565,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,11863,,14532,BAO_0000357,,B,,,,,H
1566,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,,13944,BAO_0000357,,B,,,,,H
1567,Autocuration,,,,Binding affinity against serotonergic 5-HT1a receptor,11863,,13033,BAO_0000357,,B,,,,,H
1568,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,11863,,10321,BAO_0000357,,B,,,,,H
1569,Expert,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,11863,Mus musculus,2968,BAO_0000357,,B,,,10090.0,,D
1570,Autocuration,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,11863,,13964,BAO_0000357,,B,,,,,H
1571,Autocuration,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",11863,,15527,BAO_0000357,,B,,,,,H
1572,Autocuration,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,,12248,BAO_0000219,,B,,,,CHO,H
1573,Autocuration,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,,12249,BAO_0000219,,B,,,,CHO,H
1574,Autocuration,,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,11863,,15120,BAO_0000357,,B,,,,,H
1575,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,11863,,13313,BAO_0000357,,B,,,,,H
1576,Autocuration,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,11863,,2613,BAO_0000218,,B,,,,,H
1577,Autocuration,,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,11863,,16700,BAO_0000357,,B,,,,,H
1578,Autocuration,,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,11863,,2201,BAO_0000357,,B,,,,,H
1579,Expert,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,Mus musculus,1274,BAO_0000357,,B,,,10090.0,,D
1580,Autocuration,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,11863,,1317,BAO_0000357,,B,,,,,H
1581,Autocuration,,,,Tested against 5-hydroxytryptamine 1A receptor,11863,,12146,BAO_0000357,,B,,,,,H
1582,Autocuration,,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,11863,,14059,BAO_0000357,,B,,,,,H
1583,Expert,,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,106,Oryctolagus cuniculus,14025,BAO_0000019,,B,,,9986.0,,H
1584,Autocuration,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,106,Oryctolagus cuniculus,14025,BAO_0000019,,B,,,9986.0,,H
1585,Intermediate,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105571,Gorilla gorilla,14447,BAO_0000219,,B,,,9593.0,HEK293,D
1586,Autocuration,,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,Cavia porcellus,3025,BAO_0000218,,F,In vivo,,10141.0,,H
1587,Autocuration,,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,Cavia porcellus,3025,BAO_0000218,,F,In vivo,,10141.0,,H
1588,Autocuration,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,106,Cavia porcellus,15329,BAO_0000019,,F,,,10141.0,,H
1589,Autocuration,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,106,Cavia porcellus,15329,BAO_0000019,,F,,,10141.0,,H
1590,Autocuration,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,106,Cavia porcellus,15847,BAO_0000019,,F,,,10141.0,,H
1591,Autocuration,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,106,Cavia porcellus,15847,BAO_0000019,,F,,,10141.0,,H
1592,Autocuration,,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,106,,14165,BAO_0000019,,F,,,,,H
1593,Autocuration,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),106,,14214,BAO_0000019,,F,,,,,H
1594,Autocuration,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),106,,14214,BAO_0000019,,F,,,,,H
1595,Expert,,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,106,Homo sapiens,14214,BAO_0000019,,F,,,9606.0,,D
1596,Expert,,,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,106,Homo sapiens,13729,BAO_0000219,,F,,,9606.0,CHO-K1,D
1597,Autocuration,,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,106,,3025,BAO_0000219,,F,,,,CHO,H
1598,Autocuration,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,,2391,BAO_0000357,,B,,,,,H
1599,Autocuration,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,106,,2391,BAO_0000019,,F,,,,,H
1600,Expert,,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",106,,14956,BAO_0000219,,F,,,,CHO,H
1601,Autocuration,,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,106,,2598,BAO_0000219,,F,,,,CHO,H
1602,Autocuration,,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,106,,2598,BAO_0000219,,F,,,,CHO,H
1603,Autocuration,,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,106,,2598,BAO_0000219,,F,,,,CHO,H
1604,Autocuration,,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,106,,2598,BAO_0000219,,F,,,,CHO,H
1605,Expert,,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",106,,14956,BAO_0000019,,F,,,,,H
1606,Autocuration,,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",106,,14956,BAO_0000019,,F,,,,,H
1607,Expert,,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,106,Homo sapiens,14214,BAO_0000357,,B,,,9606.0,,D
1608,Expert,,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,106,,3463,BAO_0000219,,B,,,,CHO,H
1609,Autocuration,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,106,,15331,BAO_0000357,,B,,,,,H
1610,Expert,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,106,Homo sapiens,16146,BAO_0000357,,B,,,9606.0,,D
1611,Expert,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,Homo sapiens,14159,BAO_0000219,,B,,,9606.0,CHO,D
1612,Expert,,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,106,,14158,BAO_0000219,,B,,,,CHO,H
1613,Autocuration,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,106,,14159,BAO_0000357,,B,,,,,H
1614,Expert,,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,,15250,BAO_0000219,,B,,,,CHO,H
1615,Expert,,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,106,,15250,BAO_0000219,,B,,,,CHO,H
1616,Expert,,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,,15331,BAO_0000219,,B,,,,CHO,H
1617,Expert,,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,106,,15332,BAO_0000219,,B,,,,CHO,H
1618,Expert,,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,,14956,BAO_0000219,,B,,,,CHO,H
1619,Autocuration,,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),106,,3805,BAO_0000357,,B,,,,,H
1620,Autocuration,,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,106,,14875,BAO_0000357,,B,,,,,H
1621,Autocuration,,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,Oryctolagus cuniculus,14454,BAO_0000019,,F,,,9986.0,,H
1622,Expert,,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,Oryctolagus cuniculus,14454,BAO_0000019,,F,,,9986.0,,H
1623,Autocuration,,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),105,,16288,BAO_0000357,,B,,,,,H
1624,Autocuration,,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),105,,16288,BAO_0000357,,B,,,,,H
1625,Autocuration,,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,105,,16312,BAO_0000357,,B,,,,,H
1626,Expert,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,105,Bos taurus,1348,BAO_0000357,,B,,,9913.0,,H
1627,Autocuration,,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,105,Bos taurus,5834,BAO_0000357,,B,,,9913.0,,H
1628,Autocuration,,Striatum,2435.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,Bos taurus,13366,BAO_0000019,,B,,,9913.0,,H
1629,Expert,,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,105,Bos taurus,1414,BAO_0000357,,B,,,9913.0,,H
1630,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,105,Bos taurus,14998,BAO_0000019,,B,,,9913.0,,H
1631,Autocuration,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,Bos taurus,11473,BAO_0000357,,B,,,9913.0,,H
1632,Autocuration,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,Bos taurus,11473,BAO_0000357,,B,,,9913.0,,H
1633,Autocuration,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,Bos taurus,10639,BAO_0000357,,B,,,9913.0,,H
1634,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,Bos taurus,10639,BAO_0000357,,B,,,9913.0,,H
1635,Autocuration,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,105,Bos taurus,1375,BAO_0000357,,B,,,9913.0,,H
1636,Autocuration,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,105,Bos taurus,1375,BAO_0000357,,B,,,9913.0,,H
1637,Autocuration,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,Bos taurus,16532,BAO_0000357,,B,,,9913.0,,H
1638,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,105,Bos taurus,11147,BAO_0000357,,B,,,9913.0,,H
1639,Autocuration,,Striatum,2435.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,Bos taurus,13366,BAO_0000019,,B,,,9913.0,,H
1640,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,105,Bos taurus,10444,BAO_0000019,,B,,,9913.0,,H
1641,Autocuration,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,105,Bos taurus,16532,BAO_0000357,,B,,,9913.0,,H
1642,Autocuration,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,Bos taurus,16532,BAO_0000357,,B,,,9913.0,,H
1643,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,105,Bos taurus,12827,BAO_0000249,,B,,,9913.0,,H
1644,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,105,Bos taurus,12827,BAO_0000249,,B,,,9913.0,,H
1645,Expert,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,Bos taurus,12919,BAO_0000019,,F,,,9913.0,,H
1646,Autocuration,,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,105,Bos taurus,14025,BAO_0000019,,B,,,9913.0,,H
1647,Expert,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,Bos taurus,12919,BAO_0000019,,F,,,9913.0,,H
1648,Expert,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,Bos taurus,12919,BAO_0000019,,F,,,9913.0,,H
1649,Expert,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,Bos taurus,12919,BAO_0000019,,F,,,9913.0,,H
1650,Autocuration,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105,Gorilla gorilla,14447,BAO_0000219,,B,,,9593.0,HEK293,H
1651,Intermediate,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,105570,Cavia porcellus,1375,BAO_0000019,,B,,,10141.0,,D
1652,Intermediate,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,105570,Cavia porcellus,1375,BAO_0000019,,B,,,10141.0,,D
1653,Intermediate,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,105570,Cavia porcellus,12409,BAO_0000019,,F,,,10141.0,,D
1654,Intermediate,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,Cavia porcellus,12409,BAO_0000019,,F,,,10141.0,,D
1655,Intermediate,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,105570,Cavia porcellus,12409,BAO_0000019,,F,,,10141.0,,D
1656,Intermediate,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,105570,Cavia porcellus,12409,BAO_0000019,,F,,,10141.0,,D
1657,Intermediate,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,105570,Cavia porcellus,12409,BAO_0000019,,F,,,10141.0,,D
1658,Intermediate,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,105570,Cavia porcellus,11574,BAO_0000357,,B,,,10141.0,,D
1659,Intermediate,,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,105570,Cavia porcellus,1558,BAO_0000357,,B,,,10141.0,,D
1660,Intermediate,,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,Cavia porcellus,12409,BAO_0000218,,F,,,10141.0,,D
1661,Intermediate,,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,Cavia porcellus,12409,BAO_0000218,,F,,,10141.0,,D
1662,Intermediate,,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,Cavia porcellus,12409,BAO_0000218,,F,,,10141.0,,D
1663,Intermediate,,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,105570,Cavia porcellus,12409,BAO_0000218,,F,,,10141.0,,D
1664,Intermediate,,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,105570,Cavia porcellus,12253,BAO_0000019,,B,,,10141.0,,D
1665,Intermediate,,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,105570,Cavia porcellus,12936,BAO_0000357,,B,,,10141.0,,D
1666,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,105,Cavia porcellus,13181,BAO_0000019,,B,,,10141.0,,H
1667,Intermediate,,Striatum,2435.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,105570,Cavia porcellus,12409,BAO_0000357,,B,,,10141.0,,D
1668,Intermediate,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,105570,Cavia porcellus,10639,BAO_0000357,,B,,,10141.0,,D
1669,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,51,,5254,BAO_0000357,,B,,,,,H
1670,Autocuration,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,106,,13051,BAO_0000357,,B,,,,,H
1671,Expert,,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,105,,3463,BAO_0000019,,F,,,,,H
1672,Autocuration,,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,105,,15315,BAO_0000019,,F,,,,,H
1673,Autocuration,,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,105,,6011,BAO_0000019,,F,,,,,H
1674,Expert,,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",105,Homo sapiens,14159,BAO_0000219,,F,,,9606.0,CHO,D
1675,Autocuration,,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",105,,14159,BAO_0000219,,F,,,,CHO,H
1676,Expert,,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,,15250,BAO_0000219,,B,,,,CHO,H
1677,Autocuration,,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,105,,15250,BAO_0000219,,B,,,,CHO,H
1678,Expert,,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,,15331,BAO_0000219,,F,,,,CHO,H
1679,Expert,,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,Homo sapiens,15332,BAO_0000219,,F,,,9606.0,CHO,D
1680,Expert,,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",105,,15332,BAO_0000219,,F,,,,CHO,H
1681,Autocuration,,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",105,,3294,BAO_0000219,,F,,,,CHO,H
1682,Expert,,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",105,,14158,BAO_0000219,,F,,,,CHO,H
1683,Expert,,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",105,,14956,BAO_0000219,,F,,,,CHO,H
1684,Autocuration,,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,105,,12469,BAO_0000019,,F,,,,,H
1685,Expert,,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,,3463,BAO_0000219,,F,,,,CHO,H
1686,Expert,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,Homo sapiens,15250,BAO_0000219,,F,,,9606.0,CHO,D
1687,Expert,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,Homo sapiens,15250,BAO_0000219,,F,,,9606.0,CHO,D
1688,Expert,,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",105,,14956,BAO_0000019,,F,,,,,H
1689,Autocuration,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",105,,14159,BAO_0000019,,F,,,,,H
1690,Expert,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",105,Homo sapiens,14159,BAO_0000019,,F,,,9606.0,,D
1691,Expert,,,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,105,Homo sapiens,14499,BAO_0000219,,F,,,9606.0,CHO,D
1692,Autocuration,,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,105,,15315,BAO_0000019,,F,,,,,H
1693,Autocuration,,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),105,,3294,BAO_0000219,,B,In vitro,,,,H
1694,Expert,,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,105,,3463,BAO_0000219,,B,,,,CHO,H
1695,Autocuration,,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,105,,15331,BAO_0000357,,B,,,,,H
1696,Expert,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,Homo sapiens,14159,BAO_0000219,,B,,,9606.0,CHO,D
1697,Expert,,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,105,,14158,BAO_0000219,,B,,,,CHO,H
1698,Autocuration,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,105,,14159,BAO_0000357,,B,,,,,H
1699,Expert,,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,105,,15250,BAO_0000219,,B,,,,CHO,H
1700,Expert,,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,15250,BAO_0000219,,B,,,,CHO,H
1701,Expert,,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,15331,BAO_0000219,,B,,,,CHO,H
1702,Expert,,,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,Homo sapiens,15332,BAO_0000219,,B,,,9606.0,CHO,D
1703,Expert,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,Homo sapiens,14499,BAO_0000219,,B,,,9606.0,CHO,D
1704,Expert,,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,15332,BAO_0000219,,B,,,,CHO,H
1705,Expert,,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,14956,BAO_0000219,,B,,,,CHO,H
1706,Autocuration,,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),105,,3805,BAO_0000357,,B,,,,,H
1707,Expert,,,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,105,Homo sapiens,6011,BAO_0000219,,B,,,9606.0,CHO,D
1708,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,,16190,BAO_0000219,,B,,,,CHO,H
1709,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,105,,14165,BAO_0000019,,B,,,,,H
1710,Expert,,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,105,Homo sapiens,4234,BAO_0000357,,B,,,9606.0,,D
1711,Autocuration,,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",105,,15527,BAO_0000357,,B,,,,,H
1712,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,105,,6328,BAO_0000219,,B,,,,,H
1713,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,105,,16209,BAO_0000357,,B,,,,,H
1714,Autocuration,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,105,,14770,BAO_0000357,,B,,,,,H
1715,Autocuration,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,105,,2598,BAO_0000357,,B,,,,,H
1716,Expert,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,105,,6897,BAO_0000357,,B,,,,,H
1717,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,105,,6013,BAO_0000357,,B,,,,,H
1718,Expert,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,,5843,BAO_0000357,,B,,,,,H
1719,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,105,,14454,BAO_0000357,,B,,,,,H
1720,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,105,,14454,BAO_0000357,,B,,,,,H
1721,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,105,,14454,BAO_0000357,,B,,,,,H
1722,Autocuration,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,105,,15818,BAO_0000357,,B,,,,,H
1723,Expert,,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,105,,13729,BAO_0000219,,F,,,,CHO-K1,H
1724,Expert,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),105,Homo sapiens,6011,BAO_0000219,,B,In vitro,,9606.0,,D
1725,Expert,,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,105,Homo sapiens,4234,BAO_0000357,,B,,,9606.0,,D
1726,Expert,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,,17085,BAO_0000019,,B,,,,,H
1727,Autocuration,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,105,,3025,BAO_0000357,,B,,,,,H
1728,Expert,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,105,,15315,BAO_0000357,,B,,,,,H
1729,Expert,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,105,Homo sapiens,14214,BAO_0000219,,B,,,9606.0,,D
1730,Expert,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,Homo sapiens,3804,BAO_0000357,,B,,,9606.0,,D
1731,Autocuration,,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,105,,16700,BAO_0000357,,B,,,,,H
1732,Expert,,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,105,Homo sapiens,2391,BAO_0000357,,B,,,9606.0,,D
1733,Expert,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,Homo sapiens,4175,BAO_0000357,,B,,,9606.0,,D
1734,Autocuration,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,,17085,BAO_0000019,,B,,,,,H
1735,Expert,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,105,,17085,BAO_0000019,,B,,,,,H
1736,Expert,,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,105,Homo sapiens,15926,BAO_0000357,,B,,,9606.0,,D
1737,Autocuration,,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,105,,16312,BAO_0000219,,B,,,,CHO-K1,H
1738,Autocuration,,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,105,,16312,BAO_0000219,,B,,,,CHO-K1,H
1739,Autocuration,,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,104802,,14956,BAO_0000219,,B,,,,CHO,H
1740,Autocuration,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",105,,3294,BAO_0000019,,F,,,,,H
1741,Autocuration,,,,Binding activity radioligand.,105,,12861,BAO_0000357,,B,,,,,H
1742,Autocuration,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,105,,12861,BAO_0000019,,B,,,,,H
1743,Expert,,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,105,,16312,BAO_0000219,,B,,,,CHO-K1,H
1744,Autocuration,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,,5104,BAO_0000357,,B,,,,,H
1745,Autocuration,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,,5105,BAO_0000357,,B,,,,,H
1746,Autocuration,,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,105,,14499,BAO_0000357,,B,,,,,H
1747,Expert,,,,Binding activity against human 5-hydroxytryptamine 1D receptor,105,Homo sapiens,15926,BAO_0000357,,B,,,9606.0,,D
1748,Expert,,,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,Homo sapiens,4540,BAO_0000219,,B,,,9606.0,CHO,D
1749,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,105,,15779,BAO_0000219,,B,,,,CHO,H
1750,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,105,,15779,BAO_0000219,,B,,,,CHO,H
1751,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,,6166,BAO_0000357,,B,,,,,H
1752,Autocuration,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,105,,15779,BAO_0000219,,B,,,,CHO,H
1753,Autocuration,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,105,,15779,BAO_0000219,,B,,,,CHO,H
1754,Autocuration,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,,17451,BAO_0000219,,B,,,,HEK293,H
1755,Autocuration,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,,17451,BAO_0000219,,B,,,,HEK293,H
1756,Autocuration,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,105,,17451,BAO_0000219,,B,,,,HEK293,H
1757,Autocuration,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,105,,4199,BAO_0000219,,B,,,,CHO,H
1758,Expert,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,Homo sapiens,14875,BAO_0000357,,B,,,9606.0,,D
1759,Autocuration,,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,105,,15146,BAO_0000219,,B,,,,CHO,H
1760,Autocuration,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,105,,5213,BAO_0000357,,B,,,,,H
1761,Autocuration,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,105,,14818,BAO_0000219,,B,,,,CHO,H
1762,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",105,,4829,BAO_0000219,,B,,,,CHO,H
1763,Expert,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,105,,14454,BAO_0000019,,F,,,,,H
1764,Expert,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,105,,14454,BAO_0000019,,F,,,,,H
1765,Autocuration,,,,Binding affinity against 5-HT2C receptor,108,,5254,BAO_0000357,,B,,,,,H
1766,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,108,,5254,BAO_0000357,,B,,,,,H
1767,Autocuration,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,,10639,BAO_0000357,,B,,,,,H
1768,Autocuration,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,,10639,BAO_0000019,,F,,,,,H
1769,Expert,,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",10577,,12352,BAO_0000019,,B,,,,,H
1770,Autocuration,,,,Binding affinity towards 5-HT1B was determined,10577,,9098,BAO_0000357,,B,,,,,H
1771,Expert,,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,10577,,14430,BAO_0000019,,B,,,,,H
1772,Expert,,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",10577,,13657,BAO_0000019,,B,,,,,H
1773,Autocuration,,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",10577,,13657,BAO_0000019,,B,,,,,H
1774,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10577,,15854,BAO_0000019,,B,,,,,H
1775,Expert,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,10577,Rattus norvegicus,10639,BAO_0000019,,B,,,10116.0,,D
1776,Autocuration,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,,10025,BAO_0000357,,B,,,,,H
1777,Autocuration,,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",10577,,10025,BAO_0000357,,B,,,,,H
1778,Autocuration,,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,,14286,BAO_0000249,,B,,,,,H
1779,Autocuration,,Striatum,2435.0,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,10577,,3651,BAO_0000019,,B,,,,,H
1780,Expert,,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,10577,Rattus norvegicus,14178,BAO_0000357,,B,,,10116.0,,D
1781,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,10577,,10639,BAO_0000019,,B,,,,,H
1782,Autocuration,,Striatum,2435.0,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,10577,,13605,BAO_0000019,,B,,,,,H
1783,Autocuration,,Striatum,2435.0,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,10577,,5834,BAO_0000019,,B,,,,,H
1784,Autocuration,,Striatum,2435.0,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,10577,,10922,BAO_0000357,,B,,,,,H
1785,Autocuration,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,,14286,BAO_0000249,,B,,,,,H
1786,Autocuration,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,10577,,11825,BAO_0000357,,B,,,,,H
1787,Autocuration,,Striatum,2435.0,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,10577,,14826,BAO_0000019,,B,,,,,H
1788,Autocuration,,Striatum,2435.0,Binding affinity against 5-HT1B serotonin receptor in rat striatum,10577,,9699,BAO_0000019,,B,,,,,H
1789,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,10577,,14423,BAO_0000019,,B,,,,,H
1790,Expert,,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,10577,,10062,BAO_0000357,,B,,,,,H
1791,Autocuration,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,,10062,BAO_0000357,,B,,,,,H
1792,Expert,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,10577,Rattus norvegicus,12280,BAO_0000357,,B,,,10116.0,,D
1793,Autocuration,,Striatum,2435.0,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,10577,,15412,BAO_0000357,,B,,,,,H
1794,Autocuration,,Striatum,2435.0,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,10577,,15412,BAO_0000357,,B,,,,,H
1795,Autocuration,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,,10062,BAO_0000357,,B,,,,,H
1796,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,,11147,BAO_0000357,,B,,,,,H
1797,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,10577,,9547,BAO_0000019,,B,,,,,H
1798,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,10577,,10444,BAO_0000019,,B,,,,,H
1799,Autocuration,,Striatum,2435.0,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,10577,,12469,BAO_0000019,,B,,,,,H
1800,Expert,,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,10577,,9098,BAO_0000019,,B,,,,,H
1801,Autocuration,,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,10577,,9098,BAO_0000019,,B,,,,,H
1802,Autocuration,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,10577,,9699,BAO_0000357,,B,,,,,H
1803,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,10577,,10394,BAO_0000249,,B,,,,,H
1804,Autocuration,,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,10577,,12092,BAO_0000357,,B,,,,,H
1805,Autocuration,,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,10577,,16700,BAO_0000357,,B,,,,,H
1806,Expert,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,10577,Rattus norvegicus,403,BAO_0000249,,B,,,10116.0,,D
1807,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,10577,Rattus norvegicus,12771,BAO_0000357,,B,,,10116.0,,D
1808,Autocuration,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,10577,,11642,BAO_0000019,,B,,,,,H
1809,Autocuration,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,10577,,12953,BAO_0000357,,B,,,,,H
1810,Autocuration,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,10577,,12953,BAO_0000357,,B,,,,,H
1811,Expert,,Striatum,2435.0,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,10577,,12953,BAO_0000019,,B,,,,,H
1812,Autocuration,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,10577,,12953,BAO_0000357,,B,,,,,H
1813,Autocuration,,Brain,955.0,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,,9737,BAO_0000249,,B,,,,,H
1814,Autocuration,,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,10577,,9737,BAO_0000019,,B,,,,,H
1815,Autocuration,,Brain,955.0,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,,9737,BAO_0000249,,B,,,,,H
1816,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,10577,,12827,BAO_0000357,,B,,,,,H
1817,Autocuration,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,10577,,5033,BAO_0000357,,B,,,,,H
1818,Expert,,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,10577,Rattus norvegicus,9786,BAO_0000019,,B,,,10116.0,,D
1819,Expert,,,,Binding affinity at 5-hydroxytryptamine 1B receptor,10577,,13116,BAO_0000357,,B,,,,,H
1820,Autocuration,,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,10577,,16429,BAO_0000019,,B,,,,,H
1821,Expert,,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,10577,Rattus norvegicus,12409,BAO_0000249,,B,,,10116.0,,D
1822,Autocuration,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,,15194,BAO_0000357,,B,,,,,H
1823,Autocuration,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,10577,,15194,BAO_0000357,,B,,,,,H
1824,Autocuration,,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,104686,,5486,BAO_0000019,,B,,,,,H
1825,Autocuration,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,106,,4639,BAO_0000357,,B,,,,,H
1826,Autocuration,Brain membranes,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,106,,386,BAO_0000249,,B,,,,,H
1827,Autocuration,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,106,,2474,BAO_0000357,,B,,,,,H
1828,Autocuration,,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,106,,6011,BAO_0000357,,B,,,,,H
1829,Autocuration,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,106,,5014,BAO_0000357,,B,,,,,H
1830,Autocuration,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,106,,17515,BAO_0000357,,B,,,,,H
1831,Autocuration,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,106,,4373,BAO_0000357,,B,,,,,H
1832,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,106,,1633,BAO_0000357,,B,,,,,H
1833,Autocuration,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,106,,1633,BAO_0000357,,B,,,,,H
1834,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,106,,4373,BAO_0000357,,B,,,,,H
1835,Autocuration,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,106,,4687,BAO_0000357,,B,,,,,H
1836,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,106,,11574,BAO_0000357,,B,,,,,H
1837,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,106,,10321,BAO_0000357,,B,,,,,H
1838,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,,15527,BAO_0000357,,B,,,,,H
1839,Autocuration,,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,106,,17200,BAO_0000357,,B,,,,,H
1840,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,104802,,14423,BAO_0000224,,B,,,,,H
1841,Autocuration,,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,108,Bos taurus,5834,BAO_0000357,,B,,,9913.0,,H
1842,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,108,Sus scrofa,11473,BAO_0000357,,B,,,9823.0,,H
1843,Autocuration,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,108,Sus scrofa,11473,BAO_0000357,,B,,,9823.0,,H
1844,Autocuration,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,Sus scrofa,10639,BAO_0000357,,B,,,9823.0,,H
1845,Autocuration,,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,Sus scrofa,10639,BAO_0000357,,B,,,9823.0,,H
1846,Autocuration,,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,108,Sus scrofa,14331,BAO_0000357,,B,,,9823.0,,H
1847,Autocuration,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,108,Sus scrofa,10796,BAO_0000357,,B,,,9823.0,,H
1848,Expert,,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,108,Sus scrofa,9098,BAO_0000357,,B,,,9823.0,,H
1849,Expert,,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,108,Sus scrofa,14331,BAO_0000357,,B,,,9823.0,,H
1850,Expert,,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,108,Sus scrofa,11828,BAO_0000019,,B,,,9823.0,,H
1851,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,108,Sus scrofa,11866,BAO_0000357,,B,,,9823.0,,H
1852,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,108,Oryctolagus cuniculus,13047,BAO_0000019,,B,,,9986.0,,H
1853,Autocuration,,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,12689,Rattus norvegicus,188,BAO_0000357,,B,,,10116.0,,D
1854,Autocuration,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,Rattus norvegicus,11825,BAO_0000357,,B,,,10116.0,,D
1855,Autocuration,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,Rattus norvegicus,11825,BAO_0000357,,B,,,10116.0,,D
1856,Expert,,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,12689,Rattus norvegicus,11624,BAO_0000019,,B,,,10116.0,,D
1857,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,12689,Rattus norvegicus,11139,BAO_0000357,,B,,,10116.0,,D
1858,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,12689,Rattus norvegicus,11147,BAO_0000357,,B,,,10116.0,,D
1859,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,12689,Rattus norvegicus,10444,BAO_0000019,,B,,,10116.0,,D
1860,Expert,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,Rattus norvegicus,11624,BAO_0000357,,B,,,10116.0,,D
1861,Autocuration,,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,Rattus norvegicus,11662,BAO_0000019,,B,,,10116.0,,D
1862,Autocuration,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,Rattus norvegicus,11662,BAO_0000019,,B,,,10116.0,,D
1863,Expert,,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,Rattus norvegicus,11662,BAO_0000019,,B,,,10116.0,,D
1864,Autocuration,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,Rattus norvegicus,11662,BAO_0000019,,B,,,10116.0,,D
1865,Autocuration,,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,12689,Rattus norvegicus,9098,BAO_0000357,,B,,,10116.0,,D
1866,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,12689,Rattus norvegicus,10394,BAO_0000249,,B,,,10116.0,,D
1867,Expert,,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,12689,,11933,BAO_0000357,,B,,,,,H
1868,Autocuration,,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,12689,Rattus norvegicus,12092,BAO_0000357,,B,,,10116.0,,D
1869,Autocuration,,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,12689,Rattus norvegicus,12253,BAO_0000019,,B,,,10116.0,,D
1870,Autocuration,,,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,12689,Rattus norvegicus,12253,BAO_0000219,,B,,,10116.0,HEK293,D
1871,Autocuration,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,108,,1558,BAO_0000357,,B,,,,,H
1872,Autocuration,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,,2474,BAO_0000357,,B,,,,,H
1873,Autocuration,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,,2474,BAO_0000357,,B,,,,,H
1874,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,11574,BAO_0000357,,B,,,,,H
1875,Autocuration,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,12689,,1558,BAO_0000357,,B,,,,,H
1876,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,13944,BAO_0000357,,B,,,,,H
1877,Autocuration,,,,Binding affinity against serotonergic 5-HT1c receptor,12689,,13033,BAO_0000357,,B,,,,,H
1878,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,12689,,10321,BAO_0000357,,B,,,,,H
1879,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,12689,,11866,BAO_0000357,,B,,,,,H
1880,Autocuration,,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,Oryctolagus cuniculus,14454,BAO_0000019,,B,,,9986.0,,H
1881,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,104686,,11574,BAO_0000224,,B,,,,,H
1882,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,104686,,11574,BAO_0000224,,B,,,,,H
1883,Autocuration,,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,104686,,13631,BAO_0000019,,B,,,,,H
1884,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,104686,Rattus norvegicus,9630,BAO_0000019,,B,,,10116.0,,D
1885,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,104686,Rattus norvegicus,8822,BAO_0000249,,B,,,10116.0,,D
1886,Autocuration,,Brain,955.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,104686,Rattus norvegicus,9064,BAO_0000221,,B,,,10116.0,,D
1887,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,104686,,8868,BAO_0000224,,B,,,,,H
1888,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,104686,,9064,BAO_0000224,,B,,,,,H
1889,Autocuration,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,104686,,9806,BAO_0000019,,B,,,,,H
1890,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,,9098,BAO_0000224,,B,,,,,H
1891,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,104686,,8868,BAO_0000224,,B,,,,,H
1892,Autocuration,,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,,12765,BAO_0000224,,B,,,,,H
1893,Autocuration,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,11049,BAO_0000019,,B,,,,,H
1894,Autocuration,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,11049,BAO_0000019,,B,,,,,H
1895,Autocuration,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,104686,,11049,BAO_0000019,,B,,,,,H
1896,Autocuration,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,104686,,11049,BAO_0000019,,B,,,,,H
1897,Autocuration,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,11049,BAO_0000019,,B,,,,,H
1898,Autocuration,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,104686,,11473,BAO_0000019,,B,,,,,H
1899,Autocuration,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,104686,,11473,BAO_0000019,,B,,,,,H
1900,Autocuration,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,104686,,3086,BAO_0000019,,B,,,,,H
1901,Autocuration,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,11049,BAO_0000019,,B,,,,,H
1902,Autocuration,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,11049,BAO_0000019,,B,,,,,H
1903,Autocuration,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,104686,,10639,BAO_0000019,,B,,,,,H
1904,Autocuration,,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,104686,,10922,BAO_0000019,,B,,,,,H
1905,Autocuration,,Brain,955.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,Rattus norvegicus,9064,BAO_0000221,,B,,,10116.0,,D
1906,Autocuration,,Brain,955.0,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,104686,,10748,BAO_0000221,,B,,,,,H
1907,Autocuration,Membranes,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,,11614,BAO_0000249,,B,,,,,H
1908,Autocuration,Membranes,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,,11615,BAO_0000249,,B,,,,,H
1909,Autocuration,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,104686,,11615,BAO_0000224,,B,,,,,H
1910,Autocuration,Membranes,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,,11614,BAO_0000249,,B,,,,,H
1911,Autocuration,,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,104686,,11702,BAO_0000224,,B,,,,,H
1912,Autocuration,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,11702,BAO_0000224,,B,,,,,H
1913,Autocuration,,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,104686,Rattus norvegicus,11702,BAO_0000224,,B,,,10116.0,,D
1914,Autocuration,,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,11702,BAO_0000224,,B,,,,,H
1915,Autocuration,,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,104686,,13346,BAO_0000019,,B,,,,,H
1916,Autocuration,,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,,10025,BAO_0000224,,B,,,,,H
1917,Autocuration,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,,10025,BAO_0000224,,B,,,,,H
1918,Autocuration,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,,10025,BAO_0000224,,B,,,,,H
1919,Autocuration,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,104686,,9036,BAO_0000224,,B,,,,,H
1920,Autocuration,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,104686,,9036,BAO_0000224,,B,,,,,H
1921,Autocuration,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,104686,,9161,BAO_0000019,,B,,,,,H
1922,Autocuration,,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,104686,,12304,BAO_0000019,,B,,,,,H
1923,Autocuration,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,104686,,13276,BAO_0000224,,B,,,,,H
1924,Autocuration,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,,11825,BAO_0000224,,B,,,,,H
1925,Autocuration,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,104686,,12443,BAO_0000224,,B,,,,,H
1926,Autocuration,,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,,13830,BAO_0000224,,B,,,,,H
1927,Autocuration,Membranes,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,104686,,9592,BAO_0000249,,B,,,,,H
1928,Autocuration,Membranes,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,104686,,9592,BAO_0000249,,B,,,,,H
1929,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,104686,,10881,BAO_0000224,,B,,,,,H
1930,Autocuration,,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,104686,,13605,BAO_0000019,,B,,,,,H
1931,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,104686,Rattus norvegicus,11624,BAO_0000224,,B,,,10116.0,,D
1932,Autocuration,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,,4101,BAO_0000224,,B,,,,,H
1933,Autocuration,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,,4101,BAO_0000224,,B,,,,,H
1934,Autocuration,,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,104686,,15360,BAO_0000019,,B,,,,,H
1935,Autocuration,,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,104686,,11576,BAO_0000019,,B,,,,,H
1936,Autocuration,,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,104686,,5834,BAO_0000019,,B,,,,,H
1937,Autocuration,,,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,Rattus norvegicus,2395,BAO_0000219,,B,,,10116.0,CHO-K1,D
1938,Autocuration,Membranes,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,,11965,BAO_0000249,,B,,,,,H
1939,Autocuration,,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),104686,,3967,BAO_0000224,,B,,,,,H
1940,Autocuration,Brain membranes,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),104686,,11130,BAO_0000249,,B,,,,,H
1941,Autocuration,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,,13427,BAO_0000219,,B,In vitro,,,,H
1942,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,9443,BAO_0000224,,B,,,,,H
1943,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,,9443,BAO_0000224,,B,,,,,H
1944,Autocuration,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,,11825,BAO_0000224,,B,,,,,H
1945,Autocuration,Membranes,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,104686,,12120,BAO_0000249,,B,,,,,H
1946,Autocuration,Membranes,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,104686,,12120,BAO_0000249,,B,,,,,H
1947,Autocuration,,Thoracic aorta,1515.0,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,104686,,11963,BAO_0000019,,F,,,,,H
1948,Autocuration,,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,104686,,9069,BAO_0000019,,B,,,,,H
1949,Autocuration,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,,8868,BAO_0000224,,B,,,,,H
1950,Autocuration,,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,10624,,17200,BAO_0000357,,B,,,,,H
1951,Autocuration,,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,10624,,17200,BAO_0000357,,B,,,,,H
1952,Expert,,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,17106,,13969,BAO_0000357,,B,,,,,H
1953,Expert,,,,Binding affinity for 5-hydroxytryptamine 1D receptor,17106,,13392,BAO_0000357,,B,,,,,D
1954,Autocuration,,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,1742,BAO_0000249,,B,,,,,H
1955,Autocuration,,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,1742,BAO_0000249,,B,,,,,H
1956,Autocuration,,Striatum,2435.0,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,17106,,14331,BAO_0000357,,B,,,,,H
1957,Autocuration,,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,17106,,12861,BAO_0000019,,F,,,,,H
1958,Expert,,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,17106,,12861,BAO_0000019,,B,,,,,H
1959,Autocuration,,,,Binding activity radioligand.,17106,,12861,BAO_0000357,,B,,,,,H
1960,Autocuration,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,17106,,12861,BAO_0000019,,B,,,,,H
1961,Expert,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,,12861,BAO_0000019,,B,,,,,H
1962,Autocuration,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,17106,,12861,BAO_0000019,,B,,,,,H
1963,Autocuration,,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,675,BAO_0000249,,B,,,,,H
1964,Expert,,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,17106,,12490,BAO_0000019,,B,,,,,H
1965,Expert,,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,17106,,11828,BAO_0000249,,B,,,,,H
1966,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,17106,,11866,BAO_0000357,,B,,,,,H
1967,Autocuration,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,105,Sus scrofa,773,BAO_0000357,,B,,,9823.0,,H
1968,Expert,,,,The compound was tested for intrinsic activity against 5-HT1D receptor,105,Oryctolagus cuniculus,13047,BAO_0000357,,B,,,9986.0,,H
1969,Autocuration,,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,105,Oryctolagus cuniculus,13047,BAO_0000019,,B,,,9986.0,,H
1970,Expert,,,,The compound was tested for binding affinity against 5-HT1D receptor,105,Oryctolagus cuniculus,13047,BAO_0000357,,B,,,9986.0,,H
1971,Autocuration,,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,10578,,188,BAO_0000357,,B,,,,,H
1972,Autocuration,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,10578,,10639,BAO_0000019,,F,,,,,H
1973,Autocuration,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,10578,,12438,BAO_0000019,,F,,,,,H
1974,Autocuration,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,10578,,12438,BAO_0000357,,B,,,,,H
1975,Expert,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10578,,15854,BAO_0000019,,B,,,,,H
1976,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,10578,,10394,BAO_0000249,,B,,,,,H
1977,Autocuration,,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,10578,,12092,BAO_0000357,,B,,,,,H
1978,Expert,,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,10578,,3389,BAO_0000019,,B,,,,,H
1979,Autocuration,,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,105,,6011,BAO_0000357,,B,,,,,H
1980,Autocuration,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,105,,4639,BAO_0000357,,B,,,,,H
1981,Autocuration,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,105,,2474,BAO_0000357,,B,,,,,H
1982,Autocuration,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,105,,5014,BAO_0000357,,B,,,,,H
1983,Autocuration,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,105,,17515,BAO_0000357,,B,,,,,H
1984,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,105,,11866,BAO_0000357,,B,,,,,H
1985,Autocuration,,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,105,,4687,BAO_0000357,,B,,,,,H
1986,Autocuration,,,,Tested against 5-hydroxytryptamine 1D receptor,105,,12146,BAO_0000357,,B,,,,,H
1987,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,105,,10321,BAO_0000357,,B,,,,,H
1988,Autocuration,,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,105,,13267,BAO_0000219,,B,,,,HEK293,H
1989,Expert,,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,105,Homo sapiens,1274,BAO_0000357,,B,,,9606.0,,D
1990,Autocuration,,,,,105,,15250,BAO_0000357,,B,,,,,H
1991,Autocuration,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,106,,13706,BAO_0000219,,B,,,,CHO-K1,H
1992,Autocuration,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,,13706,BAO_0000219,,B,,,,CHO-K1,H
1993,Autocuration,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,105,,13706,BAO_0000219,,B,,,,HEK293,H
1994,Autocuration,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,105,,13706,BAO_0000219,,B,,,,HEK293,H
1995,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,105,,13047,BAO_0000019,,B,,,,,H
1996,Autocuration,,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,105,,13366,BAO_0000357,,B,,,,,H
1997,Expert,,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,105,,13366,BAO_0000357,,B,,,,,H
1998,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,105,,1558,BAO_0000357,,B,,,,,H
1999,Expert,,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",105,,12902,BAO_0000219,,B,,,,CHO-K1,H
2000,Autocuration,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,,13706,BAO_0000219,,B,,,,CHO-K1,H
2001,Autocuration,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,105,,13706,BAO_0000019,,F,,,,,H
2002,Autocuration,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,105,,13706,BAO_0000019,,F,,,,,H
2003,Autocuration,,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,14251,BAO_0000019,,F,,,,,H
2004,Autocuration,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,14251,BAO_0000019,,F,,,,,H
2005,Autocuration,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,14251,BAO_0000019,,F,,,,,H
2006,Autocuration,,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,105,,13313,BAO_0000357,,B,,,,,H
2007,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,105,,13313,BAO_0000357,,B,,,,,H
2008,Autocuration,,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,105,,13366,BAO_0000357,,B,,,,,H
2009,Expert,,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,105,,13051,BAO_0000357,,B,,,,,H
2010,Expert,,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",105,,12903,BAO_0000219,,B,,,,CHO,H
2011,Autocuration,,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,105,Homo sapiens,12469,BAO_0000219,,B,,,9606.0,,D
2012,Autocuration,,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,17106,,5619,BAO_0000357,,B,,,,,H
2013,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,105,Oryctolagus cuniculus,13047,BAO_0000019,,B,,,9986.0,,H
2014,Autocuration,,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,105,,16633,BAO_0000357,,B,,,,,H
2015,Autocuration,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,,16633,BAO_0000357,,B,,,,,H
2016,Autocuration,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,,16633,BAO_0000357,,B,,,,,H
2017,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,105,,16633,BAO_0000357,,B,,,,,H
2018,Autocuration,,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,105,,3269,BAO_0000357,,B,,,,,H
2019,Expert,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,105,,12409,BAO_0000357,,B,,,,,H
2020,Autocuration,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,,13706,BAO_0000019,,F,,,,,H
2021,Autocuration,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,106,,13706,BAO_0000219,,B,,,,HEK293,H
2022,Autocuration,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,106,,13706,BAO_0000219,,B,,,,HEK293,H
2023,Autocuration,,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,,12903,BAO_0000219,,B,,,,CHO,H
2024,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,106,,13047,BAO_0000019,,B,,,,,H
2025,Expert,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,13366,BAO_0000357,,B,,,,,D
2026,Expert,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,13366,BAO_0000357,,B,,,,,D
2027,Expert,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,13366,BAO_0000357,,B,,,,,D
2028,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,106,,13366,BAO_0000357,,B,,,,,H
2029,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,106,,13366,BAO_0000357,,B,,,,,H
2030,Autocuration,,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,106,,12469,BAO_0000219,,B,,,,CHO,H
2031,Autocuration,,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,106,,13706,BAO_0000219,,B,,,,CHO-K1,H
2032,Autocuration,,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,106,,13706,BAO_0000219,,B,,,,CHO-K1,H
2033,Autocuration,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,,13706,BAO_0000019,,F,,,,,H
2034,Expert,,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",106,,12902,BAO_0000219,,B,,,,CHO-K1,H
2035,Expert,,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,105,,13051,BAO_0000357,,B,,,,,H
2036,Expert,,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,,12903,BAO_0000219,,B,,,,CHO,H
2037,Autocuration,,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,105,,1558,BAO_0000219,,F,,,,CHO-K1,H
2038,Autocuration,,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,105,,1558,BAO_0000219,,F,,,,CHO-K1,H
2039,Autocuration,,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,105,,1558,BAO_0000219,,F,,,,CHO-K1,H
2040,Autocuration,,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,105,,1558,BAO_0000219,,F,,,,CHO-K1,H
2041,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,105,,1558,BAO_0000357,,B,,,,,H
2042,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,106,Oryctolagus cuniculus,13047,BAO_0000019,,B,,,9986.0,,H
2043,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,105,,13313,BAO_0000357,,B,,,,,H
2044,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,105,,13313,BAO_0000357,,B,,,,,H
2045,Expert,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,105,,12409,BAO_0000357,,B,,,,,H
2046,Autocuration,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,10618,,15250,BAO_0000219,,B,,,,CHO,H
2047,Expert,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,10618,Homo sapiens,1348,BAO_0000357,,B,,,9606.0,,D
2048,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,10618,,1348,BAO_0000357,,B,,,,,H
2049,Expert,,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,10618,Homo sapiens,4234,BAO_0000357,,B,,,9606.0,,D
2050,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,10618,,16209,BAO_0000357,,B,,,,,H
2051,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,10618,,10444,BAO_0000019,,B,,,,,H
2052,Autocuration,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,10618,,3935,BAO_0000357,,B,,,,,H
2053,Autocuration,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,10618,,15818,BAO_0000357,,B,,,,,H
2054,Autocuration,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,10618,,17085,BAO_0000019,,B,,,,,H
2055,Expert,,,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,10618,Homo sapiens,12936,BAO_0000219,,B,,,9606.0,CHO,D
2056,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,10618,,6166,BAO_0000357,,B,,,,,H
2057,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,10618,,15779,BAO_0000219,,B,,,,CHO,H
2058,Autocuration,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,10618,,15779,BAO_0000219,,B,,,,CHO,H
2059,Autocuration,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,10618,,15779,BAO_0000219,,B,,,,CHO,H
2060,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,10618,,13181,BAO_0000357,,B,,,,,H
2061,Autocuration,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,10618,,4199,BAO_0000219,,B,,,,CHO,H
2062,Autocuration,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,10618,,14875,BAO_0000357,,B,,,,,H
2063,Autocuration,,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,10618,,15146,BAO_0000219,,B,,,,CHO,H
2064,Autocuration,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,10618,,5213,BAO_0000357,,B,,,,,H
2065,Autocuration,,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,10618,,12146,BAO_0000357,,B,,,,,H
2066,Autocuration,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,10618,,13267,BAO_0000219,,B,,,,CHO,H
2067,Autocuration,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,10618,,14818,BAO_0000219,,B,,,,CHO,H
2068,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",10618,,4829,BAO_0000219,,B,,,,CHO,H
2069,Autocuration,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,10618,,4373,BAO_0000357,,B,,,,,H
2070,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,10618,,4373,BAO_0000357,,B,,,,,H
2071,Autocuration,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,10618,,14159,BAO_0000357,,B,,,,,H
2072,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,10618,,16633,BAO_0000357,,B,,,,,H
2073,Autocuration,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",279,,17085,BAO_0000019,,F,,,,,H
2074,Expert,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",279,,17085,BAO_0000019,,F,,,,,H
2075,Autocuration,,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,279,,16209,BAO_0000019,,F,,,,,H
2076,Autocuration,,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,279,,16209,BAO_0000019,,F,,,,,H
2077,Expert,,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",279,,17085,BAO_0000019,,F,,,,,H
2078,Autocuration,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,279,,14159,BAO_0000357,,B,,,,,H
2079,Autocuration,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,279,,15250,BAO_0000219,,B,,,,CHO,H
2080,Autocuration,,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),279,,3805,BAO_0000357,,B,,,,,H
2081,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,279,,16190,BAO_0000219,,B,,,,CHO,H
2082,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,279,,16190,BAO_0000357,,B,,,,,H
2083,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,279,,16209,BAO_0000357,,B,,,,,H
2084,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,279,,16209,BAO_0000357,,B,,,,,H
2085,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,279,,16209,BAO_0000357,,B,,,,,H
2086,Autocuration,,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,279,,6866,BAO_0000357,,B,,,,,H
2087,Expert,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,279,,17085,BAO_0000019,,B,,,,,H
2088,Autocuration,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,279,,16312,BAO_0000357,,B,,,,,H
2089,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,279,,6166,BAO_0000357,,B,,,,,H
2090,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,,15779,BAO_0000219,,B,,,,CHO,H
2091,Autocuration,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,279,,4199,BAO_0000219,,B,,,,CHO,H
2092,Autocuration,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,279,,14875,BAO_0000357,,B,,,,,H
2093,Autocuration,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,279,,15146,BAO_0000219,,B,,,,CHO,H
2094,Autocuration,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,279,,5213,BAO_0000357,,B,,,,,H
2095,Autocuration,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,279,,14818,BAO_0000219,,B,,,,CHO,H
2096,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,,4829,BAO_0000219,,B,,,,CHO,H
2097,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,,4829,BAO_0000219,,B,,,,CHO,H
2098,Autocuration,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,279,,4373,BAO_0000357,,B,,,,,H
2099,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,279,,4373,BAO_0000357,,B,,,,,H
2100,Autocuration,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,279,,5014,BAO_0000357,,B,,,,,H
2101,Autocuration,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",104686,,11662,BAO_0000019,,B,,,,,H
2102,Autocuration,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,,11662,BAO_0000019,,B,,,,,H
2103,Autocuration,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,11662,BAO_0000019,,B,,,,,H
2104,Autocuration,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,,14093,BAO_0000019,,B,,,,,H
2105,Autocuration,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",104686,,11200,BAO_0000218,,F,In vivo,,,,H
2106,Autocuration,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,11200,BAO_0000019,,F,,,,,H
2107,Intermediate,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,17005,,12352,BAO_0000019,,B,,,,,H
2108,Autocuration,,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",22226,Bos taurus,13657,BAO_0000019,,B,,,9913.0,,U
2109,Autocuration,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,22226,Bos taurus,14331,BAO_0000019,,B,,,9913.0,,U
2110,Autocuration,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,22226,Bos taurus,14331,BAO_0000019,,B,,,9913.0,,U
2111,Autocuration,,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,22226,,14331,BAO_0000019,,B,,,,,U
2112,Autocuration,,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,104784,Cavia porcellus,12685,BAO_0000019,,B,,,10141.0,,H
2113,Autocuration,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,104784,Cavia porcellus,14389,BAO_0000019,,B,,,10141.0,,H
2114,Autocuration,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,104784,Cavia porcellus,14386,BAO_0000019,,B,,,10141.0,,H
2115,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,104784,,5732,BAO_0000224,,B,,,,,H
2116,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104784,,16293,BAO_0000224,,B,,,,,H
2117,Autocuration,,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,104784,,2078,BAO_0000224,,B,,,,,H
2118,Autocuration,,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,10209,,5486,BAO_0000357,,B,,,,,H
2119,Autocuration,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,,11820,BAO_0000218,,B,In vivo,,,,H
2120,Autocuration,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,,10297,BAO_0000019,,B,,,,,H
2121,Autocuration,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,104826,,13704,BAO_0000224,,B,,,,,H
2122,Autocuration,,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,104826,Mus musculus,10297,BAO_0000019,,B,,,10090.0,,D
2123,Autocuration,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,,11820,BAO_0000218,,B,In vivo,,,,H
2124,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,104826,Mus musculus,10297,BAO_0000019,,B,,,10090.0,,D
2125,Autocuration,,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,104826,,11555,BAO_0000224,,B,,,,,H
2126,Autocuration,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,104826,,11555,BAO_0000224,,B,,,,,H
2127,Autocuration,,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,104826,,11555,BAO_0000224,,B,,,,,H
2128,Autocuration,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,Mus musculus,10297,BAO_0000019,,B,,,10090.0,,D
2129,Autocuration,,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,104784,Sus scrofa,16688,BAO_0000224,,B,,,9823.0,,H
2130,Autocuration,,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,104784,Sus scrofa,16688,BAO_0000224,,B,,,9823.0,,H
2131,Autocuration,,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,,5333,BAO_0000221,,B,,,,,U
2132,Autocuration,,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,,4437,BAO_0000221,,B,,,,,U
2133,Autocuration,,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,17005,Sus scrofa,5033,BAO_0000357,,B,,,9823.0,,H
2134,Autocuration,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,,15267,BAO_0000019,,B,,,,,H
2135,Autocuration,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,,15267,BAO_0000019,,B,,,,,H
2136,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,104826,,11820,BAO_0000019,,B,,,,,H
2137,Autocuration,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,,9069,BAO_0000224,,B,,,,,H
2138,Autocuration,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,104686,Rattus norvegicus,9162,BAO_0000019,,B,,,10116.0,,D
2139,Autocuration,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,104686,,9162,BAO_0000019,,B,,,,,H
2140,Autocuration,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,104686,,9162,BAO_0000019,,B,,,,,H
2141,Autocuration,,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,104686,,10428,BAO_0000019,,F,,,,,H
2142,Autocuration,,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,104686,,9628,BAO_0000019,,B,,,,,H
2143,Autocuration,,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,104686,,12704,BAO_0000224,,B,,,,,H
2144,Autocuration,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104686,Rattus norvegicus,15453,BAO_0000224,,B,,,10116.0,,D
2145,Autocuration,,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,104686,,188,BAO_0000224,,B,,,,,H
2146,Autocuration,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,104686,,10349,BAO_0000224,,B,,,,,H
2147,Autocuration,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,104686,,10349,BAO_0000224,,B,,,,,H
2148,Autocuration,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,,8868,BAO_0000224,,B,,,,,H
2149,Autocuration,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,,10025,BAO_0000224,,B,,,,,H
2150,Autocuration,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,,10025,BAO_0000224,,B,,,,,H
2151,Autocuration,,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,104686,,11702,BAO_0000224,,B,,,,,H
2152,Autocuration,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,104686,,11702,BAO_0000224,,B,,,,,H
2153,Autocuration,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,11702,BAO_0000224,,B,,,,,H
2154,Autocuration,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,104686,,11702,BAO_0000019,,F,,,,,H
2155,Autocuration,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,104686,,11702,BAO_0000019,,F,,,,,H
2156,Autocuration,,Hippocampus,10000000.0,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,104686,,10085,BAO_0000221,,B,,,,,H
2157,Autocuration,,Hippocampus,10000000.0,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,104686,,10085,BAO_0000221,,B,,,,,H
2158,Autocuration,,Brain,955.0,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,104686,Rattus norvegicus,9630,BAO_0000221,,B,,,10116.0,,D
2159,Autocuration,,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,104686,,11070,BAO_0000019,,B,,,,,H
2160,Autocuration,Membranes,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,,9841,BAO_0000249,,B,,,,,H
2161,Autocuration,Membranes,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,,9841,BAO_0000249,,B,,,,,H
2162,Autocuration,,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,104686,,13291,BAO_0000019,,B,,,,,H
2163,Autocuration,,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,104686,,10590,BAO_0000019,,F,,,,,H
2164,Autocuration,,Brain,955.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,Rattus norvegicus,9064,BAO_0000221,,B,,,10116.0,,D
2165,Autocuration,Membranes,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,104686,Rattus norvegicus,12268,BAO_0000249,,B,,,10116.0,,D
2166,Autocuration,,Brain,955.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,104686,,13508,BAO_0000221,,B,,,,,H
2167,Autocuration,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,,11279,BAO_0000019,,F,,,,,H
2168,Autocuration,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,104686,,11200,BAO_0000019,,F,,,,,H
2169,Autocuration,,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,11200,BAO_0000019,,F,,,,,H
2170,Autocuration,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,,11200,BAO_0000019,,F,,,,,H
2171,Autocuration,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,,11200,BAO_0000019,,F,,,,,H
2172,Autocuration,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,11200,BAO_0000019,,F,,,,,H
2173,Autocuration,,Brain,955.0,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,104686,,9231,BAO_0000220,,B,,,,,H
2174,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,,9737,BAO_0000019,,B,,,,,H
2175,Autocuration,,Brain,955.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,104686,,9737,BAO_0000249,,B,,,,,H
2176,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,104686,,9737,BAO_0000019,,B,,,,,H
2177,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,,9737,BAO_0000019,,B,,,,,H
2178,Autocuration,,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,104686,Rattus norvegicus,11828,BAO_0000019,,B,,,10116.0,,D
2179,Autocuration,,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,104686,,12253,BAO_0000019,,B,,,,,H
2180,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,104686,,12253,BAO_0000019,,B,,,,,H
2181,Autocuration,,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",104686,,11279,BAO_0000019,,F,,,,,H
2182,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,104686,,11866,BAO_0000019,,B,,,,,H
2183,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,104686,Rattus norvegicus,14424,BAO_0000224,,B,,,10116.0,,D
2184,Autocuration,,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,Rattus norvegicus,15180,BAO_0000019,,B,,,10116.0,,D
2185,Autocuration,,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,Rattus norvegicus,15180,BAO_0000019,,B,,,10116.0,,D
2186,Autocuration,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,104686,Rattus norvegicus,9786,BAO_0000019,,B,,,10116.0,,D
2187,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,104686,,12132,BAO_0000224,,B,,,,,H
2188,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,104686,,5486,BAO_0000249,,B,,,,,H
2189,Autocuration,,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,104686,,15316,BAO_0000019,,B,,,,,H
2190,Autocuration,,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,104686,,16429,BAO_0000019,,B,,,,,H
2191,Autocuration,,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,104686,,14617,BAO_0000224,,B,,,,,H
2192,Autocuration,,Brain,955.0,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,104686,,11351,BAO_0000221,,B,,,,,H
2193,Autocuration,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,,11279,BAO_0000019,,F,,,,,H
2194,Autocuration,,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,9523,BAO_0000019,,B,,,,,H
2195,Autocuration,,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,9523,BAO_0000019,,B,,,,,H
2196,Autocuration,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,9523,BAO_0000019,,B,,,,,H
2197,Autocuration,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,9523,BAO_0000019,,B,,,,,H
2198,Autocuration,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,9523,BAO_0000019,,B,,,,,H
2199,Autocuration,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,9523,BAO_0000019,,B,,,,,H
2200,Autocuration,,,,Hill coefficient of compound was determined,105075,,9523,BAO_0000224,,B,,,,,H
2201,Autocuration,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,22226,,4771,BAO_0000019,,B,,,,,U
2202,Autocuration,,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,104686,Rattus norvegicus,5033,BAO_0000019,,B,,,10116.0,,D
2203,Expert,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,12687,,10845,BAO_0000019,,B,,,,,H
2204,Expert,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,12687,,10845,BAO_0000019,,B,,,,,H
2205,Autocuration,,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),12687,,16288,BAO_0000357,,B,,,,,H
2206,Autocuration,,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),12687,,16288,BAO_0000019,,B,,,,,H
2207,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,12687,,16190,BAO_0000019,,B,,,,,H
2208,Autocuration,,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,104686,Rattus norvegicus,12463,BAO_0000224,,B,,,10116.0,,D
2209,Autocuration,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",104686,,9699,BAO_0000224,,B,,,,,H
2210,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,104686,,9699,BAO_0000224,,B,,,,,H
2211,Autocuration,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,11662,BAO_0000019,,B,,,,,H
2212,Autocuration,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,104784,,1205,BAO_0000224,,B,,,,,H
2213,Autocuration,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,22226,,11376,BAO_0000219,,B,,,,,U
2214,Autocuration,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",104784,,11376,BAO_0000219,,B,,,,,H
2215,Autocuration,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,104784,,4639,BAO_0000224,,B,,,,,H
2216,Autocuration,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,104784,,2222,BAO_0000224,,B,,,,,H
2217,Autocuration,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,104784,,1558,BAO_0000224,,B,,,,,H
2218,Autocuration,,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,104784,,1089,BAO_0000224,,B,,,,,H
2219,Autocuration,Brain membranes,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,104784,,386,BAO_0000249,,B,,,,,H
2220,Autocuration,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,104784,,2474,BAO_0000224,,B,,,,,H
2221,Autocuration,,,,Binding affinity towards 5-HT2 receptor,104784,,17066,BAO_0000224,,B,,,,,H
2222,Autocuration,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104784,,959,BAO_0000224,,B,,,,,H
2223,Autocuration,,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,104784,,6398,BAO_0000224,,B,,,,,H
2224,Autocuration,,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,104686,,11889,BAO_0000224,,B,,,,,H
2225,Autocuration,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,,4221,BAO_0000224,,B,,,,,H
2226,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,104784,,11026,BAO_0000224,,B,,,,,H
2227,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,104784,,11866,BAO_0000224,,B,,,,,H
2228,Autocuration,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,,4221,BAO_0000224,,B,,,,,H
2229,Autocuration,,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,22226,,13950,BAO_0000019,,B,,,,,U
2230,Autocuration,,,,5-hydroxytryptamine 2 receptor binding affinity,104784,,1263,BAO_0000224,,B,,,,,H
2231,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,17005,,13291,BAO_0000357,,B,,,,,H
2232,Autocuration,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,17005,,10812,BAO_0000357,,B,,,,,H
2233,Autocuration,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,,13020,BAO_0000224,,B,,,,,H
2234,Autocuration,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,104784,,13021,BAO_0000224,,B,,,,,H
2235,Autocuration,,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,,13020,BAO_0000224,,B,,,,,H
2236,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,17005,,14532,BAO_0000357,,B,,,,,H
2237,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,,13944,BAO_0000357,,B,,,,,H
2238,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,,14331,BAO_0000357,,B,,,,,H
2239,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,17005,,14118,BAO_0000357,,B,,,,,H
2240,Autocuration,,,,Binding affinity against serotonergic 5-HT2 receptor,17005,,13033,BAO_0000357,,B,,,,,H
2241,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,17005,,10321,BAO_0000357,,B,,,,,H
2242,Autocuration,,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,17005,,12918,BAO_0000357,,B,,,,,H
2243,Autocuration,,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,17005,,15120,BAO_0000357,,B,,,,,H
2244,Autocuration,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,17005,,2613,BAO_0000218,,B,,,,,H
2245,Autocuration,,,,Inhibitory activity against cloned human 5-HT2 receptor,104784,Homo sapiens,13378,BAO_0000224,,B,,,9606.0,,D
2246,Autocuration,,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",104784,Homo sapiens,2331,BAO_0000219,,B,,,9606.0,CHO,D
2247,Autocuration,,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",104784,Homo sapiens,2331,BAO_0000219,,B,,,9606.0,CHO,D
2248,Autocuration,,,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",104784,Homo sapiens,2331,BAO_0000219,,B,,,9606.0,CHO,D
2249,Autocuration,,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",104784,Homo sapiens,2331,BAO_0000219,,B,,,9606.0,CHO,D
2250,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104784,,4170,BAO_0000224,,B,,,,,H
2251,Autocuration,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104784,,15453,BAO_0000224,,B,,,,,H
2252,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,17005,,1479,BAO_0000357,,B,,,,,H
2253,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,104686,,11139,BAO_0000224,,B,,,,,H
2254,Expert,,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,17005,,13969,BAO_0000357,,B,,,,,H
2255,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,17005,,13392,BAO_0000357,,B,,,,,H
2256,Expert,,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,17005,,14430,BAO_0000019,,B,,,,,H
2257,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,107,Cavia porcellus,13181,BAO_0000357,,B,,,10141.0,,H
2258,Autocuration,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,,17200,BAO_0000357,,B,,,,,H
2259,Autocuration,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,17200,BAO_0000357,,B,,,,,H
2260,Autocuration,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,,17200,BAO_0000357,,B,,,,,H
2261,Autocuration,,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,107,,13463,BAO_0000357,,B,,,,,H
2262,Autocuration,,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,,6347,BAO_0000219,,B,,,,CHO,H
2263,Expert,,,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,107,Homo sapiens,6857,BAO_0000219,,F,,,9606.0,CHO,D
2264,Autocuration,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,,4176,BAO_0000219,,F,,,,,H
2265,Autocuration,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,107,,4176,BAO_0000219,,F,,,,,H
2266,Autocuration,,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,,4176,BAO_0000219,,F,,,,,H
2267,Autocuration,,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",107,,6347,BAO_0000219,,B,,,,CHO,H
2268,Autocuration,,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",107,,6347,BAO_0000219,,B,,,,CHO,H
2269,Autocuration,,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,107,,15331,BAO_0000357,,B,,,,,H
2270,Expert,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,107,Homo sapiens,16146,BAO_0000357,,B,,,9606.0,,D
2271,Autocuration,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,15250,BAO_0000219,,B,,,,CHO,H
2272,Expert,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,107,,13631,BAO_0000219,,B,,,,,H
2273,Autocuration,,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),107,,3805,BAO_0000357,,B,,,,,H
2274,Autocuration,,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,107,,4011,BAO_0000219,,B,,,,CHO,H
2275,Expert,,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,107,,4012,BAO_0000219,,B,,,,CHO,H
2276,Expert,,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,107,,6366,BAO_0000219,,B,,,,L929,H
2277,Expert,,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,15949,BAO_0000219,,B,,,,CHO,H
2278,Autocuration,,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,107,,14093,BAO_0000019,,F,,,,,H
2279,Autocuration,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,,13481,BAO_0000019,,F,,,,,H
2280,Autocuration,,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,,6347,BAO_0000219,,B,,,,CHO,H
2281,Autocuration,,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,107,,6347,BAO_0000219,,B,,,,CHO,H
2282,Autocuration,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,107,,14093,BAO_0000019,,F,,,,,H
2283,Autocuration,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,107,,14093,BAO_0000019,,F,,,,,H
2284,Autocuration,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,,13481,BAO_0000019,,F,,,,,H
2285,Autocuration,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,107,,14442,BAO_0000357,,B,,,,,H
2286,Autocuration,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,,14442,BAO_0000357,,B,,,,,H
2287,Autocuration,,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,107,,14755,BAO_0000357,,B,,,,,H
2288,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,107,,16441,BAO_0000357,,B,,,,,H
2289,Autocuration,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,107,,14744,BAO_0000357,,B,,,,,H
2290,Expert,,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,16659,BAO_0000219,,B,,,,CHO,H
2291,Autocuration,,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,107,,3307,BAO_0000357,,B,,,,,H
2292,Expert,,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,107,Homo sapiens,6857,BAO_0000019,,B,,,9606.0,,D
2293,Expert,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,107,,5635,BAO_0000357,,B,,,,,H
2294,Expert,,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,107,Homo sapiens,4234,BAO_0000357,,B,,,9606.0,,D
2295,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,,15527,BAO_0000357,,B,,,,,H
2296,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,107,,6588,BAO_0000219,,B,,,,CHO,H
2297,Expert,,,,Binding affinity towards human 5-HT2A receptor in BEK cells,107,,13631,BAO_0000219,,B,,,,,H
2298,Autocuration,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,107,,17723,BAO_0000357,,B,,,,,H
2299,Autocuration,,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,,14770,BAO_0000357,,B,,,,,H
2300,Expert,,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,Homo sapiens,16293,BAO_0000357,,B,,,9606.0,,D
2301,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,,16209,BAO_0000357,,B,,,,,H
2302,Autocuration,,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,107,,12469,BAO_0000219,,B,,,,,H
2303,Autocuration,,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,107,,15363,BAO_0000357,,B,,,,,H
2304,Autocuration,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,107,,15363,BAO_0000357,,B,,,,,H
2305,Expert,,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",107,,16441,BAO_0000019,,B,,,,,H
2306,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,107,,8,BAO_0000357,,B,,,,,H
2307,Autocuration,,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,107,,4176,BAO_0000219,,B,,,,HEK293,H
2308,Autocuration,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,107,,17085,BAO_0000019,,B,,,,,H
2309,Autocuration,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,17200,BAO_0000357,,B,,,,,H
2310,Expert,,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,Homo sapiens,17200,BAO_0000357,,B,,,9606.0,,D
2311,Expert,,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,107,Homo sapiens,4013,BAO_0000219,,B,,,9606.0,CHO,D
2312,Autocuration,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,107,,5088,BAO_0000357,,B,,,,,H
2313,Expert,,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,107,Homo sapiens,5088,BAO_0000357,,B,,,9606.0,,D
2314,Autocuration,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,107,,5088,BAO_0000357,,B,,,,,H
2315,Expert,,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,107,Homo sapiens,5088,BAO_0000357,,B,,,9606.0,,D
2316,Autocuration,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,107,,5088,BAO_0000357,,B,,,,,H
2317,Autocuration,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,107,,5088,BAO_0000357,,B,,,,,H
2318,Autocuration,,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,104686,,9786,BAO_0000019,,B,,,,,H
2319,Autocuration,,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,104686,Rattus norvegicus,9205,BAO_0000019,,B,,,10116.0,,D
2320,Autocuration,,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,104686,,11257,BAO_0000224,,B,,,,,H
2321,Autocuration,,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,,9362,BAO_0000019,,B,,,,,H
2322,Autocuration,,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,,9362,BAO_0000019,,B,,,,,H
2323,Autocuration,,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,104686,,10590,BAO_0000224,,B,,,,,H
2324,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,,10468,BAO_0000019,,B,,,,,H
2325,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,104686,,13050,BAO_0000019,,B,,,,,H
2326,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,104686,,11624,BAO_0000019,,B,,,,,H
2327,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,,10468,BAO_0000019,,B,,,,,H
2328,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,104686,,10330,BAO_0000224,,B,,,,,H
2329,Autocuration,,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,,10062,BAO_0000224,,B,,,,,H
2330,Autocuration,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,,11642,BAO_0000224,,B,,,,,H
2331,Autocuration,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,,10062,BAO_0000224,,B,,,,,H
2332,Autocuration,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,,13427,BAO_0000219,,B,In vitro,,,,H
2333,Autocuration,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,Rattus norvegicus,12280,BAO_0000224,,B,,,10116.0,,D
2334,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,104686,Rattus norvegicus,4101,BAO_0000224,,B,,,10116.0,,D
2335,Autocuration,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,104686,,10062,BAO_0000224,,B,,,,,H
2336,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,104686,,11147,BAO_0000224,,B,,,,,H
2337,Autocuration,,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,Rattus norvegicus,2395,BAO_0000219,,B,,,10116.0,CHO-K1,D
2338,Autocuration,,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,Rattus norvegicus,2395,BAO_0000219,,B,,,10116.0,CHO-K1,D
2339,Autocuration,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,104686,Rattus norvegicus,9098,BAO_0000019,,B,,,10116.0,,D
2340,Autocuration,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,104686,,9098,BAO_0000019,,B,,,,,H
2341,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,104686,Rattus norvegicus,9098,BAO_0000019,,B,,,10116.0,,D
2342,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,9443,BAO_0000224,,B,,,,,H
2343,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,,9443,BAO_0000224,,B,,,,,H
2344,Autocuration,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",104686,,9699,BAO_0000019,,B,,,,,H
2345,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,104686,,9699,BAO_0000019,,B,,,,,H
2346,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,,9098,BAO_0000224,,B,,,,,H
2347,Autocuration,,,,Affinity for 5-hydroxytryptamine 2 receptor,104686,Rattus norvegicus,3070,BAO_0000224,,B,,,10116.0,,D
2348,Autocuration,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,104686,,9547,BAO_0000224,,B,,,,,H
2349,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,104686,,10444,BAO_0000019,,B,,,,,H
2350,Autocuration,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,104686,,14617,BAO_0000019,,B,,,,,H
2351,Autocuration,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,104686,,14617,BAO_0000019,,B,,,,,H
2352,Autocuration,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),104686,,11130,BAO_0000224,,B,,,,,H
2353,Autocuration,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),104686,,11130,BAO_0000218,,B,In vivo,,,,H
2354,Autocuration,,Brain,955.0,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,104686,,14542,BAO_0000221,,B,,,,,H
2355,Autocuration,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,104686,,2797,BAO_0000224,,B,,,,,H
2356,Autocuration,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,,11332,BAO_0000019,,B,,,,,H
2357,Autocuration,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,,11332,BAO_0000019,,B,,,,,H
2358,Autocuration,,Frontal cortex,1870.0,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,104686,,10752,BAO_0000019,,B,,,,,H
2359,Autocuration,,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,,1185,BAO_0000224,,B,,,,,H
2360,Autocuration,,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,,1185,BAO_0000224,,B,,,,,H
2361,Autocuration,,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,104686,Rattus norvegicus,11624,BAO_0000224,,B,,,10116.0,,D
2362,Autocuration,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,104686,,1344,BAO_0000019,,B,,,,,H
2363,Autocuration,,Striatum,2435.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,104686,Rattus norvegicus,15453,BAO_0000019,,B,,,10116.0,,D
2364,Autocuration,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,,11662,BAO_0000019,,B,,,,,H
2365,Autocuration,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,11662,BAO_0000019,,B,,,,,H
2366,Autocuration,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,104686,,10796,BAO_0000224,,B,,,,,H
2367,Autocuration,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,,9069,BAO_0000224,,B,,,,,H
2368,Autocuration,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,104686,Rattus norvegicus,8814,BAO_0000019,,B,,,10116.0,,D
2369,Autocuration,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,104686,Rattus norvegicus,8908,BAO_0000019,,B,,,10116.0,,D
2370,Autocuration,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,,9098,BAO_0000019,,B,,,,,H
2371,Autocuration,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,104686,,9098,BAO_0000019,,B,,,,,H
2372,Autocuration,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,,9098,BAO_0000019,,B,,,,,H
2373,Autocuration,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,104686,,9098,BAO_0000019,,B,,,,,H
2374,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,104686,,9098,BAO_0000249,,B,,,,,H
2375,Autocuration,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,104686,,9098,BAO_0000019,,B,,,,,H
2376,Autocuration,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,104686,,9098,BAO_0000019,,B,,,,,H
2377,Autocuration,,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,104686,,9161,BAO_0000019,,B,,,,,H
2378,Autocuration,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,104686,,9161,BAO_0000019,,B,,,,,H
2379,Autocuration,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,104686,,9161,BAO_0000019,,B,,,,,H
2380,Autocuration,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,104686,,9161,BAO_0000019,,B,,,,,H
2381,Autocuration,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,104686,,9161,BAO_0000019,,B,,,,,H
2382,Autocuration,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,104686,,9161,BAO_0000019,,B,,,,,H
2383,Autocuration,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,104686,,9161,BAO_0000019,,B,,,,,H
2384,Autocuration,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,104686,,9161,BAO_0000019,,B,,,,,H
2385,Autocuration,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,104686,,9161,BAO_0000019,,B,,,,,H
2386,Autocuration,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,104686,,9161,BAO_0000019,,B,,,,,H
2387,Autocuration,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,104686,,9161,BAO_0000019,,B,,,,,H
2388,Autocuration,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,104686,,9161,BAO_0000019,,B,,,,,H
2389,Autocuration,,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,104686,,12094,BAO_0000019,,B,,,,,H
2390,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,104686,,12018,BAO_0000249,,B,,,,,H
2391,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,104686,,10394,BAO_0000249,,B,,,,,H
2392,Autocuration,,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,104686,,15260,BAO_0000224,,B,,,,,H
2393,Autocuration,,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,104686,Rattus norvegicus,11624,BAO_0000224,,B,,,10116.0,,D
2394,Autocuration,,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,104686,,13654,BAO_0000224,,B,,,,,H
2395,Autocuration,,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,104686,,9541,BAO_0000019,,B,,,,,H
2396,Autocuration,,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,104686,,11933,BAO_0000224,,B,,,,,H
2397,Autocuration,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,104686,,15538,BAO_0000019,,B,,,,,H
2398,Autocuration,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,104686,,15538,BAO_0000019,,B,,,,,H
2399,Autocuration,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,104686,,15538,BAO_0000019,,B,,,,,H
2400,Autocuration,,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,104686,,8841,BAO_0000019,,B,,,,,D
2401,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,104686,,1455,BAO_0000224,,B,,,,,H
2402,Autocuration,,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,104686,,1455,BAO_0000224,,B,,,,,H
2403,Autocuration,,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,104686,,11752,BAO_0000019,,B,,,,,H
2404,Autocuration,,Brain,955.0,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,104686,,11642,BAO_0000221,,B,,,,,H
2405,Autocuration,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,104686,,12092,BAO_0000224,,B,,,,,H
2406,Autocuration,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,104686,,3967,BAO_0000224,,B,,,,,H
2407,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,Rattus norvegicus,12771,BAO_0000224,,B,,,10116.0,,D
2408,Autocuration,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,104686,,11642,BAO_0000019,,B,,,,,H
2409,Autocuration,,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,104686,,11628,BAO_0000224,,B,,,,,H
2410,Autocuration,,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,,13654,BAO_0000224,,B,,,,,H
2411,Autocuration,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,11200,BAO_0000019,,F,,,,,H
2412,Autocuration,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,11200,BAO_0000019,,F,,,,,H
2413,Autocuration,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,,11200,BAO_0000218,,F,In vivo,,,,H
2414,Autocuration,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,,11200,BAO_0000218,,F,In vivo,,,,H
2415,Autocuration,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,,11200,BAO_0000218,,F,In vivo,,,,H
2416,Autocuration,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,,11200,BAO_0000218,,F,In vivo,,,,H
2417,Expert,,Brain,955.0,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,12687,,15436,BAO_0000221,,B,,,,,H
2418,Expert,,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,Rattus norvegicus,15436,BAO_0000019,,B,,,10116.0,,D
2419,Autocuration,,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,12687,,14025,BAO_0000019,,B,,,,,H
2420,Autocuration,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,12687,,4342,BAO_0000357,,B,,,,,H
2421,Expert,,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,12687,Rattus norvegicus,13735,BAO_0000019,,B,,,10116.0,,D
2422,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,12687,Rattus norvegicus,5816,BAO_0000357,,B,,,10116.0,,D
2423,Expert,,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,12687,,14287,BAO_0000019,,B,,,,,H
2424,Autocuration,,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,12687,,15738,BAO_0000357,,B,,,,,H
2425,Expert,,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,12687,Rattus norvegicus,15738,BAO_0000357,,B,,,10116.0,,D
2426,Autocuration,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,12687,,15026,BAO_0000019,,B,,,,,H
2427,Expert,,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,,16647,BAO_0000019,,B,,,,,H
2428,Autocuration,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,12687,,16647,BAO_0000019,,B,,,,,H
2429,Expert,,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,12687,Rattus norvegicus,13345,BAO_0000019,,B,,,10116.0,,D
2430,Autocuration,Membranes,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,12687,,1543,BAO_0000249,,B,,,,,H
2431,Autocuration,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,12687,,12444,BAO_0000019,,B,,,,,H
2432,Expert,,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,12687,,16404,BAO_0000019,,B,,,,,H
2433,Autocuration,,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,12687,,16404,BAO_0000219,,B,,,,CHO,H
2434,Expert,,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,12687,,15577,BAO_0000357,,B,,,,,H
2435,Autocuration,,,,Serotonergic activity of the compound.,12687,,15577,BAO_0000357,,B,,,,,H
2436,Autocuration,,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,12687,,2495,BAO_0000249,,B,,,,,H
2437,Expert,,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,12687,Rattus norvegicus,15042,BAO_0000019,,B,,,10116.0,,D
2438,Expert,,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,12687,,15026,BAO_0000249,,B,,,,,H
2439,Expert,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,Rattus norvegicus,12919,BAO_0000019,,F,,,10116.0,,D
2440,Expert,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,Rattus norvegicus,12919,BAO_0000019,,F,,,10116.0,,D
2441,Expert,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,Rattus norvegicus,12919,BAO_0000019,,F,,,10116.0,,D
2442,Autocuration,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,15194,BAO_0000357,,B,,,,,H
2443,Autocuration,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,12687,,15194,BAO_0000357,,B,,,,,H
2444,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,,4820,BAO_0000357,,B,,,,,H
2445,Autocuration,,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,107,,6736,BAO_0000357,,B,,,,,H
2446,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,107,,5163,BAO_0000357,,B,,,,,H
2447,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,107,,5163,BAO_0000357,,B,,,,,H
2448,Autocuration,,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,107,,6011,BAO_0000357,,B,,,,,H
2449,Expert,,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,107,Homo sapiens,14294,BAO_0000357,,B,,,9606.0,,D
2450,Autocuration,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,107,,5014,BAO_0000357,,B,,,,,H
2451,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,,17066,BAO_0000357,,B,,,,,H
2452,Autocuration,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,107,,17515,BAO_0000357,,B,,,,,H
2453,Expert,,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,107,,6736,BAO_0000357,,B,,,,,H
2454,Expert,,,,Affinity for 5-hydroxytryptamine 2A receptor,107,,5163,BAO_0000357,,B,,,,,H
2455,Expert,,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,107,,16911,BAO_0000219,,B,,,,NIH3T3,H
2456,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,107,,6841,BAO_0000357,,B,,,,,H
2457,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,107,,6119,BAO_0000357,,B,,,,,H
2458,Autocuration,,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,107,,3962,BAO_0000357,,B,,,,,H
2459,Autocuration,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,107,,4373,BAO_0000357,,B,,,,,H
2460,Autocuration,,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,107,,4373,BAO_0000357,,B,,,,,H
2461,Autocuration,,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,107,,3962,BAO_0000019,,F,,,,,H
2462,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,107,,1633,BAO_0000357,,B,,,,,H
2463,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,107,,4373,BAO_0000357,,B,,,,,H
2464,Expert,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,107,,6576,BAO_0000357,,B,,,,,H
2465,Autocuration,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,107,,4687,BAO_0000357,,B,,,,,H
2466,Autocuration,,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,107,,16946,BAO_0000357,,B,,,,,H
2467,Autocuration,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,107,,14159,BAO_0000357,,B,,,,,H
2468,Expert,,,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,107,Mus musculus,3032,BAO_0000219,,B,,,10090.0,CHO,H
2469,Autocuration,,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,107,,16655,BAO_0000357,,B,,,,,H
2470,Autocuration,,,,Binding affinity at 5-hydroxytryptamine 2A receptor,107,,13964,BAO_0000357,,B,,,,,H
2471,Expert,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,107,,16989,BAO_0000357,,B,,,,,H
2472,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,107,,16117,BAO_0000357,,B,,,,,H
2473,Autocuration,,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,107,,16700,BAO_0000357,,B,,,,,H
2474,Autocuration,,,,Affinity against 5-hydroxytryptamine 2A receptor,107,,3269,BAO_0000357,,B,,,,,H
2475,Expert,,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,107,Homo sapiens,1274,BAO_0000357,,B,,,9606.0,,D
2476,Autocuration,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,107,,1317,BAO_0000357,,B,,,,,H
2477,Autocuration,,,,Tested against 5-hydroxytryptamine 2A receptor,107,,12146,BAO_0000357,,B,,,,,H
2478,Autocuration,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,,12652,BAO_0000224,,B,,,,,H
2479,Autocuration,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,105075,,12652,BAO_0000224,,B,,,,,H
2480,Autocuration,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,105075,,12652,BAO_0000224,,B,,,,,H
2481,Autocuration,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,,12652,BAO_0000224,,B,,,,,H
2482,Autocuration,,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),107,,16647,BAO_0000357,,B,,,,,H
2483,Expert,,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,227,Homo sapiens,15851,BAO_0000219,,B,,,9606.0,HEK293,D
2484,Expert,,,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,227,Homo sapiens,6857,BAO_0000219,,F,,,9606.0,CHO,D
2485,Autocuration,,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),227,,3805,BAO_0000357,,B,,,,,H
2486,Expert,,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,227,Homo sapiens,6491,BAO_0000357,,B,,,9606.0,,D
2487,Autocuration,,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,227,,14093,BAO_0000019,,F,,,,,H
2488,Autocuration,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,227,,13481,BAO_0000019,,F,,,,,H
2489,Autocuration,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,227,,14093,BAO_0000019,,F,,,,,H
2490,Autocuration,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,227,,14093,BAO_0000019,,F,,,,,H
2491,Autocuration,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,227,,14093,BAO_0000019,,F,,,,,H
2492,Autocuration,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,,13481,BAO_0000019,,F,,,,,H
2493,Autocuration,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,227,,14442,BAO_0000357,,B,,,,,H
2494,Autocuration,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,227,,14442,BAO_0000357,,B,,,,,H
2495,Autocuration,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,,14442,BAO_0000357,,B,,,,,H
2496,Autocuration,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,107,,12369,BAO_0000357,,B,,,,,H
2497,Expert,,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,107,,12369,BAO_0000357,,B,,,,,H
2498,Expert,,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,107,,12369,BAO_0000357,,B,,,,,H
2499,Autocuration,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,107,,14447,BAO_0000019,,B,,,,,H
2500,Autocuration,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,107,,14447,BAO_0000019,,B,,,,,H
2501,Autocuration,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,17451,BAO_0000219,,B,,,,NIH3T3,H
2502,Autocuration,,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,,6857,BAO_0000219,,F,,,,CHO,H
2503,Expert,,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,Homo sapiens,6857,BAO_0000219,,F,,,9606.0,CHO,D
2504,Autocuration,,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,104817,,5635,BAO_0000224,,B,,,,,H
2505,Autocuration,,,,Binding activity radioligand.,107,,12861,BAO_0000357,,B,,,,,H
2506,Autocuration,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,107,,12861,BAO_0000019,,B,,,,,H
2507,Autocuration,,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,,5105,BAO_0000219,,B,,,,L929,H
2508,Expert,,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,,5104,BAO_0000219,,B,,,,L929,H
2509,Expert,,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,107,,5105,BAO_0000219,,B,,,,L929,H
2510,Autocuration,,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,107,,5105,BAO_0000219,,B,,,,L929,H
2511,Autocuration,,,,Binding affinity against 5-HT2A receptor,107,,5254,BAO_0000357,,B,,,,,H
2512,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,107,,5254,BAO_0000357,,B,,,,,H
2513,Autocuration,,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,107,,13267,BAO_0000219,,B,,,,HEK293,H
2514,Autocuration,,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,107,,13267,BAO_0000219,,B,,,,HEK293,H
2515,Expert,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,107,Homo sapiens,14157,BAO_0000219,,B,,,9606.0,HEK293,D
2516,Expert,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,Homo sapiens,12936,BAO_0000219,,B,,,9606.0,HEK293,D
2517,Expert,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,107,,14068,BAO_0000357,,B,,,,,H
2518,Expert,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,Homo sapiens,12936,BAO_0000219,,B,,,9606.0,HEK293,D
2519,Expert,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,Homo sapiens,12936,BAO_0000219,,B,,,9606.0,HEK293,D
2520,Expert,,,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,107,Homo sapiens,4540,BAO_0000219,,B,,,9606.0,HEK293,D
2521,Expert,,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,107,,6166,BAO_0000357,,B,,,,,H
2522,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,,17296,BAO_0000219,,B,,,,HEK293,H
2523,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,,17296,BAO_0000219,,B,,,,HEK293,H
2524,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,107,,17296,BAO_0000219,,B,,,,HEK293,H
2525,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,107,Homo sapiens,15779,BAO_0000219,,B,,,9606.0,HEK293,D
2526,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,107,,14391,BAO_0000219,,B,,,,HEK293,H
2527,Expert,,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",107,,15851,BAO_0000219,,B,,,,HEK293,H
2528,Expert,,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,107,Homo sapiens,15851,BAO_0000219,,B,,,9606.0,HEK293,D
2529,Expert,,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,107,,3832,BAO_0000219,,B,,,,HEK293,H
2530,Expert,,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,107,,3833,BAO_0000219,,B,,,,HEK293,H
2531,Expert,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,Homo sapiens,12936,BAO_0000219,,B,,,9606.0,HEK293,D
2532,Autocuration,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,107,,17451,BAO_0000219,,B,,,,NIH3T3,H
2533,Autocuration,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,17451,BAO_0000219,,B,,,,NIH3T3,H
2534,Autocuration,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,17451,BAO_0000219,,B,,,,NIH3T3,H
2535,Autocuration,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,107,,4199,BAO_0000219,,B,,,,HEK293,H
2536,Autocuration,,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,107,,1883,BAO_0000219,,B,,,,CHO-K1,H
2537,Expert,,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,107,,1883,BAO_0000219,,B,,,,CHO-K1,H
2538,Expert,,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,Homo sapiens,14875,BAO_0000357,,B,,,9606.0,,D
2539,Autocuration,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,107,,15146,BAO_0000219,,B,,,,HEK293,H
2540,Autocuration,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,107,,5213,BAO_0000219,,B,,,,HEK293,H
2541,Expert,,,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,107,Homo sapiens,16404,BAO_0000219,,B,,,9606.0,CHO,D
2542,Autocuration,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,107,,14818,BAO_0000219,,B,,,,HEK293,H
2543,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",107,,4829,BAO_0000219,,B,,,,HEK293,H
2544,Autocuration,,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,10620,,12652,BAO_0000219,,F,,,,NIH3T3,H
2545,Expert,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,107,,4682,BAO_0000219,,B,,,,NIH3T3,H
2546,Autocuration,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,10620,,12652,BAO_0000019,,F,,,,,H
2547,Autocuration,,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,10621,,4921,BAO_0000357,,B,,,,,H
2548,Autocuration,,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,10621,,4921,BAO_0000357,,B,,,,,H
2549,Autocuration,,,,Binding affinity against rabbit aorta 5-HT2A receptor,107,Oryctolagus cuniculus,16312,BAO_0000357,,B,,,9986.0,,H
2550,Expert,,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,107,Oryctolagus cuniculus,14998,BAO_0000357,,B,,,9986.0,,H
2551,Expert,,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,107,Oryctolagus cuniculus,14025,BAO_0000357,,B,,,9986.0,,H
2552,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,107,Oryctolagus cuniculus,13047,BAO_0000019,,B,,,9986.0,,H
2553,Expert,,,,The compound was tested for binding affinity against 5-HT2A receptor,107,Oryctolagus cuniculus,13047,BAO_0000357,,B,,,9986.0,,H
2554,Autocuration,,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,10576,,1883,BAO_0000219,,B,,,,CHO-K1,H
2555,Autocuration,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,12687,,13463,BAO_0000019,,B,,,,,H
2556,Autocuration,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,,13463,BAO_0000019,,B,,,,,H
2557,Autocuration,,Stomach,945.0,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,12687,,13463,BAO_0000019,,B,,,,,H
2558,Expert,,Stomach,945.0,Binding affinity for 5-HT 2A in rat stomach fundus,12687,Rattus norvegicus,13463,BAO_0000019,,B,,,10116.0,,D
2559,Autocuration,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,,13463,BAO_0000019,,B,,,,,H
2560,Expert,,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,12687,,16326,BAO_0000219,,B,,,,NIH3T3,H
2561,Autocuration,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,12687,,14093,BAO_0000019,,F,,,,,H
2562,Autocuration,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,12687,,14093,BAO_0000019,,F,,,,,H
2563,Autocuration,,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,,15740,BAO_0000357,,B,,,,,H
2564,Autocuration,,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,12687,,16633,BAO_0000357,,B,,,,,H
2565,Expert,,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,12687,Rattus norvegicus,17200,BAO_0000019,,F,,,10116.0,,D
2566,Autocuration,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,17133,BAO_0000357,,B,,,,,H
2567,Autocuration,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,17133,BAO_0000357,,B,,,,,H
2568,Autocuration,,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,17133,BAO_0000357,,B,,,,,H
2569,Autocuration,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,17200,BAO_0000219,,F,,,,,H
2570,Autocuration,,,,Efficacy at 5-hydroxytryptamine 2A receptor,12687,,15363,BAO_0000019,,F,,,,,H
2571,Autocuration,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,,17200,BAO_0000357,,B,,,,,H
2572,Expert,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,Rattus norvegicus,17200,BAO_0000357,,B,,,10116.0,,D
2573,Expert,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),12687,Rattus norvegicus,17200,BAO_0000357,,B,,,10116.0,,D
2574,Expert,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,Rattus norvegicus,17200,BAO_0000219,,F,,,10116.0,,D
2575,Autocuration,,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,17200,BAO_0000219,,F,,,,,H
2576,Autocuration,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,12687,,17211,BAO_0000019,,B,,,,,H
2577,Expert,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,12687,,17331,BAO_0000019,,B,,,,,H
2578,Expert,,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,12687,,13565,BAO_0000249,,B,,,,,H
2579,Expert,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,12687,,13730,BAO_0000357,,B,,,,,H
2580,Expert,,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,12687,,12416,BAO_0000019,,B,,,,,H
2581,Autocuration,,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,12687,,15295,BAO_0000357,,B,,,,,H
2582,Autocuration,,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,12687,,1742,BAO_0000019,,B,,,,,H
2583,Autocuration,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,12687,,15295,BAO_0000357,,B,,,,,H
2584,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,12687,,14970,BAO_0000019,,B,,,,,H
2585,Expert,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,12687,,16693,BAO_0000019,,B,,,,,H
2586,Expert,,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,12687,Rattus norvegicus,14776,BAO_0000019,,B,,,10116.0,,D
2587,Autocuration,,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,14286,BAO_0000249,,B,,,,,H
2588,Expert,,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,Rattus norvegicus,17200,BAO_0000019,,B,,,10116.0,,D
2589,Expert,,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),12687,,15306,BAO_0000357,,B,,,,,H
2590,Expert,,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,12687,Rattus norvegicus,14178,BAO_0000357,,B,,,10116.0,,D
2591,Expert,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,12687,Rattus norvegicus,14229,BAO_0000019,,B,,,10116.0,,D
2592,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,12687,,12884,BAO_0000357,,B,,,,,H
2593,Expert,,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",12687,,13149,BAO_0000357,,B,,,,,H
2594,Expert,,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,12687,Rattus norvegicus,15295,BAO_0000019,,B,,,10116.0,,D
2595,Autocuration,,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,12687,,15740,BAO_0000357,,B,,,,,H
2596,Autocuration,,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",12687,,15185,BAO_0000019,,B,,,,,H
2597,Autocuration,,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",12687,,15185,BAO_0000019,,B,,,,,H
2598,Expert,,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,12687,,17529,BAO_0000019,,B,,,,,H
2599,Autocuration,,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,,14826,BAO_0000019,,B,,,,,H
2600,Expert,,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,12687,,17211,BAO_0000019,,B,,,,,H
2601,Autocuration,,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,,14826,BAO_0000019,,B,,,,,H
2602,Autocuration,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,,14093,BAO_0000019,,B,,,,,H
2603,Autocuration,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,12687,,14093,BAO_0000019,,B,,,,,H
2604,Expert,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,12687,,13246,BAO_0000219,,B,,,,NIH3T3,H
2605,Expert,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,12687,,13246,BAO_0000357,,B,,,,,H
2606,Expert,,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,Rattus norvegicus,15436,BAO_0000019,,B,,,10116.0,,D
2607,Expert,,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,Rattus norvegicus,15436,BAO_0000019,,B,,,10116.0,,D
2608,Autocuration,,Brain,955.0,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,12687,,14442,BAO_0000221,,B,,,,,H
2609,Expert,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,12687,,12457,BAO_0000357,,B,,,,,H
2610,Expert,,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,12687,,12457,BAO_0000219,,B,,,,NIH3T3,H
2611,Autocuration,,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",12687,,14755,BAO_0000221,,F,,,,,H
2612,Autocuration,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,12687,,4707,BAO_0000357,,B,,,,,H
2613,Expert,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,12687,,13297,BAO_0000357,,B,,,,,H
2614,Expert,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,12687,,17331,BAO_0000019,,B,,,,,H
2615,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,12687,,4664,BAO_0000019,,B,,,,,H
2616,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,,16633,BAO_0000357,,B,,,,,H
2617,Expert,,,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,12687,Rattus norvegicus,4664,BAO_0000219,,B,,,10116.0,NIH3T3,D
2618,Expert,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,16133,BAO_0000357,,B,,,,,H
2619,Expert,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,16133,BAO_0000357,,B,,,,,H
2620,Expert,,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,12687,Rattus norvegicus,14060,BAO_0000019,,B,,,10116.0,,D
2621,Expert,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,16326,BAO_0000357,,B,,,,,H
2622,Expert,,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,12687,,16659,BAO_0000219,,B,,,,CHO,H
2623,Autocuration,,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,12687,,14776,BAO_0000019,,B,,,,,H
2624,Autocuration,,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,12687,,13481,BAO_0000357,,B,,,,,H
2625,Autocuration,,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,12687,,17386,BAO_0000357,,B,,,,,H
2626,Expert,,,,Binding affinity for 5-hydroxytryptamine 2A receptor,12687,Rattus norvegicus,6611,BAO_0000357,,B,,,10116.0,,D
2627,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,12687,,14423,BAO_0000019,,B,,,,,H
2628,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,12687,,15412,BAO_0000019,,B,,,,,H
2629,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,12687,,15412,BAO_0000019,,B,,,,,H
2630,Autocuration,,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,12687,,6238,BAO_0000019,,B,,,,,H
2631,Expert,,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,12687,,6648,BAO_0000357,,B,,,,,H
2632,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,12687,,5667,BAO_0000357,,B,,,,,H
2633,Expert,,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,12687,Rattus norvegicus,6611,BAO_0000357,,B,,,10116.0,,D
2634,Autocuration,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,13481,BAO_0000357,,B,,,,,H
2635,Autocuration,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,12687,,13481,BAO_0000357,,B,,,,,H
2636,Expert,,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,12687,,15558,BAO_0000219,,B,,,,NIH3T3,H
2637,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,12687,,6013,BAO_0000357,,B,,,,,H
2638,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,,16633,BAO_0000357,,B,,,,,H
2639,Autocuration,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,12687,,6013,BAO_0000357,,B,,,,,H
2640,Expert,,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,12687,Rattus norvegicus,6013,BAO_0000357,,B,,,10116.0,,D
2641,Autocuration,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,12687,,6013,BAO_0000357,,B,,,,,H
2642,Expert,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,12687,,6013,BAO_0000357,,B,,,,,H
2643,Autocuration,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,12687,,6013,BAO_0000357,,B,,,,,H
2644,Autocuration,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,12687,,6013,BAO_0000357,,B,,,,,H
2645,Autocuration,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,,16293,BAO_0000357,,B,,,,,H
2646,Expert,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,12687,,17175,BAO_0000219,,B,,,,NIH3T3,H
2647,Expert,,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,Rattus norvegicus,13278,BAO_0000357,,B,,,10116.0,,D
2648,Autocuration,,Caudate-putamen,5383.0,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,12687,,3682,BAO_0000019,,B,,,,,H
2649,Autocuration,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,12687,,2014,BAO_0000357,,B,,,,,H
2650,Autocuration,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,12687,,2014,BAO_0000357,,B,,,,,H
2651,Autocuration,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,12687,,4932,BAO_0000357,,B,,,,,H
2652,Autocuration,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,12687,,4932,BAO_0000019,,B,,,,,H
2653,Autocuration,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,12687,,3935,BAO_0000357,,B,,,,,H
2654,Expert,,Hippocampus,10000000.0,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,12687,Rattus norvegicus,5432,BAO_0000221,,B,,,10116.0,,D
2655,Autocuration,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,,15818,BAO_0000357,,B,,,,,H
2656,Autocuration,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,12687,,13672,BAO_0000357,,B,,,,,H
2657,Autocuration,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,12687,,13672,BAO_0000357,,B,,,,,H
2658,Expert,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,12687,,14749,BAO_0000219,,B,,,,NIH3T3,H
2659,Autocuration,,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,12687,,13462,BAO_0000019,,B,,,,,H
2660,Autocuration,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,,15740,BAO_0000357,,B,,,,,H
2661,Expert,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,,16647,BAO_0000019,,B,,,,,H
2662,Autocuration,,Brain,955.0,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,12687,,13345,BAO_0000221,,B,,,,,H
2663,Autocuration,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,16740,BAO_0000249,,B,,,,,H
2664,Autocuration,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,16740,BAO_0000249,,B,,,,,H
2665,Expert,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,12687,Rattus norvegicus,15535,BAO_0000019,,B,,,10116.0,,D
2666,Expert,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,16740,BAO_0000249,,B,,,,,H
2667,Autocuration,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,16740,BAO_0000249,,B,,,,,H
2668,Autocuration,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,16740,BAO_0000249,,B,,,,,H
2669,Expert,,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,12687,Rattus norvegicus,4795,BAO_0000019,,B,,,10116.0,,D
2670,Expert,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,12687,,8,BAO_0000019,,B,,,,,H
2671,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,12687,,8,BAO_0000019,,B,,,,,H
2672,Expert,,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,Rattus norvegicus,17200,BAO_0000019,,B,,,10116.0,,D
2673,Expert,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,12687,Rattus norvegicus,2148,BAO_0000019,,B,,,10116.0,,D
2674,Expert,,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",105102,Rattus norvegicus,13345,BAO_0000224,,B,,,10116.0,,D
2675,Autocuration,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,5088,BAO_0000357,,B,,,,,H
2676,Autocuration,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,5088,BAO_0000357,,B,,,,,H
2677,Autocuration,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,12687,,17133,BAO_0000357,,B,,,,,H
2678,Expert,,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,12687,Rattus norvegicus,17133,BAO_0000357,,B,,,10116.0,,D
2679,Autocuration,,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,12687,,16532,BAO_0000357,,B,,,,,H
2680,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,12687,,15086,BAO_0000357,,B,,,,,H
2681,Expert,,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,Rattus norvegicus,2309,BAO_0000019,,B,,,10116.0,,D
2682,Expert,,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,12687,,12953,BAO_0000019,,B,,,,,H
2683,Autocuration,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,12687,,12953,BAO_0000019,,B,,,,,H
2684,Autocuration,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,12687,,12953,BAO_0000019,,B,,,,,H
2685,Autocuration,,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,12687,,16659,BAO_0000219,,B,,,,CHO,H
2686,Autocuration,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,,16740,BAO_0000019,,B,,,,,H
2687,Autocuration,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,,16740,BAO_0000019,,B,,,,,H
2688,Autocuration,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,12687,,17133,BAO_0000357,,B,,,,,H
2689,Autocuration,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,12687,,17211,BAO_0000019,,B,,,,,H
2690,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,12687,,17331,BAO_0000019,,B,,,,,H
2691,Autocuration,,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,12687,,16633,BAO_0000218,,B,,,,,H
2692,Autocuration,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,12687,,16633,BAO_0000218,,B,,,,,H
2693,Autocuration,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,12687,,16633,BAO_0000218,,B,,,,,H
2694,Expert,,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,12687,,15026,BAO_0000357,,B,,,,,H
2695,Expert,,,,Ratio of pKi of 5-HT2A to that of D2 receptor,12687,,15026,BAO_0000357,,B,,,,,H
2696,Expert,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,,16404,BAO_0000224,,B,,,,,H
2697,Expert,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,,16404,BAO_0000224,,B,,,,,H
2698,Expert,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,105075,,16404,BAO_0000224,,B,,,,,H
2699,Autocuration,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,12687,,16404,BAO_0000357,,B,,,,,H
2700,Expert,,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,12687,,16326,BAO_0000357,,B,,,,,H
2701,Autocuration,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,12687,,15847,BAO_0000019,,F,,,,,H
2702,Autocuration,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,12687,,15847,BAO_0000019,,F,,,,,H
2703,Autocuration,,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,12687,,15329,BAO_0000019,,F,,,,,H
2704,Expert,,Thoracic aorta,1515.0,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,12687,,16404,BAO_0000019,,F,,,,,H
2705,Expert,,Thoracic aorta,1515.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,12687,,16404,BAO_0000019,,F,,,,,H
2706,Autocuration,,Thoracic aorta,1515.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,12687,,16404,BAO_0000019,,F,,,,,H
2707,Autocuration,,,,Binding activity radioligand.,12687,,12861,BAO_0000357,,B,,,,,H
2708,Expert,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,,12861,BAO_0000019,,B,,,,,H
2709,Autocuration,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,12687,,12861,BAO_0000019,,B,,,,,H
2710,Expert,,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,12687,,12490,BAO_0000019,,B,,,,,H
2711,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,12687,,12827,BAO_0000219,,B,,,,N1E-115,H
2712,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,12687,,12827,BAO_0000219,,B,,,,N1E-115,H
2713,Autocuration,,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,12687,,12918,BAO_0000019,,B,,,,,H
2714,Expert,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,12687,Rattus norvegicus,12919,BAO_0000019,,F,,,10116.0,,D
2715,Autocuration,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,108,,17723,BAO_0000357,,B,,,,,H
2716,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,6013,BAO_0000357,,B,,,,,H
2717,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,108,,16293,BAO_0000357,,B,,,,,H
2718,Expert,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,,3857,BAO_0000019,,B,,,,,H
2719,Expert,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,108,,3857,BAO_0000019,,B,,,,,H
2720,Expert,,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,,3857,BAO_0000019,,B,,,,,H
2721,Autocuration,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,,15363,BAO_0000357,,B,,,,,H
2722,Autocuration,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,,15363,BAO_0000357,,B,,,,,H
2723,Expert,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,108,,16441,BAO_0000019,,B,,,,,H
2724,Expert,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,108,,16441,BAO_0000019,,B,,,,,H
2725,Autocuration,,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,108,,4176,BAO_0000219,,B,,,,HEK293,H
2726,Autocuration,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,108,,17085,BAO_0000019,,B,,,,,H
2727,Expert,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,108,Homo sapiens,17200,BAO_0000357,,B,,,9606.0,,D
2728,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,108,,5088,BAO_0000357,,B,,,,,H
2729,Autocuration,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,108,,5088,BAO_0000357,,B,,,,,H
2730,Autocuration,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,5088,BAO_0000357,,B,,,,,H
2731,Autocuration,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,108,,5088,BAO_0000357,,B,,,,,H
2732,Autocuration,,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,16659,BAO_0000219,,B,,,,CHO,H
2733,Autocuration,,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,108,,16659,BAO_0000219,,B,,,,CHO,H
2734,Autocuration,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,108,,17451,BAO_0000219,,B,,,,NIH3T3,H
2735,Expert,,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,108,Homo sapiens,6857,BAO_0000219,,F,,,9606.0,CHO,D
2736,Expert,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,,3857,BAO_0000019,,B,,,,,H
2737,Autocuration,,,,Binding activity radioligand.,108,,12861,BAO_0000357,,B,,,,,H
2738,Autocuration,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,108,,12861,BAO_0000019,,B,,,,,H
2739,Expert,,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,108,,5104,BAO_0000219,,B,,,,CHO,H
2740,Expert,,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,108,,5105,BAO_0000219,,B,,,,CHO,H
2741,Autocuration,,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,108,,5105,BAO_0000219,,B,,,,CHO,H
2742,Autocuration,,,,Binding affinity against 5-HT2C receptor,108,,5254,BAO_0000357,,B,,,,,H
2743,Autocuration,,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,108,,13267,BAO_0000219,,B,,,,HEK293,H
2744,Expert,,,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,108,Homo sapiens,14157,BAO_0000219,,B,,,9606.0,HEK293,D
2745,Expert,,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,Homo sapiens,12936,BAO_0000219,,B,,,9606.0,HEK293,D
2746,Expert,,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,108,,14068,BAO_0000357,,B,,,,,H
2747,Expert,,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,Homo sapiens,12936,BAO_0000219,,B,,,9606.0,HEK293,D
2748,Expert,,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,108,Homo sapiens,4540,BAO_0000219,,B,,,9606.0,HEK293,D
2749,Expert,,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,108,Homo sapiens,4540,BAO_0000219,,B,,,9606.0,HEK293,D
2750,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,108,,6166,BAO_0000357,,B,,,,,H
2751,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,108,,17296,BAO_0000219,,B,,,,HEK293,H
2752,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,108,,17296,BAO_0000219,,B,,,,HEK293,H
2753,Autocuration,,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,,15779,BAO_0000219,,B,,,,HEK293,H
2754,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,,15779,BAO_0000219,,B,,,,HEK293,H
2755,Expert,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,108,,14391,BAO_0000219,,B,,,,HEK293,H
2756,Autocuration,,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",108,,15779,BAO_0000219,,B,,,,HEK293,H
2757,Expert,,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",108,,15851,BAO_0000219,,B,,,,HEK293,H
2758,Expert,,,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,108,Homo sapiens,15851,BAO_0000219,,B,,,9606.0,HEK293,D
2759,Autocuration,,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",108,,15779,BAO_0000219,,B,,,,HEK293,H
2760,Expert,,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,108,,3832,BAO_0000219,,B,,,,HEK293,H
2761,Expert,,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,108,,3833,BAO_0000219,,B,,,,HEK293,H
2762,Autocuration,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,108,,17451,BAO_0000219,,B,,,,NIH3T3,H
2763,Autocuration,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,108,,4199,BAO_0000219,,B,,,,HEK293,H
2764,Expert,,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,108,,1883,BAO_0000219,,B,,,,CHO-K1,H
2765,Expert,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,108,Homo sapiens,4321,BAO_0000357,,B,,,9606.0,,D
2766,Autocuration,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,108,,14875,BAO_0000357,,B,,,,,H
2767,Autocuration,,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,108,,15146,BAO_0000219,,B,,,,HEK293,H
2768,Autocuration,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,108,,5213,BAO_0000219,,B,,,,HEK293,H
2769,Autocuration,,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,108,,16404,BAO_0000219,,B,,,,HeLa,H
2770,Autocuration,,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,108,,13267,BAO_0000019,,F,,,,,H
2771,Autocuration,,Hippocampus,10000000.0,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,108,,13267,BAO_0000221,,F,,,,,H
2772,Autocuration,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,108,,14818,BAO_0000219,,B,,,,HEK293,H
2773,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",108,,4829,BAO_0000219,,B,,,,HEK293,H
2774,Autocuration,,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,11864,,13463,BAO_0000357,,B,,,,,H
2775,Autocuration,,Stomach,945.0,Binding affinity analysed on 5-HT 2C in rat stomach fundus,11864,,13463,BAO_0000019,,B,,,,,H
2776,Autocuration,,Stomach,945.0,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,11864,,13463,BAO_0000019,,B,,,,,H
2777,Autocuration,,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,11864,,12652,BAO_0000219,,F,,,,A9,H
2778,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,,4682,BAO_0000219,,B,,,,NIH3T3,H
2779,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,11864,,4682,BAO_0000219,,B,,,,NIH3T3,H
2780,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,,4682,BAO_0000219,,B,,,,NIH3T3,H
2781,Autocuration,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,11864,,12652,BAO_0000019,,F,,,,,H
2782,Autocuration,,Stomach,945.0,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,12689,Mus musculus,13463,BAO_0000019,,B,,,10090.0,,H
2783,Expert,,Stomach,945.0,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,12689,Rattus norvegicus,13463,BAO_0000019,,B,,,10116.0,,D
2784,Expert,,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,108,,13969,BAO_0000357,,B,,,,,H
2785,Expert,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,108,Sus scrofa,13392,BAO_0000357,,B,,,9823.0,,H
2786,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,13392,BAO_0000357,,B,,,,,H
2787,Expert,,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,108,,14430,BAO_0000019,,B,,,,,H
2788,Autocuration,,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,108,,1742,BAO_0000019,,B,,,,,H
2789,Autocuration,,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,108,,14286,BAO_0000249,,B,,,,,H
2790,Autocuration,,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,108,,5619,BAO_0000357,,B,,,,,H
2791,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,,15086,BAO_0000357,,B,,,,,H
2792,Autocuration,,,,Binding activity radioligand.,108,,12861,BAO_0000357,,B,,,,,H
2793,Expert,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,108,,12861,BAO_0000019,,B,,,,,H
2794,Autocuration,,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,108,,12861,BAO_0000019,,B,,,,,H
2795,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,108,,12827,BAO_0000249,,B,,,,,H
2796,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,108,,12827,BAO_0000249,,B,,,,,H
2797,Expert,,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,Sus scrofa,12919,BAO_0000019,,F,,,9823.0,,H
2798,Expert,,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,Sus scrofa,12919,BAO_0000019,,F,,,9823.0,,H
2799,Autocuration,,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,108,Sus scrofa,16429,BAO_0000357,,B,,,9823.0,,H
2800,Autocuration,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,108,Sus scrofa,773,BAO_0000019,,B,,,9823.0,,H
2801,Autocuration,,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,108,Sus scrofa,5033,BAO_0000357,,B,,,9823.0,,H
2802,Autocuration,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,,12861,BAO_0000019,,B,,,,,H
2803,Autocuration,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,12689,,14093,BAO_0000019,,F,,,,,H
2804,Expert,,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,12689,,14970,BAO_0000357,,B,,,,,H
2805,Autocuration,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,12689,,14970,BAO_0000357,,B,,,,,H
2806,Autocuration,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,12689,,14970,BAO_0000357,,B,,,,,H
2807,Expert,,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,12689,Rattus norvegicus,14178,BAO_0000357,,B,,,10116.0,,D
2808,Expert,,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,12689,Rattus norvegicus,14178,BAO_0000357,,B,,,10116.0,,D
2809,Expert,Brain membranes,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,12689,Rattus norvegicus,14229,BAO_0000249,,B,,,10116.0,,D
2810,Autocuration,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,12689,,16532,BAO_0000357,,B,,,,,H
2811,Autocuration,,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,12689,,14826,BAO_0000019,,B,,,,,H
2812,Autocuration,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,12689,,17211,BAO_0000019,,B,,,,,H
2813,Expert,,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,12689,,17211,BAO_0000219,,B,In vitro,,,,H
2814,Expert,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,12689,,13246,BAO_0000219,,B,,,,NIH3T3,H
2815,Expert,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,12689,,13246,BAO_0000357,,B,,,,,H
2816,Expert,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,12689,,12457,BAO_0000357,,B,,,,,H
2817,Expert,,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,12689,,12457,BAO_0000219,,B,,,,NIH3T3,H
2818,Autocuration,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,12689,,4707,BAO_0000357,,B,,,,,H
2819,Expert,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,12689,,13297,BAO_0000357,,B,,,,,H
2820,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,,16633,BAO_0000357,,B,,,,,H
2821,Expert,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,,16133,BAO_0000357,,B,,,,,H
2822,Expert,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,12689,,16326,BAO_0000357,,B,,,,,H
2823,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,12689,,14423,BAO_0000019,,B,,,,,H
2824,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,12689,,15412,BAO_0000019,,B,,,,,H
2825,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,12689,,15412,BAO_0000019,,B,,,,,H
2826,Expert,,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,12689,,15558,BAO_0000219,,B,,,,A9,H
2827,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,,16633,BAO_0000357,,B,,,,,H
2828,Expert,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,12689,,6013,BAO_0000357,,B,,,,,H
2829,Expert,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,12689,,17175,BAO_0000219,,B,In vitro,,,,H
2830,Autocuration,,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,12689,,12469,BAO_0000219,,B,,,,,H
2831,Autocuration,,Caudate-putamen,5383.0,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,12689,,3682,BAO_0000019,,B,,,,,H
2832,Autocuration,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,12689,,4932,BAO_0000357,,B,,,,,H
2833,Autocuration,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,12689,,4932,BAO_0000019,,B,,,,,H
2834,Autocuration,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,12689,,3935,BAO_0000357,,B,,,,,H
2835,Autocuration,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,12689,,15818,BAO_0000357,,B,,,,,H
2836,Autocuration,,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,12689,,15818,BAO_0000357,,B,,,,,H
2837,Expert,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,12689,,14749,BAO_0000219,,B,,,,,H
2838,Autocuration,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,12689,,15740,BAO_0000357,,B,,,,,H
2839,Expert,,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,12689,Rattus norvegicus,17133,BAO_0000357,,B,,,10116.0,,D
2840,Autocuration,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,12689,,16532,BAO_0000357,,B,,,,,H
2841,Autocuration,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,12689,,12369,BAO_0000357,,B,,,,,H
2842,Expert,,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,12689,,12369,BAO_0000219,,B,,,,,H
2843,Expert,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,12689,Rattus norvegicus,2309,BAO_0000019,,B,,,10116.0,,D
2844,Autocuration,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,12689,,12953,BAO_0000357,,B,,,,,H
2845,Autocuration,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,12689,,12953,BAO_0000019,,B,,,,,H
2846,Autocuration,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,12689,,12953,BAO_0000357,,B,,,,,H
2847,Expert,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,12689,,12953,BAO_0000357,,B,,,,,H
2848,Autocuration,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,12689,,17133,BAO_0000357,,B,,,,,H
2849,Autocuration,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,12689,,17211,BAO_0000019,,B,,,,,H
2850,Autocuration,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,12689,,17211,BAO_0000019,,B,,,,,H
2851,Autocuration,,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,12689,,14025,BAO_0000019,,B,,,,,H
2852,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,12689,,14998,BAO_0000019,,B,,,,,H
2853,Autocuration,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,12689,,4342,BAO_0000357,,B,,,,,H
2854,Expert,,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,12689,Rattus norvegicus,13735,BAO_0000019,,B,,,10116.0,,D
2855,Autocuration,,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,12689,,13181,BAO_0000357,,B,,,,,H
2856,Autocuration,,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,12689,,1883,BAO_0000219,,B,,,,CHO-K1,H
2857,Autocuration,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,,15194,BAO_0000357,,B,,,,,H
2858,Autocuration,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,12689,,15194,BAO_0000357,,B,,,,,H
2859,Autocuration,,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,12689,,14579,BAO_0000019,,F,,,,,H
2860,Autocuration,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,,4639,BAO_0000357,,B,,,,,H
2861,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,4820,BAO_0000357,,B,,,,,H
2862,Autocuration,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,227,,14442,BAO_0000357,,B,,,,,H
2863,Autocuration,,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,227,,14755,BAO_0000357,,B,,,,,H
2864,Autocuration,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,227,,14744,BAO_0000357,,B,,,,,H
2865,Expert,,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,227,Homo sapiens,6857,BAO_0000019,,B,,,9606.0,,D
2866,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,227,,16209,BAO_0000357,,B,,,,,H
2867,Autocuration,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,,15363,BAO_0000357,,B,,,,,H
2868,Autocuration,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,,15363,BAO_0000357,,B,,,,,H
2869,Autocuration,,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,227,,15363,BAO_0000357,,B,,,,,H
2870,Autocuration,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,227,,17085,BAO_0000019,,B,,,,,H
2871,Expert,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,227,Homo sapiens,17200,BAO_0000357,,B,,,9606.0,,D
2872,Expert,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,Homo sapiens,15851,BAO_0000219,,B,,,9606.0,HEK293,D
2873,Expert,,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,Homo sapiens,15851,BAO_0000219,,B,,,9606.0,HEK293,D
2874,Expert,,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,Homo sapiens,6857,BAO_0000219,,F,,,9606.0,CHO,D
2875,Expert,,,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,Homo sapiens,6857,BAO_0000219,,F,,,9606.0,CHO,D
2876,Autocuration,,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,15779,BAO_0000219,,B,,,,HEK293,H
2877,Expert,,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,227,,15851,BAO_0000219,,B,,,,HEK293,H
2878,Autocuration,,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",227,,15779,BAO_0000219,,B,,,,HEK293,H
2879,Expert,,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,227,Homo sapiens,14157,BAO_0000219,,B,,,9606.0,HEK293,D
2880,Expert,,,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,227,Homo sapiens,4540,BAO_0000219,,B,,,9606.0,HEK293,D
2881,Autocuration,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,227,,6166,BAO_0000357,,B,,,,,H
2882,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,227,,15779,BAO_0000219,,B,,,,HEK293,H
2883,Expert,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,227,,14391,BAO_0000219,,B,,,,HEK293,H
2884,Expert,,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,227,,3832,BAO_0000219,,B,,,,HEK293,H
2885,Expert,,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,227,,3833,BAO_0000219,,B,,,,HEK293,H
2886,Expert,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,227,Homo sapiens,15851,BAO_0000219,,B,,,9606.0,HEK293,D
2887,Expert,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,227,Homo sapiens,15851,BAO_0000219,,B,,,9606.0,HEK293,D
2888,Autocuration,,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,227,,4199,BAO_0000219,,B,,,,HEK293,H
2889,Expert,,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,227,,1883,BAO_0000219,,B,,,,CHO-K1,H
2890,Expert,,,,Binding affinity against 5-hydroxytryptamine 2B receptor,227,,4321,BAO_0000357,,B,,,,,H
2891,Autocuration,,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,227,,15146,BAO_0000219,,B,,,,HEK293,H
2892,Autocuration,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,227,,5213,BAO_0000219,,B,,,,HEK293,H
2893,Autocuration,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,227,,14818,BAO_0000219,,B,,,,HEK293,H
2894,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,4829,BAO_0000219,,B,,,,HEK293,H
2895,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,4829,BAO_0000219,,B,,,,HEK293,H
2896,Autocuration,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,227,Oryctolagus cuniculus,14025,BAO_0000019,,B,,,9986.0,,H
2897,Expert,,Stomach,945.0,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,12688,,13463,BAO_0000019,,B,,,,,H
2898,Expert,,Stomach,945.0,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,12688,,7259,BAO_0000357,,B,,,,,H
2899,Autocuration,,Stomach,945.0,Affinity against serotonergic receptor in the isolated rat stomach fundus,12688,,7259,BAO_0000357,,B,,,,,H
2900,Expert,,Stomach,945.0,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,12688,Rattus norvegicus,7185,BAO_0000019,,F,,,10116.0,,D
2901,Expert,,,,Antagonistic against 5-hydroxytryptamine 2B receptor,12688,Rattus norvegicus,7185,BAO_0000019,,F,,,10116.0,,D
2902,Autocuration,,Stomach,945.0,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,12688,,13267,BAO_0000019,,F,,,,,H
2903,Expert,,Stomach,945.0,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,12688,Rattus norvegicus,13735,BAO_0000357,,B,,,10116.0,,D
2904,Autocuration,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,12688,,15738,BAO_0000019,,F,,,,,H
2905,Autocuration,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,12688,,15738,BAO_0000019,,F,,,,,H
2906,Autocuration,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,12688,,15738,BAO_0000019,,F,,,,,H
2907,Expert,,Stomach,945.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,Rattus norvegicus,12936,BAO_0000357,,B,,,10116.0,,D
2908,Expert,,Stomach,945.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,Rattus norvegicus,12936,BAO_0000357,,B,,,10116.0,,D
2909,Expert,,Stomach,945.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,Rattus norvegicus,12936,BAO_0000357,,B,,,10116.0,,D
2910,Expert,,Stomach,945.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,Rattus norvegicus,12936,BAO_0000357,,B,,,10116.0,,D
2911,Autocuration,,Stomach,945.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,16404,BAO_0000019,,F,,,,,H
2912,Expert,,Stomach,945.0,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,16404,BAO_0000019,,F,,,,,H
2913,Autocuration,,Stomach,945.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,12688,,16404,BAO_0000019,,F,,,,,H
2914,Autocuration,,Stomach,945.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,12688,,16404,BAO_0000019,,F,,,,,H
2915,Expert,,Stomach,945.0,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,12688,Rattus norvegicus,16404,BAO_0000019,,F,,,10116.0,,D
2916,Autocuration,,Thoracic aorta,1515.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,12688,,16404,BAO_0000019,,F,,,,,H
2917,Autocuration,,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,,7483,BAO_0000357,,B,,,,,H
2918,Expert,,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,12688,,7483,BAO_0000357,,B,,,,,H
2919,Autocuration,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,,7483,BAO_0000357,,B,,,,,H
2920,Autocuration,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,12688,,7483,BAO_0000357,,B,,,,,H
2922,Autocuration,,Stomach,945.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,Rattus norvegicus,16404,BAO_0000019,,F,,,10116.0,,D
2923,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,227,,6347,BAO_0000357,,B,,,,,H
2924,Autocuration,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,227,,4373,BAO_0000357,,B,,,,,H
2925,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,227,,4373,BAO_0000357,,B,,,,,H
2926,Autocuration,,,,Evaluated for the binding affinity to 5-HT 2B receptor,227,,4687,BAO_0000357,,B,,,,,H
2927,Autocuration,,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,227,,16946,BAO_0000357,,B,,,,,H
2928,Autocuration,,,,Binding affinities against 5-hydroxytryptamine 2B receptor,227,,16633,BAO_0000357,,B,,,,,H
2929,Autocuration,,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,227,,16633,BAO_0000357,,B,,,,,H
2930,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,227,,16633,BAO_0000357,,B,,,,,H
2931,Expert,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,,15026,BAO_0000357,,B,,,,,H
2932,Autocuration,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,Bos taurus,15738,BAO_0000357,,B,,,9913.0,,H
2933,Autocuration,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,108,Bos taurus,15738,BAO_0000357,,B,,,9913.0,,H
2934,Autocuration,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,108,Bos taurus,15738,BAO_0000357,,B,,,9913.0,,H
2935,Autocuration,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,108,Bos taurus,15738,BAO_0000357,,B,,,9913.0,,H
2936,Expert,,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,108,Bos taurus,16404,BAO_0000357,,B,,,9913.0,,H
2937,Expert,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,Bos taurus,15026,BAO_0000357,,B,,,9913.0,,H
2938,Autocuration,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,Bos taurus,15738,BAO_0000357,,B,,,9913.0,,H
2939,Autocuration,,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,108,Cavia porcellus,16312,BAO_0000019,,B,,,10141.0,,H
2940,Intermediate,,Striatum,2435.0,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,20033,Cavia porcellus,5486,BAO_0000357,,B,,,10141.0,,D
2941,Autocuration,,,,Binding affinity against 5-HT1A receptor,51,,5254,BAO_0000357,,B,,,,,H
2942,Expert,,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,108,,3857,BAO_0000219,,F,,,,CHO,H
2943,Expert,,,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,108,Homo sapiens,6857,BAO_0000219,,F,,,9606.0,CHO,D
2944,Autocuration,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,108,,4176,BAO_0000219,,F,,,,,H
2945,Autocuration,,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,108,,6347,BAO_0000219,,B,,,,CHO,H
2946,Autocuration,,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",108,,6347,BAO_0000219,,B,,,,CHO,H
2947,Expert,,,,Inhibition of human 5-hydroxytryptamine 2C receptor,108,Homo sapiens,16146,BAO_0000357,,B,,,9606.0,,D
2948,Autocuration,,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),108,,3805,BAO_0000357,,B,,,,,H
2949,Autocuration,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,,3857,BAO_0000019,,B,,,,,H
2950,Autocuration,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,108,,5635,BAO_0000357,,B,,,,,H
2951,Autocuration,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,,5635,BAO_0000357,,B,,,,,H
2952,Autocuration,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,,5635,BAO_0000357,,B,,,,,H
2953,Expert,,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,108,,4012,BAO_0000219,,B,,,,CHO,H
2954,Expert,,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,108,,6366,BAO_0000219,,B,,,,CHO,H
2955,Expert,,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,15949,BAO_0000219,,B,,,,CHO,H
2956,Autocuration,,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,108,,17211,BAO_0000219,,B,,,,CHO,H
2957,Expert,,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,108,Homo sapiens,6491,BAO_0000357,,B,,,9606.0,,D
2958,Autocuration,,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,108,,14093,BAO_0000019,,F,,,,,H
2959,Autocuration,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,108,,13481,BAO_0000019,,F,,,,,H
2960,Expert,,,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,108,Rattus norvegicus,6347,BAO_0000219,,B,,,10116.0,CHO,H
2961,Autocuration,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,108,,14093,BAO_0000019,,F,,,,,H
2962,Autocuration,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,108,,14093,BAO_0000019,,F,,,,,H
2963,Autocuration,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,13481,BAO_0000019,,F,,,,,H
2964,Autocuration,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,108,,14442,BAO_0000357,,B,,,,,H
2965,Autocuration,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,108,,14442,BAO_0000357,,B,,,,,H
2966,Autocuration,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,108,,14442,BAO_0000357,,B,,,,,H
2967,Autocuration,,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,108,,14755,BAO_0000357,,B,,,,,H
2968,Autocuration,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,108,,14744,BAO_0000357,,B,,,,,H
2969,Expert,,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,16659,BAO_0000219,,B,,,,CHO,H
2970,Expert,,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,108,Homo sapiens,6857,BAO_0000019,,B,,,9606.0,,D
2971,Expert,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,108,,5635,BAO_0000357,,B,,,,,H
2972,Expert,,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,108,Homo sapiens,4234,BAO_0000357,,B,,,9606.0,,D
2973,Autocuration,,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,108,,16209,BAO_0000357,,B,,,,,H
2974,Autocuration,Membranes,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,104698,Rattus norvegicus,5778,BAO_0000249,,B,,,10116.0,,D
2975,Autocuration,,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,104698,,5094,BAO_0000223,,B,,,,,H
2976,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,104698,Rattus norvegicus,809,BAO_0000019,,B,,,10116.0,,D
2977,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,104698,,1578,BAO_0000019,,B,,,,,H
2978,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,104698,,809,BAO_0000019,,B,,,,,H
2979,Autocuration,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,104698,,12469,BAO_0000219,,B,,,,,H
2980,Autocuration,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,104698,,14290,BAO_0000019,,B,,,,,H
2981,Autocuration,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,104698,,14290,BAO_0000019,,B,,,,,H
2982,Autocuration,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,104698,,10609,BAO_0000223,,B,,,,,H
2983,Autocuration,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,104698,,10609,BAO_0000223,,B,,,,,H
2984,Autocuration,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,104698,,10609,BAO_0000223,,B,,,,,H
2985,Autocuration,,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,,15253,BAO_0000249,,B,,,,,H
2986,Autocuration,,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,,15253,BAO_0000249,,B,,,,,H
2987,Autocuration,Membranes,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,104698,,11683,BAO_0000249,,B,,,,,H
2988,Autocuration,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,104698,,12092,BAO_0000223,,B,,,,,H
2989,Autocuration,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,,1946,BAO_0000019,,B,,,,,H
2990,Autocuration,,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,104698,,11623,BAO_0000223,,B,,,,,H
2991,Autocuration,,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,104698,,11623,BAO_0000223,,B,,,,,H
2992,Autocuration,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,104698,,14788,BAO_0000019,,B,,,,,H
2993,Autocuration,,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,104698,Rattus norvegicus,5432,BAO_0000019,,B,,,10116.0,,D
2994,Autocuration,,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,14826,BAO_0000249,,B,,,,,H
2995,Autocuration,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,104698,,2222,BAO_0000223,,B,,,,,H
2996,Autocuration,,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,104698,,11963,BAO_0000019,,B,,,,,H
2997,Autocuration,,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,104698,,14145,BAO_0000019,,B,,,,,H
2998,Autocuration,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,104698,,17819,BAO_0000019,,B,,,,,H
2999,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,,10394,BAO_0000249,,B,,,,,H
3000,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,,10394,BAO_0000249,,B,,,,,H
3001,Autocuration,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,,15034,BAO_0000019,,B,,,,,H
3002,Autocuration,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,,691,BAO_0000019,,B,,,,,H
3003,Autocuration,Membranes,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,104698,,12092,BAO_0000249,,B,,,,,H
3004,Autocuration,,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,104698,Rattus norvegicus,11752,BAO_0000223,,B,,,10116.0,,D
3005,Autocuration,,Brain,955.0,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,104698,,11752,BAO_0000221,,B,,,,,H
3006,Autocuration,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,104698,,301,BAO_0000019,,B,,,,,H
3007,Autocuration,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,104698,,16532,BAO_0000223,,B,,,,,H
3008,Autocuration,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,,16532,BAO_0000223,,B,,,,,H
3009,Autocuration,,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,104698,,12092,BAO_0000223,,B,,,,,H
3010,Autocuration,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,104698,,11684,BAO_0000223,,B,,,,,H
3011,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,104698,,11684,BAO_0000223,,B,,,,,H
3012,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,104698,,12953,BAO_0000019,,B,,,,,H
3013,Autocuration,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,104698,,12953,BAO_0000019,,B,,,,,H
3014,Autocuration,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,104698,,12953,BAO_0000223,,B,,,,,H
3015,Autocuration,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,104698,,12861,BAO_0000019,,B,,,,,H
3016,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3017,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3018,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3019,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3020,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3021,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3022,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3023,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3024,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3025,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3026,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3027,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3028,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3029,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3030,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3031,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3032,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3033,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3034,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,104698,,10609,BAO_0000019,,F,,,,,H
3035,Autocuration,,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,104698,,12861,BAO_0000019,,B,,,,,H
3036,Autocuration,,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,Rattus norvegicus,12861,BAO_0000019,,B,,,10116.0,,D
3037,Autocuration,,,,Binding activity radioligand.,104698,,12861,BAO_0000223,,B,,,,,H
3038,Autocuration,Brain membranes,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,104698,,10728,BAO_0000249,,B,,,,,H
3039,Autocuration,Brain membranes,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,104698,,10728,BAO_0000249,,B,,,,,H
3040,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,108,,5163,BAO_0000357,,B,,,,,H
3041,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,108,,5163,BAO_0000357,,B,,,,,H
3042,Autocuration,,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,108,,6011,BAO_0000357,,B,,,,,H
3043,Autocuration,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,108,,5014,BAO_0000357,,B,,,,,H
3044,Autocuration,,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,108,,5635,BAO_0000357,,B,,,,,H
3045,Expert,,,,Affinity for 5-hydroxytryptamine 2C receptor,108,,5163,BAO_0000357,,B,,,,,H
3046,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,6841,BAO_0000357,,B,,,,,H
3047,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,108,,6119,BAO_0000357,,B,,,,,H
3048,Autocuration,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,108,,4373,BAO_0000357,,B,,,,,H
3049,Autocuration,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,108,,1633,BAO_0000357,,B,,,,,H
3050,Expert,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,108,,1633,BAO_0000357,,B,,,,,H
3051,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,108,,4373,BAO_0000357,,B,,,,,H
3052,Expert,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,108,,6576,BAO_0000357,,B,,,,,H
3053,Autocuration,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,108,,4687,BAO_0000357,,B,,,,,H
3054,Autocuration,,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,108,,12146,BAO_0000357,,B,,,,,H
3055,Autocuration,,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,108,,12146,BAO_0000357,,B,,,,,H
3056,Autocuration,,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,108,,16946,BAO_0000357,,B,,,,,H
3057,Autocuration,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,108,,14159,BAO_0000357,,B,,,,,H
3058,Autocuration,,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,108,,16700,BAO_0000357,,B,,,,,H
3059,Autocuration,,,,Affinity against 5-hydroxytryptamine 2C receptor,108,,3269,BAO_0000357,,B,,,,,H
3060,Expert,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,108,Homo sapiens,1274,BAO_0000357,,B,,,9606.0,,D
3061,Autocuration,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,108,,1317,BAO_0000357,,B,,,,,H
3062,Autocuration,,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,144,Bos taurus,5834,BAO_0000357,,B,,,9913.0,,H
3063,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,144,Bos taurus,11147,BAO_0000357,,B,,,9913.0,,H
3064,Expert,,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,104714,Cavia porcellus,14145,BAO_0000019,,F,,,10141.0,,H
3065,Autocuration,,Ileum,2116.0,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,Cavia porcellus,10561,BAO_0000221,,B,,,10141.0,,H
3066,Autocuration,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,104714,Cavia porcellus,15847,BAO_0000019,,F,,,10141.0,,H
3067,Autocuration,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,104714,Cavia porcellus,15847,BAO_0000019,,F,,,10141.0,,H
3068,Autocuration,,Ileum,2116.0,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,Cavia porcellus,10561,BAO_0000221,,B,,,10141.0,,H
3069,Autocuration,,Ileum,2116.0,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,104714,Cavia porcellus,11454,BAO_0000221,,B,,,10141.0,,H
3070,Autocuration,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3071,Autocuration,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3072,Autocuration,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3073,Autocuration,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3074,Autocuration,,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3075,Autocuration,,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3076,Autocuration,,Ileum,2116.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",104714,Cavia porcellus,15253,BAO_0000221,,F,,,10141.0,,H
3077,Autocuration,,Ileum,2116.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",104714,Cavia porcellus,15253,BAO_0000221,,F,,,10141.0,,H
3078,Autocuration,,Ileum,2116.0,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,104714,Cavia porcellus,11963,BAO_0000221,,F,,,10141.0,,H
3079,Autocuration,,Ileum,2116.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,104714,Cavia porcellus,1946,BAO_0000221,,B,,,10141.0,,H
3080,Autocuration,,Ileum,2116.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,104714,Cavia porcellus,1946,BAO_0000221,,B,,,10141.0,,H
3081,Autocuration,,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,104714,Cavia porcellus,12045,BAO_0000223,,B,,,10141.0,,H
3082,Autocuration,,Ileum,2116.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,Cavia porcellus,1559,BAO_0000221,,B,,,10141.0,,H
3083,Autocuration,,Ileum,2116.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,Cavia porcellus,273,BAO_0000221,,F,,,10141.0,,H
3084,Autocuration,,Ileum,2116.0,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),104714,Cavia porcellus,273,BAO_0000221,,F,,,10141.0,,H
3085,Autocuration,,Ileum,2116.0,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,104714,Cavia porcellus,188,BAO_0000221,,F,,,10141.0,,H
3086,Autocuration,,Ileum,2116.0,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,104714,Cavia porcellus,12919,BAO_0000221,,F,,,10141.0,,H
3087,Autocuration,,Ileum,2116.0,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,104714,Cavia porcellus,12918,BAO_0000221,,F,,,10141.0,,H
3088,Autocuration,,Ileum,2116.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,Cavia porcellus,1559,BAO_0000221,,B,,,10141.0,,H
3089,Autocuration,,Ileum,2116.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,Cavia porcellus,273,BAO_0000221,,F,,,10141.0,,H
3090,Autocuration,,Ileum,2116.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,Cavia porcellus,1559,BAO_0000221,,B,,,10141.0,,H
3091,Autocuration,,Ileum,2116.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,104714,Cavia porcellus,1559,BAO_0000221,,B,,,10141.0,,H
3092,Autocuration,,Ileum,2116.0,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,104714,Cavia porcellus,1559,BAO_0000221,,B,,,10141.0,,H
3093,Autocuration,,Ileum,2116.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,104714,Cavia porcellus,14424,BAO_0000221,,B,,,10141.0,,H
3094,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,22226,Cavia porcellus,13181,BAO_0000019,,B,,,10141.0,,U
3095,Autocuration,,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,51,,5486,BAO_0000357,,B,,,,,H
3096,Expert,,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,104714,Homo sapiens,6491,BAO_0000223,,B,,,9606.0,,D
3097,Autocuration,,,,Binding affinity towards 5-HT3 receptor,104714,,6013,BAO_0000223,,B,,,,,H
3098,Autocuration,,,,Binding activity radioligand.,104714,,12861,BAO_0000223,,B,,,,,H
3099,Autocuration,,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,104714,,12861,BAO_0000019,,B,,,,,H
3100,Autocuration,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,,5104,BAO_0000223,,B,,,,,H
3101,Autocuration,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,,5105,BAO_0000223,,B,,,,,H
3102,Autocuration,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,104714,,5104,BAO_0000223,,B,,,,,H
3103,Autocuration,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,22226,,3935,BAO_0000019,,B,,,,,U
3104,Expert,,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,105030,,13657,BAO_0000219,,B,,,,NG108-15,H
3105,Autocuration,,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",105030,,10369,BAO_0000218,,B,In vivo,,,,H
3106,Autocuration,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,,10369,BAO_0000019,,B,,,,,H
3107,Autocuration,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,105030,,12918,BAO_0000224,,B,,,,,H
3108,Autocuration,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,105030,,12918,BAO_0000224,,B,,,,,H
3109,Autocuration,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,,10369,BAO_0000019,,B,,,,,H
3110,Autocuration,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,105030,,773,BAO_0000019,,B,,,,,H
3111,Autocuration,,,,5-hydroxytryptamine 3 receptor agonism in mouse,105030,,12918,BAO_0000218,,F,,,,,H
3112,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,105030,,10561,BAO_0000219,,B,,,,,H
3113,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,,12827,BAO_0000019,,B,,,,,H
3114,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,,12827,BAO_0000019,,B,,,,,H
3115,Autocuration,,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,105030,,12918,BAO_0000224,,B,,,,,H
3116,Autocuration,,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,,273,BAO_0000219,,B,,,,,H
3117,Autocuration,,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,,273,BAO_0000219,,B,,,,,H
3118,Autocuration,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,105030,,10561,BAO_0000224,,B,,,,,H
3119,Autocuration,,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,105030,,5033,BAO_0000219,,B,In vitro,,,,H
3120,Autocuration,,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,105030,,16429,BAO_0000219,,B,,,,N1E-115,H
3121,Autocuration,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,11765,,10322,BAO_0000019,,B,,,,,H
3122,Autocuration,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,11765,,14331,BAO_0000219,,B,,,,,H
3123,Autocuration,,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,10630,Mus musculus,13462,BAO_0000357,,B,,,10090.0,,D
3124,Autocuration,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,,12861,BAO_0000019,,B,,,,,H
3125,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,144,Sus scrofa,15086,BAO_0000357,,B,,,9823.0,,H
3126,Autocuration,,,,Binding activity radioligand.,144,Sus scrofa,12861,BAO_0000357,,B,,,9823.0,,H
3127,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,104714,Oryctolagus cuniculus,10561,BAO_0000223,,B,,,9986.0,,H
3128,Autocuration,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,104714,Oryctolagus cuniculus,10561,BAO_0000223,,B,,,9986.0,,H
3129,Autocuration,,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,104714,Oryctolagus cuniculus,10561,BAO_0000223,,B,,,9986.0,,H
3130,Autocuration,,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104714,Oryctolagus cuniculus,10561,BAO_0000019,,B,,,9986.0,,H
3131,Autocuration,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,Oryctolagus cuniculus,273,BAO_0000019,,F,,,9986.0,,H
3132,Autocuration,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,Oryctolagus cuniculus,273,BAO_0000019,,F,,,9986.0,,H
3133,Autocuration,,Ileum,2116.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,Oryctolagus cuniculus,273,BAO_0000221,,F,,,9986.0,,H
3134,Autocuration,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,Oryctolagus cuniculus,273,BAO_0000019,,F,,,9986.0,,H
3135,Autocuration,,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,Oryctolagus cuniculus,273,BAO_0000019,,F,,,9986.0,,H
3136,Autocuration,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,Oryctolagus cuniculus,273,BAO_0000019,,F,,,9986.0,,H
3137,Autocuration,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,Oryctolagus cuniculus,273,BAO_0000019,,F,,,9986.0,,H
3138,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,104714,Oryctolagus cuniculus,13047,BAO_0000219,,B,,,9986.0,CHO,H
3139,Autocuration,,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,104698,Rattus norvegicus,1650,BAO_0000019,,B,,,10116.0,,D
3140,Autocuration,,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),12020,,16288,BAO_0000019,,B,,,,,H
3141,Autocuration,,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),12020,,16288,BAO_0000357,,B,,,,,H
3142,Autocuration,,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,104698,Rattus norvegicus,10254,BAO_0000019,,B,,,10116.0,,D
3143,Autocuration,,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",104698,,14532,BAO_0000019,,B,,,,,H
3144,Autocuration,,Heart,948.0,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,,13392,BAO_0000218,,F,In vivo,,,,H
3145,Autocuration,,Heart,948.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,,13392,BAO_0000019,,F,,,,,H
3146,Autocuration,,Heart,948.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,,13392,BAO_0000019,,F,,,,,H
3147,Autocuration,,Heart,948.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",104698,,13392,BAO_0000019,,F,,,,,H
3148,Autocuration,,Heart,948.0,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,,13392,BAO_0000019,,F,,,,,H
3149,Autocuration,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",104698,,13392,BAO_0000019,,F,,,,,H
3150,Autocuration,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,,13392,BAO_0000019,,F,,,,,H
3151,Autocuration,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,,13392,BAO_0000019,,F,,,,,H
3152,Autocuration,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",104698,,13392,BAO_0000019,,F,,,,,H
3153,Autocuration,,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),104698,Rattus norvegicus,1089,BAO_0000218,,F,In vivo,,10116.0,,D
3154,Autocuration,,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),104698,,1089,BAO_0000218,,F,In vivo,,,,H
3155,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,Rattus norvegicus,11454,BAO_0000218,,F,In vivo,,10116.0,,D
3156,Autocuration,,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,104698,Rattus norvegicus,11454,BAO_0000019,,F,,,10116.0,,D
3157,Autocuration,,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,104698,Rattus norvegicus,12205,BAO_0000218,,F,In vivo,,10116.0,,D
3158,Autocuration,,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),104698,Rattus norvegicus,1089,BAO_0000019,,F,,,10116.0,,D
3159,Autocuration,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,,5094,BAO_0000019,,B,,,,,H
3160,Autocuration,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,104698,Rattus norvegicus,2622,BAO_0000019,,B,,,10116.0,,D
3161,Autocuration,,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,104698,,245,BAO_0000223,,B,,,,,H
3162,Autocuration,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,104698,,14788,BAO_0000019,,B,,,,,H
3163,Autocuration,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,104698,,14788,BAO_0000019,,B,,,,,H
3164,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,104698,,3020,BAO_0000249,,B,,,,,H
3165,Autocuration,,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,104698,,1742,BAO_0000019,,B,,,,,H
3166,Autocuration,,Brain,955.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,104698,,17394,BAO_0000249,,B,,,,,H
3167,Autocuration,,Brain,955.0,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,104698,,17394,BAO_0000221,,B,,,,,H
3168,Autocuration,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,17394,BAO_0000249,,B,,,,,H
3169,Autocuration,,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,14286,BAO_0000249,,B,,,,,H
3170,Autocuration,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,104698,,14178,BAO_0000019,,B,,,,,H
3171,Autocuration,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,104698,Rattus norvegicus,14178,BAO_0000019,,B,,,10116.0,,D
3172,Autocuration,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,104698,Rattus norvegicus,14178,BAO_0000019,,B,,,10116.0,,D
3173,Autocuration,,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,104698,Rattus norvegicus,14178,BAO_0000223,,B,,,10116.0,,D
3174,Autocuration,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,,15034,BAO_0000019,,B,,,,,H
3175,Autocuration,Membranes,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",104698,,1089,BAO_0000249,,B,,,,,H
3176,Autocuration,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,104698,Rattus norvegicus,1089,BAO_0000019,,B,,,10116.0,,D
3177,Autocuration,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,,16532,BAO_0000223,,B,,,,,H
3178,Autocuration,,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,104698,Rattus norvegicus,12801,BAO_0000223,,B,,,10116.0,,D
3179,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),104698,,15194,BAO_0000219,,B,,,,NG108-15,H
3180,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,104698,,15194,BAO_0000219,,B,,,,NG108-15,H
3181,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,104698,,15194,BAO_0000019,,B,,,,,H
3182,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,104698,,15194,BAO_0000019,,B,,,,,H
3183,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,104698,,15194,BAO_0000019,,B,,,,,H
3184,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,104698,,15194,BAO_0000019,,B,,,,,H
3185,Autocuration,,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,104698,,10610,BAO_0000019,,F,,,,,H
3186,Autocuration,,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,104698,Rattus norvegicus,10355,BAO_0000019,,F,,,10116.0,,D
3187,Autocuration,,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",104698,,691,BAO_0000019,,F,,,,,H
3188,Autocuration,,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,104698,,10611,BAO_0000218,,F,,,,,H
3189,Autocuration,,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,104698,,12801,BAO_0000218,,F,In vivo,,,,H
3190,Autocuration,,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,104698,,10609,BAO_0000218,,F,,,,,H
3191,Autocuration,,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3192,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3193,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),104698,,11454,BAO_0000218,,F,In vivo,,,,H
3194,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,104698,Rattus norvegicus,11454,BAO_0000218,,F,In vivo,,10116.0,,D
3195,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3196,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3197,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3198,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3199,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3200,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3201,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3202,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3203,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3204,Autocuration,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3205,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3206,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3207,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3208,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3209,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3210,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3211,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3212,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3213,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3214,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3215,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3216,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3217,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3218,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3219,Autocuration,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,104698,,11454,BAO_0000218,,F,In vivo,,,,H
3220,Autocuration,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",104698,,670,BAO_0000218,,F,,,,,H
3221,Autocuration,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",104698,,670,BAO_0000218,,F,,,,,H
3222,Autocuration,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,104698,,10321,BAO_0000218,,F,In vivo,,,,H
3223,Autocuration,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,104698,,10321,BAO_0000218,,F,In vivo,,,,H
3224,Autocuration,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,104698,,10321,BAO_0000218,,F,In vivo,,,,H
3225,Autocuration,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,104698,,10321,BAO_0000218,,F,In vivo,,,,H
3226,Autocuration,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,104698,,10321,BAO_0000218,,F,In vivo,,,,H
3227,Autocuration,,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),104698,,10322,BAO_0000218,,F,In vivo,,,,H
3228,Autocuration,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,,15412,BAO_0000019,,F,,,,,H
3229,Autocuration,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,,15412,BAO_0000019,,F,,,,,H
3230,Autocuration,,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,104698,Rattus norvegicus,15412,BAO_0000223,,B,,,10116.0,,D
3231,Autocuration,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,104698,,15412,BAO_0000019,,F,,,,,H
3232,Intermediate,,Hippocampus,10000000.0,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,104698,,15412,BAO_0000221,,B,,,,,D
3233,Autocuration,,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,104698,Rattus norvegicus,15412,BAO_0000019,,B,,,10116.0,,D
3234,Autocuration,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,104698,Rattus norvegicus,17394,BAO_0000019,,B,,,10116.0,,D
3235,Autocuration,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,104698,,12457,BAO_0000223,,B,,,,,H
3236,Autocuration,,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,104698,,12457,BAO_0000019,,B,,,,,H
3237,Autocuration,,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,104698,,12205,BAO_0000019,,B,,,,,H
3238,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,104698,,14532,BAO_0000019,,B,,,,,H
3239,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,104698,,1122,BAO_0000019,,B,,,,,H
3240,Autocuration,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,,5094,BAO_0000019,,B,,,,,H
3241,Intermediate,,Ileum,2116.0,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,20033,Cavia porcellus,809,BAO_0000221,,F,,,10141.0,,D
3242,Intermediate,,Ileum,2116.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,20033,Cavia porcellus,809,BAO_0000221,,F,,,10141.0,,D
3243,Intermediate,,Ileum,2116.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",20033,Cavia porcellus,14290,BAO_0000221,,F,,,10141.0,,D
3244,Intermediate,,Ileum,2116.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",20033,Cavia porcellus,14290,BAO_0000221,,F,,,10141.0,,D
3245,Intermediate,,Ileum,2116.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,Cavia porcellus,14290,BAO_0000221,,F,,,10141.0,,D
3246,Intermediate,,Ileum,2116.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,Cavia porcellus,14290,BAO_0000221,,F,,,10141.0,,D
3247,Intermediate,,Ileum,2116.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",20033,Cavia porcellus,14290,BAO_0000221,,F,,,10141.0,,D
3248,Intermediate,,Ileum,2116.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,20033,Cavia porcellus,13961,BAO_0000221,,F,,,10141.0,,D
3249,Intermediate,,Ileum,2116.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,20033,Cavia porcellus,13961,BAO_0000221,,F,,,10141.0,,D
3250,Intermediate,,Ileum,2116.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,20033,Cavia porcellus,809,BAO_0000221,,F,,,10141.0,,D
3251,Intermediate,,Ileum,2116.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,20033,Cavia porcellus,809,BAO_0000221,,F,,,10141.0,,D
3252,Intermediate,,Ileum,2116.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,20033,Cavia porcellus,809,BAO_0000221,,F,,,10141.0,,D
3253,Intermediate,,Ileum,2116.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",20033,Cavia porcellus,14290,BAO_0000221,,F,,,10141.0,,D
3254,Intermediate,,Ileum,2116.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",20033,Cavia porcellus,14290,BAO_0000221,,F,,,10141.0,,D
3255,Intermediate,,Ileum,2116.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",20033,Cavia porcellus,14290,BAO_0000221,,F,,,10141.0,,D
3256,Intermediate,,Ileum,2116.0,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,20033,Cavia porcellus,14290,BAO_0000221,,F,,,10141.0,,D
3257,Intermediate,,Ileum,2116.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,Cavia porcellus,14290,BAO_0000221,,F,,,10141.0,,D
3258,Intermediate,,Ileum,2116.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,Cavia porcellus,14290,BAO_0000221,,F,,,10141.0,,D
3259,Intermediate,,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,Cavia porcellus,15034,BAO_0000357,,B,,,10141.0,,D
3260,Intermediate,,Striatum,2435.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,Cavia porcellus,5094,BAO_0000249,,B,,,10141.0,,D
3261,Intermediate,,Striatum,2435.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,Cavia porcellus,5094,BAO_0000249,,B,,,10141.0,,D
3262,Intermediate,,Striatum,2435.0,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,20033,Cavia porcellus,5399,BAO_0000357,,B,,,10141.0,,D
3263,Intermediate,,Striatum,2435.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,Cavia porcellus,17394,BAO_0000357,,B,,,10141.0,,D
3264,Intermediate,,Striatum,2435.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,Cavia porcellus,17394,BAO_0000357,,B,,,10141.0,,D
3265,Intermediate,,Striatum,2435.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,Cavia porcellus,17394,BAO_0000357,,B,,,10141.0,,D
3266,Intermediate,,Ileum,2116.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,20033,Cavia porcellus,13961,BAO_0000221,,F,,,10141.0,,D
3267,Intermediate,,Ileum,2116.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,20033,Cavia porcellus,13961,BAO_0000221,,F,,,10141.0,,D
3268,Intermediate,,Ileum,2116.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,Cavia porcellus,13961,BAO_0000221,,F,,,10141.0,,D
3269,Intermediate,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,20033,Cavia porcellus,16946,BAO_0000357,,B,,,10141.0,,D
3270,Intermediate,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,20033,Cavia porcellus,16946,BAO_0000357,,B,,,10141.0,,D
3271,Intermediate,,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,20033,Cavia porcellus,15034,BAO_0000019,,F,,,10141.0,,D
3272,Intermediate,,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,20033,Cavia porcellus,15034,BAO_0000019,,F,,,10141.0,,D
3273,Intermediate,,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,20033,Cavia porcellus,12918,BAO_0000019,,F,,,10141.0,,D
3274,Intermediate,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,20033,Cavia porcellus,16946,BAO_0000357,,B,,,10141.0,,D
3275,Intermediate,,Striatum,2435.0,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,Cavia porcellus,17394,BAO_0000357,,B,,,10141.0,,D
3276,Intermediate,,Striatum,2435.0,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,20033,Cavia porcellus,15034,BAO_0000357,,B,,,10141.0,,D
3277,Intermediate,,Striatum,2435.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,Cavia porcellus,5094,BAO_0000249,,B,,,10141.0,,D
3278,Intermediate,,Striatum,2435.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,Cavia porcellus,5094,BAO_0000249,,B,,,10141.0,,D
3279,Intermediate,,Ileum,2116.0,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,20033,Cavia porcellus,17358,BAO_0000221,,B,,,10141.0,,D
3280,Expert,,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,20033,Cavia porcellus,12953,BAO_0000357,,B,,,10141.0,,D
3281,Intermediate,,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,Cavia porcellus,12953,BAO_0000357,,B,,,10141.0,,D
3282,Intermediate,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,20033,Cavia porcellus,12953,BAO_0000357,,B,,,10141.0,,D
3283,Intermediate,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,Cavia porcellus,12953,BAO_0000357,,B,,,10141.0,,D
3284,Intermediate,,Ileum,2116.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,Cavia porcellus,273,BAO_0000221,,F,,,10141.0,,D
3285,Intermediate,,Ileum,2116.0,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,20033,Cavia porcellus,12918,BAO_0000221,,F,,,10141.0,,D
3286,Intermediate,,Ileum,2116.0,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,20033,Cavia porcellus,12919,BAO_0000221,,F,,,10141.0,,D
3287,Intermediate,,Ileum,2116.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,20033,Cavia porcellus,273,BAO_0000221,,F,,,10141.0,,D
3288,Intermediate,,Ileum,2116.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,Cavia porcellus,273,BAO_0000221,,F,,,10141.0,,D
3289,Intermediate,,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,20033,Cavia porcellus,13181,BAO_0000357,,B,,,10141.0,,D
3290,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,168,Cavia porcellus,13181,BAO_0000357,,B,,,10141.0,,H
3291,Intermediate,,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,20033,Cavia porcellus,15034,BAO_0000019,,F,,,10141.0,,D
3292,Intermediate,,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,Cavia porcellus,5033,BAO_0000357,,B,,,10141.0,,D
3293,Intermediate,,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,20033,Cavia porcellus,1980,BAO_0000019,,B,,,10141.0,,D
3294,Autocuration,,,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,168,Cavia porcellus,13181,BAO_0000219,,B,,,10141.0,HEK293,H
3295,Intermediate,,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,20033,Cavia porcellus,14287,BAO_0000019,,B,,,10141.0,,D
3296,Intermediate,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,20033,Cavia porcellus,1317,BAO_0000357,,B,,,10141.0,,D
3297,Intermediate,,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,20033,Cavia porcellus,15316,BAO_0000357,,B,,,10141.0,,D
3298,Intermediate,,Striatum,2435.0,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,20033,Cavia porcellus,16429,BAO_0000357,,B,,,10141.0,,D
3299,Intermediate,,Hippocampus,10000000.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,20033,Cavia porcellus,14818,BAO_0000221,,B,,,10141.0,,D
3300,Intermediate,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,20033,Cavia porcellus,15194,BAO_0000357,,B,,,10141.0,,D
3301,Intermediate,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,20033,Cavia porcellus,15194,BAO_0000357,,B,,,10141.0,,D
3302,Intermediate,,Ileum,2116.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,Cavia porcellus,13961,BAO_0000221,,F,,,10141.0,,D
3303,Autocuration,,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,108,,5486,BAO_0000357,,B,,,,,H
3304,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,168,,16209,BAO_0000357,,B,,,,,H
3305,Autocuration,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,168,,17085,BAO_0000019,,B,,,,,H
3306,Autocuration,,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,168,,4199,BAO_0000219,,B,,,,HeLa,H
3307,Autocuration,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,168,,15146,BAO_0000357,,B,,,,,H
3308,Autocuration,,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,168,,5213,BAO_0000357,,B,,,,,H
3309,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",168,,4829,BAO_0000219,,B,,,,HeLa,H
3310,Autocuration,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,10622,,17358,BAO_0000357,,B,,,,,H
3311,Autocuration,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,10622,,17358,BAO_0000357,,B,,,,,H
3312,Autocuration,,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,10622,,16946,BAO_0000219,,B,,,,,H
3313,Autocuration,,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,10622,,17358,BAO_0000357,,B,,,,,H
3314,Autocuration,,Cardiac atrium,2081.0,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,11249,,268,BAO_0000019,,F,,,,,H
3315,Autocuration,,Cardiac atrium,2081.0,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,11249,,268,BAO_0000019,,F,,,,,H
3316,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,11249,,15086,BAO_0000357,,B,,,,,H
3317,Autocuration,,Hippocampus,10000000.0,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,11249,,14875,BAO_0000221,,B,,,,,H
3318,Autocuration,,Hippocampus,10000000.0,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,168,Sus scrofa,13267,BAO_0000221,,B,,,9823.0,,H
3319,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,168,Oryctolagus cuniculus,13047,BAO_0000019,,B,,,9986.0,,H
3320,Expert,,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,10623,Rattus norvegicus,1650,BAO_0000357,,B,,,10116.0,,D
3321,Autocuration,,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,,567,BAO_0000019,,F,,,,,H
3322,Autocuration,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,10623,,17358,BAO_0000357,,B,,,,,H
3323,Autocuration,,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,10623,,188,BAO_0000357,,B,,,,,H
3324,Autocuration,,,,lntrinsic activity relative to 5-HT receptor,10623,,670,BAO_0000019,,F,,,,,H
3325,Autocuration,,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,10623,,204,BAO_0000019,,F,,,,,H
3326,Expert,,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,10623,,1946,BAO_0000019,,F,,,,,H
3327,Autocuration,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,10623,,6398,BAO_0000019,,F,,,,,H
3328,Autocuration,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,10623,,6398,BAO_0000019,,F,,,,,H
3329,Autocuration,,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,10623,,17358,BAO_0000019,,F,,,,,H
3330,Autocuration,,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,10623,,6398,BAO_0000019,,F,,,,,H
3331,Expert,,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,10623,,11752,BAO_0000357,,B,,,,,H
3332,Autocuration,,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,10623,,809,BAO_0000019,,F,,,,,H
3333,Expert,,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,10623,Rattus norvegicus,14178,BAO_0000357,,B,,,10116.0,,D
3334,Autocuration,,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,,567,BAO_0000357,,B,,,,,H
3335,Autocuration,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,10623,,1946,BAO_0000357,,B,,,,,H
3336,Autocuration,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,10623,,1946,BAO_0000357,,B,,,,,H
3337,Expert,,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,10623,Rattus norvegicus,13961,BAO_0000019,,B,,,10116.0,,D
3338,Autocuration,,Striatum,2435.0,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,10623,,6238,BAO_0000249,,B,,,,,H
3339,Autocuration,,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,10623,,14290,BAO_0000249,,B,,,,,H
3340,Expert,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,10623,,14290,BAO_0000249,,B,,,,,H
3341,Expert,,Striatum,2435.0,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,Rattus norvegicus,809,BAO_0000019,,B,,,10116.0,,D
3342,Autocuration,,Striatum,2435.0,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,,1578,BAO_0000019,,B,,,,,H
3343,Expert,,Striatum,2435.0,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,10623,,16709,BAO_0000249,,B,,,,,H
3344,Expert,,Striatum,2435.0,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,10623,,1946,BAO_0000019,,B,,,,,H
3345,Expert,,Striatum,2435.0,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,10623,,15253,BAO_0000249,,B,,,,,H
3346,Expert,,Striatum,2435.0,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,,4535,BAO_0000249,,B,,,,,H
3347,Expert,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,10623,,13961,BAO_0000249,,B,,,,,H
3348,Autocuration,,Brain,955.0,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,10623,,17358,BAO_0000221,,F,,,,,H
3349,Autocuration,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,10623,,15847,BAO_0000019,,F,,,,,H
3350,Autocuration,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,10623,,15847,BAO_0000019,,F,,,,,H
3351,Autocuration,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,10623,,670,BAO_0000019,,F,,,,,H
3352,Autocuration,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,10623,,670,BAO_0000019,,F,,,,,H
3353,Autocuration,,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,,1317,BAO_0000019,,F,,,,,H
3354,Expert,,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,10623,Rattus norvegicus,12936,BAO_0000357,,B,,,10116.0,,D
3355,Expert,,Striatum,2435.0,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,,4535,BAO_0000249,,B,,,,,H
3356,Expert,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,10623,Rattus norvegicus,14424,BAO_0000019,,F,,,10116.0,,D
3357,Expert,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,10623,,14424,BAO_0000019,,F,,,,,H
3358,Expert,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,,14424,BAO_0000019,,F,,,,,H
3359,Expert,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,10623,Rattus norvegicus,14424,BAO_0000019,,F,,,10116.0,,D
3360,Autocuration,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,10623,,14424,BAO_0000019,,F,,,,,H
3361,Expert,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,10623,,14424,BAO_0000019,,F,,,,,H
3362,Expert,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),10623,,14424,BAO_0000218,,F,,,,,H
3363,Autocuration,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,,14424,BAO_0000019,,F,,,,,H
3364,Autocuration,,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,168,Rattus norvegicus,1980,BAO_0000019,,F,,,10116.0,,H
3365,Autocuration,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,168,,4639,BAO_0000019,,F,,,,,H
3366,Autocuration,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,168,,17358,BAO_0000357,,B,,,,,H
3367,Autocuration,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,168,,17358,BAO_0000357,,B,,,,,H
3368,Autocuration,,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,168,,17358,BAO_0000357,,B,,,,,H
3369,Autocuration,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,168,,1558,BAO_0000357,,B,,,,,H
3370,Autocuration,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,17358,BAO_0000019,,F,,,,,H
3371,Autocuration,,,,In vitro binding affinity towards 5-HT4 receptor was determined,168,,16117,BAO_0000357,,B,,,,,H
3372,Autocuration,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,17358,BAO_0000019,,F,,,,,H
3373,Autocuration,,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,168,,17358,BAO_0000019,,F,,,,,H
3374,Autocuration,,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,168,,17358,BAO_0000357,,B,,,,,H
3375,Autocuration,,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,168,,17358,BAO_0000357,,B,,,,,H
3376,Autocuration,,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,168,,17358,BAO_0000357,,B,,,,,H
3377,Autocuration,,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,168,,17358,BAO_0000357,,B,,,,,H
3378,Expert,,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,168,,1274,BAO_0000357,,B,,,,,H
3379,Autocuration,Brain membranes,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,104698,,10728,BAO_0000249,,B,,,,,H
3380,Autocuration,Brain membranes,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,104698,,11695,BAO_0000249,,B,,,,,H
3381,Autocuration,Brain membranes,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,104698,,11695,BAO_0000249,,B,,,,,H
3382,Autocuration,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,104698,,12490,BAO_0000019,,B,,,,,H
3383,Autocuration,,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,Rattus norvegicus,11828,BAO_0000019,,B,,,10116.0,,D
3384,Autocuration,,Hippocampus,10000000.0,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,104698,,12253,BAO_0000221,,B,,,,,H
3385,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104698,,10561,BAO_0000019,,B,,,,,H
3386,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,104698,,10561,BAO_0000019,,B,,,,,H
3387,Autocuration,,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,104698,,14432,BAO_0000019,,F,,,,,H
3388,Autocuration,,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,104698,Rattus norvegicus,12936,BAO_0000223,,B,,,10116.0,,D
3389,Autocuration,,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,104698,Rattus norvegicus,1274,BAO_0000223,,B,,,10116.0,,D
3390,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,104698,,1980,BAO_0000019,,B,,,,,H
3391,Autocuration,,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,104698,,670,BAO_0000249,,B,,,,,H
3392,Autocuration,,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,104698,Rattus norvegicus,968,BAO_0000019,,B,,,10116.0,,D
3393,Autocuration,,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,104698,,14287,BAO_0000019,,B,,,,,H
3394,Autocuration,,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,104698,,567,BAO_0000019,,B,,,,,H
3395,Autocuration,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,104698,,13267,BAO_0000019,,B,,,,,H
3396,Autocuration,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,104698,,14826,BAO_0000249,,B,,,,,H
3397,Autocuration,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,104698,,15194,BAO_0000223,,B,,,,,H
3398,Autocuration,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,104698,,15194,BAO_0000223,,B,,,,,H
3399,Autocuration,,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,104698,Rattus norvegicus,10394,BAO_0000223,,B,,,10116.0,,D
3400,Expert,,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",10576,,13657,BAO_0000249,,B,,,,,D
3401,Autocuration,,Brain,955.0,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,12020,,1879,BAO_0000221,,F,,,,,H
3402,Autocuration,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,12020,,1879,BAO_0000019,,F,,,,,H
3403,Autocuration,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,12020,,1879,BAO_0000019,,F,,,,,H
3404,Autocuration,,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,12020,,204,BAO_0000218,,F,In vivo,,,,H
3405,Autocuration,,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,,1879,BAO_0000019,,B,,,,,H
3406,Autocuration,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,12020,,1879,BAO_0000357,,B,,,,,H
3407,Autocuration,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,,1879,BAO_0000019,,B,,,,,H
3408,Autocuration,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,12020,,1879,BAO_0000019,,B,,,,,H
3409,Autocuration,,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",104698,,10641,BAO_0000019,,B,,,,,H
3410,Autocuration,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,12020,,773,BAO_0000019,,B,,,,,H
3411,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,104698,,11952,BAO_0000249,,B,,,,,H
3412,Autocuration,,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,12020,Rattus norvegicus,14145,BAO_0000019,,F,,,10116.0,,D
3413,Expert,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,144,,17066,BAO_0000357,,B,,,,,H
3414,Autocuration,,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,104714,,6398,BAO_0000223,,B,,,,,H
3415,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,22226,,10321,BAO_0000019,,B,,,,,U
3416,Autocuration,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,104714,,511,BAO_0000019,,F,,,,,H
3417,Autocuration,,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,4639,BAO_0000223,,B,,,,,H
3418,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,4639,BAO_0000223,,B,,,,,H
3419,Autocuration,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3420,Autocuration,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3421,Autocuration,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3422,Autocuration,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,104714,,1558,BAO_0000223,,B,,,,,H
3423,Autocuration,,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,104714,,268,BAO_0000019,,F,,,,,H
3424,Autocuration,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,104714,,2474,BAO_0000223,,B,,,,,H
3425,Autocuration,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,104714,,5067,BAO_0000019,,F,,,,,H
3426,Autocuration,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,104714,,5067,BAO_0000019,,F,,,,,H
3427,Autocuration,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,104714,,5067,BAO_0000019,,F,,,,,H
3428,Autocuration,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,104714,,5067,BAO_0000223,,B,,,,,H
3429,Autocuration,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,104714,,5067,BAO_0000019,,F,,,,,H
3430,Autocuration,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,104714,,5067,BAO_0000019,,F,,,,,H
3431,Autocuration,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,104714,,5067,BAO_0000019,,F,,,,,H
3432,Autocuration,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,104714,,5067,BAO_0000223,,B,,,,,H
3433,Autocuration,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,104714,,5067,BAO_0000223,,B,,,,,H
3434,Autocuration,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,104714,,5067,BAO_0000019,,F,,,,,H
3435,Autocuration,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,104714,,5067,BAO_0000223,,B,,,,,H
3436,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,5067,BAO_0000223,,B,,,,,H
3437,Autocuration,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,104714,,14331,BAO_0000219,,B,,,,,H
3438,Autocuration,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,104714,,5067,BAO_0000223,,B,,,,,H
3439,Autocuration,,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,104714,,6179,BAO_0000219,,B,,,,NG108-15,H
3440,Autocuration,,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,104714,,4265,BAO_0000019,,B,,,,,H
3441,Autocuration,,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,104714,,4265,BAO_0000219,,B,,,,NG108-15,H
3442,Autocuration,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,104714,,17358,BAO_0000223,,B,,,,,H
3443,Autocuration,,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,104714,,17358,BAO_0000223,,B,,,,,H
3444,Autocuration,,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,104714,,13628,BAO_0000219,,B,In vitro,,,,H
3445,Autocuration,,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,104714,,4612,BAO_0000223,,B,,,,,H
3446,Autocuration,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,104714,,17358,BAO_0000019,,F,,,,,H
3447,Autocuration,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3448,Autocuration,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3449,Autocuration,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3450,Autocuration,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3451,Autocuration,,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,104714,,511,BAO_0000223,,B,,,,,H
3452,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,1479,BAO_0000223,,B,,,,,H
3453,Autocuration,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,104714,,1317,BAO_0000223,,B,,,,,H
3454,Autocuration,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,104714,,12146,BAO_0000223,,B,,,,,H
3455,Autocuration,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,104714,,12146,BAO_0000223,,B,,,,,H
3456,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,104714,,13969,BAO_0000223,,B,,,,,H
3457,Expert,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,108,,13392,BAO_0000357,,B,,,,,H
3458,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104698,,13392,BAO_0000223,,B,,,,,H
3459,Autocuration,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,144,,14159,BAO_0000357,,B,,,,,H
3460,Autocuration,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,144,,1558,BAO_0000357,,B,,,,,H
3461,Autocuration,,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,144,,16655,BAO_0000357,,B,,,,,H
3462,Autocuration,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,,13020,BAO_0000223,,B,,,,,H
3463,Autocuration,,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,104714,,13021,BAO_0000223,,B,,,,,H
3464,Autocuration,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,,13020,BAO_0000223,,B,,,,,H
3465,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,144,,10321,BAO_0000019,,B,,,,,H
3466,Autocuration,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,,15818,BAO_0000357,,B,,,,,H
3467,Autocuration,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,,15818,BAO_0000357,,B,,,,,H
3468,Autocuration,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,144,,17358,BAO_0000357,,B,,,,,H
3469,Autocuration,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,144,,2222,BAO_0000357,,B,,,,,H
3470,Autocuration,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,144,,10322,BAO_0000019,,B,,,,,H
3471,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,144,,16117,BAO_0000357,,B,,,,,H
3472,Autocuration,,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,144,,17200,BAO_0000357,,B,,,,,H
3473,Autocuration,,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,144,,17358,BAO_0000019,,F,,,,,H
3474,Autocuration,,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,144,,16700,BAO_0000357,,B,,,,,H
3475,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,144,,1980,BAO_0000019,,B,,,,,H
3476,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,144,,1980,BAO_0000019,,B,,,,,H
3477,Autocuration,,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,104714,,12409,BAO_0000223,,B,,,,,H
3478,Autocuration,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,,4365,BAO_0000357,,B,,,,,H
3479,Autocuration,,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,144,,4365,BAO_0000019,,F,,,,,H
3480,Autocuration,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,,4365,BAO_0000357,,B,,,,,H
3481,Expert,,,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,12020,Rattus norvegicus,6769,BAO_0000219,,F,,,10116.0,Oocytes,D
3482,Expert,,,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,12020,Rattus norvegicus,6769,BAO_0000219,,F,,,10116.0,Oocytes,D
3483,Expert,,,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,12020,Rattus norvegicus,6769,BAO_0000219,,F,,,10116.0,Oocytes,D
3484,Intermediate,,Ileum,2116.0,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,20033,Cavia porcellus,809,BAO_0000221,,F,,,10141.0,,D
3485,Intermediate,,Ileum,2116.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,20033,Cavia porcellus,809,BAO_0000221,,F,,,10141.0,,D
3486,Intermediate,,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,20033,Cavia porcellus,14290,BAO_0000019,,F,,,10141.0,,D
3487,Intermediate,,Ileum,2116.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,20033,Cavia porcellus,17358,BAO_0000221,,B,,,10141.0,,D
3488,Intermediate,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,20033,Cavia porcellus,17358,BAO_0000357,,B,,,10141.0,,D
3489,Intermediate,,Ileum,2116.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,20033,Cavia porcellus,17358,BAO_0000221,,B,,,10141.0,,D
3490,Autocuration,,Ileum,2116.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,10209,,17386,BAO_0000221,,B,,,,,H
3491,Autocuration,,,,Affinity against 5-hydroxytryptamine 7 receptor,10209,,3269,BAO_0000357,,B,,,,,H
3492,Autocuration,,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,Cavia porcellus,7721,BAO_0000224,,B,,,10141.0,,H
3493,Autocuration,,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,Cavia porcellus,7721,BAO_0000224,,B,,,10141.0,,H
3494,Autocuration,,Ileum,2116.0,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,104841,Cavia porcellus,9117,BAO_0000221,,B,,,10141.0,,H
3495,Autocuration,,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,Cavia porcellus,7721,BAO_0000224,,B,,,10141.0,,H
3496,Autocuration,,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,Cavia porcellus,7721,BAO_0000224,,B,,,10141.0,,H
3497,Autocuration,,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,Cavia porcellus,15796,BAO_0000019,,F,,,10141.0,,H
3498,Autocuration,,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,Cavia porcellus,15796,BAO_0000019,,F,,,10141.0,,H
3499,Expert,,Cardiac atrium,2081.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,168,Homo sapiens,15650,BAO_0000219,,B,,,9606.0,,D
3500,Expert,,Cardiac atrium,2081.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,168,Homo sapiens,15650,BAO_0000219,,B,,,9606.0,,D
3501,Autocuration,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",104841,Homo sapiens,6866,BAO_0000019,,F,,,9606.0,,D
3502,Expert,,Cardiac atrium,2081.0,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",168,Homo sapiens,15650,BAO_0000219,,F,,,9606.0,,D
3503,Autocuration,,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,22226,Mus musculus,10063,BAO_0000019,,B,,,10090.0,,U
3504,Autocuration,,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,22226,Mus musculus,12665,BAO_0000019,,B,,,10090.0,,U
3505,Autocuration,,,,5-hydroxytryptamine receptor binding affinity was determined in rats,104705,,7504,BAO_0000019,,B,,,,,H
3506,Autocuration,,,,Binding affinity at rat 5-hydroxytryptamine receptor.,104705,,7504,BAO_0000224,,B,,,,,H
3507,Autocuration,,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,104705,,7038,BAO_0000019,,B,,,,,H
3508,Autocuration,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,104705,,7626,BAO_0000224,,B,,,,,H
3509,Autocuration,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,104705,,7626,BAO_0000224,,B,,,,,H
3510,Autocuration,,Stomach,945.0,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,104705,,7185,BAO_0000019,,F,,,,,H
3511,Autocuration,,Stomach,945.0,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,104705,,7185,BAO_0000019,,F,,,,,H
3512,Autocuration,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,104705,,7185,BAO_0000019,,F,,,,,H
3513,Autocuration,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,104705,,6960,BAO_0000224,,B,,,,,H
3514,Autocuration,,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",104705,,6960,BAO_0000224,,B,,,,,H
3515,Autocuration,,Hippocampus,10000000.0,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,,12416,BAO_0000221,,B,,,,,H
3516,Expert,,,,Binding affinity for rat 5-hydroxytryptamine transporter.,12198,,15753,BAO_0000357,,B,,,,,H
3517,Autocuration,,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,104705,,8062,BAO_0000019,,B,,,,,H
3518,Autocuration,,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,104705,Rattus norvegicus,9036,BAO_0000019,,B,,,10116.0,,D
3519,Autocuration,,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,104705,Rattus norvegicus,15067,BAO_0000224,,B,,,10116.0,,D
3520,Expert,,Brain,955.0,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,12198,Rattus norvegicus,15753,BAO_0000019,,F,,,10116.0,,D
3521,Expert,,Cerebellum,2037.0,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,12198,Rattus norvegicus,15753,BAO_0000221,,F,,,10116.0,,D
3522,Autocuration,,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,104705,Rattus norvegicus,15295,BAO_0000019,,B,,,10116.0,,D
3523,Autocuration,,,,Percent binding affinity against 5-hydroxytryptamine receptor,104705,Rattus norvegicus,6347,BAO_0000224,,B,,,10116.0,,D
3524,Autocuration,,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,22226,,6763,BAO_0000019,,B,,,,,U
3525,Autocuration,,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,104705,Rattus norvegicus,12092,BAO_0000224,,B,,,10116.0,,D
3526,Autocuration,,,,Affinity against 5-hydroxytryptamine receptor was determined,104705,Rattus norvegicus,1579,BAO_0000224,,B,,,10116.0,,D
3527,Autocuration,,Stomach,945.0,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,104705,Rattus norvegicus,1579,BAO_0000019,,B,,,10116.0,,D
3528,Expert,,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,Homo sapiens,5963,BAO_0000219,,B,In vitro,,9606.0,,D
3529,Expert,,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,Homo sapiens,5963,BAO_0000219,,B,In vitro,,9606.0,,D
3530,Autocuration,,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,18065,,5030,BAO_0000357,,B,,,,,H
3531,Expert,,,,Inhibition of 5-hydroxytryptamine reuptake,121,,15796,BAO_0000357,,B,,,,,H
3532,Autocuration,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",18065,,15413,BAO_0000019,,F,,,,,H
3533,Autocuration,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",18065,,15413,BAO_0000019,,F,,,,,H
3534,Autocuration,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",18065,,15413,BAO_0000019,,F,,,,,H
3535,Autocuration,,,,Tested for 5-hydroxytryptamine receptor uptake,18065,,12409,BAO_0000019,,F,,,,,H
3536,Expert,,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,Homo sapiens,16909,BAO_0000219,,B,,,9606.0,CHO,D
3537,Expert,,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,51,Homo sapiens,16909,BAO_0000019,,F,,,9606.0,,D
3538,Autocuration,,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,10576,Homo sapiens,15629,BAO_0000249,,B,,,9606.0,,H
3539,Autocuration,,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,10576,,15629,BAO_0000357,,B,,,,,H
3540,Expert,,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,10576,,15629,BAO_0000249,,B,,,,,H
3541,Autocuration,,Striatum,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3542,Autocuration,,Striatum,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3543,Autocuration,,Striatum,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3544,Autocuration,,Striatum,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3545,Autocuration,,Striatum,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3546,Autocuration,,Striatum,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3547,Autocuration,,Striatum,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3548,Autocuration,,Striatum,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3549,Autocuration,,Striatum,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3550,Autocuration,,Striatum,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3551,Autocuration,,Striatum,2435.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3552,Autocuration,,Limbic system,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3553,Autocuration,,Limbic system,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3554,Autocuration,,Limbic system,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3555,Autocuration,,Limbic system,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3556,Autocuration,,Limbic system,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3557,Autocuration,,Limbic system,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3558,Autocuration,,Limbic system,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3559,Expert,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,168,,1274,BAO_0000357,,B,,,,,H
3560,Autocuration,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,17358,BAO_0000019,,F,,,,,H
3561,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,168,,14532,BAO_0000357,,B,,,,,H
3562,Expert,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,168,,16989,BAO_0000357,,B,,,,,H
3563,Autocuration,,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,168,,17200,BAO_0000357,,B,,,,,H
3564,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,168,,15779,BAO_0000357,,B,,,,,H
3565,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,,15779,BAO_0000357,,B,,,,,H
3566,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,,15779,BAO_0000357,,B,,,,,H
3567,Autocuration,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,168,,15650,BAO_0000219,,B,,,,COS-7,H
3568,Autocuration,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,168,,15650,BAO_0000219,,B,,,,COS-7,H
3569,Autocuration,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,168,,15650,BAO_0000219,,B,,,,COS-7,H
3570,Autocuration,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,168,,15650,BAO_0000219,,B,,,,COS-7,H
3571,Autocuration,,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,,17046,BAO_0000219,,B,,,,C6,H
3572,Expert,,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,,17046,BAO_0000219,,B,,,,C6,H
3573,Expert,,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,168,,15650,BAO_0000219,,B,,,,C6,H
3574,Expert,,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,168,,17046,BAO_0000219,,B,,,,C6,H
3575,Expert,,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,10624,,17066,BAO_0000357,,B,,,,,H
3576,Autocuration,,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,105,,17200,BAO_0000357,,B,,,,,H
3577,Expert,,,,Binding affinity against 5-hydroxytryptamine 5A receptor,10624,Homo sapiens,16146,BAO_0000357,,B,,,9606.0,,D
3578,Autocuration,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,10624,,15250,BAO_0000219,,B,,,,CHO,H
3579,Expert,,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,10624,Homo sapiens,6491,BAO_0000357,,B,,,9606.0,,D
3580,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,Homo sapiens,17066,BAO_0000357,,B,,,9606.0,,D
3581,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,10624,Homo sapiens,17066,BAO_0000357,,B,,,9606.0,,D
3582,Expert,,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,10624,Homo sapiens,4234,BAO_0000357,,B,,,9606.0,,D
3583,Autocuration,,,,Binding affinity towards 5-HT5A receptor,10624,,6013,BAO_0000357,,B,,,,,H
3584,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,10624,,17175,BAO_0000357,,B,,,,,H
3585,Autocuration,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,,15818,BAO_0000357,,B,,,,,H
3586,Autocuration,,,,Binding affinity towards cloned human 5-HT5A receptor was determined,10624,,6166,BAO_0000357,,B,,,,,H
3587,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10624,,15779,BAO_0000219,,B,,,,HEK293,H
3588,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10624,,15779,BAO_0000219,,B,,,,HEK293,H
3589,Autocuration,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),10624,,5213,BAO_0000219,,B,,,,HEK293,H
3590,Expert,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,10625,Mus musculus,17066,BAO_0000357,,B,,,10090.0,,D
3591,Expert,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,10625,Mus musculus,17066,BAO_0000357,,B,,,10090.0,,D
3592,Expert,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,10625,Mus musculus,17066,BAO_0000357,,B,,,10090.0,,D
3593,Expert,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,10625,Mus musculus,17066,BAO_0000357,,B,,,10090.0,,D
3594,Expert,,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,10625,Mus musculus,17066,BAO_0000357,,B,,,10090.0,,D
3595,Expert,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,10625,,17175,BAO_0000357,,B,,,,,H
3596,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10576,,16190,BAO_0000219,,B,,,,HEK293,H
3597,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10626,,16190,BAO_0000219,,B,,,,HEK293,H
3598,Expert,,,,Binding affinity towards 5-HT5a receptor,10624,,4820,BAO_0000357,,B,,,,,H
3599,Expert,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,10624,Homo sapiens,17066,BAO_0000357,,B,,,9606.0,,D
3600,Expert,,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,10624,,17066,BAO_0000357,,B,,,,,H
3601,Expert,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,10624,,17175,BAO_0000357,,B,,,,,H
3602,Autocuration,,,,Binding affinities against 5-hydroxytryptamine 5A receptor,10624,,16633,BAO_0000357,,B,,,,,H
3603,Autocuration,,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,10624,,16633,BAO_0000357,,B,,,,,H
3604,Autocuration,,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,10624,,16700,BAO_0000357,,B,,,,,H
3605,Autocuration,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,104714,Cavia porcellus,4639,BAO_0000019,,F,,,10141.0,,H
3606,Autocuration,,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,104714,,5486,BAO_0000223,,B,,,,,H
3607,Expert,,,,Inhibition of human 5-hydroxytryptamine 6 receptor,10627,Homo sapiens,16146,BAO_0000357,,B,,,9606.0,,D
3608,Expert,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,10627,Homo sapiens,17273,BAO_0000357,,B,,,9606.0,,D
3609,Autocuration,,,,Inhibition against human 5-hydroxytryptamine 6 receptor,10627,,17687,BAO_0000357,,B,,,,,H
3610,Expert,,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,10627,Homo sapiens,6491,BAO_0000357,,B,,,9606.0,,D
3611,Expert,,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,10627,,16190,BAO_0000219,,B,,,,HeLa,H
3612,Expert,,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,10627,Homo sapiens,17066,BAO_0000357,,B,,,9606.0,,D
3613,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,Homo sapiens,17066,BAO_0000357,,B,,,9606.0,,D
3614,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,10627,Homo sapiens,17066,BAO_0000357,,B,,,9606.0,,D
3615,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,10627,Homo sapiens,17066,BAO_0000357,,B,,,9606.0,,D
3616,Expert,,,,Binding affinity against 5-hydroxytryptamine 6 receptor,10627,Homo sapiens,3555,BAO_0000357,,B,,,9606.0,,D
3617,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,5808,BAO_0000357,,B,,,,,H
3618,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,6013,BAO_0000357,,B,,,,,H
3619,Expert,,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",10627,,15818,BAO_0000219,,B,,,,HEK293,H
3620,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,10627,,16209,BAO_0000357,,B,,,,,H
3621,Expert,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,10627,,3935,BAO_0000219,,B,,,,HEK293,H
3622,Autocuration,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,15818,BAO_0000357,,B,,,,,H
3623,Expert,,,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,Homo sapiens,3805,BAO_0000219,,B,,,9606.0,HEK293,D
3624,Expert,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,10627,,16441,BAO_0000019,,B,,,,,H
3625,Expert,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10627,,16441,BAO_0000019,,B,,,,,H
3626,Expert,,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,10627,,6786,BAO_0000219,,B,,,,COS-7,H
3627,Expert,,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,10627,Homo sapiens,4234,BAO_0000357,,B,,,9606.0,,D
3628,Autocuration,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,10627,,17085,BAO_0000019,,B,,,,,H
3629,Autocuration,,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,10627,,17200,BAO_0000357,,B,,,,,H
3630,Autocuration,,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,,17451,BAO_0000219,,B,,,,HEK293,H
3631,Autocuration,,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,10627,,3935,BAO_0000019,,F,,,,,H
3632,Autocuration,,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,10627,,5033,BAO_0000357,,B,,,,,H
3633,Expert,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,,4540,BAO_0000357,,B,,,,,H
3634,Expert,,,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,Homo sapiens,4540,BAO_0000219,,B,,,9606.0,HeLa,D
3635,Expert,,,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,Homo sapiens,4540,BAO_0000219,,B,,,9606.0,HeLa,D
3636,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,10627,,17296,BAO_0000219,,B,,,,HeLa,H
3637,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,,17296,BAO_0000219,,B,,,,HeLa,H
3638,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,,17296,BAO_0000219,,B,,,,HeLa,H
3639,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,10627,,15779,BAO_0000219,,B,,,,CHO,H
3640,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10627,,15779,BAO_0000219,,B,,,,HEK293,H
3641,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,10627,,15779,BAO_0000219,,B,,,,HEK293,H
3642,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10627,,15779,BAO_0000219,,B,,,,HEK293,H
3643,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,10627,,15779,BAO_0000219,,B,,,,HeLa,H
3644,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,6166,BAO_0000357,,B,,,,,H
3645,Autocuration,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,10627,,17451,BAO_0000219,,B,,,,HeLa,H
3646,Autocuration,,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,10627,,15316,BAO_0000357,,B,,,,,H
3647,Expert,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,,4199,BAO_0000357,,B,,,,,H
3648,Expert,,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,10627,,15146,BAO_0000219,,B,,,,HeLa,H
3649,Autocuration,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),10627,,5213,BAO_0000357,,B,,,,,H
3650,Autocuration,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,10627,,16429,BAO_0000219,,B,,,,,H
3651,Autocuration,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,10627,,14818,BAO_0000219,,B,,,,HeLa,H
3652,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",10627,,4829,BAO_0000219,,B,,,,HeLa,H
3653,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",10627,,4829,BAO_0000219,,B,,,,HeLa,H
3654,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",10627,,4829,BAO_0000219,,B,,,,HeLa,H
3655,Autocuration,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,10628,,15250,BAO_0000219,,B,,,,CHO,H
3656,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,10628,,14423,BAO_0000019,,B,,,,,H
3657,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,10628,,15086,BAO_0000357,,B,,,,,H
3658,Autocuration,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,10628,,4342,BAO_0000357,,B,,,,,H
3659,Autocuration,,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,10627,Homo sapiens,16190,BAO_0000219,,B,,,9606.0,HeLa,D
3660,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,4820,BAO_0000357,,B,,,,,H
3661,Autocuration,,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,10627,,4639,BAO_0000357,,B,,,,,H
3662,Expert,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,Homo sapiens,17066,BAO_0000019,,F,,,9606.0,,D
3663,Autocuration,,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,10627,,6011,BAO_0000357,,B,,,,,H
3664,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,17066,BAO_0000357,,B,,,,,H
3665,Autocuration,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,10627,,17515,BAO_0000357,,B,,,,,H
3666,Autocuration,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,5014,BAO_0000357,,B,,,,,H
3667,Autocuration,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,10627,,4373,BAO_0000357,,B,,,,,H
3668,Expert,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,10627,,17066,BAO_0000019,,F,,,,,H
3669,Expert,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,,17066,BAO_0000019,,F,,,,,H
3670,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,10627,,4373,BAO_0000357,,B,,,,,H
3671,Autocuration,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,4687,BAO_0000357,,B,,,,,H
3672,Autocuration,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,10627,,16946,BAO_0000357,,B,,,,,H
3673,Autocuration,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,10627,,16946,BAO_0000357,,B,,,,,H
3674,Autocuration,,,,Binding affinities against 5-hydroxytryptamine 6 receptor,10627,,16633,BAO_0000357,,B,,,,,H
3675,Autocuration,,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,10627,,16633,BAO_0000357,,B,,,,,H
3676,Expert,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,10627,Homo sapiens,17066,BAO_0000357,,B,,,9606.0,,D
3677,Autocuration,,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,10627,,16700,BAO_0000357,,B,,,,,H
3678,Autocuration,,,,Affinity against 5-hydroxytryptamine 6 receptor,10627,,3269,BAO_0000357,,B,,,,,H
3679,Autocuration,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],10627,,5486,BAO_0000357,,B,,,,,H
3680,Expert,,,,Inhibition of human 5-hydroxytryptamine 7 receptor,10209,Homo sapiens,16146,BAO_0000357,,B,,,9606.0,,D
3681,Autocuration,,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,10209,,5014,BAO_0000219,,B,,,,HEK293,H
3682,Autocuration,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,10209,,15463,BAO_0000357,,B,,,,,H
3683,Autocuration,,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),10209,,3805,BAO_0000357,,B,,,,,H
3684,Expert,,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,10209,,5014,BAO_0000219,,B,,,,HEK293,H
3685,Expert,,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,10209,Homo sapiens,6491,BAO_0000357,,B,,,9606.0,,D
3686,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,10209,,16190,BAO_0000219,,B,,,,CHO,H
3687,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,Homo sapiens,17066,BAO_0000357,,B,,,9606.0,,D
3688,Expert,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,10209,Homo sapiens,17066,BAO_0000357,,B,,,9606.0,,D
3689,Expert,,,,Binding affinity against 5-hydroxytryptamine 7 receptor,10209,Homo sapiens,3555,BAO_0000357,,B,,,9606.0,,D
3690,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,10209,,6588,BAO_0000219,,B,,,,CHO,H
3691,Autocuration,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,10209,,15463,BAO_0000357,,B,,,,,H
3692,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,,6013,BAO_0000357,,B,,,,,H
3693,Autocuration,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,10209,,16209,BAO_0000357,,B,,,,,H
3694,Autocuration,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,10209,,3935,BAO_0000357,,B,,,,,H
3695,Autocuration,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,,15818,BAO_0000357,,B,,,,,H
3696,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,10209,,5014,BAO_0000219,,B,,,,HEK293,H
3697,Expert,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,10209,,16441,BAO_0000019,,B,,,,,H
3698,Expert,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10209,,16441,BAO_0000019,,B,,,,,H
3699,Expert,,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,10209,Homo sapiens,4234,BAO_0000357,,B,,,9606.0,,D
3700,Autocuration,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,10209,,17085,BAO_0000019,,B,,,,,H
3701,Autocuration,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,10209,,17200,BAO_0000357,,B,,,,,H
3702,Autocuration,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,10209,,17451,BAO_0000219,,B,,,,CHO,H
3703,Autocuration,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,10209,,17085,BAO_0000019,,B,,,,,H
3704,Autocuration,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,10209,,5104,BAO_0000357,,B,,,,,H
3705,Autocuration,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,10209,,5104,BAO_0000357,,B,,,,,H
3706,Expert,,,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,Homo sapiens,5033,BAO_0000219,,B,,,9606.0,COS-7,D
3707,Autocuration,,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,,5486,BAO_0000219,,B,,,,COS-7,H
3708,Expert,,,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,10209,Homo sapiens,4540,BAO_0000219,,B,,,9606.0,HEK293,D
3709,Expert,,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,10209,,6166,BAO_0000357,,B,,,,,H
3710,Expert,,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,10209,,17342,BAO_0000219,,B,,,,HEK293,H
3711,Expert,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,10209,,17342,BAO_0000357,,B,,,,,H
3712,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,10209,,17296,BAO_0000357,,B,,,,,H
3713,Expert,,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,10209,,16429,BAO_0000219,,B,,,,,H
3714,Autocuration,,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,10209,,15779,BAO_0000219,,B,,,,HEK293,H
3715,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,15779,BAO_0000219,,B,,,,HEK293,H
3716,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,15779,BAO_0000219,,B,,,,HEK293,H
3717,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,15779,BAO_0000219,,B,,,,HEK293,H
3718,Autocuration,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,10209,,15779,BAO_0000219,,B,,,,HEK293,H
3719,Autocuration,,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,10209,,17451,BAO_0000219,,B,,,,CHO,H
3720,Autocuration,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),10209,,4199,BAO_0000219,,B,,,,HEK293,H
3721,Expert,,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,10209,,4199,BAO_0000219,,B,,,,HEK293,D
3722,Autocuration,,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),10209,,4199,BAO_0000219,,B,,,,HEK293,H
3723,Intermediate,,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,10209,,3680,BAO_0000219,,B,,,,HEK293,D
3724,Intermediate,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,10209,,3680,BAO_0000357,,B,,,,,D
3725,Autocuration,,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,10209,,15316,BAO_0000219,,B,,,,COS-7,H
3726,Autocuration,,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,10209,,15146,BAO_0000219,,B,,,,HEK293,H
3727,Expert,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,10209,,5213,BAO_0000219,,B,,,,HEK293,H
3728,Autocuration,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),10209,,5213,BAO_0000219,,B,,,,HEK293,H
3729,Expert,,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,10209,Homo sapiens,14818,BAO_0000219,,B,,,9606.0,HEK293,D
3730,Autocuration,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,10209,,14818,BAO_0000219,,B,,,,HEK293,H
3731,Autocuration,,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,10209,,14818,BAO_0000219,,B,,,,HEK293,H
3732,Autocuration,,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",10209,,4829,BAO_0000219,,B,,,,HEK293,H
3733,Autocuration,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,10209,Homo sapiens,17200,BAO_0000357,,B,,,9606.0,,D
3734,Expert,,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,10022,Mus musculus,17066,BAO_0000357,,B,,,10090.0,,D
3735,Autocuration,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,10209,Oryctolagus cuniculus,14025,BAO_0000019,,B,,,9986.0,,H
3736,Autocuration,,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,11923,,15250,BAO_0000219,,B,,,,CHO,H
3737,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,11923,,16372,BAO_0000219,,B,,,,CHO,H
3738,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,11923,,16372,BAO_0000219,,B,,,,CHO,H
3739,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,11923,,16372,BAO_0000219,,B,,,,CHO,H
3740,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,11923,,16372,BAO_0000219,,B,,,,CHO,H
3741,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,11923,,16372,BAO_0000219,,B,,,,CHO,H
3742,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,11923,,16372,BAO_0000219,,B,,,,CHO,H
3743,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,11923,,16372,BAO_0000219,,B,,,,CHO,H
3744,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,11923,,16372,BAO_0000219,,B,,,,CHO,H
3745,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,11923,,16372,BAO_0000219,,B,,,,CHO,H
3746,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,11923,,16372,BAO_0000219,,B,,,,CHO,H
3747,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,11923,,16372,BAO_0000219,,B,,,,CHO,H
3748,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,11923,,16372,BAO_0000219,,B,,,,CHO,H
3749,Expert,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,11923,,17066,BAO_0000357,,B,,,,,H
3750,Expert,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,11923,Rattus norvegicus,17066,BAO_0000357,,B,,,10116.0,,D
3751,Expert,,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,11923,,17386,BAO_0000357,,B,,,,,H
3752,Autocuration,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,11923,,14423,BAO_0000019,,B,,,,,H
3753,Expert,,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,11923,Rattus norvegicus,15874,BAO_0000357,,B,,,10116.0,,D
3754,Expert,,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,11923,Rattus norvegicus,15874,BAO_0000357,,B,,,10116.0,,D
3755,Expert,,,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,11923,Rattus norvegicus,16372,BAO_0000219,,B,,,10116.0,CHO,D
3756,Autocuration,,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,11923,,4622,BAO_0000357,,B,,,,,H
3757,Autocuration,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,11923,,15086,BAO_0000357,,B,,,,,H
3758,Autocuration,,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",11923,,16372,BAO_0000219,,B,,,,CHO,H
3759,Autocuration,,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",11923,,16372,BAO_0000219,,B,,,,CHO,H
3760,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,11923,,16372,BAO_0000219,,B,,,,CHO,H
3761,Autocuration,,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,11923,,16372,BAO_0000219,,B,,,,CHO,H
3762,Autocuration,,Ileum,2116.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,11923,,17386,BAO_0000221,,F,,,,,H
3763,Autocuration,,Ileum,2116.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,11923,,17386,BAO_0000221,,F,,,,,H
3764,Autocuration,,Ileum,2116.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,11923,,17386,BAO_0000221,,F,,,,,H
3765,Expert,Membranes,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,11923,Rattus norvegicus,5831,BAO_0000249,,B,,,10116.0,,D
3766,Autocuration,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,11923,,4342,BAO_0000357,,B,,,,,H
3767,Expert,,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,11923,,17319,BAO_0000357,,B,,,,,H
3768,Expert,,Hypothalamus,1898.0,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,11923,,17342,BAO_0000019,,B,,,,,H
3769,Autocuration,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,11923,,17342,BAO_0000357,,B,,,,,H
3770,Expert,,Hypothalamus,1898.0,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,11923,,3680,BAO_0000249,,B,,,,,H
3771,Expert,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,11923,,3680,BAO_0000357,,B,,,,,H
3772,Expert,,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,11923,Rattus norvegicus,17319,BAO_0000219,,F,,,10116.0,HEK293,D
3773,Expert,,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,11923,Rattus norvegicus,17319,BAO_0000219,,F,,,10116.0,HEK293,D
3774,Autocuration,,,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,11923,Rattus norvegicus,17319,BAO_0000219,,F,,,10116.0,HEK293,D
3775,Expert,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,,4820,BAO_0000357,,B,,,,,H
3776,Autocuration,,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,10209,,4639,BAO_0000357,,B,,,,,H
3777,Autocuration,,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,10209,,6011,BAO_0000357,,B,,,,,H
3778,Expert,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,Homo sapiens,17066,BAO_0000357,,B,,,9606.0,,D
3779,Expert,,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,10209,,17066,BAO_0000357,,B,,,,,H
3780,Autocuration,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,10209,,17515,BAO_0000357,,B,,,,,H
3781,Autocuration,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,10209,,4373,BAO_0000357,,B,,,,,H
3782,Expert,,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,10209,,17066,BAO_0000019,,F,,,,,H
3783,Autocuration,,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,10209,,4373,BAO_0000357,,B,,,,,H
3784,Autocuration,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,10209,,4373,BAO_0000357,,B,,,,,H
3785,Autocuration,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,10209,,4687,BAO_0000357,,B,,,,,H
3786,Expert,,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,10209,,17342,BAO_0000357,,B,,,,,H
3787,Autocuration,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,10209,,16946,BAO_0000357,,B,,,,,H
3788,Autocuration,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,10209,,16946,BAO_0000357,,B,,,,,H
3789,Autocuration,,,,Binding affinities against 5-hydroxytryptamine 7 receptor,10209,,16633,BAO_0000357,,B,,,,,H
3790,Autocuration,,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,10209,,16633,BAO_0000357,,B,,,,,H
3791,Expert,,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,10209,,17066,BAO_0000357,,B,,,,,H
3792,Autocuration,,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,10209,,16700,BAO_0000357,,B,,,,,H
3793,Autocuration,,Ileum,2116.0,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,10209,,17386,BAO_0000221,,B,,,,,H
3794,Autocuration,,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,55,,14080,BAO_0000019,,F,,,,,H
3795,Expert,,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,55,Homo sapiens,14080,BAO_0000019,,F,,,9606.0,,D
3796,Autocuration,,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,55,,409,BAO_0000357,,B,,,,,H
3797,Autocuration,,,,In vitro inhibition of human recombinant lipoxygenase enzyme,55,,409,BAO_0000357,,B,,,,,H
3798,Autocuration,,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,55,,409,BAO_0000357,,B,,,,,H
3799,Expert,,Blood,178.0,Inhibition of 5-lipoxygenase in human whole blood.,55,,11090,BAO_0000357,,B,,,,,H
3800,Expert,,Blood,178.0,Inhibition of 5-lipoxygenase in human whole blood.,55,,11090,BAO_0000357,,B,,,,,H
3801,Autocuration,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,55,,948,BAO_0000357,,B,,,,,H
3802,Autocuration,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),55,,948,BAO_0000357,,B,,,,,H
3803,Expert,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,55,,13622,BAO_0000219,,F,,,,,H
3804,Autocuration,,Blood,178.0,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,55,,13622,BAO_0000019,,F,,,,,H
3805,Autocuration,,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,55,,9637,BAO_0000357,,B,,,,,H
3806,Autocuration,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),55,,11320,BAO_0000357,,B,,,,,H
3807,Expert,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,55,,11320,BAO_0000357,,B,,,,,H
3808,Autocuration,,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,55,,6838,BAO_0000357,,B,,,,,H
3809,Expert,,Blood,178.0,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),55,Homo sapiens,17667,BAO_0000357,,B,,,9606.0,,D
3810,Autocuration,,,,In vitro potency against human 5-Lipoxygenase,55,,12703,BAO_0000357,,B,,,,,H
3811,Expert,,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,55,Homo sapiens,14312,BAO_0000019,,F,,,9606.0,,D
3812,Autocuration,,Blood,178.0,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,55,,14312,BAO_0000019,,F,,,,,H
3813,Autocuration,,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,55,,5364,BAO_0000019,,F,,,,,H
3814,Autocuration,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,55,,951,BAO_0000219,,B,,,,,H
3815,Autocuration,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,55,,951,BAO_0000219,,B,,,,,H
3816,Autocuration,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,55,,951,BAO_0000219,,B,,,,,H
3817,Autocuration,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,55,,951,BAO_0000219,,B,,,,,H
3818,Autocuration,,,,Inhibition of human 5-lipoxygenase in human cells,55,,12365,BAO_0000219,,B,,,,,H
3819,Expert,,,,Inhibition of human neutrophil 5-lipoxygenase,55,,10603,BAO_0000357,,B,,,,,H
3820,Autocuration,,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,55,,10501,BAO_0000019,,B,,,,,H
3821,Expert,,Blood,178.0,Inhibition of 5-lipoxygenase from human whole blood,55,,12281,BAO_0000357,,B,,,,,H
3822,Autocuration,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,55,,2567,BAO_0000357,,B,,,,,H
3823,Autocuration,,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,55,,2567,BAO_0000219,,B,,,,,H
3824,Expert,,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,55,,10193,BAO_0000357,,B,,,,,H
3825,Autocuration,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,,10193,BAO_0000357,,B,,,,,H
3826,Expert,,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,55,,13623,BAO_0000357,,B,,,,,H
3827,Autocuration,,,,Tested against 5-lipoxygenase,55,,12780,BAO_0000357,,B,,,,,H
3828,Autocuration,,,,Tested for activity against 5-Lipoxygenase (5-LO),55,,12780,BAO_0000357,,B,,,,,H
3829,Autocuration,,,,Tested for activity against 5-lipoxygenase,55,,12780,BAO_0000357,,B,,,,,H
3830,Autocuration,,,,Tested for inhibition of 5-HPETE production by human 5-LO,55,,11966,BAO_0000357,,B,,,,,H
3831,Autocuration,,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,55,,5364,BAO_0000019,,F,,,,,H
3832,Expert,,,,Inhibition of Human 5-lipoxygenase,55,,13165,BAO_0000357,,B,,,,,H
3833,Autocuration,,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,55,,5364,BAO_0000019,,B,,,,,H
3834,Autocuration,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,,11311,BAO_0000219,,B,,,,,H
3835,Autocuration,,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],55,,11311,BAO_0000219,,B,,,,,H
3836,Autocuration,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,55,,14863,BAO_0000019,,B,,,,,H
3837,Autocuration,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,55,,14863,BAO_0000019,,B,,,,,H
3838,Autocuration,,Blood,178.0,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),55,,11087,BAO_0000357,,B,,,,,H
3839,Autocuration,,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,55,,455,BAO_0000357,,B,,,,,H
3840,Autocuration,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,,13183,BAO_0000357,,B,,,,,H
3841,Expert,,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,55,,10319,BAO_0000019,,B,,,,,H
3842,Autocuration,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,,10193,BAO_0000357,,B,,,,,H
3843,Autocuration,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,55,,951,BAO_0000219,,B,,,,,H
3844,Autocuration,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,55,,951,BAO_0000219,,B,,,,,H
3845,Autocuration,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,55,,951,BAO_0000219,,B,,,,,H
3846,Autocuration,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,55,,951,BAO_0000219,,B,,,,,H
3847,Expert,,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,55,,9859,BAO_0000357,,B,,,,,H
3848,Expert,,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,55,,9859,BAO_0000357,,B,,,,,H
3849,Autocuration,,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,55,,9859,BAO_0000357,,B,,,,,H
3850,Autocuration,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,55,,2567,BAO_0000357,,B,,,,,H
3851,Autocuration,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,55,,10193,BAO_0000357,,B,,,,,H
3852,Autocuration,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,,10193,BAO_0000357,,B,,,,,H
3853,Autocuration,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,55,,949,BAO_0000019,,B,,,,,H
3854,Autocuration,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,55,,949,BAO_0000019,,B,,,,,H
3855,Expert,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,55,,10603,BAO_0000357,,B,,,,,H
3856,Expert,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,55,,10603,BAO_0000357,,B,,,,,H
3857,Autocuration,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,55,,10603,BAO_0000019,,F,,,,,H
3858,Expert,,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,55,,10603,BAO_0000357,,B,,,,,H
3859,Expert,,,,Inhibition of lipoxygenase at the concentration of 1 uM,55,,10603,BAO_0000357,,B,,,,,H
3860,Autocuration,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,55,,10193,BAO_0000357,,B,,,,,H
3861,Expert,,,,Inhibition of 5-Lipoxygenase (5-LOX),55,Homo sapiens,14580,BAO_0000357,,B,,,9606.0,,D
3862,Expert,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,17087,,11090,BAO_0000357,,B,,,,,H
3863,Expert,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,17087,,11090,BAO_0000357,,B,,,,,H
3864,Autocuration,,,,Inhibitory activity against lipoxygenase-2 in mice,17087,,6339,BAO_0000357,,B,,,,,H
3865,Expert,,,,Inhibitory activity against murine lipoxygenase-2.,17087,,6339,BAO_0000357,,B,,,,,H
3866,Expert,,,,Inhibition of 5-lipoxygenase from mouse macrophage,17087,Mus musculus,12281,BAO_0000357,,B,,,10090.0,,D
3867,Autocuration,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,17087,,11311,BAO_0000357,,B,,,,,H
3868,Autocuration,,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,Sus scrofa,11089,BAO_0000019,,B,,,9823.0,,H
3869,Autocuration,,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,55,Sus scrofa,10091,BAO_0000019,,B,,,9823.0,,H
3870,Autocuration,,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,55,Oryctolagus cuniculus,14352,BAO_0000019,,B,,,9986.0,,H
3871,Expert,,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,12166,Rattus norvegicus,13329,BAO_0000019,,B,,,10116.0,,D
3872,Autocuration,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",12166,,13329,BAO_0000019,,B,,,,,H
3873,Autocuration,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",12166,,13329,BAO_0000019,,B,,,,,H
3874,Autocuration,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",12166,,13329,BAO_0000019,,B,,,,,H
3875,Expert,,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),12166,,13329,BAO_0000019,,B,,,,,H
3876,Expert,,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",12166,,13329,BAO_0000019,,B,,,,,H
3877,Autocuration,,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,12166,,13329,BAO_0000019,,B,,,,,H
3878,Autocuration,,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),12166,,11311,BAO_0000019,,B,,,,,H
3879,Autocuration,,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,12166,,11311,BAO_0000019,,B,,,,,H
3880,Autocuration,,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",12166,,105,BAO_0000219,,B,,,,RBL-1,H
3881,Autocuration,,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",12166,,105,BAO_0000219,,B,,,,RBL-1,H
3882,Autocuration,,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),12166,,9138,BAO_0000357,,B,,,,,H
3883,Autocuration,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",12166,,9138,BAO_0000357,,B,,,,,H
3884,Autocuration,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",12166,,9138,BAO_0000357,,B,,,,,H
3885,Autocuration,,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,12166,,14427,BAO_0000357,,B,,,,,H
3886,Autocuration,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",12166,,13329,BAO_0000019,,B,,,,,H
3887,Autocuration,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",12166,,13329,BAO_0000019,,B,,,,,H
3888,Expert,,,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,12166,Rattus norvegicus,14427,BAO_0000219,,B,,,10116.0,RBL-2H3,D
3889,Autocuration,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,12166,,14427,BAO_0000357,,B,,,,,H
3890,Autocuration,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,12166,,14427,BAO_0000357,,B,,,,,H
3891,Expert,,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,12166,,10293,BAO_0000219,,B,,,,RBL-1,H
3892,Expert,,,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,12166,Rattus norvegicus,338,BAO_0000219,,B,,,10116.0,RBL-1,D
3893,Autocuration,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),12166,,303,BAO_0000357,,B,,,,,H
3894,Autocuration,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,12166,,303,BAO_0000219,,B,,,,RBL-1,H
3895,Expert,,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,12166,,9247,BAO_0000219,,B,,,,RBL-1,H
3896,Autocuration,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,12166,,9247,BAO_0000219,,B,,,,RBL-1,H
3897,Autocuration,,,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,12166,,137,BAO_0000219,,B,,,,RBL-1,H
3898,Expert,,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,12166,,11481,BAO_0000357,,B,,,,,H
3899,Expert,,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",12166,,11481,BAO_0000357,,B,,,,,H
3900,Expert,,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,12166,,9029,BAO_0000357,,B,,,,,H
3901,Autocuration,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,12166,,1701,BAO_0000019,,B,,,,,H
3902,Autocuration,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,12166,,1701,BAO_0000019,,B,,,,,H
3903,Autocuration,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,12166,,1701,BAO_0000019,,B,,,,,H
3904,Autocuration,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,12166,,1701,BAO_0000019,,B,,,,,H
3905,Expert,,,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,12166,,13358,BAO_0000219,,F,,,,RBL-1,H
3906,Expert,,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,12166,,1175,BAO_0000219,,B,,,,RBL-1,H
3907,Expert,,,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,12166,,8797,BAO_0000219,,B,,,,RBL-1,H
3908,Autocuration,,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,12166,,8797,BAO_0000019,,B,,,,,H
3909,Expert,,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,12166,Rattus norvegicus,577,BAO_0000357,,B,,,10116.0,,D
3910,Expert,,,,In vitro inhibitory activity against RBL-1 5-LO,12166,,9295,BAO_0000219,,B,,,,RBL-1,H
3911,Autocuration,,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),12166,,9295,BAO_0000219,,B,,,,RBL-1,H
3912,Autocuration,,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),12166,,9295,BAO_0000219,,B,,,,RBL-1,H
3913,Autocuration,,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,12166,,9295,BAO_0000218,,B,,,,,H
3914,Autocuration,,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,12166,,9295,BAO_0000357,,B,,,,,H
3915,Autocuration,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,12166,,216,BAO_0000218,,B,,,,,H
3916,Autocuration,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,12166,,11090,BAO_0000219,,B,,,,RBL-1,H
3917,Autocuration,,Blood,178.0,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,12166,,11090,BAO_0000019,,B,,,,,H
3918,Expert,,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,12166,,10091,BAO_0000357,,B,,,,,H
3919,Autocuration,,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,12166,,10274,BAO_0000019,,F,,,,,H
3920,Autocuration,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,12166,,13622,BAO_0000219,,F,,,,,H
3921,Expert,,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,12166,,12118,BAO_0000219,,B,,,,RBL-1,H
3922,Expert,,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,12166,,12576,BAO_0000357,,B,,,,,H
3923,Expert,,,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,12166,,9546,BAO_0000219,,B,,,,RBL-1,H
3924,Autocuration,,,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,12166,,9521,BAO_0000219,,B,,,,RBL-1,H
3925,Expert,,,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,12166,,10626,BAO_0000219,,B,,,,RBL-1,H
3926,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3927,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3928,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3929,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3930,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3931,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3932,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3933,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3934,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3935,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3936,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3937,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3938,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3939,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3940,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3941,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3942,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3943,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3944,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3945,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3946,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3947,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3948,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3949,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
3950,Expert,,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,12166,,9401,BAO_0000019,,B,,,,,H
3951,Autocuration,,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,12166,,10325,BAO_0000019,,B,,,,,H
3952,Expert,,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,12166,,1556,BAO_0000219,,F,,,,RBL-2H3,H
3953,Expert,,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,12166,,1556,BAO_0000219,,F,,,,RBL-2H3,H
3954,Expert,,,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,12166,Rattus norvegicus,961,BAO_0000219,,B,,,10116.0,RBL-1,D
3955,Autocuration,,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,12166,,6838,BAO_0000019,,B,,,,,H
3956,Expert,,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),12166,,10325,BAO_0000019,,B,,,,,H
3957,Expert,,,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,12166,Rattus norvegicus,9209,BAO_0000219,,B,,,10116.0,RBL-1,D
3958,Expert,,,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,12166,,11520,BAO_0000219,,B,,,,RBL-1,H
3959,Autocuration,,,,In vitro inhibitory activity against 5-lipoxygenase was determined,12166,,137,BAO_0000357,,B,,,,,H
3960,Autocuration,,,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,12166,,4717,BAO_0000219,,B,,,,RBL-1,H
3961,Expert,,,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,12166,,10636,BAO_0000219,,B,,,,RBL-1,H
3962,Expert,,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,12166,Rattus norvegicus,14312,BAO_0000019,,F,,,10116.0,,D
3963,Autocuration,,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,12166,,1203,BAO_0000219,,B,,,,RBL-1,H
3964,Autocuration,,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,12166,,1203,BAO_0000019,,B,,,,,H
3965,Expert,,,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,12166,,13622,BAO_0000219,,B,,,,RBL-1,H
3966,Autocuration,,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,12166,,9793,BAO_0000357,,B,,,,,H
3967,Expert,,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,12166,Rattus norvegicus,1143,BAO_0000219,,B,,,10116.0,RBL-1,D
3968,Expert,,,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,12166,Rattus norvegicus,11854,BAO_0000219,,B,,,10116.0,RBL-1,D
3969,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,3595,BAO_0000219,,B,,,,RBL-1,H
3970,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),12166,,3595,BAO_0000219,,B,,,,RBL-1,H
3971,Expert,,,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,12166,Rattus norvegicus,10501,BAO_0000219,,B,,,10116.0,RBL-1,D
3972,Expert,,,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,12526,BAO_0000219,,B,,,,RBL-1,H
3973,Autocuration,,Limbic system,349.0,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3974,Autocuration,,Limbic system,349.0,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,,10034,BAO_0000019,,F,,,,,H
3975,Autocuration,,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,10825,,10034,BAO_0000019,,F,,,,,H
3976,Autocuration,,Hippocampus,10000000.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,10046,BAO_0000221,,B,,,,,H
3977,Autocuration,,Hippocampus,10000000.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,10046,BAO_0000221,,B,,,,,H
3978,Autocuration,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,,10046,BAO_0000019,,B,,,,,H
3979,Autocuration,,Blood,178.0,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,55,Canis lupus familiaris,12079,BAO_0000019,,F,,,9615.0,,H
3980,Autocuration,,Blood,178.0,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,55,,12079,BAO_0000019,,F,,,,,H
3981,Autocuration,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],12166,,11311,BAO_0000219,,B,,,,,H
3982,Expert,,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,17140,,12338,BAO_0000219,,B,,,,,H
3983,Expert,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,17140,,12143,BAO_0000219,,B,,,,,H
3984,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),17140,,12143,BAO_0000219,,B,,,,,H
3985,Expert,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,17140,,12143,BAO_0000219,,B,,,,,H
3986,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,17140,,12143,BAO_0000219,,B,,,,,H
3987,Expert,,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,17140,,12365,BAO_0000357,,B,,,,,H
3988,Expert,,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,17140,,13500,BAO_0000357,,B,,,,,H
3989,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
3990,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
3991,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
3992,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
3993,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
3994,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
3995,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
3996,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
3997,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
3998,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
3999,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4000,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4001,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4002,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4003,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4004,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4005,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4006,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4007,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4008,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4009,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4010,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4011,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4012,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4013,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4014,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4015,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4016,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4017,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4018,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4019,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4020,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4021,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4022,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4023,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4024,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4025,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4026,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4027,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4028,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4029,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4030,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4031,Autocuration,,Blood,178.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4032,Autocuration,,Blood,178.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4033,Autocuration,,Blood,178.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4034,Autocuration,,Blood,178.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,Canis lupus familiaris,12832,BAO_0000218,,F,In vivo,,9615.0,,H
4035,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,55,Canis lupus familiaris,3595,BAO_0000218,,B,,,9615.0,,H
4036,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,55,Canis lupus familiaris,3595,BAO_0000218,,B,,,9615.0,,H
4037,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,55,Canis lupus familiaris,3595,BAO_0000218,,B,,,9615.0,,H
4038,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,55,Canis lupus familiaris,3595,BAO_0000218,,B,,,9615.0,,H
4039,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,55,Canis lupus familiaris,3595,BAO_0000218,,B,,,9615.0,,H
4040,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,55,Canis lupus familiaris,3595,BAO_0000218,,B,,,9615.0,,H
4041,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,55,Canis lupus familiaris,3595,BAO_0000218,,B,,,9615.0,,H
4042,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,55,Canis lupus familiaris,3595,BAO_0000218,,B,,,9615.0,,H
4043,Autocuration,,,,Ability to inhibit 5-lipoxygenase in guinea pig,55,Cavia porcellus,9203,BAO_0000357,,B,,,10141.0,,H
4044,Expert,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),55,Cavia porcellus,82,BAO_0000357,,B,,,10141.0,,H
4045,Autocuration,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,55,Cavia porcellus,11090,BAO_0000357,,B,,,10141.0,,H
4046,Autocuration,,Blood,178.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",55,Cavia porcellus,12832,BAO_0000218,,B,,,10141.0,,H
4047,Autocuration,,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,55,Cavia porcellus,1065,BAO_0000357,,B,,,10141.0,,H
4048,Autocuration,,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,55,Cavia porcellus,1065,BAO_0000357,,B,,,10141.0,,H
4049,Expert,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,55,Cavia porcellus,12832,BAO_0000019,,B,,,10141.0,,H
4050,Expert,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,55,Cavia porcellus,12832,BAO_0000019,,B,,,10141.0,,H
4051,Autocuration,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,55,Cavia porcellus,12832,BAO_0000019,,B,,,10141.0,,H
4052,Autocuration,,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,55,Cavia porcellus,10504,BAO_0000019,,B,,,10141.0,,H
4053,Autocuration,,,,Inhibitory activity against 5-lipoxygenase,55,Cavia porcellus,7788,BAO_0000357,,B,,,10141.0,,H
4054,Autocuration,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,55,Cavia porcellus,10001,BAO_0000357,,B,,,10141.0,,H
4055,Autocuration,,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,55,Cavia porcellus,10193,BAO_0000357,,B,,,10141.0,,H
4056,Autocuration,,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,55,Cavia porcellus,13243,BAO_0000357,,B,,,10141.0,,H
4057,Autocuration,,,,Inhibitory activity uM,55,Cavia porcellus,13243,BAO_0000357,,B,,,10141.0,,H
4058,Autocuration,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,55,Cavia porcellus,969,BAO_0000219,,B,,,10141.0,,H
4059,Autocuration,,,,Inhibitory activity against 5-lipoxygenase at 10 uM,55,Cavia porcellus,10001,BAO_0000357,,B,,,10141.0,,H
4060,Autocuration,,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,55,Cavia porcellus,7788,BAO_0000357,,B,,,10141.0,,H
4061,Autocuration,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,55,Cavia porcellus,10001,BAO_0000357,,B,,,10141.0,,H
4062,Autocuration,,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,Cavia porcellus,10193,BAO_0000357,,B,,,10141.0,,H
4063,Autocuration,,,,Inhibitory activity uM,55,Cavia porcellus,13243,BAO_0000357,,B,,,10141.0,,H
4064,Autocuration,,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,55,Cavia porcellus,13243,BAO_0000357,,B,,,10141.0,,H
4065,Expert,,,,Inhibitory activity uM,55,Cavia porcellus,13243,BAO_0000357,,B,,,10141.0,,H
4066,Autocuration,,,,Inhibitory activity uM,55,Cavia porcellus,13243,BAO_0000019,,F,,,10141.0,,H
4067,Autocuration,,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,55,Cavia porcellus,10504,BAO_0000019,,B,,,10141.0,,H
4068,Autocuration,,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,55,Cavia porcellus,7788,BAO_0000357,,B,,,10141.0,,H
4069,Expert,,Ileum,2116.0,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,55,Cavia porcellus,10546,BAO_0000221,,F,,,10141.0,,H
4070,Autocuration,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,,13183,BAO_0000357,,B,,,,,H
4071,Autocuration,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,,13183,BAO_0000357,,B,,,,,H
4072,Autocuration,,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),55,,2578,BAO_0000357,,B,,,,,H
4073,Expert,,,,In vitro inhibition of human 5-Lipoxygenase.,55,,12780,BAO_0000357,,B,,,,,H
4074,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4075,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4076,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4077,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4078,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4079,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4080,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4081,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4082,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4083,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4084,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4085,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4086,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4087,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4088,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4089,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4090,Autocuration,Microsomes,Liver,2107.0,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4091,Autocuration,Microsomes,Liver,2107.0,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4092,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4093,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4094,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4095,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4096,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4097,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4098,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4099,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4100,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4101,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4102,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4103,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4104,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4105,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4106,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4107,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4108,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4109,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4110,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4111,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4112,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4113,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4114,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4115,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4116,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4117,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4118,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4119,Autocuration,Microsomes,Liver,2107.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4120,Autocuration,Microsomes,Liver,2107.0,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4121,Autocuration,Microsomes,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4122,Autocuration,Microsomes,Liver,2107.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4123,Autocuration,Microsomes,Liver,2107.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4124,Autocuration,Microsomes,Liver,2107.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4125,Autocuration,Microsomes,Liver,2107.0,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4126,Autocuration,Microsomes,Liver,2107.0,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4127,Intermediate,,,,In vitro inhibition of 7226/S myeloma cancer cell line,80433,Homo sapiens,10797,BAO_0000219,,F,,,9606.0,RPMI-8226,N
4128,Intermediate,,,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),80698,Homo sapiens,6881,BAO_0000219,,F,,,9606.0,BEL-7404 tumor cell line,N
4129,Intermediate,,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,80640,Homo sapiens,3838,BAO_0000219,,F,,,9606.0,786-0,N
4130,Intermediate,,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,80640,Homo sapiens,3838,BAO_0000219,,F,,,9606.0,786-0,N
4131,Expert,,,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,81264,Cricetulus griseus,12981,BAO_0000219,,F,,,10029.0,V79,N
4132,Expert,,,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,81264,Cricetulus griseus,12981,BAO_0000219,,F,,,10029.0,V79,N
4133,Intermediate,,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,80635,Rattus norvegicus,7653,BAO_0000219,,F,,,10116.0,7800C1 cell line,N
4134,Intermediate,,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,80635,Rattus norvegicus,7653,BAO_0000219,,F,,,10116.0,7800C1 cell line,N
4135,Intermediate,,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,80635,Rattus norvegicus,7653,BAO_0000219,,F,,,10116.0,7800C1 cell line,N
4136,Intermediate,,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,80635,Rattus norvegicus,7653,BAO_0000219,,F,,,10116.0,7800C1 cell line,N
4137,Intermediate,,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,80635,Rattus norvegicus,7653,BAO_0000219,,F,,,10116.0,7800C1 cell line,N
4138,Intermediate,,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,80635,Rattus norvegicus,7653,BAO_0000219,,F,,,10116.0,7800C1 cell line,N
4139,Intermediate,,,,In vitro antitumor activity against renal 786-0 tumor cell lines,80640,Homo sapiens,17229,BAO_0000219,,F,,,9606.0,786-0,N
4140,Intermediate,,,,Cytotoxic activity against 786-0 Renal cancer cell line,80640,Homo sapiens,12858,BAO_0000219,,F,,,9606.0,786-0,N
4141,Intermediate,,,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,80640,Homo sapiens,16325,BAO_0000219,,F,,,9606.0,786-0,N
4142,Intermediate,,,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,80640,Homo sapiens,16325,BAO_0000219,,F,,,9606.0,786-0,N
4143,Intermediate,,,,In vitro antitumor activity against human renal 786-0 cell line,80640,Homo sapiens,5858,BAO_0000219,,F,,,9606.0,786-0,N
4144,Intermediate,,,,Inhibition of Renal cancer in 786-0 cancer cell lines,80640,Homo sapiens,16325,BAO_0000219,,F,,,9606.0,786-0,N
4145,Intermediate,,,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,80640,Homo sapiens,14696,BAO_0000219,,F,,,9606.0,786-0,N
4146,Intermediate,,,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,80640,Homo sapiens,3786,BAO_0000219,,F,,,9606.0,786-0,N
4147,Intermediate,,,,inhibition of the growth of renal cancer(786-0) cell line,80640,Homo sapiens,14696,BAO_0000219,,F,,,9606.0,786-0,N
4148,Intermediate,,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),80640,Homo sapiens,14769,BAO_0000219,,F,,,9606.0,786-0,N
4149,Intermediate,,,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,80640,Homo sapiens,15354,BAO_0000219,,F,,,9606.0,786-0,N
4150,Intermediate,,,,The IC50 value was measured on 786-0 cell line in ovarian tumor,80640,Homo sapiens,14255,BAO_0000219,,F,,,9606.0,786-0,N
4151,Intermediate,,,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,80640,Homo sapiens,14255,BAO_0000219,,F,,,9606.0,786-0,N
4152,Intermediate,,,,The IC50 value was measured on 786-0 cell line in renal tumor type.,80640,Homo sapiens,14255,BAO_0000219,,F,,,9606.0,786-0,N
4153,Intermediate,,,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,80640,Homo sapiens,14696,BAO_0000219,,F,,,9606.0,786-0,N
4154,Intermediate,,,,Tested for cytotoxic activity against renal cancer 786-0 cell line,80640,Homo sapiens,12016,BAO_0000219,,F,,,9606.0,786-0,N
4155,Intermediate,,,,Compound was tested for growth inhibitory activity against 786-0 cell line,80640,Homo sapiens,2597,BAO_0000219,,F,,,9606.0,786-0,N
4156,Autocuration,,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,12166,,12526,BAO_0000219,,B,,,,RBL-1,H
4157,Autocuration,,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,12166,,12526,BAO_0000219,,B,,,,RBL-1,H
4158,Autocuration,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,12166,,14799,BAO_0000019,,B,,,,,H
4159,Expert,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,3595,BAO_0000219,,B,,,,RBL-1,H
4160,Expert,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),12166,,3595,BAO_0000219,,B,,,,RBL-1,H
4161,Autocuration,,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,12166,,12767,BAO_0000357,,B,,,,,H
4162,Autocuration,,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,12166,,10997,BAO_0000219,,B,,,,,H
4163,Autocuration,,,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,12166,,11388,BAO_0000219,,B,,,,RBL-1,H
4164,Autocuration,,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,12166,,167,BAO_0000357,,B,,,,,H
4165,Autocuration,,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",12166,,167,BAO_0000357,,B,,,,,H
4166,Expert,,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,12166,,13744,BAO_0000357,,B,,,,,H
4167,Autocuration,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,12166,,1630,BAO_0000357,,B,,,,,H
4168,Autocuration,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),12166,,1630,BAO_0000357,,B,,,,,H
4169,Expert,,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",12166,Rattus norvegicus,969,BAO_0000019,,B,,,10116.0,,D
4170,Autocuration,,,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,12166,,13621,BAO_0000219,,B,,,,RBL-1,H
4171,Autocuration,,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,12166,,10089,BAO_0000357,,B,,,,,H
4172,Expert,,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,12166,,10193,BAO_0000357,,B,,,,,H
4173,Autocuration,,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,12166,,11966,BAO_0000357,,B,,,,,H
4174,Autocuration,,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12166,,12251,BAO_0000019,,B,,,,,H
4175,Autocuration,,,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),12166,,211,BAO_0000219,,B,,,,RBL-1,H
4176,Expert,,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12166,,12251,BAO_0000019,,F,,,,,H
4177,Autocuration,,,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,12166,,12495,BAO_0000219,,B,,,,RBL-1,H
4178,Autocuration,,,,Tested for its inhibitory activity against 5-lipoxygenase,12166,,414,BAO_0000357,,B,,,,,H
4179,Autocuration,,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,12166,,414,BAO_0000357,,B,,,,,H
4180,Expert,,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",12166,,10325,BAO_0000019,,B,,,,,H
4181,Expert,,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,12166,,11966,BAO_0000019,,B,,,,,H
4182,Expert,,,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,,165,BAO_0000219,,B,,,,RBL-1,H
4183,Autocuration,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,12166,,165,BAO_0000219,,B,,,,RBL-1,H
4184,Autocuration,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,,165,BAO_0000219,,B,,,,RBL-1,H
4185,Expert,,,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,,165,BAO_0000219,,B,,,,RBL-1,H
4186,Autocuration,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,12166,,11311,BAO_0000218,,B,,,,,H
4187,Autocuration,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,12166,,11311,BAO_0000219,,B,,,,RBL-1,H
4188,Autocuration,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,12166,,11311,BAO_0000219,,B,,,,RBL-1,H
4189,Autocuration,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],12166,,11311,BAO_0000219,,B,,,,,H
4190,Autocuration,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),12166,,11311,BAO_0000219,,B,,,,,H
4191,Autocuration,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),12166,,11311,BAO_0000218,,B,In vivo,,,,H
4192,Autocuration,,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,12166,,11311,BAO_0000219,,F,,,,RBL-2H3,H
4193,Autocuration,,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,12166,,11311,BAO_0000219,,F,,,,RBL-2H3,H
4194,Autocuration,,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],12166,,11311,BAO_0000019,,B,,,,,H
4195,Autocuration,,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,12166,,11732,BAO_0000019,,B,,,,,H
4196,Expert,,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,12166,,11732,BAO_0000019,,B,,,,,H
4197,Expert,,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,12166,,11087,BAO_0000019,,B,,,,,H
4198,Autocuration,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,12166,,11087,BAO_0000019,,B,,,,,H
4199,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,12166,,11087,BAO_0000219,,B,,,,RBL-1,H
4200,Expert,,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,12166,Rattus norvegicus,11087,BAO_0000357,,B,,,10116.0,,D
4201,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,12166,,496,BAO_0000219,,B,,,,RBL-1,H
4202,Expert,,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,12166,,13986,BAO_0000219,,F,,,,RBL-1,H
4203,Autocuration,,,,Compound was evaluated for the inhibition of 5-lipoxygenase,12166,,11520,BAO_0000357,,B,,,,,H
4204,Autocuration,,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,12166,,10293,BAO_0000219,,B,,,,RBL-1,H
4205,Autocuration,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,12166,,303,BAO_0000219,,B,,,,RBL-1,H
4206,Autocuration,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,12166,,303,BAO_0000219,,B,,,,RBL-1,H
4207,Autocuration,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,12166,,9247,BAO_0000219,,B,,,,RBL-1,H
4208,Expert,,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,12166,Rattus norvegicus,9247,BAO_0000219,,B,,,10116.0,RBL-1,D
4209,Autocuration,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,12166,,9247,BAO_0000219,,B,,,,RBL-1,H
4210,Autocuration,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,12166,,9247,BAO_0000219,,B,,,,RBL-1,H
4211,Autocuration,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,12166,,9247,BAO_0000219,,B,,,,RBL-1,H
4212,Autocuration,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,12166,,9247,BAO_0000219,,B,,,,RBL-1,H
4213,Autocuration,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,12166,,9247,BAO_0000219,,B,,,,RBL-1,H
4214,Autocuration,,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,12166,,9247,BAO_0000219,,B,,,,RBL-1,H
4215,Expert,,,,Inhibitory activity against 5-lipoxygenase at 10 uM,12166,Rattus norvegicus,11481,BAO_0000357,,B,,,10116.0,,D
4216,Autocuration,,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,12166,,105,BAO_0000357,,B,,,,,H
4217,Expert,,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,12166,,9029,BAO_0000357,,B,,,,,H
4218,Expert,,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,12166,,1175,BAO_0000219,,B,,,,RBL-1,H
4219,Autocuration,,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,12166,,12118,BAO_0000219,,B,,,,RBL-1,H
4220,Autocuration,,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,12166,,12118,BAO_0000219,,B,,,,RBL-1,H
4221,Autocuration,,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,12166,,12118,BAO_0000219,,B,,,,RBL-1,H
4222,Autocuration,,,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,12166,,9225,BAO_0000219,,B,,,,RBL-1,H
4223,Autocuration,,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,12166,,9401,BAO_0000019,,B,,,,,H
4224,Autocuration,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,12166,,137,BAO_0000357,,B,,,,,H
4225,Autocuration,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,12166,,137,BAO_0000357,,B,,,,,H
4226,Autocuration,,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,12166,,4717,BAO_0000219,,B,,,,RBL-1,H
4227,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,12166,,3595,BAO_0000219,,B,,,,RBL-1,H
4228,Autocuration,,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,12166,,10501,BAO_0000219,,B,,,,RBL-1,H
4229,Autocuration,,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,12166,,10501,BAO_0000219,,B,,,,RBL-1,H
4230,Autocuration,,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,12166,,10501,BAO_0000219,,B,,,,RBL-1,H
4231,Autocuration,,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,12526,BAO_0000219,,B,,,,RBL-1,H
4232,Expert,,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,12166,Rattus norvegicus,14799,BAO_0000219,,B,,,10116.0,RBL-1,D
4233,Autocuration,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,12166,,14799,BAO_0000019,,B,,,,,H
4234,Autocuration,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,12166,,3595,BAO_0000219,,B,,,,RBL-1,H
4235,Expert,,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,,3595,BAO_0000219,,B,,,,RBL-1,H
4236,Autocuration,,,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,12526,BAO_0000219,,B,,,,RBL-1,H
4237,Autocuration,,,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,12526,BAO_0000219,,B,,,,RBL-1,H
4238,Autocuration,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,12166,,10193,BAO_0000019,,B,,,,,H
4239,Autocuration,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,12166,,10193,BAO_0000019,,B,,,,,H
4240,Autocuration,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,12166,,10193,BAO_0000019,,B,,,,,H
4241,Autocuration,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,12166,,10193,BAO_0000019,,B,,,,,H
4242,Expert,,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),12166,,9138,BAO_0000357,,B,,,,,H
4243,Autocuration,,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,12166,,9138,BAO_0000357,,B,,,,,H
4244,Autocuration,,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,12166,,11966,BAO_0000019,,B,,,,,H
4245,Autocuration,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,12166,,165,BAO_0000219,,B,,,,RBL-1,H
4246,Autocuration,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,12166,,165,BAO_0000219,,B,,,,RBL-1,H
4247,Autocuration,,,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,12166,,11311,BAO_0000219,,B,,,,RBL-2H3,H
4248,Autocuration,,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,12166,,11311,BAO_0000219,,B,,,,RBL-2H3,H
4249,Autocuration,,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,12166,,11311,BAO_0000219,,F,,,,RBL-2H3,H
4250,Autocuration,,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,12166,,11311,BAO_0000019,,F,,,,,H
4251,Autocuration,,,,The compound was tested for inhibition of isolated 5-lipoxygenase,12166,,11311,BAO_0000357,,B,,,,,H
4252,Autocuration,,,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,12166,,11311,BAO_0000219,,F,,,,RBL-2H3,H
4253,Autocuration,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,12166,,11087,BAO_0000019,,B,,,,,H
4254,Autocuration,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,12166,,11087,BAO_0000019,,B,,,,,H
4255,Autocuration,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,12166,,11087,BAO_0000019,,B,,,,,H
4256,Autocuration,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,12166,,11087,BAO_0000019,,B,,,,,H
4257,Autocuration,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,12166,,11087,BAO_0000019,,B,,,,,H
4258,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,12166,,496,BAO_0000219,,B,,,,RBL-1,H
4259,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,12166,,496,BAO_0000219,,B,,,,RBL-1,H
4260,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,12166,,13986,BAO_0000219,,F,,,,RBL-1,H
4261,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,12166,,13986,BAO_0000219,,F,,,,RBL-1,H
4262,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,12166,,13986,BAO_0000219,,F,,,,RBL-1,H
4263,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,12166,,13986,BAO_0000219,,F,,,,RBL-1,H
4264,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,12166,,13986,BAO_0000219,,F,,,,RBL-1,H
4265,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,12166,,13986,BAO_0000219,,F,,,,RBL-1,H
4266,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,12166,,13986,BAO_0000219,,F,,,,RBL-1,H
4267,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,12166,,13986,BAO_0000219,,F,,,,RBL-1,H
4268,Autocuration,,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,12166,,13986,BAO_0000219,,F,,,,RBL-1,H
4269,Expert,,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,12166,Rattus norvegicus,13986,BAO_0000019,,F,,,10116.0,,D
4270,Autocuration,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,12166,,10193,BAO_0000357,,B,,,,,H
4271,Autocuration,,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,12166,,9295,BAO_0000357,,B,,,,,H
4272,Autocuration,,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,12166,,4717,BAO_0000219,,B,,,,RBL-1,H
4273,Autocuration,,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,12166,,4717,BAO_0000219,,B,,,,RBL-1,H
4274,Autocuration,,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,12166,,11854,BAO_0000219,,B,,,,RBL-1,H
4275,Autocuration,,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,12166,,11854,BAO_0000219,,B,,,,RBL-1,H
4276,Autocuration,,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,12166,,11854,BAO_0000219,,B,,,,RBL-1,H
4277,Autocuration,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,12166,,10193,BAO_0000019,,B,,,,,H
4278,Autocuration,,,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,12166,,9295,BAO_0000219,,B,,,,RBL-1,H
4279,Autocuration,,,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,12166,,9295,BAO_0000219,,B,,,,RBL-1,H
4280,Autocuration,,,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,12166,,9295,BAO_0000219,,B,,,,RBL-1,H
4281,Autocuration,,,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,12166,,9295,BAO_0000219,,B,,,,RBL-1,H
4282,Autocuration,,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,12166,,165,BAO_0000219,,B,,,,RBL-1,H
4283,Autocuration,,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,12166,,11311,BAO_0000219,,B,,,,,H
4284,Expert,,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),12166,Homo sapiens,10489,BAO_0000219,,B,,,9606.0,RBL-1,H
4285,Expert,,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),12166,Rattus norvegicus,10489,BAO_0000219,,B,,,10116.0,RBL-1,D
4286,Expert,,,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),12166,Rattus norvegicus,10489,BAO_0000219,,B,,,10116.0,RBL-1,D
4287,Autocuration,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,12166,Rattus norvegicus,14799,BAO_0000019,,B,,,10116.0,,D
4288,Autocuration,,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),12054,Glycine max,9295,BAO_0000357,,B,,,3847.0,,H
4289,Autocuration,,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",22226,,16811,BAO_0000019,,B,,,,,U
4290,Expert,,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,55,,168,BAO_0000357,,B,,,,,H
4291,Autocuration,,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,55,,6309,BAO_0000357,,B,,,,,H
4292,Autocuration,,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,55,,6309,BAO_0000357,,B,,,,,H
4293,Autocuration,,,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,55,,3092,BAO_0000219,,B,,,,RBL-1,H
4294,Expert,,,,Inhibitory activity against 5-lipoxygenase.,55,,168,BAO_0000357,,B,,,,,H
4295,Autocuration,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,55,,168,BAO_0000357,,B,,,,,H
4296,Autocuration,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,55,,168,BAO_0000357,,B,,,,,H
4297,Autocuration,,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,55,,168,BAO_0000357,,B,,,,,H
4298,Expert,,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,55,,12338,BAO_0000019,,F,,,,,H
4299,Autocuration,,,,Tested for the inhibitory activity against 5-lipoxygenase,55,,4501,BAO_0000357,,B,,,,,H
4300,Autocuration,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,55,,1132,BAO_0000357,,B,,,,,H
4301,Autocuration,,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,55,,2117,BAO_0000357,,B,,,,,H
4302,Autocuration,,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,55,,168,BAO_0000357,,B,,,,,H
4303,Autocuration,,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,55,,168,BAO_0000357,,B,,,,,H
4304,Autocuration,,,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,12166,,13575,BAO_0000219,,B,,,,RBL-1,H
4305,Autocuration,,,,,12166,,11089,BAO_0000357,,B,,,,,H
4306,Autocuration,,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),10102,,216,BAO_0000357,,B,,,,,H
4307,Autocuration,,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,10102,,13165,BAO_0000019,,B,,,,,H
4308,Autocuration,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,10102,,3278,BAO_0000357,,B,,,,,H
4309,Expert,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,10102,,3278,BAO_0000357,,B,,,,,H
4310,Autocuration,,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,10102,,11966,BAO_0000357,,B,,,,,H
4311,Autocuration,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",10102,,175,BAO_0000357,,B,,,,,H
4312,Autocuration,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",10102,,175,BAO_0000357,,B,,,,,H
4313,Autocuration,,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,10102,,13449,BAO_0000357,,B,,,,,H
4314,Autocuration,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,11238,,12014,BAO_0000019,,B,,,,,H
4315,Autocuration,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),11238,,12014,BAO_0000019,,B,,,,,H
4316,Autocuration,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),11238,,12014,BAO_0000019,,B,,,,,H
4317,Intermediate,,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,100284,,99,BAO_0000220,,B,,,,,S
4318,Autocuration,,,,The dark toxicity against 543 human galactophore carcinoma cells,22226,Homo sapiens,4349,BAO_0000019,,F,,,9606.0,,U
4319,Expert,,,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,80623,Homo sapiens,4071,BAO_0000219,,F,,,9606.0,Panel (56 tumour cell lines),N
4320,Expert,,,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,80008,Homo sapiens,17589,BAO_0000219,,F,,,9606.0,5637,N
4321,Intermediate,,,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,80008,Homo sapiens,15002,BAO_0000219,,F,,,9606.0,5637,N
4322,Intermediate,,,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",80008,Homo sapiens,13958,BAO_0000219,,F,,,9606.0,5637,N
4323,Expert,,,,Growth inhibition against human 5637 cell lines,80008,Homo sapiens,17589,BAO_0000219,,F,,,9606.0,5637,N
4324,Expert,,,,Antitumor activity against human bladder carcinoma 5637 cells.,80008,Homo sapiens,16748,BAO_0000219,,F,,,9606.0,5637,N
4325,Intermediate,,,,Antitumor activity against human bladder carcinoma 5637 cells,80008,Homo sapiens,16747,BAO_0000219,,F,,,9606.0,5637,N
4326,Intermediate,,,,Antitumor activity against human bladder carcinoma 5637 cells,80008,Homo sapiens,16747,BAO_0000219,,F,,,9606.0,5637,N
4327,Expert,,,,In vitro inhibition of bovine trypsin(Trp).,10443,Bos taurus,15285,BAO_0000357,,B,,,9913.0,,D
4328,Expert,,,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,240,Cercopithecidae,3726,BAO_0000219,,B,,,9527.0,CV-1,H
4329,Autocuration,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,10577,,5033,BAO_0000357,,B,,,,,H
4330,Autocuration,,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,104698,,11756,BAO_0000019,,F,,,,,H
4331,Autocuration,,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,22226,,11953,BAO_0000218,,F,In vivo,,,,U
4332,Intermediate,,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,20033,Cavia porcellus,5033,BAO_0000357,,B,,,10141.0,,D
4333,Expert,Microsomes,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,17045,Rattus norvegicus,11347,BAO_0000251,,A,,,10116.0,,H
4334,Expert,Microsomes,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,17045,Rattus norvegicus,11347,BAO_0000251,,A,,,10116.0,,H
4335,Intermediate,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,22226,,1229,BAO_0000019,,F,,,,,U
4336,Intermediate,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,22226,,1229,BAO_0000019,,F,,,,,U
4337,Expert,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,11938,Trypanosoma brucei,17588,BAO_0000019,,B,,,5691.0,,H
4338,Autocuration,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,11938,Trypanosoma brucei,17588,BAO_0000019,,B,,,5691.0,,H
4339,Expert,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,11938,Ovis aries,17588,BAO_0000019,,B,,,9940.0,,H
4340,Autocuration,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,11938,Ovis aries,17588,BAO_0000019,,B,,,9940.0,,H
4341,Autocuration,,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,11938,,16485,BAO_0000357,,B,,,,,H
4342,Intermediate,,,,Average inhibitory concentration against 60 human cell lines was reported,22226,Homo sapiens,4337,BAO_0000019,,F,,,9606.0,,U
4343,Expert,,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,22226,Homo sapiens,4112,BAO_0000019,,F,,,9606.0,,U
4344,Intermediate,,,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,80315,Homo sapiens,16160,BAO_0000219,,F,,,9606.0,Panel NCI-60 (60 carcinoma cell lines),N
4345,Intermediate,,,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,80315,Homo sapiens,16160,BAO_0000219,,F,,,9606.0,Panel NCI-60 (60 carcinoma cell lines),N
4346,Expert,,,,In vitro mean growth inhibitory activity against 60-cell panel,80315,,17376,BAO_0000219,,F,,,,Panel NCI-60 (60 carcinoma cell lines),N
4347,Expert,,,,In vitro mean growth lethal concentration against 60-cell panel,80315,,17376,BAO_0000219,,F,,,,Panel NCI-60 (60 carcinoma cell lines),N
4348,Expert,,,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,80315,,17376,BAO_0000219,,F,,,,Panel NCI-60 (60 carcinoma cell lines),N
4349,Expert,,,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,80315,,17376,BAO_0000219,,F,,,,Panel NCI-60 (60 carcinoma cell lines),N
4350,Autocuration,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,104775,,3241,BAO_0000019,,F,,,,,H
4351,Autocuration,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,104775,,3241,BAO_0000019,,F,,,,,H
4352,Expert,,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,275,,3725,BAO_0000357,,B,,,,,H
4353,Expert,,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,50425,Plasmodium falciparum,10805,BAO_0000218,,F,,,5833.0,,N
4354,Expert,,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,50425,Plasmodium falciparum,10805,BAO_0000218,,F,,,5833.0,,N
4355,Expert,,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,50425,Plasmodium falciparum,10805,BAO_0000218,,F,,,5833.0,,N
4356,Expert,,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,50425,Plasmodium falciparum,10805,BAO_0000218,,F,,,5833.0,,N
4357,Intermediate,,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,50425,Plasmodium falciparum,10805,BAO_0000218,,F,,,5833.0,,N
4358,Intermediate,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,80628,Mus musculus,10144,BAO_0000218,,F,,,10090.0,6C3HED,N
4359,Intermediate,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,80628,Mus musculus,10144,BAO_0000218,,F,,,10090.0,6C3HED,N
4360,Intermediate,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,80628,Mus musculus,10144,BAO_0000218,,F,,,10090.0,6C3HED,N
4361,Intermediate,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,80628,Mus musculus,10144,BAO_0000218,,F,,,10090.0,6C3HED,N
4362,Intermediate,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,80628,Mus musculus,10144,BAO_0000218,,F,,,10090.0,6C3HED,N
4363,Intermediate,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,80628,Mus musculus,10144,BAO_0000218,,F,,,10090.0,6C3HED,N
4364,Autocuration,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,22224,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,,U
4365,Autocuration,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,22224,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,,U
4366,Autocuration,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),22224,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,,U
4367,Autocuration,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,22224,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,,U
4368,Autocuration,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,22224,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,,U
4369,Autocuration,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,22224,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,,U
4370,Autocuration,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,22224,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,,U
4371,Autocuration,,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",22224,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,,U
4372,Autocuration,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),22224,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,,U
4373,Autocuration,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),22224,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,,U
4374,Autocuration,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,22224,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,,U
4375,Autocuration,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,22224,Mus musculus,10144,BAO_0000218,,F,,,10090.0,,U
4376,Autocuration,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,22224,Mus musculus,10144,BAO_0000218,,F,,,10090.0,,U
4377,Autocuration,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,22224,Mus musculus,10144,BAO_0000218,,F,,,10090.0,,U
4378,Autocuration,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,22224,Mus musculus,10144,BAO_0000218,,F,,,10090.0,,U
4379,Autocuration,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,22224,Mus musculus,10685,BAO_0000218,,F,,,10090.0,,U
4380,Autocuration,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,22224,Mus musculus,10685,BAO_0000218,,F,,,10090.0,,U
4381,Autocuration,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,22224,Mus musculus,10685,BAO_0000218,,F,,,10090.0,,U
4382,Autocuration,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,22224,Mus musculus,10685,BAO_0000218,,F,,,10090.0,,U
4383,Autocuration,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,22224,Mus musculus,10685,BAO_0000218,,A,,,10090.0,,U
4384,Autocuration,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,22224,Mus musculus,10685,BAO_0000218,,A,,,10090.0,,U
4385,Autocuration,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,22224,Mus musculus,10685,BAO_0000218,,A,,,10090.0,,U
4386,Autocuration,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,22224,Mus musculus,10685,BAO_0000218,,A,,,10090.0,,U
4387,Intermediate,,,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",80628,Mus musculus,8831,BAO_0000218,,F,,,10090.0,6C3HED,N
4388,Autocuration,,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,22224,,11704,BAO_0000218,,F,In vivo,,,,U
4389,Intermediate,,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,50594,Mus musculus,11704,BAO_0000218,,A,,,10090.0,,N
4390,Intermediate,,,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,80628,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,6C3HED,N
4391,Intermediate,,,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,80628,Mus musculus,10685,BAO_0000218,,F,In vivo,,10090.0,6C3HED,N
4392,Expert,,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),80628,Mus musculus,11368,BAO_0000218,,F,,,10090.0,6C3HED,N
4393,Intermediate,,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),80628,Mus musculus,11368,BAO_0000218,,F,,,10090.0,6C3HED,N
4394,Expert,,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),80628,Mus musculus,11368,BAO_0000218,,F,,,10090.0,6C3HED,N
4395,Autocuration,,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",22226,Staphylococcus aureus,17763,BAO_0000019,,B,,,1280.0,,U
4396,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4397,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4398,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4399,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4400,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4401,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4402,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4403,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4404,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4405,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4406,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4407,Autocuration,Microsomes,Liver,2107.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,22226,Rattus norvegicus,7411,BAO_0000251,,B,,,10116.0,,U
4408,Autocuration,,Plasma,1969.0,The apparent total plasma clearance in monkey,22224,Cercopithecidae,347,BAO_0000218,,A,In vivo,,9527.0,,U
4409,Autocuration,,,,Compound was evaluated for Hepatic clearance in monkey,22224,Cercopithecidae,3341,BAO_0000218,,A,In vivo,,9527.0,,U
4410,Autocuration,,,,Lower clearance in monkey (i.v.) at 0.5 mpk,22224,Cercopithecidae,17853,BAO_0000218,,A,In vivo,,9527.0,,U
4411,Autocuration,,,,Plasma clearance in rhesus monkey,22224,Cercopithecidae,4514,BAO_0000218,,A,In vivo,,9527.0,,U
4412,Autocuration,,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,22224,Cercopithecidae,6062,BAO_0000218,,A,In vivo,,9527.0,,U
4413,Autocuration,,,,Plasma clearance of compound was determined in monkey,22224,Cercopithecidae,6821,BAO_0000218,,A,In vivo,,9527.0,,U
4414,Autocuration,,,,Plasma clearance was calculated in rhesus monkey,22224,Cercopithecidae,6057,BAO_0000218,,A,In vivo,,9527.0,,U
4415,Autocuration,,,,Plasma clearance in rhesus monkey,22224,Cercopithecidae,5145,BAO_0000218,,A,In vivo,,9527.0,,U
4416,Autocuration,,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,Cercopithecidae,6641,BAO_0000218,,A,In vivo,,9527.0,,U
4417,Autocuration,,,,Plasma clearance was evaluated in rhesus,22224,Cercopithecidae,5472,BAO_0000218,,A,In vivo,,9527.0,,U
4418,Autocuration,,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,22224,Cercopithecidae,4257,BAO_0000218,,A,In vivo,,9527.0,,U
4419,Autocuration,,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,Cercopithecidae,5546,BAO_0000218,,A,In vivo,,9527.0,,U
4420,Autocuration,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,Cercopithecidae,5334,BAO_0000218,,A,In vivo,,9527.0,,U
4421,Autocuration,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,Cercopithecidae,5334,BAO_0000218,,A,In vivo,,9527.0,,U
4422,Autocuration,,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,22224,Cercopithecidae,17509,BAO_0000218,,A,In vivo,,9527.0,,U
4423,Autocuration,,,,Cmax in monkey after administration of 1 mg/kg iv,22224,Cercopithecidae,6535,BAO_0000218,,A,In vivo,,9527.0,,U
4424,Autocuration,,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,22224,Cercopithecidae,5668,BAO_0000218,,A,In vivo,,9527.0,,U
4425,Autocuration,,,,Cmax in cynomolgus monkey by iv administration,22224,Cercopithecidae,5922,BAO_0000218,,A,In vivo,,9527.0,,U
4426,Autocuration,,,,Cmax in cynomolgus monkey by po administration,22224,Cercopithecidae,5922,BAO_0000218,,A,In vivo,,9527.0,,U
4427,Autocuration,,,,Cmax value evaluated in monkey,22224,Cercopithecidae,6078,BAO_0000218,,A,In vivo,,9527.0,,U
4428,Autocuration,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,Cercopithecidae,2661,BAO_0000218,,A,In vivo,,9527.0,,U
4429,Autocuration,,Plasma,1969.0,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,22224,Cercopithecidae,3249,BAO_0000218,,A,In vivo,,9527.0,,U
4430,Autocuration,,Plasma,1969.0,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,22224,Cercopithecidae,3249,BAO_0000218,,A,In vivo,,9527.0,,U
4431,Autocuration,,Plasma,1969.0,Maximal plasma concentration in squirrel monkeys,22224,Cercopithecidae,5553,BAO_0000218,,A,In vivo,,9527.0,,U
4432,Autocuration,,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,Cercopithecidae,1916,BAO_0000218,,A,In vivo,,9527.0,,U
4433,Autocuration,,Plasma,1969.0,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,22224,Cercopithecidae,6227,BAO_0000218,,A,In vivo,,9527.0,,U
4434,Autocuration,,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,Cercopithecidae,4809,BAO_0000218,,A,In vivo,,9527.0,,U
4435,Autocuration,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4436,Autocuration,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4437,Autocuration,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4438,Autocuration,,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4439,Autocuration,,Plasma,1969.0,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,22224,Cercopithecidae,6221,BAO_0000218,,A,In vivo,,9527.0,,U
4440,Autocuration,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,22224,Cercopithecidae,167,BAO_0000218,,A,,,9527.0,,U
4441,Autocuration,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,22224,Cercopithecidae,167,BAO_0000218,,A,,,9527.0,,U
4442,Autocuration,,,,Absolute bioavailability was evaluated in monkey,22224,monkey,4257,BAO_0000218,,A,In vivo,,9443.0,,U
4443,Autocuration,,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,22224,monkey,6221,BAO_0000218,,A,In vivo,,9443.0,,U
4444,Autocuration,,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,22224,monkey,17667,BAO_0000218,,A,In vivo,,9443.0,,U
4445,Autocuration,,,,Bioavailability of compound was determined in rhesus monkey,22224,Macaca mulatta,17267,BAO_0000218,,A,In vivo,,9544.0,,U
4446,Autocuration,,,,Bioavailability determined after oral administration in marmoset,22224,marmosets,4256,BAO_0000218,,A,In vivo,,38020.0,,U
4447,Autocuration,,,,Oral bioavailability in cynomolgus monkey,22224,Macaca fascicularis,4256,BAO_0000218,,A,In vivo,,9541.0,,U
4448,Autocuration,,,,Bioavailability in monkey (p.o.) at 2.0 mpk,22224,monkey,17853,BAO_0000218,,A,In vivo,,9443.0,,U
4449,Autocuration,,,,Bioavailability was evaluated after oral administration in monkey,22224,monkey,16365,BAO_0000218,,A,In vivo,,9443.0,,U
4450,Autocuration,,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,Macaca fascicularis,1916,BAO_0000218,,A,In vivo,,9541.0,,U
4451,Autocuration,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,Macaca mulatta,5334,BAO_0000218,,A,In vivo,,9544.0,,U
4452,Autocuration,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,Macaca mulatta,5334,BAO_0000218,,A,In vivo,,9544.0,,U
4453,Autocuration,,,,Bioavailability of the compound was determined in monkey,22224,monkey,17592,BAO_0000218,,A,In vivo,,9443.0,,U
4454,Autocuration,,,,Bioavailability in squirrel monkey (dose 5 mg/kg),22224,Saimiri sciureus,1399,BAO_0000218,,A,In vivo,,9521.0,,U
4455,Autocuration,,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,monkey,4809,BAO_0000218,,A,In vivo,,9443.0,,U
4456,Autocuration,,,,Oral bioavailability in monkey,22224,monkey,3341,BAO_0000218,,A,In vivo,,9443.0,,U
4457,Autocuration,,,,Compound was tested for bioavailability in squirrel monkey,22224,Saimiri sciureus,64,BAO_0000218,,A,In vivo,,9521.0,,U
4458,Autocuration,,,,Oral bioavailability in Rhesus monkey,22224,Macaca mulatta,5005,BAO_0000218,,A,In vivo,,9544.0,,U
4459,Autocuration,,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),22224,Macaca mulatta,5005,BAO_0000218,,A,In vivo,,9544.0,,U
4460,Autocuration,,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,22224,Macaca fascicularis,5237,BAO_0000218,,A,In vivo,,9541.0,,U
4461,Autocuration,,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,22224,Macaca fascicularis,5237,BAO_0000218,,A,In vivo,,9541.0,,U
4462,Autocuration,,,,Oral bioavailability in monkey (dose 5 mg/kg),22224,monkey,5302,BAO_0000218,,A,In vivo,,9443.0,,U
4463,Autocuration,,,,Oral bioavailability of compound at 5 mg/kg in monkey,22224,monkey,17667,BAO_0000218,,A,In vivo,,9443.0,,U
4464,Intermediate,,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,50588,Canis lupus familiaris,6161,BAO_0000218,,A,In vivo,,9615.0,,N
4465,Intermediate,,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,50588,Canis lupus familiaris,6161,BAO_0000218,,A,In vivo,,9615.0,,N
4466,Intermediate,,Plasma,1969.0,Plasma half life determined,50588,Canis lupus familiaris,3854,BAO_0000218,,A,,,9615.0,,N
4467,Intermediate,,Plasma,1969.0,Plasma half life in dog,50588,Canis lupus familiaris,993,BAO_0000218,,A,,,9615.0,,N
4468,Intermediate,,Plasma,1969.0,Plasma half-life in Beagle dogs,50588,Canis lupus familiaris,4514,BAO_0000218,,A,,,9615.0,,N
4469,Intermediate,,Plasma,1969.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,Canis lupus familiaris,5334,BAO_0000218,,A,In vivo,,9615.0,,N
4470,Intermediate,,Plasma,1969.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),50588,Canis lupus familiaris,5334,BAO_0000218,,A,In vivo,,9615.0,,N
4471,Intermediate,,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,50588,Canis lupus familiaris,1466,BAO_0000218,,A,In vivo,,9615.0,,N
4472,Intermediate,,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,50588,Canis lupus familiaris,1466,BAO_0000218,,A,In vivo,,9615.0,,N
4473,Intermediate,,,,Tested for the half life period in dog,50588,Canis lupus familiaris,5313,BAO_0000218,,A,,,9615.0,,N
4474,Intermediate,,,,Tested for the half life period in dog at dosage of 10 mpk,50588,Canis lupus familiaris,5313,BAO_0000218,,A,In vivo,,9615.0,,N
4475,Intermediate,,,,The compound was tested for half life in dog,50588,Canis lupus familiaris,3880,BAO_0000218,,A,,,9615.0,,N
4476,Intermediate,,Plasma,1969.0,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",50588,Canis lupus familiaris,3639,BAO_0000218,,A,,,9615.0,,N
4477,Intermediate,,,,The half life was determined,50588,Canis lupus familiaris,3880,BAO_0000218,,A,,,9615.0,,N
4478,Intermediate,,Plasma,1969.0,The plasma half-life in dogs,50588,Canis lupus familiaris,3918,BAO_0000218,,A,,,9615.0,,N
4479,Intermediate,,Plasma,1969.0,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,50588,Canis lupus familiaris,16452,BAO_0000218,,A,,,9615.0,,N
4480,Intermediate,,,,Half life in dog,50588,Canis lupus familiaris,17796,BAO_0000218,,A,,,9615.0,,N
4481,Intermediate,,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,50588,Canis lupus familiaris,5983,BAO_0000218,,A,In vivo,,9615.0,,N
4482,Intermediate,,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,50588,Canis lupus familiaris,1466,BAO_0000218,,A,In vivo,,9615.0,,N
4483,Intermediate,,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,Canis lupus familiaris,16456,BAO_0000218,,A,In vivo,,9615.0,,N
4484,Expert,,,,Cmax in ferrets after 30 mg/kg oral dose,50506,Mustela putorius furo,6113,BAO_0000218,,A,In vivo,,9669.0,,N
4485,Expert,,,,Emesis in ferrets at 30 mg/kg oral dose,50506,Mustela putorius furo,6113,BAO_0000218,,F,In vivo,,9669.0,,N
4486,Autocuration,,,,Bioavailability in cynomolgus monkey,22224,Macaca fascicularis,17796,BAO_0000218,,A,In vivo,,9541.0,,U
4487,Intermediate,,,,Volume of distribution in cynomolgus,100710,Macaca fascicularis,17796,BAO_0000218,,A,In vivo,,9541.0,,N
4488,Autocuration,,Plasma,1969.0,AUC tested in guinea pig when 3 mg/kg dose was given perorally,22224,Cavia porcellus,5308,BAO_0000218,,A,,,10141.0,,U
4489,Autocuration,,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,22224,Cavia porcellus,4877,BAO_0000218,,A,,,10141.0,,U
4490,Autocuration,,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",22224,Cavia porcellus,4876,BAO_0000218,,A,,,10141.0,,U
4491,Autocuration,,Plasma,1969.0,AUC in guinea pig after 3mg/kg oral dose,22224,Cavia porcellus,4878,BAO_0000218,,A,In vivo,,10141.0,,U
4492,Autocuration,,,,Bioavailability in guinea pig was tested,22224,Cavia porcellus,5308,BAO_0000218,,A,In vivo,,10141.0,,U
4493,Autocuration,,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,22224,Cavia porcellus,4877,BAO_0000218,,A,In vivo,,10141.0,,U
4494,Autocuration,,,,Tested for the oral bioavailability of the compound,22224,Cavia porcellus,4876,BAO_0000218,,A,In vivo,,10141.0,,U
4495,Autocuration,,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,22224,Cavia porcellus,4876,BAO_0000218,,A,In vivo,,10141.0,,U
4496,Autocuration,,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,22224,Cavia porcellus,5308,BAO_0000218,,A,In vivo,,10141.0,,U
4497,Autocuration,,Lung,2048.0,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,22224,Cavia porcellus,4877,BAO_0000218,,A,In vivo,,10141.0,,U
4498,Autocuration,,,,Cmax in guinea pig after 3mg/kg oral dose,22224,Cavia porcellus,4878,BAO_0000218,,A,In vivo,,10141.0,,U
4499,Autocuration,,Blood,178.0,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,22224,Cavia porcellus,5689,BAO_0000019,,A,,,10141.0,,U
4500,Autocuration,,Brain,955.0,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,22224,Cavia porcellus,5689,BAO_0000019,,A,,,10141.0,,U
4501,Autocuration,,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,22224,Cavia porcellus,5689,BAO_0000019,,A,,,10141.0,,U
4502,Autocuration,,Intestine,160.0,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,22224,Cavia porcellus,5689,BAO_0000019,,A,,,10141.0,,U
4503,Autocuration,,Kidney,2113.0,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,22224,Cavia porcellus,5689,BAO_0000019,,A,,,10141.0,,U
4504,Autocuration,,Liver,2107.0,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,22224,Cavia porcellus,5689,BAO_0000019,,A,,,10141.0,,U
4505,Autocuration,,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,22224,Cavia porcellus,5689,BAO_0000019,,A,,,10141.0,,U
4506,Autocuration,,Spleen,2106.0,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,22224,Cavia porcellus,5689,BAO_0000019,,A,,,10141.0,,U
4507,Autocuration,,,,Elimination T1/2 in Guinea pig (PO dose),22224,Cavia porcellus,14465,BAO_0000218,,A,In vivo,,10141.0,,U
4508,Autocuration,,,,Partition coefficient was measured as -log (counts per min ),22224,Cavia porcellus,5689,BAO_0000019,,A,,,10141.0,,U
4509,Autocuration,,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,22224,Cavia porcellus,611,BAO_0000218,,A,In vivo,,10141.0,,U
4510,Autocuration,,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,22224,Cavia porcellus,611,BAO_0000218,,A,In vivo,,10141.0,,U
4511,Autocuration,,,,Elimination T1/2 in Guinea pig (PO dose),22224,Cavia porcellus,14465,BAO_0000218,,A,In vivo,,10141.0,,U
4512,Autocuration,,,,"Tested for the half life period of the compound, intravenously",22224,Cavia porcellus,4876,BAO_0000218,,A,In vivo,,10141.0,,U
4513,Autocuration,,,,Half-life was measured,22224,Cavia porcellus,5689,BAO_0000019,,A,,,10141.0,,U
4514,Autocuration,,,,The time required for onset of inotropy after addition of a single dose of delta F75,22224,Cavia porcellus,7515,BAO_0000019,,A,,,10141.0,,U
4515,Autocuration,,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,22224,Cavia porcellus,17667,BAO_0000218,,A,In vivo,,10141.0,,U
4516,Autocuration,,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,22224,Cavia porcellus,17667,BAO_0000218,,A,In vivo,,10141.0,,U
4517,Autocuration,,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,22224,Cricetulus griseus,4727,BAO_0000218,,A,In vivo,,10029.0,,U
4518,Intermediate,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
4519,Intermediate,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
4520,Intermediate,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
4521,Intermediate,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
4522,Intermediate,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
4523,Intermediate,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
4524,Intermediate,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
4525,Intermediate,,Blood,178.0,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4526,Intermediate,,Blood,178.0,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4527,Intermediate,,Blood,178.0,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4528,Intermediate,,Bone,10000001.0,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4529,Intermediate,,Bone,10000001.0,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4530,Intermediate,,Bone,10000001.0,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4531,Intermediate,,Brain,955.0,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4532,Intermediate,,Brain,955.0,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4533,Intermediate,,Brain,955.0,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4534,Intermediate,,Heart,948.0,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4535,Intermediate,,Heart,948.0,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4536,Intermediate,,Heart,948.0,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4537,Intermediate,,Intestine,160.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4538,Intermediate,,Intestine,160.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4539,Intermediate,,Intestine,160.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4540,Intermediate,,Kidney,2113.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4541,Intermediate,,Kidney,2113.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4542,Intermediate,,Kidney,2113.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4543,Intermediate,,Liver,2107.0,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4544,Intermediate,,Liver,2107.0,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4545,Intermediate,,Liver,2107.0,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4546,Intermediate,,Lung,2048.0,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4547,Intermediate,,Lung,2048.0,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4548,Intermediate,,Lung,2048.0,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4549,Intermediate,,Muscle tissue,2385.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4550,Intermediate,,Muscle tissue,2385.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4551,Intermediate,,Muscle tissue,2385.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4552,Intermediate,,Spleen,2106.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4553,Intermediate,,Spleen,2106.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4554,Intermediate,,Spleen,2106.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4555,Intermediate,,Stomach,945.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4556,Intermediate,,Stomach,945.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4557,Intermediate,,Stomach,945.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,50594,Mus musculus,3655,BAO_0000218,,A,In vivo,,10090.0,,N
4558,Intermediate,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
4559,Intermediate,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,50594,Mus musculus,16597,BAO_0000218,,F,In vivo,,10090.0,,N
4560,Intermediate,,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
4561,Intermediate,,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
4562,Intermediate,,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,50594,Mus musculus,17764,BAO_0000218,,A,In vivo,,10090.0,,N
4563,Intermediate,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4564,Intermediate,,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,81034,Homo sapiens,3830,BAO_0000219,,F,,,9606.0,A2780,N
4565,Intermediate,,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,81034,Homo sapiens,3829,BAO_0000219,,F,,,9606.0,A2780,N
4566,Intermediate,,,,Compound was evaluated for cytotoxicity against A2780 cell lines.,81034,Homo sapiens,2040,BAO_0000219,,F,,,9606.0,A2780,N
4567,Intermediate,,,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,81034,Homo sapiens,15684,BAO_0000219,,F,,,9606.0,A2780,N
4568,Intermediate,,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,81034,Homo sapiens,15684,BAO_0000219,,F,,,9606.0,A2780,N
4569,Intermediate,,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,81034,Homo sapiens,15684,BAO_0000219,,F,,,9606.0,A2780,N
4570,Intermediate,,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,81034,Homo sapiens,15684,BAO_0000219,,F,,,9606.0,A2780,N
4571,Intermediate,,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,81034,Homo sapiens,15684,BAO_0000219,,F,,,9606.0,A2780,N
4572,Intermediate,,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,81034,Homo sapiens,15684,BAO_0000219,,F,,,9606.0,A2780,N
4573,Intermediate,,,,Compound was evaluated for cytotoxicity against A2780 cell line,81034,Homo sapiens,2859,BAO_0000219,,F,,,9606.0,A2780,N
4574,Intermediate,,,,In vitro inhibitory activity against human tumor cell line A2780,81034,Homo sapiens,5618,BAO_0000219,,F,,,9606.0,A2780,N
4575,Intermediate,,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,81034,Homo sapiens,15684,BAO_0000219,,F,,,9606.0,A2780,N
4576,Intermediate,,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,81034,Homo sapiens,15684,BAO_0000219,,F,,,9606.0,A2780,N
4577,Intermediate,,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,81034,Homo sapiens,15684,BAO_0000219,,F,,,9606.0,A2780,N
4578,Intermediate,,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,81034,Homo sapiens,15684,BAO_0000219,,F,,,9606.0,A2780,N
4579,Intermediate,,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,81034,Homo sapiens,2113,BAO_0000219,,F,,,9606.0,A2780,N
4580,Intermediate,,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,81034,Homo sapiens,2113,BAO_0000219,,F,,,9606.0,A2780,N
4581,Intermediate,,,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,81034,Homo sapiens,16745,BAO_0000219,,F,,,9606.0,A2780,N
4582,Expert,,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,Homo sapiens,16597,BAO_0000218,,F,,,9606.0,A2780,N
4583,Intermediate,,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,81034,Homo sapiens,15684,BAO_0000219,,F,,,9606.0,A2780,N
4584,Intermediate,,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,81034,Homo sapiens,15684,BAO_0000219,,F,,,9606.0,A2780,N
4585,Intermediate,,,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,81034,Homo sapiens,2040,BAO_0000219,,F,,,9606.0,A2780,N
4586,Intermediate,,,,Relative resistance factor in A2780 cisplatin-resistant line,81034,Homo sapiens,2040,BAO_0000219,,F,,,9606.0,A2780,N
4587,Intermediate,,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,81034,Homo sapiens,16165,BAO_0000219,,F,,,9606.0,A2780,N
4588,Intermediate,,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,81034,Homo sapiens,16165,BAO_0000219,,F,,,9606.0,A2780,N
4589,Expert,,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,Homo sapiens,16597,BAO_0000218,,F,,,9606.0,A2780,N
4590,Expert,,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,Homo sapiens,16597,BAO_0000218,,F,,,9606.0,A2780,N
4591,Intermediate,,,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,81034,Homo sapiens,3992,BAO_0000219,,F,,,9606.0,A2780,N
4592,Intermediate,,,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,81034,Homo sapiens,10553,BAO_0000219,,F,,,9606.0,A2780,N
4593,Intermediate,,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,81034,Homo sapiens,15608,BAO_0000219,,F,,,9606.0,A2780,N
4594,Intermediate,,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,81034,Homo sapiens,15608,BAO_0000219,,F,,,9606.0,A2780,N
4595,Intermediate,,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,81034,Homo sapiens,15608,BAO_0000219,,F,,,9606.0,A2780,N
4596,Intermediate,,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,81034,Homo sapiens,15608,BAO_0000219,,F,,,9606.0,A2780,N
4597,Intermediate,,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,81034,Homo sapiens,15608,BAO_0000219,,F,,,9606.0,A2780,N
4598,Intermediate,,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,81034,Homo sapiens,15608,BAO_0000219,,F,,,9606.0,A2780,N
4599,Intermediate,,,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,81034,Homo sapiens,15569,BAO_0000219,,F,,,9606.0,A2780,N
4600,Intermediate,,,,Antiproliferative effect of compound on A2780/DX cell line,81034,Homo sapiens,17420,BAO_0000219,,F,,,9606.0,A2780,N
4601,Intermediate,,,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,81034,Homo sapiens,17420,BAO_0000219,,F,,,9606.0,A2780,N
4602,Intermediate,,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),81034,Homo sapiens,15099,BAO_0000219,,F,,,9606.0,A2780,N
4603,Intermediate,,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),81034,Homo sapiens,15099,BAO_0000219,,F,,,9606.0,A2780,N
4604,Intermediate,,,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,81034,Homo sapiens,17672,BAO_0000219,,F,,,9606.0,A2780,N
4605,Intermediate,,,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,81034,Homo sapiens,17672,BAO_0000219,,F,,,9606.0,A2780,N
4606,Intermediate,,,,In vitro cytotoxicity against A2780ADR cell line,81034,Homo sapiens,17270,BAO_0000219,,F,,,9606.0,A2780,N
4607,Intermediate,,,,In vitro cytotoxicity against A2780CIS cell line,81034,Homo sapiens,17270,BAO_0000219,,F,,,9606.0,A2780,N
4608,Intermediate,,,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,81034,Homo sapiens,5574,BAO_0000219,,F,,,9606.0,A2780,N
4609,Intermediate,,,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,81034,Homo sapiens,2113,BAO_0000219,,F,,,9606.0,A2780,N
4610,Intermediate,,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,Homo sapiens,16913,BAO_0000219,,F,,,9606.0,A2780,N
4611,Intermediate,,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,Homo sapiens,16913,BAO_0000219,,F,,,9606.0,A2780,N
4612,Autocuration,,,,Oral bioavailability of compound in rhesus macaques,22224,Macaca mulatta,17839,BAO_0000218,,A,In vivo,,9544.0,,U
4613,Autocuration,,,,Oral bioavailability in monkey,22224,monkey,6821,BAO_0000218,,A,In vivo,,9443.0,,U
4614,Autocuration,,,,Oral bioavailability evaluated in monkey,22224,monkey,6078,BAO_0000218,,A,In vivo,,9443.0,,U
4615,Autocuration,,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),22224,monkey,6535,BAO_0000218,,A,In vivo,,9443.0,,U
4616,Autocuration,,,,Oral bioavailability in Rhesus monkey,22224,Macaca mulatta,4449,BAO_0000218,,A,In vivo,,9544.0,,U
4617,Autocuration,,,,Oral bioavailability was calculated in rhesus monkey,22224,Macaca mulatta,6057,BAO_0000218,,A,In vivo,,9544.0,,U
4618,Autocuration,,,,Oral bioavailability in cynomolgus monkey,22224,Macaca fascicularis,5922,BAO_0000218,,A,In vivo,,9541.0,,U
4619,Autocuration,,,,Oral bioavailability in monkey,22224,monkey,5940,BAO_0000218,,A,In vivo,,9443.0,,U
4620,Autocuration,,,,Oral bioavailability in monkey,22224,monkey,6265,BAO_0000218,,A,In vivo,,9443.0,,U
4621,Autocuration,,,,Oral bioavailability in monkey (dose 1 mg/kg),22224,monkey,6265,BAO_0000218,,A,In vivo,,9443.0,,U
4622,Autocuration,,,,Oral bioavailability in monkey (dose 5 mg/kg),22224,monkey,6265,BAO_0000218,,A,In vivo,,9443.0,,U
4623,Autocuration,,,,Oral bioavailability in monkey,22224,monkey,5940,BAO_0000218,,A,In vivo,,9443.0,,U
4624,Autocuration,,,,Oral bioavailability in monkey,22224,monkey,5940,BAO_0000218,,A,In vivo,,9443.0,,U
4625,Autocuration,,,,Oral bioavailability in rhesus monkey,22224,Macaca mulatta,4514,BAO_0000218,,A,In vivo,,9544.0,,U
4626,Autocuration,,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,22224,Macaca mulatta,5546,BAO_0000218,,A,In vivo,,9544.0,,U
4627,Autocuration,,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,22224,Saimiri sciureus,5553,BAO_0000218,,A,In vivo,,9521.0,,U
4628,Autocuration,,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,monkey,6641,BAO_0000218,,A,In vivo,,9443.0,,U
4629,Autocuration,,,,Oral bioavailability in Rhesus monkey,22224,Macaca mulatta,5472,BAO_0000218,,A,In vivo,,9544.0,,U
4630,Autocuration,,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),22224,Macaca mulatta,5668,BAO_0000218,,A,In vivo,,9544.0,,U
4631,Autocuration,,,,Oral bioavailability in monkey at 10 mg/kg of the compound,22224,monkey,5711,BAO_0000218,,A,In vivo,,9443.0,,U
4632,Autocuration,,,,Bioavailability in Rhesus monkey,22224,Macaca mulatta,5145,BAO_0000218,,A,In vivo,,9544.0,,U
4633,Autocuration,,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,,,9527.0,,U
4634,Autocuration,,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,,,9527.0,,U
4635,Autocuration,,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,22224,Cercopithecidae,3249,BAO_0000218,,A,In vivo,,9527.0,,U
4636,Autocuration,,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,22224,Cercopithecidae,3249,BAO_0000218,,A,In vivo,,9527.0,,U
4637,Autocuration,,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4638,Autocuration,,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4639,Autocuration,,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4640,Autocuration,,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,Cercopithecidae,4809,BAO_0000218,,A,In vivo,,9527.0,,U
4641,Autocuration,,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,Cercopithecidae,4809,BAO_0000218,,A,In vivo,,9527.0,,U
4642,Autocuration,Microsomes,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),22224,Cercopithecidae,14294,BAO_0000251,,A,,,9527.0,,U
4643,Autocuration,Microsomes,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),22224,Cercopithecidae,14294,BAO_0000251,,A,,,9527.0,,U
4644,Autocuration,Microsomes,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),22224,Cercopithecidae,14294,BAO_0000251,,A,,,9527.0,,U
4645,Autocuration,Microsomes,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),22224,Cercopithecidae,14294,BAO_0000251,,A,,,9527.0,,U
4646,Autocuration,,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,In vivo,,9527.0,,U
4647,Autocuration,,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,In vivo,,9527.0,,U
4648,Autocuration,,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
4649,Autocuration,,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,,,9527.0,,U
4650,Autocuration,,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,,,9527.0,,U
4651,Autocuration,,,,Elimination Half-life of compound was determined in monkey,22224,Cercopithecidae,6821,BAO_0000019,,A,,,9527.0,,U
4652,Autocuration,,,,Half life of compound was determined in rhesus monkey,22224,Cercopithecidae,17267,BAO_0000019,,A,,,9527.0,,U
4653,Autocuration,,Plasma,1969.0,Half life in monkey plasma,22224,Cercopithecidae,5819,BAO_0000366,,A,,,9527.0,,U
4654,Autocuration,,Plasma,1969.0,Half life in monkey plasma; Not detected,22224,Cercopithecidae,5819,BAO_0000366,,A,,,9527.0,,U
4655,Autocuration,,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,Cercopithecidae,1916,BAO_0000218,,A,In vivo,,9527.0,,U
4656,Autocuration,,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,22224,Cercopithecidae,17509,BAO_0000218,,A,In vivo,,9527.0,,U
4657,Autocuration,,,,Terminal half life of the compound.,22224,Cercopithecidae,1399,BAO_0000019,,A,,,9527.0,,U
4658,Autocuration,,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,Cercopithecidae,1916,BAO_0000218,,A,In vivo,,9527.0,,U
4659,Autocuration,,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,Cercopithecidae,4809,BAO_0000218,,A,In vivo,,9527.0,,U
4660,Autocuration,,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,Cercopithecidae,5546,BAO_0000218,,A,,,9527.0,,U
4661,Autocuration,,Urine,1088.0,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,,,9527.0,,U
4662,Autocuration,,Urine,1088.0,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,,,9527.0,,U
4663,Autocuration,,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,22224,Cercopithecidae,4257,BAO_0000218,,A,In vivo,,9527.0,,U
4664,Autocuration,,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,22224,Cercopithecidae,6221,BAO_0000218,,A,In vivo,,9527.0,,U
4665,Autocuration,,,,Volume of distribution was evaluated in rhesus,22224,Cercopithecidae,5472,BAO_0000218,,A,In vivo,,9527.0,,U
4666,Autocuration,,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,22224,Cricetulus griseus,4727,BAO_0000218,,A,In vivo,,10029.0,,U
4667,Autocuration,,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,22224,Cricetulus griseus,4727,BAO_0000218,,A,In vivo,,10029.0,,U
4668,Autocuration,,,,Bioavailability in hamster was determined,22224,Cricetulus griseus,4727,BAO_0000218,,A,In vivo,,10029.0,,U
4669,Autocuration,,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,22224,Cricetulus griseus,4727,BAO_0000218,,A,In vivo,,10029.0,,U
4670,Autocuration,,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,22224,Cricetulus griseus,4727,BAO_0000218,,A,In vivo,,10029.0,,U
4671,Autocuration,,Blood,178.0,Half life of compound was determined in hamster blood,22224,Cricetulus griseus,4727,BAO_0000221,,A,,,10029.0,,U
4672,Autocuration,,,,Michaelis-Menten constant of the compound.,22224,Sus scrofa,1452,BAO_0000019,,A,,,9823.0,,U
4673,Autocuration,,,,Vmax value was measured at 0 uM concentration of silyl ether.,22224,Sus scrofa,1452,BAO_0000019,,A,,,9823.0,,U
4674,Autocuration,,,,Vmax value was measured at 10 uM concentration of silyl ether.,22224,Sus scrofa,1452,BAO_0000019,,A,,,9823.0,,U
4675,Autocuration,,,,Vmax value was measured at 5 uM concentration of silyl ether.,22224,Sus scrofa,1452,BAO_0000019,,A,,,9823.0,,U
4676,Expert,,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,235,Homo sapiens,11706,BAO_0000357,,B,,,9606.0,,D
4677,Autocuration,,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,22224,Homo sapiens,1916,BAO_0000218,,A,,,9606.0,,U
4678,Autocuration,,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),22224,Homo sapiens,17791,BAO_0000019,,A,,,9606.0,,U
4679,Autocuration,,,,Active metabolite of ifosfamide determined in humans; A-Active,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4680,Autocuration,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,22224,Homo sapiens,6567,BAO_0000019,,A,,,9606.0,,U
4681,Autocuration,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,22224,Homo sapiens,6567,BAO_0000019,,A,,,9606.0,,U
4682,Autocuration,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,22224,Homo sapiens,6567,BAO_0000019,,A,,,9606.0,,U
4683,Autocuration,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,22224,Homo sapiens,6567,BAO_0000019,,A,,,9606.0,,U
4684,Autocuration,,,,Compound was evaluated for oral bioavailability in human,22224,Homo sapiens,17791,BAO_0000218,,A,,,9606.0,,U
4685,Autocuration,,Urine,1088.0,Metabolite of ifosfamide determined in urine; NF-Not found,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4686,Autocuration,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),22224,Homo sapiens,6852,BAO_0000019,,A,,,9606.0,,U
4687,Autocuration,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,22224,Homo sapiens,6852,BAO_0000019,,A,,,9606.0,,U
4688,Autocuration,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,22224,Homo sapiens,6852,BAO_0000019,,A,,,9606.0,,U
4689,Autocuration,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,22224,Homo sapiens,6852,BAO_0000019,,A,,,9606.0,,U
4690,Autocuration,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,22224,Homo sapiens,6852,BAO_0000019,,A,,,9606.0,,U
4691,Autocuration,,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),22224,Homo sapiens,6852,BAO_0000019,,A,,,9606.0,,U
4692,Autocuration,,,,Percent of compound in healthy individuals (Group D),22224,Homo sapiens,6852,BAO_0000019,,A,,,9606.0,,U
4693,Autocuration,Microsomes,Liver,2107.0,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,22224,Homo sapiens,4397,BAO_0000251,,A,,,9606.0,,U
4694,Autocuration,,,,Binding towards human plasma protein at 10 uM,22224,Homo sapiens,17409,BAO_0000019,,A,,,9606.0,,U
4695,Autocuration,,,,Binding towards human plasma protein at 100 uM,22224,Homo sapiens,17409,BAO_0000019,,A,,,9606.0,,U
4696,Autocuration,,,,Human plasma protein binding activity was determined,22224,Homo sapiens,17176,BAO_0000019,,A,,,9606.0,,U
4697,Autocuration,,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),22224,Homo sapiens,15444,BAO_0000019,,A,,,9606.0,,U
4698,Autocuration,,,,Percent binding of compound towards human plasma protein was determined,22224,Homo sapiens,17267,BAO_0000019,,A,,,9606.0,,U
4699,Autocuration,Microsomes,Liver,2107.0,Plasma clearance in human liver microsomes,22224,Homo sapiens,5944,BAO_0000251,,A,In vitro,,9606.0,,U
4700,Autocuration,Microsomes,Liver,2107.0,In vitro intrinsic clearance in human liver microsome,22224,Homo sapiens,5668,BAO_0000251,,A,In vitro,,9606.0,,U
4701,Autocuration,Microsomes,Liver,2107.0,In vitro intrinsic clearance in human liver microsome,22224,Homo sapiens,5669,BAO_0000251,,A,In vitro,,9606.0,,U
4702,Autocuration,Microsomes,,,In vitro microsome metabolism clearance in human was determined,22224,Homo sapiens,5041,BAO_0000251,,A,In vitro,,9606.0,,U
4703,Autocuration,Microsomes,,,In vitro microsome metabolism clearance in human was determined; High,22224,Homo sapiens,5041,BAO_0000251,,A,In vitro,,9606.0,,U
4704,Autocuration,Microsomes,,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,22224,Homo sapiens,5041,BAO_0000251,,A,In vitro,,9606.0,,U
4705,Autocuration,Microsomes,Liver,2107.0,Pharmacokinetic property (clearance) in human liver microsome,22224,Homo sapiens,5676,BAO_0000251,,A,In vitro,,9606.0,,U
4706,Autocuration,Microsomes,Liver,2107.0,Plasma clearance in human liver microsomes,22224,Homo sapiens,5944,BAO_0000251,,A,In vitro,,9606.0,,U
4707,Autocuration,Microsomes,Liver,2107.0,In vitro clearance in human liver microsomes,22224,Homo sapiens,17538,BAO_0000251,,A,In vitro,,9606.0,,U
4708,Autocuration,Microsomes,Liver,2107.0,Intrinsic clearance in human liver microsomes was determined,22224,Homo sapiens,6331,BAO_0000251,,A,In vitro,,9606.0,,U
4709,Autocuration,Microsomes,Liver,2107.0,Intrinsic clearance in human liver microsomes was determined,22224,Homo sapiens,5948,BAO_0000251,,A,In vitro,,9606.0,,U
4710,Autocuration,,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,22224,Homo sapiens,5965,BAO_0000218,,A,In vivo,,9606.0,,U
4711,Autocuration,,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,22224,Homo sapiens,1916,BAO_0000218,,A,In vivo,,9606.0,,U
4712,Autocuration,,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,22224,Homo sapiens,5965,BAO_0000218,,A,,,9606.0,,U
4713,Autocuration,,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,22224,Homo sapiens,1299,BAO_0000019,,A,,,9606.0,,U
4714,Autocuration,,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,22224,Homo sapiens,1299,BAO_0000019,,A,,,9606.0,,U
4715,Autocuration,,Urine,1088.0,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4716,Autocuration,,Urine,1088.0,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4717,Autocuration,,Urine,1088.0,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4718,Autocuration,,Urine,1088.0,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4719,Intermediate,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4720,Intermediate,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4721,Intermediate,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4722,Intermediate,,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4723,Intermediate,,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),50594,Mus musculus,14294,BAO_0000218,,A,,,10090.0,,N
4724,Intermediate,,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),50594,Mus musculus,14294,BAO_0000218,,A,,,10090.0,,N
4725,Intermediate,,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),50594,Mus musculus,14294,BAO_0000218,,A,,,10090.0,,N
4726,Intermediate,,Liver,2107.0,In vitro metabolic potential in mouse liver microsomes,50594,Mus musculus,6251,BAO_0000218,,A,,,10090.0,,N
4727,Intermediate,,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,50594,Mus musculus,17582,BAO_0000218,,A,,,10090.0,,N
4728,Intermediate,,Adrenal gland,2369.0,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),50594,Mus musculus,17811,BAO_0000218,,A,,,10090.0,,N
4729,Intermediate,,Brain,955.0,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,50594,Mus musculus,17811,BAO_0000218,,A,,,10090.0,,N
4730,Intermediate,,Brain,955.0,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,50594,Mus musculus,17811,BAO_0000218,,A,,,10090.0,,N
4731,Intermediate,,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),50594,Mus musculus,17811,BAO_0000218,,A,,,10090.0,,N
4732,Intermediate,,Kidney,2113.0,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),50594,Mus musculus,17811,BAO_0000218,,A,,,10090.0,,N
4733,Intermediate,,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),50594,Mus musculus,17811,BAO_0000218,,A,,,10090.0,,N
4734,Intermediate,,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,50594,Mus musculus,5288,BAO_0000218,,A,,,10090.0,,N
4735,Intermediate,,Serum,1977.0,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,50594,Mus musculus,2717,BAO_0000218,,A,,,10090.0,,N
4736,Intermediate,,Serum,1977.0,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,50594,Mus musculus,2717,BAO_0000218,,A,,,10090.0,,N
4737,Intermediate,,Serum,1977.0,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,50594,Mus musculus,2717,BAO_0000218,,A,,,10090.0,,N
4738,Intermediate,,Plasma,1969.0,Half life of compound was determined in plasma of mice at 24 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,In vivo,,10090.0,,N
4739,Intermediate,,Plasma,1969.0,Half life of compound was determined in plasma of mice at 40 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,In vivo,,10090.0,,N
4740,Intermediate,,Plasma,1969.0,Half life of compound was determined in plasma of mice at 5 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,In vivo,,10090.0,,N
4741,Intermediate,,,,Half life after intraperitoneal administration in mice at 18 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4742,Intermediate,,,,Half life after intraperitoneal administration in mice at 23 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4743,Intermediate,,,,Half life after intraperitoneal administration in mice at 25 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4744,Intermediate,,,,Half life after intraperitoneal administration in mice at 26 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4745,Intermediate,,,,Half life after intravenous administration in mice at 23 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4746,Intermediate,,,,Half life after intravenous administration in mice at 24 uM/kg,50594,Mus musculus,17764,BAO_0000218,,A,In vivo,,10090.0,,N
4747,Intermediate,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
4748,Intermediate,,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,50594,Mus musculus,2675,BAO_0000218,,A,In vivo,,10090.0,,N
4749,Intermediate,,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,50594,Mus musculus,2675,BAO_0000218,,A,In vivo,,10090.0,,N
4750,Intermediate,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
4751,Intermediate,,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",50594,Mus musculus,4890,BAO_0000218,,A,In vivo,,10090.0,,N
4752,Intermediate,,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,50594,Mus musculus,429,BAO_0000218,,A,In vivo,,10090.0,,N
4753,Intermediate,,Blood,178.0,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,50594,Mus musculus,17837,BAO_0000218,,A,In vivo,,10090.0,,N
4754,Intermediate,,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
4755,Intermediate,,,,Half life at a dose of 10 mg/kg peroral administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
4756,Intermediate,,,,Half life in ob/ob mice,50594,Mus musculus,6619,BAO_0000218,,A,,,10090.0,,N
4757,Intermediate,,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,50594,Mus musculus,4066,BAO_0000218,,A,In vivo,,10090.0,,N
4758,Intermediate,,,,Half-life was measured in mouse,50594,Mus musculus,4239,BAO_0000218,,A,,,10090.0,,N
4759,Intermediate,,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,50594,Mus musculus,5969,BAO_0000218,,A,In vivo,,10090.0,,N
4760,Intermediate,,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,50594,Mus musculus,8999,BAO_0000218,,A,,,10090.0,,N
4761,Intermediate,,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,50594,Mus musculus,8999,BAO_0000218,,A,,,10090.0,,N
4762,Intermediate,,Brain,955.0,T2 in brain of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,,,10090.0,,N
4763,Intermediate,,Kidney,2113.0,T2 in kidney of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,,,10090.0,,N
4764,Intermediate,,Liver,2107.0,T2 in liver of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,,,10090.0,,N
4765,Intermediate,,Lung,2048.0,T2 in lungs of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,,,10090.0,,N
4766,Intermediate,,Spleen,2106.0,T2 in spleen of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,,,10090.0,,N
4767,Intermediate,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
4768,Intermediate,,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",50594,Mus musculus,4890,BAO_0000218,,A,In vivo,,10090.0,,N
4769,Intermediate,,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,50594,Mus musculus,429,BAO_0000218,,A,In vivo,,10090.0,,N
4770,Intermediate,,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,50594,Mus musculus,429,BAO_0000218,,A,In vivo,,10090.0,,N
4771,Intermediate,,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,50594,Mus musculus,5969,BAO_0000218,,A,In vivo,,10090.0,,N
4772,Intermediate,,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,Homo sapiens,16913,BAO_0000219,,F,,,9606.0,A2780,N
4773,Intermediate,,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,Homo sapiens,16913,BAO_0000219,,F,,,9606.0,A2780,N
4774,Intermediate,,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,Homo sapiens,16913,BAO_0000219,,F,,,9606.0,A2780,N
4775,Intermediate,,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,Homo sapiens,16913,BAO_0000219,,F,,,9606.0,A2780,N
4776,Intermediate,,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,Homo sapiens,16913,BAO_0000219,,F,,,9606.0,A2780,N
4777,Intermediate,,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,Homo sapiens,16913,BAO_0000219,,F,,,9606.0,A2780,N
4778,Intermediate,,,,In vitro cytotoxicity against A2780TAX cell line,81034,Homo sapiens,17270,BAO_0000219,,F,,,9606.0,A2780,N
4779,Intermediate,,,,In vitro inhibitory activity against human tumor cell line A2780cis,80017,Homo sapiens,5618,BAO_0000219,,F,,,9606.0,A2780cisR,N
4780,Expert,,,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,81034,Homo sapiens,17777,BAO_0000219,,F,,,9606.0,A2780,N
4781,Intermediate,,,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,80017,Homo sapiens,16112,BAO_0000219,,F,,,9606.0,A2780cisR,N
4782,Intermediate,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),80017,Homo sapiens,15748,BAO_0000219,,F,,,9606.0,A2780cisR,N
4783,Intermediate,,,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,81034,Homo sapiens,6633,BAO_0000219,,F,,,9606.0,A2780,N
4784,Intermediate,,,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,81034,Homo sapiens,16930,BAO_0000219,,F,,,9606.0,A2780,N
4785,Intermediate,,,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,81034,Homo sapiens,17496,BAO_0000219,,F,,,9606.0,A2780,N
4786,Expert,,,,In vitro antitumor activity against A2780cisR cell line.,81034,Homo sapiens,12989,BAO_0000219,,F,,,9606.0,A2780,N
4787,Intermediate,,,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),81034,Homo sapiens,4840,BAO_0000219,,F,,,9606.0,A2780,N
4788,Expert,,,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,81034,Homo sapiens,12989,BAO_0000219,,F,,,9606.0,A2780,N
4789,Intermediate,,,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,80017,Homo sapiens,16745,BAO_0000219,,F,,,9606.0,A2780cisR,N
4790,Expert,,,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,81034,Homo sapiens,16597,BAO_0000219,,F,,,9606.0,A2780,N
4791,Expert,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,11736,Rattus norvegicus,16547,BAO_0000019,,B,,,10116.0,,D
4792,Expert,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),11736,,16547,BAO_0000019,,F,,,,,H
4793,Expert,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),11736,Rattus norvegicus,16547,BAO_0000019,,F,,,10116.0,,D
4794,Expert,,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,278,Homo sapiens,15856,BAO_0000219,,F,,,9606.0,HEK293,D
4795,Expert,,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,278,Homo sapiens,15856,BAO_0000219,,F,,,9606.0,HEK293,D
4796,Expert,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,11831,Mus musculus,16547,BAO_0000019,,B,,,10090.0,,D
4797,Expert,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),11831,,16547,BAO_0000019,,F,,,,,H
4798,Expert,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),11831,Mus musculus,16547,BAO_0000019,,F,,,10090.0,,D
4799,Expert,,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,280,,17402,BAO_0000357,,B,,,,,H
4800,Autocuration,,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),22226,Homo sapiens,11746,BAO_0000219,,F,,,9606.0,T-cells,U
4801,Autocuration,,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,22226,Homo sapiens,11746,BAO_0000219,,F,,,9606.0,T-cells,U
4802,Intermediate,,,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,80018,Homo sapiens,5455,BAO_0000219,,F,,,9606.0,A-375,N
4803,Intermediate,,,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,80018,Homo sapiens,2068,BAO_0000219,,F,,,9606.0,A-375,N
4804,Intermediate,,,,In vitro antitumor activity against A375cell line extracted form melanoma,80018,Homo sapiens,2683,BAO_0000219,,F,,,9606.0,A-375,N
4805,Expert,,,,Inhibition of cell growth in (A375) melan cell line,80018,Homo sapiens,15313,BAO_0000219,,F,,,9606.0,A-375,N
4806,Intermediate,,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,80018,Homo sapiens,13739,BAO_0000219,,F,,,9606.0,A-375,N
4807,Intermediate,,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,80018,Homo sapiens,13739,BAO_0000219,,F,,,9606.0,A-375,N
4808,Intermediate,,,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,80018,Homo sapiens,14750,BAO_0000219,,F,,,9606.0,A-375,N
4809,Intermediate,,,,Antiproliferative activity measured against A427 human lung carcinoma,80019,Homo sapiens,14777,BAO_0000219,,F,,,9606.0,A-427,N
4810,Intermediate,,,,Antiproliferative activity measured against A427 human lung carcinoma,80019,Homo sapiens,14777,BAO_0000219,,F,,,9606.0,A-427,N
4811,Intermediate,,,,Cytotoxicity against lung carcinoma A427 tumor cell lines,80019,Homo sapiens,17672,BAO_0000219,,F,,,9606.0,A-427,N
4812,Intermediate,,,,Inhibition of large cell lung carcinoma (A427),80019,Homo sapiens,14368,BAO_0000219,,F,,,9606.0,A-427,N
4813,Intermediate,,,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,80019,Homo sapiens,14368,BAO_0000219,,F,,,9606.0,A-427,N
4814,Intermediate,,,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,80019,Homo sapiens,13866,BAO_0000219,,F,,,9606.0,A-427,N
4815,Intermediate,,,,Inhibitory concentration in human lung carcinoma A427 cell line,80019,Homo sapiens,2545,BAO_0000219,,F,,,9606.0,A-427,N
4816,Intermediate,,,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,80019,Homo sapiens,2545,BAO_0000219,,F,,,9606.0,A-427,N
4817,Autocuration,,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,22224,Cercopithecidae,6062,BAO_0000218,,A,In vivo,,9527.0,,U
4818,Autocuration,,,,Tested for volume of distribution upon iv administration to african green monkey,22224,Cercopithecidae,4578,BAO_0000218,,A,In vivo,,9527.0,,U
4819,Autocuration,,,,Volume of distribution in monkey,22224,Cercopithecidae,17592,BAO_0000218,,A,In vivo,,9527.0,,U
4820,Autocuration,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,Macaca mulatta,5005,BAO_0000218,,A,In vivo,,9544.0,,U
4821,Autocuration,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,22224,Macaca mulatta,5005,BAO_0000218,,A,In vivo,,9544.0,,U
4822,Autocuration,,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,22224,Cercopithecidae,5922,BAO_0000218,,A,In vivo,,9527.0,,U
4823,Autocuration,,,,The distribution volume after intravenous administration in cynomolgus monkeys,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4824,Autocuration,,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4825,Autocuration,,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4826,Autocuration,,,,Volume displacement was calculated in rhesus monkey,22224,Cercopithecidae,6057,BAO_0000218,,A,In vivo,,9527.0,,U
4827,Autocuration,,,,Volume of distribution in steady state was determined in rhesus monkey,22224,Cercopithecidae,5145,BAO_0000218,,A,In vivo,,9527.0,,U
4828,Autocuration,,,,Volume of distribution of compound was determined in monkey,22224,Cercopithecidae,6821,BAO_0000218,,A,In vivo,,9527.0,,U
4829,Autocuration,,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,Cercopithecidae,5334,BAO_0000218,,A,In vivo,,9527.0,,U
4830,Autocuration,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,Cercopithecidae,5334,BAO_0000218,,A,In vivo,,9527.0,,U
4831,Autocuration,,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,Cercopithecidae,6641,BAO_0000218,,A,In vivo,,9527.0,,U
4832,Autocuration,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,Cercopithecidae,2661,BAO_0000218,,A,In vivo,,9527.0,,U
4833,Autocuration,,,,Volume distribution in monkey after administration of 1 mg/kg iv,22224,Cercopithecidae,6535,BAO_0000218,,A,In vivo,,9527.0,,U
4834,Autocuration,,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,Cercopithecidae,4809,BAO_0000218,,A,In vivo,,9527.0,,U
4835,Autocuration,,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,22224,Cercopithecidae,6062,BAO_0000218,,A,In vivo,,9527.0,,U
4836,Autocuration,,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,In vivo,,9527.0,,U
4837,Autocuration,,,,Oral systemic bioavailability upon iv administration to african green monkey,22224,Cercopithecidae,4578,BAO_0000218,,A,In vivo,,9527.0,,U
4838,Autocuration,,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,Cercopithecidae,4809,BAO_0000218,,A,In vivo,,9527.0,,U
4839,Autocuration,,,,Baboon plasma free fraction. ,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
4840,Autocuration,,,,Area under the curve was calculated in rhesus monkey after iv administration,22224,Cercopithecidae,6057,BAO_0000218,,A,,,9527.0,,U
4841,Autocuration,,,,Area under the curve was calculated in rhesus monkey after peroral administration,22224,Cercopithecidae,6057,BAO_0000019,,A,,,9527.0,,U
4842,Autocuration,,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,22224,Cercopithecidae,17853,BAO_0000019,,A,,,9527.0,,U
4843,Autocuration,,,,Half life period in monkey after 5 mg/kg dose,22224,Cercopithecidae,5302,BAO_0000218,,A,In vivo,,9527.0,,U
4844,Autocuration,,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,22224,Cercopithecidae,4257,BAO_0000218,,A,In vivo,,9527.0,,U
4845,Autocuration,,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,22224,Cercopithecidae,4257,BAO_0000218,,A,In vivo,,9527.0,,U
4846,Autocuration,,Plasma,1969.0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,22224,Cercopithecidae,13501,BAO_0000218,,A,In vivo,,9527.0,,U
4847,Autocuration,,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,22224,Cercopithecidae,5394,BAO_0000218,,A,In vivo,,9527.0,,U
4848,Autocuration,,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,Cercopithecidae,2661,BAO_0000218,,A,In vivo,,9527.0,,U
4849,Autocuration,,,,Compound was evaluated for terminal half life in monkey,22224,Cercopithecidae,3341,BAO_0000019,,A,,,9527.0,,U
4850,Autocuration,,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,22224,Cercopithecidae,3045,BAO_0000218,,A,In vivo,,9527.0,,U
4851,Autocuration,,Plasma,1969.0,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,Macaca mulatta,5005,BAO_0000218,,A,In vivo,,9544.0,,U
4852,Autocuration,,,,Half life of compound was determined in squirrel monkey,22224,Cercopithecidae,4847,BAO_0000019,,A,,,9527.0,,U
4853,Autocuration,,,,Half life after iv administration in cynomolgus monkey,22224,Macaca fascicularis,4256,BAO_0000218,,A,In vivo,,9541.0,,U
4854,Autocuration,,Plasma,1969.0,Half life in monkey plasma after administration of 1 mg/kg iv,22224,Cercopithecidae,6535,BAO_0000218,,A,In vivo,,9527.0,,U
4855,Autocuration,,,,Half life was calculated in rhesus monkey,22224,Cercopithecidae,6057,BAO_0000019,,A,,,9527.0,,U
4856,Autocuration,,,,Half life in monkey,22224,Cercopithecidae,17592,BAO_0000019,,A,,,9527.0,,U
4857,Autocuration,,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,Cercopithecidae,6641,BAO_0000218,,A,In vivo,,9527.0,,U
4858,Autocuration,,,,Half life was evaluated in rhesus,22224,Cercopithecidae,5472,BAO_0000019,,A,,,9527.0,,U
4859,Autocuration,,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,22224,Cercopithecidae,6221,BAO_0000218,,A,In vivo,,9527.0,,U
4860,Autocuration,,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,22224,Cercopithecidae,5668,BAO_0000218,,A,In vivo,,9527.0,,U
4861,Autocuration,,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,Cercopithecidae,4809,BAO_0000218,,A,In vivo,,9527.0,,U
4862,Autocuration,,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,Cercopithecidae,5546,BAO_0000218,,A,In vivo,,9527.0,,U
4863,Autocuration,,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,22224,Cercopithecidae,5553,BAO_0000218,,A,In vivo,,9527.0,,U
4864,Autocuration,,,,Half-life was calculated in monkey,22224,Cercopithecidae,6078,BAO_0000019,,A,,,9527.0,,U
4865,Autocuration,,,,Half-life in Squirrel monkey,22224,Cercopithecidae,5147,BAO_0000019,,A,,,9527.0,,U
4866,Autocuration,,,,Half-life in rhesus monkey,22224,Cercopithecidae,5145,BAO_0000019,,A,,,9527.0,,U
4867,Autocuration,,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,22224,Cercopithecidae,6062,BAO_0000218,,A,In vivo,,9527.0,,U
4868,Autocuration,,,,Half-life period after intravenous administration in cynomolgus monkeys,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4869,Autocuration,,,,Half-life period after oral administration in cynomolgus monkeys,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4870,Autocuration,,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
4871,Autocuration,,Urine,1088.0,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4872,Autocuration,,Urine,1088.0,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4873,Autocuration,,Urine,1088.0,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4874,Autocuration,,Urine,1088.0,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4875,Autocuration,,Urine,1088.0,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4876,Autocuration,,Urine,1088.0,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4877,Autocuration,,Urine,1088.0,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4878,Autocuration,,Urine,1088.0,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4879,Autocuration,,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,22224,Homo sapiens,1916,BAO_0000218,,A,In vivo,,9606.0,,U
4880,Autocuration,,,,Oral bioavailability in human,22224,Homo sapiens,16643,BAO_0000218,,A,In vivo,,9606.0,,U
4881,Autocuration,,,,Compound was tested for human plasma protein binding,22224,Homo sapiens,17248,BAO_0000019,,A,,,9606.0,,U
4882,Autocuration,,,,Compound was tested for human plasma protein binding; Not determined,22224,Homo sapiens,17248,BAO_0000019,,A,,,9606.0,,U
4883,Autocuration,,,,Protein binding activity of compound in human plasma; % Free,22224,Homo sapiens,6241,BAO_0000019,,A,,,9606.0,,U
4884,Autocuration,,,,Unbound fraction (plasma),22224,Homo sapiens,17716,BAO_0000019,,A,,,9606.0,,U
4885,Autocuration,,Plasma,1969.0,Half life for the hydrolysis of compound in human blood serum,22224,Homo sapiens,17605,BAO_0000366,,A,,,9606.0,,U
4886,Autocuration,,Plasma,1969.0,Half life period in human plasma using phosphate buffer (0.08 M),22224,Homo sapiens,17625,BAO_0000366,,A,,,9606.0,,U
4887,Autocuration,,Plasma,1969.0,Half life period in human plasma using phosphate buffer (0.1 M),22224,Homo sapiens,17625,BAO_0000366,,A,,,9606.0,,U
4888,Autocuration,,Plasma,1969.0,Half-life in human plasma was determined,22224,Homo sapiens,17747,BAO_0000366,,A,,,9606.0,,U
4889,Autocuration,,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,22224,Homo sapiens,15613,BAO_0000019,,A,,,9606.0,,U
4890,Autocuration,,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),22224,Homo sapiens,354,BAO_0000019,,A,,,9606.0,,U
4891,Autocuration,,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",22224,Homo sapiens,3741,BAO_0000019,,A,,,9606.0,,U
4892,Autocuration,,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",22224,Homo sapiens,3741,BAO_0000019,,A,,,9606.0,,U
4893,Autocuration,,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",22224,Homo sapiens,3741,BAO_0000019,,A,,,9606.0,,U
4894,Autocuration,,,,Partition coefficient (logP),22224,Homo sapiens,17599,BAO_0000019,,A,,,9606.0,,U
4895,Autocuration,,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,22224,Homo sapiens,5486,BAO_0000019,,A,,,9606.0,,U
4896,Autocuration,Microsomes,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,22224,Homo sapiens,5600,BAO_0000251,,A,,,9606.0,,U
4897,Autocuration,,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),22224,Homo sapiens,14294,BAO_0000019,,A,,,9606.0,,U
4898,Autocuration,,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),22224,Homo sapiens,14294,BAO_0000019,,A,,,9606.0,,U
4899,Autocuration,,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),22224,Homo sapiens,14294,BAO_0000019,,A,,,9606.0,,U
4900,Autocuration,Microsomes,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),22224,Homo sapiens,14294,BAO_0000251,,A,,,9606.0,,U
4901,Autocuration,Microsomes,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),22224,Homo sapiens,14294,BAO_0000251,,A,,,9606.0,,U
4902,Autocuration,Microsomes,,,Metabolism of compound in human microsomes; Trace,22224,Homo sapiens,14294,BAO_0000251,,A,,,9606.0,,U
4903,Autocuration,Microsomes,Liver,2107.0,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,22224,Homo sapiens,6260,BAO_0000251,,A,,,9606.0,,U
4904,Autocuration,Microsomes,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,22224,Homo sapiens,6187,BAO_0000251,,A,,,9606.0,,U
4905,Autocuration,Microsomes,Liver,2107.0,In vitro metabolic potential in human liver microsomes,22224,Homo sapiens,6251,BAO_0000251,,A,,,9606.0,,U
4906,Autocuration,,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,22224,Homo sapiens,3246,BAO_0000019,,A,,,9606.0,,U
4907,Autocuration,,,,Tested for human plasma protein binding of the compound; Not tested,22224,Homo sapiens,17313,BAO_0000019,,A,,,9606.0,,U
4908,Autocuration,,,,Compound was tested for percent protein binding (PB) in human,22224,Homo sapiens,6227,BAO_0000019,,A,,,9606.0,,U
4909,Autocuration,,Plasma,1969.0,Protein binding in human plasma,22224,Homo sapiens,5530,BAO_0000019,,A,,,9606.0,,U
4910,Autocuration,,,,Permeability coefficient (B to A) in Caco-2 cell,22224,Homo sapiens,6108,BAO_0000019,,A,,,9606.0,,U
4911,Autocuration,,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,22224,Homo sapiens,6108,BAO_0000019,,A,,,9606.0,,U
4912,Autocuration,,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),22224,Homo sapiens,2774,BAO_0000019,,A,,,9606.0,,U
4913,Autocuration,,,,In vitro rate of absorption observed as Caco-2 permeability in humans,22224,Homo sapiens,16643,BAO_0000019,,A,,,9606.0,,U
4914,Autocuration,,,,Cellular permeability of compound was determined in Caco-2 cells; High,22224,Homo sapiens,17582,BAO_0000219,,A,,,9606.0,Caco-2,U
4915,Autocuration,,,,Permeability in Caco-2 cells of compound,22224,Homo sapiens,6838,BAO_0000219,,A,,,9606.0,Caco-2,U
4916,Autocuration,,,,Permeability coefficient (A to B) in Caco-2 cell,22224,Homo sapiens,6108,BAO_0000019,,A,,,9606.0,,U
4917,Autocuration,,,,Permeability coefficient (B to A) in Caco-2 cell,22224,Homo sapiens,6108,BAO_0000019,,A,,,9606.0,,U
4918,Autocuration,,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),22224,Homo sapiens,6108,BAO_0000019,,A,,,9606.0,,U
4919,Autocuration,,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,22224,Homo sapiens,2146,BAO_0000019,,A,,,9606.0,,U
4920,Autocuration,,,,Compound was tested for protein binding in human plasma,22224,Homo sapiens,4514,BAO_0000019,,A,,,9606.0,,U
4921,Autocuration,,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,22224,Homo sapiens,6108,BAO_0000019,,A,,,9606.0,,U
4922,Autocuration,,Urine,1088.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
4923,Intermediate,,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,50594,Mus musculus,5969,BAO_0000218,,A,In vivo,,10090.0,,N
4924,Intermediate,,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,Mus musculus,3277,BAO_0000218,,A,In vivo,,10090.0,,N
4925,Intermediate,,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,50594,Mus musculus,3802,BAO_0000218,,A,In vivo,,10090.0,,N
4926,Intermediate,,Plasma,1969.0,Time taken to reach maximum concentration in plasma upon oral administration in mouse,50594,Mus musculus,2862,BAO_0000218,,A,In vivo,,10090.0,,N
4927,Intermediate,,Plasma,1969.0,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,Mus musculus,6348,BAO_0000218,,A,In vivo,,10090.0,,N
4928,Intermediate,,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4929,Intermediate,,,,Tmax after oral administration at 30 mg/kg in ICR mouse,50594,Mus musculus,5781,BAO_0000218,,A,In vivo,,10090.0,,N
4930,Intermediate,,,,Tmax after peroral administration in mice at 2.4 uM/kg,50594,Mus musculus,17764,BAO_0000218,,A,In vivo,,10090.0,,N
4931,Intermediate,,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,50594,Mus musculus,4066,BAO_0000218,,A,In vivo,,10090.0,,N
4932,Intermediate,,Brain,955.0,Tmax in brain of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,In vivo,,10090.0,,N
4933,Intermediate,,Kidney,2113.0,Tmax in kidney of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,In vivo,,10090.0,,N
4934,Intermediate,,Liver,2107.0,Tmax in liver of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,In vivo,,10090.0,,N
4935,Intermediate,,Lung,2048.0,Tmax in lungs of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,In vivo,,10090.0,,N
4936,Intermediate,,,,Tmax in mice at 18 uM/kg i.p. administration,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4937,Intermediate,,,,Tmax in mice at 23 uM/kg i.v. administration,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4938,Intermediate,,,,Tmax in mice at 25 uM/kg i.p. administration,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4939,Intermediate,,,,Tmax in mice at 26 uM/kg i.p. administration,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
4940,Intermediate,,Spleen,2106.0,Tmax in spleen of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,In vivo,,10090.0,,N
4941,Intermediate,,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
4942,Intermediate,,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
4943,Intermediate,,,,Tmax value in IRC mice,50594,Mus musculus,5951,BAO_0000218,,A,,,10090.0,,N
4944,Intermediate,,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,Mus musculus,5506,BAO_0000218,,A,In vivo,,10090.0,,N
4945,Intermediate,,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,Mus musculus,5506,BAO_0000218,,A,In vivo,,10090.0,,N
4946,Intermediate,,Urine,1088.0,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),50594,Mus musculus,429,BAO_0000218,,A,,,10090.0,,N
4947,Intermediate,,Urine,1088.0,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),50594,Mus musculus,429,BAO_0000218,,A,,,10090.0,,N
4948,Intermediate,,Urine,1088.0,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),50594,Mus musculus,4066,BAO_0000218,,A,,,10090.0,,N
4949,Intermediate,,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,Mus musculus,17734,BAO_0000218,,A,,,10090.0,,N
4950,Intermediate,,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,Mus musculus,17734,BAO_0000218,,A,,,10090.0,,N
4951,Intermediate,,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,50594,Mus musculus,6062,BAO_0000218,,A,In vivo,,10090.0,,N
4952,Intermediate,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,50594,Mus musculus,5969,BAO_0000218,,A,In vivo,,10090.0,,N
4953,Intermediate,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,50594,Mus musculus,5969,BAO_0000218,,A,In vivo,,10090.0,,N
4954,Intermediate,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,Mus musculus,5969,BAO_0000218,,A,In vivo,,10090.0,,N
4955,Intermediate,,,,Vd in mice,50594,Mus musculus,5980,BAO_0000218,,A,In vivo,,10090.0,,N
4956,Intermediate,,,,Volume of distribution in mouse,50594,Mus musculus,17592,BAO_0000218,,A,In vivo,,10090.0,,N
4957,Intermediate,,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,Mus musculus,6348,BAO_0000218,,A,In vivo,,10090.0,,N
4958,Intermediate,,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,In vivo,,10090.0,,N
4959,Intermediate,,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,In vivo,,10090.0,,N
4960,Intermediate,,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,In vivo,,10090.0,,N
4961,Intermediate,,,,Pharmacokinetic property (vdss) was measured in mouse,50594,Mus musculus,4239,BAO_0000218,,A,In vivo,,10090.0,,N
4962,Intermediate,,,,Value distribution upon iv administration in mouse,50594,Mus musculus,2862,BAO_0000218,,A,In vivo,,10090.0,,N
4963,Intermediate,,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,Mus musculus,17734,BAO_0000218,,A,In vivo,,10090.0,,N
4964,Intermediate,,,,Volume of distribution was evaluated in mice after intravenous administration,50594,Mus musculus,2675,BAO_0000218,,A,In vivo,,10090.0,,N
4965,Intermediate,,,,Volume of distribution was evaluated in mice after oral administration,50594,Mus musculus,2675,BAO_0000218,,A,In vivo,,10090.0,,N
4966,Intermediate,,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,50594,Mus musculus,17837,BAO_0000218,,A,In vivo,,10090.0,,N
4967,Intermediate,,,,Steady state volume of distribution was determined in mice,50594,Mus musculus,5727,BAO_0000218,,A,In vivo,,10090.0,,N
4968,Intermediate,,,,Volume distribution (steady state) of compound was determined in mouse,50594,Mus musculus,17852,BAO_0000218,,A,In vivo,,10090.0,,N
4969,Intermediate,,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,50594,Mus musculus,17764,BAO_0000218,,A,In vivo,,10090.0,,N
4970,Intermediate,,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
4971,Intermediate,,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,50594,Mus musculus,6062,BAO_0000218,,A,In vivo,,10090.0,,N
4972,Intermediate,,Kidney,2113.0,Biodistribution of compound (oxidized form) in in kidney tissue,50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
4973,Intermediate,,Blood,178.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
4974,Intermediate,,Blood,178.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
4975,Intermediate,,Blood,178.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
4976,Intermediate,,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,80019,Homo sapiens,10708,BAO_0000219,,F,,,9606.0,A-427,N
4977,Expert,,,,Inhibition of A431 human squamous cell carcinoma cell proliferation,80852,Homo sapiens,16597,BAO_0000219,,F,,,9606.0,A-431,N
4978,Expert,,,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,80852,Homo sapiens,16062,BAO_0000219,,F,,,9606.0,A-431,N
4979,Expert,,,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,80852,Homo sapiens,16062,BAO_0000219,,F,,,9606.0,A-431,N
4980,Expert,,,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,80852,Homo sapiens,16958,BAO_0000219,,F,,,9606.0,A-431,N
4981,Expert,,,,Inhibition of A431 human carcinoma cell proliferation,80852,Homo sapiens,6700,BAO_0000219,,F,,,9606.0,A-431,N
4982,Expert,,,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,80852,Homo sapiens,17226,BAO_0000219,,F,,,9606.0,A-431,N
4983,Intermediate,,,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,80852,Homo sapiens,6828,BAO_0000219,,F,,,9606.0,A-431,N
4984,Intermediate,,,,In vitro cytotoxicity against epidermoid carcinoma cell line,80852,Homo sapiens,12314,BAO_0000219,,F,,,9606.0,A-431,N
4985,Expert,,,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",9,Homo sapiens,13412,BAO_0000218,,F,,,9606.0,A-431,D
4986,Intermediate,,,,Antiproliferative activity of compound was measured on human tumor cell line A431.,80852,Homo sapiens,13299,BAO_0000219,,F,,,9606.0,A-431,N
4987,Intermediate,,,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,80852,Homo sapiens,17420,BAO_0000219,,F,,,9606.0,A-431,N
4988,Intermediate,,,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,80852,Homo sapiens,13678,BAO_0000219,,F,,,9606.0,A-431,N
4989,Expert,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,9,,14171,BAO_0000219,,F,,,,A-431,H
4990,Expert,,,,Tested for antiproliferative activity against human A431 cells,80852,Homo sapiens,6333,BAO_0000219,,F,,,9606.0,A-431,N
4991,Expert,,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,9,Homo sapiens,2356,BAO_0000219,,F,,,9606.0,A-431,D
4992,Expert,,,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,80852,Homo sapiens,15578,BAO_0000219,,F,,,9606.0,A-431,N
4993,Expert,,,,Inhibition of A431 cell proliferation,80852,Homo sapiens,5126,BAO_0000219,,F,,,9606.0,A-431,N
4994,Expert,,,,Cytotoxic effect on A431 human epidermoid carcinoma cells,80852,Homo sapiens,6844,BAO_0000219,,F,,,9606.0,A-431,N
4995,Expert,,,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),80852,Homo sapiens,6844,BAO_0000219,,F,,,9606.0,A-431,N
4996,Intermediate,,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,80852,Homo sapiens,4925,BAO_0000219,,F,,,9606.0,A-431,N
4997,Intermediate,,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,80852,Homo sapiens,4925,BAO_0000219,,F,,,9606.0,A-431,N
4998,Intermediate,,,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,80852,Homo sapiens,13978,BAO_0000219,,F,,,9606.0,A-431,N
4999,Intermediate,,,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,80852,Homo sapiens,16786,BAO_0000219,,F,,,9606.0,A-431,N
5000,Expert,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,9,,13412,BAO_0000219,,F,,,,A-431,H
5001,Intermediate,,,,In vivo antiproliferative activity against A431 cell line,80852,Homo sapiens,17824,BAO_0000218,,F,,,9606.0,A-431,N
5002,Expert,,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,9,Homo sapiens,12751,BAO_0000219,,F,,,9606.0,A-431,D
5003,Expert,,,,Inhibition of A431 human epidermoid carcinoma cell proliferation,80852,Homo sapiens,12380,BAO_0000219,,F,,,9606.0,A-431,N
5004,Expert,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,9,Homo sapiens,4959,BAO_0000219,,F,,,9606.0,A-431,D
5005,Intermediate,,,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),80852,Homo sapiens,6333,BAO_0000219,,F,,,9606.0,A-431,N
5006,Intermediate,,,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),80852,Homo sapiens,6333,BAO_0000219,,F,,,9606.0,A-431,N
5007,Intermediate,,,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),80852,Homo sapiens,6333,BAO_0000219,,F,,,9606.0,A-431,N
5008,Expert,,,,Inhibition of EGFR overexpressing A431 cell proliferation,9,Homo sapiens,5296,BAO_0000019,,F,,,9606.0,,D
5009,Expert,,,,Inhibition of A431 cell proliferation,80852,Homo sapiens,12624,BAO_0000219,,F,,,9606.0,A-431,N
5010,Expert,,,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,9,Homo sapiens,14926,BAO_0000219,,F,,,9606.0,A-431,D
5011,Expert,,,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",9,Homo sapiens,14926,BAO_0000219,,F,,,9606.0,A-431,D
5012,Expert,,,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),9,,14926,BAO_0000219,,F,,,,A-431,H
5013,Intermediate,,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,80852,Homo sapiens,15144,BAO_0000219,,F,,,9606.0,A-431,N
5014,Intermediate,,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,80852,Homo sapiens,15144,BAO_0000219,,F,,,9606.0,A-431,N
5015,Intermediate,,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,80852,Homo sapiens,5245,BAO_0000219,,F,,,9606.0,A-431,N
5016,Intermediate,,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,80852,Homo sapiens,5245,BAO_0000219,,F,,,9606.0,A-431,N
5017,Intermediate,,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,80852,Homo sapiens,5245,BAO_0000219,,F,,,9606.0,A-431,N
5018,Intermediate,,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,80852,Homo sapiens,5245,BAO_0000219,,F,,,9606.0,A-431,N
5019,Intermediate,,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,80852,Homo sapiens,5245,BAO_0000219,,F,,,9606.0,A-431,N
5020,Autocuration,,,,Half-life period in cynomolgus monkey,22224,Cercopithecidae,5922,BAO_0000019,,A,,,9527.0,,U
5021,Autocuration,,Plasma,1969.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",22224,Cercopithecidae,1116,BAO_0000366,,A,In vitro,,9527.0,,U
5022,Autocuration,,,,Longer half-life in monkey (i.v.) at 0.5 mpk,22224,Cercopithecidae,17853,BAO_0000218,,A,In vivo,,9527.0,,U
5023,Autocuration,,Plasma,1969.0,Plasma half life in monkey,22224,Cercopithecidae,993,BAO_0000366,,A,,,9527.0,,U
5024,Autocuration,,Plasma,1969.0,Plasma half-life in rhesus monkey,22224,Cercopithecidae,4514,BAO_0000366,,A,,,9527.0,,U
5025,Autocuration,,Plasma,1969.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,Cercopithecidae,5334,BAO_0000218,,A,In vivo,,9527.0,,U
5026,Autocuration,,Plasma,1969.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,Cercopithecidae,5334,BAO_0000218,,A,In vivo,,9527.0,,U
5027,Autocuration,,,,Tested for half life upon iv administration to african green monkey,22224,Cercopithecidae,4578,BAO_0000218,,A,In vivo,,9527.0,,U
5028,Autocuration,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,Cercopithecidae,2661,BAO_0000218,,A,In vivo,,9527.0,,U
5029,Autocuration,,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
5030,Autocuration,,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
5031,Autocuration,,,,The time for peak concentration value after oral administration in cynomolgus monkeys,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
5032,Autocuration,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5033,Autocuration,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5034,Autocuration,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5035,Autocuration,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5036,Autocuration,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5037,Autocuration,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5038,Autocuration,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5039,Autocuration,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5040,Autocuration,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5041,Autocuration,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5042,Autocuration,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5043,Autocuration,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5044,Autocuration,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5045,Autocuration,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5046,Autocuration,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5047,Autocuration,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,22224,Cercopithecidae,11271,BAO_0000019,,A,,,9527.0,,U
5048,Intermediate,,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),50597,Rattus norvegicus,5809,BAO_0000218,,A,In vivo,,10116.0,,N
5049,Intermediate,,Plasma,1969.0,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,Rattus norvegicus,17720,BAO_0000218,,A,In vivo,,10116.0,,N
5050,Intermediate,,Plasma,1969.0,AUC value in rat after IV administration at a dose of 10 mg/kg,50597,Rattus norvegicus,3546,BAO_0000218,,A,,,10116.0,,N
5051,Intermediate,,Plasma,1969.0,AUC value in rat after oral administration at a dose of 10 mg/kg,50597,Rattus norvegicus,3546,BAO_0000218,,A,,,10116.0,,N
5052,Intermediate,,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,50597,Rattus norvegicus,3546,BAO_0000218,,A,In vivo,,10116.0,,N
5053,Intermediate,,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,50597,Rattus norvegicus,3546,BAO_0000218,,A,In vivo,,10116.0,,N
5054,Intermediate,,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,50597,Rattus norvegicus,3546,BAO_0000218,,A,In vivo,,10116.0,,N
5055,Intermediate,,,,Vc value in rat after IV administration at a dose of 10 mg/kg,50597,Rattus norvegicus,3546,BAO_0000218,,A,,,10116.0,,N
5056,Intermediate,,,,Half life period in rat after IV administration at a dose of 10 mg/kg,50597,Rattus norvegicus,3546,BAO_0000218,,A,In vivo,,10116.0,,N
5057,Autocuration,,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,22224,Papio hamadryas,10625,BAO_0000019,,A,,,9557.0,,U
5058,Autocuration,,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),22224,Papio hamadryas,10625,BAO_0000019,,A,,,9557.0,,U
5059,Autocuration,,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),22224,Papio hamadryas,10625,BAO_0000019,,A,,,9557.0,,U
5060,Autocuration,,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,22224,Papio hamadryas,10625,BAO_0000019,,A,,,9557.0,,U
5061,Autocuration,,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,22224,Papio hamadryas,10625,BAO_0000019,,A,,,9557.0,,U
5062,Autocuration,,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,22224,Papio hamadryas,10625,BAO_0000019,,A,,,9557.0,,U
5063,Autocuration,,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,22224,Papio hamadryas,10625,BAO_0000019,,A,,,9557.0,,U
5064,Autocuration,,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,22224,Papio hamadryas,10625,BAO_0000019,,A,,,9557.0,,U
5065,Autocuration,,,,Area under curve after 1 mpk peroral administration to beagles,22224,beagle,3510,BAO_0000019,,A,,,9615.0,,U
5066,Autocuration,,,,Area under curve after 2 mpk peroral administration to beagles,22224,beagle,3510,BAO_0000019,,A,,,9615.0,,U
5067,Autocuration,,,,Cmax value after 1 mpk peroral administration to beagles,22224,beagle,3510,BAO_0000218,,A,In vivo,,9615.0,,U
5068,Autocuration,,Urine,1088.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
5069,Autocuration,,Urine,1088.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
5070,Autocuration,,Urine,1088.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
5071,Autocuration,,Urine,1088.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
5072,Autocuration,,Urine,1088.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
5073,Autocuration,,Urine,1088.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
5074,Autocuration,,Urine,1088.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,22224,Homo sapiens,7766,BAO_0000019,,A,,,9606.0,,U
5075,Autocuration,Microsomes,Liver,2107.0,Metabolic stability observed at 30 min after administration in human liver microsomes,22224,Homo sapiens,16643,BAO_0000251,,A,,,9606.0,,U
5076,Autocuration,,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,22224,Homo sapiens,6852,BAO_0000019,,A,,,9606.0,,U
5077,Autocuration,,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,22224,Homo sapiens,6852,BAO_0000019,,A,,,9606.0,,U
5078,Autocuration,,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,22224,Homo sapiens,6852,BAO_0000019,,A,,,9606.0,,U
5079,Autocuration,Microsomes,Liver,2107.0,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",22224,Homo sapiens,6567,BAO_0000251,,A,,,9606.0,,U
5080,Autocuration,,,,Metabolic stability (% remaining at 30 mins) in human S9.,22224,Homo sapiens,6570,BAO_0000019,,A,,,9606.0,,U
5081,Autocuration,,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,22224,Homo sapiens,6570,BAO_0000019,,A,,,9606.0,,U
5082,Autocuration,Microsomes,Liver,2107.0,Percent parent compound remaining after 20 min incubation with human liver microsomes,22224,Homo sapiens,5237,BAO_0000251,,A,,,9606.0,,U
5083,Autocuration,Microsomes,Liver,2107.0,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,22224,Homo sapiens,5237,BAO_0000251,,A,,,9606.0,,U
5084,Autocuration,Microsomes,Liver,2107.0,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,22224,Homo sapiens,5237,BAO_0000251,,A,,,9606.0,,U
5085,Autocuration,,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,22224,Homo sapiens,5202,BAO_0000218,,A,,,9606.0,,U
5086,Autocuration,,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,22224,Homo sapiens,5481,BAO_0000019,,A,,,9606.0,,U
5087,Autocuration,,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,22224,Homo sapiens,5481,BAO_0000019,,A,,,9606.0,,U
5088,Autocuration,,,,The percent remaining in human plasma after 30 min was determined,22224,Homo sapiens,3956,BAO_0000019,,A,,,9606.0,,U
5089,Autocuration,,Plasma,1969.0,Conversion rate of the prodrug in human plasma,22224,Homo sapiens,5074,BAO_0000366,,A,,,9606.0,,U
5090,Autocuration,,Plasma,1969.0,Conversion rate of the prodrug in human plasma; ND means no data,22224,Homo sapiens,5074,BAO_0000366,,A,,,9606.0,,U
5091,Autocuration,,Blood,178.0,Half life of compound was determined in human blood,22224,Homo sapiens,4727,BAO_0000221,,A,,,9606.0,,U
5092,Autocuration,,,,Half life of compound was determined in man with once daily dosing,22224,Homo sapiens,5965,BAO_0000019,,A,,,9606.0,,U
5093,Autocuration,Microsomes,,,Half life in human microsomes,22224,Homo sapiens,5732,BAO_0000251,,A,In vitro,,9606.0,,U
5094,Autocuration,,Plasma,1969.0,Half life in human plasma,22224,Homo sapiens,5819,BAO_0000366,,A,,,9606.0,,U
5095,Autocuration,,Plasma,1969.0,Half life in human plasma; Not detected,22224,Homo sapiens,5819,BAO_0000366,,A,,,9606.0,,U
5096,Autocuration,,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,22224,Homo sapiens,1916,BAO_0000218,,A,In vivo,,9606.0,,U
5097,Autocuration,Microsomes,Liver,2107.0,Half-life for oxidative metabolic stability was determined using rat liver microsomes,22224,Homo sapiens,6597,BAO_0000251,,A,In vitro,,9606.0,,U
5098,Autocuration,,Plasma,1969.0,Half-life in human plasma,22224,Homo sapiens,5229,BAO_0000366,,A,,,9606.0,,U
5099,Autocuration,,Plasma,1969.0,Half-life of the parent prodrug in plasma,22224,Homo sapiens,5229,BAO_0000366,,A,,,9606.0,,U
5100,Autocuration,,Plasma,1969.0,In vitro half life in human plasma was determined,22224,Homo sapiens,2192,BAO_0000366,,A,In vitro,,9606.0,,U
5101,Autocuration,Microsomes,Liver,2107.0,The compound was tested In Vitro for half life in human liver microsomes.,22224,Homo sapiens,3032,BAO_0000251,,A,In vitro,,9606.0,,U
5102,Autocuration,,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,22224,Homo sapiens,1916,BAO_0000218,,A,In vivo,,9606.0,,U
5103,Autocuration,,,,Observed volume of distribution,22224,Homo sapiens,17716,BAO_0000218,,A,In vivo,,9606.0,,U
5104,Autocuration,,,,Oral bioavailability in human,22224,Homo sapiens,15778,BAO_0000218,,A,In vivo,,9606.0,,U
5105,Autocuration,,,,Tested for human plasma protein binding of the compound,22224,Homo sapiens,17313,BAO_0000019,,A,,,9606.0,,U
5106,Autocuration,,,,"First order rate constant, k was determined in human plasma",22224,Homo sapiens,4231,BAO_0000019,,A,,,9606.0,,U
5107,Autocuration,,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,22224,Homo sapiens,4755,BAO_0000019,,A,,,9606.0,,U
5108,Autocuration,,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,22224,Homo sapiens,4755,BAO_0000019,,A,,,9606.0,,U
5109,Autocuration,Microsomes,Liver,2107.0,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,22224,Homo sapiens,16907,BAO_0000251,,A,,,9606.0,,U
5110,Autocuration,,,,The compound was tested for the plasma binding in human,22224,Homo sapiens,10839,BAO_0000019,,A,,,9606.0,,U
5111,Autocuration,,,,Plasma protein binding (human),22224,Homo sapiens,10839,BAO_0000019,,A,,,9606.0,,U
5112,Autocuration,Microsomes,Liver,2107.0,Compound was evaluated for half-life in human liver microsomes,22224,Homo sapiens,3199,BAO_0000251,,A,In vitro,,9606.0,,U
5113,Autocuration,,Blood,178.0,Half life measured in vitro for its stability in human blood,22224,Homo sapiens,1345,BAO_0000221,,A,In vitro,,9606.0,,U
5114,Autocuration,,Serum,1977.0,Half life in human serum,22224,Homo sapiens,4297,BAO_0000019,,A,,,9606.0,,U
5115,Autocuration,,Serum,1977.0,Half life in human serum; ND=not determined,22224,Homo sapiens,4297,BAO_0000019,,A,,,9606.0,,U
5116,Autocuration,,,,Half life were determined in CEM-SS cell extract in decomposition step 1,22224,Homo sapiens,4297,BAO_0000019,,A,,,9606.0,,U
5117,Autocuration,,,,Half life were determined in CEM-SS cell extract in decomposition step 2,22224,Homo sapiens,4297,BAO_0000019,,A,,,9606.0,,U
5118,Autocuration,,Plasma,1969.0,Half life of the in human plasma,22224,Homo sapiens,4231,BAO_0000366,,A,,,9606.0,,U
5119,Autocuration,S9,,,Half life period in human hepatic S9 fraction was determined,22224,Homo sapiens,5633,BAO_0000220,,A,In vitro,,9606.0,,U
5120,Autocuration,Microsomes,Liver,2107.0,Half life period in human liver microsome was determined,22224,Homo sapiens,5633,BAO_0000251,,A,In vitro,,9606.0,,U
5121,Autocuration,,,,Half life period was determined; 6-7,22224,Homo sapiens,17791,BAO_0000019,,A,,,9606.0,,U
5122,Autocuration,,,,Half life period was evaluated in human,22224,Homo sapiens,17791,BAO_0000019,,A,,,9606.0,,U
5123,Autocuration,,Plasma,1969.0,Half life time in human plasma,22224,Homo sapiens,3160,BAO_0000366,,A,,,9606.0,,U
5124,Intermediate,,Brain,955.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5125,Intermediate,,Heart,948.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5126,Intermediate,,Heart,948.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5127,Intermediate,,Kidney,2113.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5128,Intermediate,,Kidney,2113.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5129,Intermediate,,Kidney,2113.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5130,Intermediate,,Liver,2107.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5131,Intermediate,,Liver,2107.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5132,Intermediate,,Liver,2107.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5133,Intermediate,,Spleen,2106.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5134,Intermediate,,Spleen,2106.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5135,Intermediate,,Spleen,2106.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5136,Intermediate,,Brain,955.0,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5137,Intermediate,,Blood,178.0,Biodistribution of compound (oxidized form) in blood tissue,50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5138,Intermediate,,Blood,178.0,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5139,Intermediate,,Blood,178.0,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5140,Intermediate,,Blood,178.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5141,Intermediate,,Blood,178.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5142,Intermediate,,Blood,178.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5143,Intermediate,,Brain,955.0,Biodistribution of compound (oxidized form) in brain tissue of mice,50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5144,Intermediate,,Brain,955.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5145,Intermediate,,Brain,955.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5146,Intermediate,,Brain,955.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5147,Intermediate,,Brain,955.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5148,Intermediate,,Brain,955.0,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5149,Intermediate,,Heart,948.0,Biodistribution of compound (oxidized form) in heart tissue of mice,50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5150,Intermediate,,Heart,948.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5151,Intermediate,,Heart,948.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5152,Intermediate,,Heart,948.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5153,Intermediate,,Heart,948.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5154,Intermediate,,Heart,948.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5155,Intermediate,,Kidney,2113.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5156,Intermediate,,Kidney,2113.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5157,Intermediate,,Kidney,2113.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5158,Intermediate,,Kidney,2113.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5159,Intermediate,,Kidney,2113.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5160,Intermediate,,Liver,2107.0,Biodistribution of compound (oxidized form) in liver tissue,50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5161,Intermediate,,Liver,2107.0,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5162,Intermediate,,Liver,2107.0,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,Mus musculus,16438,BAO_0000218,,A,In vivo,,10090.0,,N
5163,Intermediate,,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,80852,Homo sapiens,5245,BAO_0000219,,F,,,9606.0,A-431,N
5164,Intermediate,,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,80852,Homo sapiens,5245,BAO_0000219,,F,,,9606.0,A-431,N
5165,Expert,,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",80852,,16289,BAO_0000218,,F,,,,A-431,N
5166,Expert,,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",80852,,16289,BAO_0000218,,F,,,,A-431,N
5167,Expert,,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,Homo sapiens,16093,BAO_0000219,,F,,,9606.0,A-431,D
5168,Intermediate,,,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",80852,Homo sapiens,16825,BAO_0000219,,F,,,9606.0,A-431,N
5169,Intermediate,,,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,80852,Homo sapiens,4848,BAO_0000219,,F,,,9606.0,A-431,N
5170,Expert,,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,9,Homo sapiens,14827,BAO_0000219,,F,,,9606.0,A-431,D
5171,Expert,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,9,Homo sapiens,14827,BAO_0000219,,F,,,9606.0,A-431,D
5172,Expert,,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",80852,,16289,BAO_0000218,,F,,,,A-431,N
5173,Expert,,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",80852,,16289,BAO_0000218,,F,,,,A-431,N
5174,Expert,,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",80852,,16289,BAO_0000218,,F,,,,A-431,N
5175,Expert,,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",80852,,16289,BAO_0000218,,F,,,,A-431,N
5176,Expert,,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",80852,,16289,BAO_0000218,,F,,,,A-431,N
5177,Expert,,,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",9,Homo sapiens,16289,BAO_0000219,,F,,,9606.0,A-431,D
5178,Expert,,,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,9,,16289,BAO_0000219,,F,,,,A-431,H
5179,Expert,,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",80852,,16289,BAO_0000218,,F,,,,A-431,N
5180,Expert,,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",80852,,16289,BAO_0000218,,F,,,,A-431,N
5181,Expert,,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",80852,,16289,BAO_0000218,,F,,,,A-431,N
5182,Expert,,,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,Mus musculus,14555,BAO_0000218,,F,,,10090.0,A-431,N
5183,Expert,,,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,Mus musculus,14555,BAO_0000218,,F,,,10090.0,A-431,N
5184,Expert,,,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,Mus musculus,14555,BAO_0000218,,F,,,10090.0,A-431,N
5185,Expert,,,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,Mus musculus,14555,BAO_0000218,,F,,,10090.0,A-431,N
5186,Expert,,,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,80852,Homo sapiens,1937,BAO_0000219,,F,,,9606.0,A-431,N
5187,Intermediate,,,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,80852,Homo sapiens,13739,BAO_0000219,,F,,,9606.0,A-431,N
5188,Intermediate,,,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,80852,Homo sapiens,3558,BAO_0000219,,F,,,9606.0,A-431,N
5189,Intermediate,,,,Dose giving a 50% decrease in the living cell number (A437 cells),80852,Homo sapiens,3558,BAO_0000219,,F,,,9606.0,A-431,N
5190,Expert,,,,In vitro inhibitory concentration against proliferation of A459 cell line.,80682,Homo sapiens,17686,BAO_0000219,,F,,,9606.0,A549,N
5191,Intermediate,,,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,80682,Homo sapiens,5305,BAO_0000219,,F,,,9606.0,A549,N
5192,Intermediate,,,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,80682,Homo sapiens,3614,BAO_0000219,,F,,,9606.0,A549,N
5193,Intermediate,,,,In vitro antitumor activity against renal A498 tumor cell lines,80021,Homo sapiens,17229,BAO_0000219,,F,,,9606.0,A498,N
5194,Intermediate,,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",80021,Homo sapiens,15935,BAO_0000219,,F,,,9606.0,A498,N
5195,Intermediate,,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",80021,Homo sapiens,15935,BAO_0000219,,F,,,9606.0,A498,N
5196,Intermediate,,,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,80021,Homo sapiens,15560,BAO_0000219,,F,,,9606.0,A498,N
5197,Intermediate,,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,80021,Homo sapiens,13891,BAO_0000219,,F,,,9606.0,A498,N
5198,Intermediate,,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,80021,Homo sapiens,13891,BAO_0000219,,F,,,9606.0,A498,N
5199,Intermediate,,,,Cytotoxicity on kidney carcinoma (A-498) cell line,80021,Homo sapiens,13788,BAO_0000219,,F,,,9606.0,A498,N
5200,Intermediate,,,,Compound was evaluated against Human cell line renal A498,80021,Homo sapiens,15403,BAO_0000219,,F,,,9606.0,A498,N
5201,Intermediate,,,,Compound was tested for inhibition of A498 human renal cancer cell line,80021,Homo sapiens,1009,BAO_0000219,,F,,,9606.0,A498,N
5202,Intermediate,,,,Growth inhibitory activity against A498 human cancer cell line,80021,Homo sapiens,1043,BAO_0000219,,F,,,9606.0,A498,N
5203,Intermediate,,,,In vitro antitumor activity against human renal A498 cell line,80021,Homo sapiens,5858,BAO_0000219,,F,,,9606.0,A498,N
5204,Intermediate,,,,In vitro cytotoxic activity against renal (A498) cell line,80021,Homo sapiens,5958,BAO_0000219,,F,,,9606.0,A498,N
5205,Intermediate,,,,In vitro cytotoxic activity against human renal cancer (A498) cell line,80021,Homo sapiens,5506,BAO_0000219,,F,,,9606.0,A498,N
5206,Intermediate,,,,Tested for cytostatic activity against renal A498 cell line,80021,Homo sapiens,12781,BAO_0000219,,F,,,9606.0,A498,N
5207,Intermediate,,,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,80021,Homo sapiens,14399,BAO_0000219,,F,,,9606.0,A498,N
5208,Expert,,,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,80021,Homo sapiens,5958,BAO_0000219,,F,,,9606.0,A498,N
5209,Autocuration,,,,Cmax value after 2 mpk peroral administration to beagles,22224,beagle,3510,BAO_0000218,,A,In vivo,,9615.0,,U
5210,Autocuration,,,,Bioavailability,22224,Canis lupus familiaris,3510,BAO_0000218,beagle,A,In vivo,,9615.0,,U
5211,Autocuration,,,,Bioavailability after 1 mpk peroral administration to beagles,22224,Canis lupus familiaris,3510,BAO_0000218,beagle,A,In vivo,,9615.0,,U
5212,Autocuration,,,,Bioavailability after 2 mpk peroral administration to beagles,22224,Canis lupus familiaris,3510,BAO_0000218,beagle,A,In vivo,,9615.0,,U
5213,Autocuration,,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,22224,Bos taurus,3085,BAO_0000019,,A,,,9913.0,,U
5214,Autocuration,,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,22224,Bos taurus,3085,BAO_0000019,,A,,,9913.0,,U
5215,Autocuration,,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,22224,Bos taurus,3085,BAO_0000019,,A,,,9913.0,,U
5216,Autocuration,,,,Solubility against bovine alpha-chymotrypsin,22224,Bos taurus,9372,BAO_0000019,,A,,,9913.0,,U
5217,Autocuration,,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,22224,Bos taurus,3085,BAO_0000019,,A,,,9913.0,,U
5218,Autocuration,,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,22224,Bos taurus,3085,BAO_0000019,,A,,,9913.0,,U
5219,Autocuration,,Spleen,2106.0,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,22224,Bos taurus,1469,BAO_0000221,,A,,,9913.0,,U
5220,Autocuration,,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,22224,Bos taurus,4297,BAO_0000019,,A,,,9913.0,,U
5221,Autocuration,,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,22224,Bos taurus,4297,BAO_0000019,,A,,,9913.0,,U
5222,Autocuration,,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,22224,Bos taurus,17585,BAO_0000019,,A,,,9913.0,,U
5223,Autocuration,,Spleen,2106.0,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,22224,Bos taurus,1336,BAO_0000221,,A,,,9913.0,,U
5224,Autocuration,,,,Half life in presence of 2 mg/mL BSA at pH 8.8,22224,Bos taurus,3085,BAO_0000019,,A,,,9913.0,,U
5225,Autocuration,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,22224,Bos taurus,2857,BAO_0000019,,A,,,9913.0,,U
5226,Autocuration,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,22224,Bos taurus,2857,BAO_0000019,,A,,,9913.0,,U
5227,Autocuration,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,22224,Bos taurus,2857,BAO_0000019,,A,,,9913.0,,U
5228,Autocuration,,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),22224,Bos taurus,1540,BAO_0000019,,A,,,9913.0,,U
5229,Intermediate,,Plasma,1969.0,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,50588,Canis lupus familiaris,6316,BAO_0000218,,A,,,9615.0,,N
5230,Intermediate,,Plasma,1969.0,AUC after administration at 100 mg/kg/day in dogs,50588,Canis lupus familiaris,17594,BAO_0000218,,A,,,9615.0,,N
5231,Intermediate,,Plasma,1969.0,AUC in dog at 0-24 hr by peroral administration at 3 mpk,50588,Canis lupus familiaris,4953,BAO_0000218,,A,,,9615.0,,N
5232,Intermediate,,Plasma,1969.0,AUC value after 15 mg/kg iv dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,,,9615.0,,N
5233,Intermediate,,Plasma,1969.0,AUC value after 30 mg/kg po dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,,,9615.0,,N
5234,Intermediate,,Plasma,1969.0,AUC value after administration of 4 mg/Kg oral dose in dog,50588,Canis lupus familiaris,2959,BAO_0000218,,A,,,9615.0,,N
5235,Intermediate,,Plasma,1969.0,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,50588,Canis lupus familiaris,17594,BAO_0000218,,A,,,9615.0,,N
5236,Intermediate,,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,50588,Canis lupus familiaris,5356,BAO_0000218,,A,,,9615.0,,N
5237,Intermediate,,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,50588,Canis lupus familiaris,16807,BAO_0000218,,A,,,9615.0,,N
5238,Intermediate,,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,50588,Canis lupus familiaris,4527,BAO_0000218,,A,,,9615.0,,N
5239,Intermediate,,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,50588,Canis lupus familiaris,4527,BAO_0000218,,A,,,9615.0,,N
5240,Intermediate,,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,50588,Canis lupus familiaris,15660,BAO_0000218,,A,,,9615.0,,N
5241,Intermediate,,,,Area under curve determined in dogs after oral administration of 10 mg/kg,50588,Canis lupus familiaris,15660,BAO_0000218,,A,,,9615.0,,N
5242,Intermediate,,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,Canis lupus familiaris,5802,BAO_0000218,,A,,,9615.0,,N
5243,Expert,,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,Canis lupus familiaris,3598,BAO_0000218,,A,,,9615.0,,N
5244,Expert,,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,50588,Canis lupus familiaris,3598,BAO_0000218,,A,,,9615.0,,N
5245,Intermediate,,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),50588,Canis lupus familiaris,5944,BAO_0000218,,A,,,9615.0,,N
5246,Intermediate,,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,50588,Canis lupus familiaris,5944,BAO_0000218,,A,,,9615.0,,N
5247,Intermediate,,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),50588,Canis lupus familiaris,5944,BAO_0000218,,A,,,9615.0,,N
5248,Intermediate,,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,50588,Canis lupus familiaris,5944,BAO_0000218,,A,,,9615.0,,N
5249,Intermediate,,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,50588,Canis lupus familiaris,4186,BAO_0000218,,A,,,9615.0,,N
5250,Intermediate,,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,Canis lupus familiaris,5007,BAO_0000218,,A,,,9615.0,,N
5251,Intermediate,,,,Area under curve was determine after peroral administration at 10 mpk in dog,50588,Canis lupus familiaris,5668,BAO_0000218,,A,,,9615.0,,N
5252,Intermediate,,,,Area under curve was determine after peroral administration at 5 mpk in dog,50588,Canis lupus familiaris,5668,BAO_0000218,,A,,,9615.0,,N
5253,Intermediate,,,,Area under curve was determined,50588,Canis lupus familiaris,5006,BAO_0000218,,A,,,9615.0,,N
5254,Intermediate,,,,Area under curve in dogs,50588,Canis lupus familiaris,5006,BAO_0000218,,A,,,9615.0,,N
5255,Intermediate,,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,50588,Canis lupus familiaris,3771,BAO_0000218,,A,,,9615.0,,N
5256,Intermediate,,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),50588,Canis lupus familiaris,3771,BAO_0000218,,A,,,9615.0,,N
5257,Intermediate,,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,50588,Canis lupus familiaris,3771,BAO_0000218,,A,,,9615.0,,N
5258,Intermediate,,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,Canis lupus familiaris,1916,BAO_0000218,,A,,,9615.0,,N
5259,Intermediate,,,,Area under curve value in dog at a dose of 5 mg/kg,50588,Canis lupus familiaris,5302,BAO_0000218,,A,,,9615.0,,N
5260,Intermediate,,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,50588,Canis lupus familiaris,5600,BAO_0000218,,A,,,9615.0,,N
5261,Intermediate,,,,Area under curve was determined after 0.3 mg/kg po administration in dog,50588,Canis lupus familiaris,5600,BAO_0000218,,A,,,9615.0,,N
5262,Intermediate,,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,50588,Canis lupus familiaris,17764,BAO_0000218,,A,,,9615.0,,N
5263,Intermediate,,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,50588,Canis lupus familiaris,4368,BAO_0000218,,A,,,9615.0,,N
5264,Autocuration,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,22224,Homo sapiens,5318,BAO_0000019,,A,,,9606.0,,U
5265,Autocuration,,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,22224,Homo sapiens,5318,BAO_0000019,,A,,,9606.0,,U
5266,Autocuration,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,22224,Homo sapiens,5318,BAO_0000019,,A,,,9606.0,,U
5267,Autocuration,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,22224,Homo sapiens,5318,BAO_0000019,,A,,,9606.0,,U
5268,Autocuration,,Blood,178.0,Time taken to reduce 50% of the concentration of compound in blood plasma,22224,Homo sapiens,14518,BAO_0000221,,A,,,9606.0,,U
5269,Autocuration,,Plasma,1969.0,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",22224,Homo sapiens,2209,BAO_0000366,,A,,,9606.0,,U
5270,Autocuration,,Plasma,1969.0,Half life in human plasma,22224,Homo sapiens,6787,BAO_0000366,,A,,,9606.0,,U
5271,Autocuration,,Plasma,1969.0,Half life in human plasma was reported,22224,Homo sapiens,4898,BAO_0000366,,A,,,9606.0,,U
5272,Autocuration,,Serum,1977.0,Half life in human serum,22224,Homo sapiens,6072,BAO_0000019,,A,,,9606.0,,U
5273,Autocuration,,Plasma,1969.0,Half life upon exposure to human plasma,22224,Homo sapiens,16907,BAO_0000366,,A,,,9606.0,,U
5274,Autocuration,Microsomes,,,t1/2 in human microsomes,22224,Homo sapiens,5656,BAO_0000251,,A,In vitro,,9606.0,,U
5275,Autocuration,,Plasma,1969.0,Half life period in 80% human plasma at 37 degree Centigrade,22224,Homo sapiens,4755,BAO_0000366,,A,,,9606.0,,U
5276,Autocuration,,Zone of skin,14.0,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),22224,Homo sapiens,17503,BAO_0000221,,A,,,9606.0,,U
5277,Autocuration,,Plasma,1969.0,Half-life measured in in vitro Cathepsin B assay in human plasma,22224,Homo sapiens,12357,BAO_0000366,,A,In vitro,,9606.0,,U
5278,Autocuration,,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,22224,Homo sapiens,3076,BAO_0000019,,A,,,9606.0,,U
5279,Autocuration,Microsomes,Liver,2107.0,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,22224,Homo sapiens,6410,BAO_0000251,,A,In vitro,,9606.0,,U
5280,Autocuration,,Plasma,1969.0,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",22224,Homo sapiens,3741,BAO_0000366,,A,,,9606.0,,U
5281,Autocuration,,Plasma,1969.0,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",22224,Homo sapiens,3741,BAO_0000366,,A,,,9606.0,,U
5282,Autocuration,,Plasma,1969.0,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",22224,Homo sapiens,3741,BAO_0000366,,A,,,9606.0,,U
5283,Autocuration,,,,Half-life in the CEM cell extracts,22224,Homo sapiens,1540,BAO_0000019,,A,,,9606.0,,U
5284,Autocuration,,Plasma,1969.0,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,22224,Homo sapiens,2905,BAO_0000366,,A,,,9606.0,,U
5285,Autocuration,,Plasma,1969.0,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,22224,Homo sapiens,2905,BAO_0000366,,A,,,9606.0,,U
5286,Autocuration,,,,Half-life was determined,22224,Homo sapiens,5523,BAO_0000019,,A,,,9606.0,,U
5287,Autocuration,,Blood,178.0,Half-life (human blood stability),22224,Homo sapiens,1499,BAO_0000221,,A,,,9606.0,,U
5288,Autocuration,,Blood,178.0,Half-life (human blood stability); no data,22224,Homo sapiens,1499,BAO_0000221,,A,,,9606.0,,U
5289,Autocuration,,Plasma,1969.0,Half-life in human plasma,22224,Homo sapiens,17065,BAO_0000366,,A,,,9606.0,,U
5290,Autocuration,,,,CYP3A4 metabolism half-life (t1/2),22224,Homo sapiens,6861,BAO_0000019,,A,,,9606.0,,U
5291,Autocuration,,Blood,178.0,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),22224,Homo sapiens,1499,BAO_0000221,,A,,,9606.0,,U
5292,Autocuration,,Plasma,1969.0,In vitro half life in human plasma,22224,Homo sapiens,530,BAO_0000366,,A,In vitro,,9606.0,,U
5293,Autocuration,,Plasma,1969.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",22224,Homo sapiens,1116,BAO_0000366,,A,In vitro,,9606.0,,U
5294,Autocuration,,Plasma,1969.0,In vitro hydrolysis in human plasma,22224,Homo sapiens,6695,BAO_0000366,,A,In vitro,,9606.0,,U
5295,Autocuration,,Plasma,1969.0,In vitro hydrolysis in human plasma; no data,22224,Homo sapiens,6695,BAO_0000366,,A,In vitro,,9606.0,,U
5296,Autocuration,Microsomes,Liver,2107.0,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,22224,Homo sapiens,10,BAO_0000251,,A,In vitro,,9606.0,,U
5297,Autocuration,,Plasma,1969.0,Plasma half life in human,22224,Homo sapiens,993,BAO_0000366,,A,,,9606.0,,U
5298,Autocuration,,Plasma,1969.0,Stability after incubation with human plasma (at 37 degree C),22224,Homo sapiens,15429,BAO_0000366,,A,,,9606.0,,U
5299,Autocuration,,Plasma,1969.0,T1/2 was evaluated in human plasma,22224,Homo sapiens,1675,BAO_0000366,,A,,,9606.0,,U
5300,Autocuration,,Plasma,1969.0,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",22224,Homo sapiens,2209,BAO_0000366,,A,,,9606.0,,U
5301,Autocuration,,Plasma,1969.0,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",22224,Homo sapiens,2209,BAO_0000366,,A,,,9606.0,,U
5302,Autocuration,,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,22224,Homo sapiens,5318,BAO_0000019,,A,,,9606.0,,U
5303,Autocuration,,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,22224,Homo sapiens,2412,BAO_0000019,,A,In vitro,,9606.0,,U
5304,Autocuration,,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,22224,Homo sapiens,2412,BAO_0000019,,A,In vitro,,9606.0,,U
5305,Autocuration,,Plasma,1969.0,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,22224,Homo sapiens,2906,BAO_0000366,,A,,,9606.0,,U
5306,Autocuration,,Plasma,1969.0,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,22224,Homo sapiens,2906,BAO_0000366,,A,,,9606.0,,U
5307,Autocuration,,,,Time taken for 50% to be consumed by serum PON1 was determined,22224,Homo sapiens,5495,BAO_0000019,,A,,,9606.0,,U
5308,Autocuration,,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,22224,Homo sapiens,5495,BAO_0000019,,A,,,9606.0,,U
5309,Autocuration,Microsomes,Liver,2107.0,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,22224,Homo sapiens,4397,BAO_0000251,,A,,,9606.0,,U
5310,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5311,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5312,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5313,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5314,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5315,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5316,Intermediate,,,,Compound tested for growth inhibition of renal cancer cell line 786-0,80640,Homo sapiens,6058,BAO_0000219,,F,,,9606.0,786-0,N
5317,Intermediate,,,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,80640,Homo sapiens,17708,BAO_0000219,,F,,,9606.0,786-0,N
5318,Expert,,,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,80640,Homo sapiens,14017,BAO_0000219,,F,,,9606.0,786-0,N
5319,Intermediate,,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",80640,Homo sapiens,16818,BAO_0000219,,F,,,9606.0,786-0,N
5320,Intermediate,,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",80640,Homo sapiens,16818,BAO_0000219,,F,,,9606.0,786-0,N
5321,Intermediate,,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",80640,Homo sapiens,16818,BAO_0000219,,F,,,9606.0,786-0,N
5322,Intermediate,,,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,80640,Homo sapiens,11970,BAO_0000219,,F,,,9606.0,786-0,N
5323,Intermediate,,,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,80640,Homo sapiens,12400,BAO_0000219,,F,,,9606.0,786-0,N
5324,Expert,,,,Cytotoxic effect on renal cancer line 786-0,80640,Homo sapiens,12888,BAO_0000219,,F,,,9606.0,786-0,N
5325,Intermediate,,,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,80640,Homo sapiens,15300,BAO_0000219,,F,,,9606.0,786-0,N
5326,Intermediate,,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),80640,Homo sapiens,14769,BAO_0000219,,F,,,9606.0,786-0,N
5327,Intermediate,,,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",80640,Homo sapiens,15895,BAO_0000219,,F,,,9606.0,786-0,N
5328,Intermediate,,,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,80640,Homo sapiens,17376,BAO_0000219,,F,,,9606.0,786-0,N
5329,Intermediate,,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,80640,Homo sapiens,14882,BAO_0000219,,F,,,9606.0,786-0,N
5330,Intermediate,,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),80640,Homo sapiens,14882,BAO_0000219,,F,,,9606.0,786-0,N
5331,Intermediate,,,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,80640,Homo sapiens,15176,BAO_0000219,,F,,,9606.0,786-0,N
5332,Intermediate,,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,80640,Homo sapiens,12696,BAO_0000219,,F,,,9606.0,786-0,N
5333,Intermediate,,,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),80640,Homo sapiens,2496,BAO_0000219,,F,,,9606.0,786-0,N
5334,Intermediate,,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,80641,Homo sapiens,11831,BAO_0000219,,F,,,9606.0,791T cell line,N
5335,Intermediate,,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),80641,Homo sapiens,11831,BAO_0000219,,F,,,9606.0,791T cell line,N
5336,Intermediate,,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,80641,Homo sapiens,11831,BAO_0000219,,F,,,9606.0,791T cell line,N
5337,Intermediate,,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),80641,Homo sapiens,11831,BAO_0000219,,F,,,9606.0,791T cell line,N
5338,Intermediate,,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),80641,Homo sapiens,11831,BAO_0000219,,F,,,9606.0,791T cell line,N
5339,Intermediate,,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,80641,Homo sapiens,11831,BAO_0000219,,F,,,9606.0,791T cell line,N
5340,Intermediate,,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),80641,Homo sapiens,11831,BAO_0000219,,F,,,9606.0,791T cell line,N
5341,Intermediate,,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),80641,Homo sapiens,11831,BAO_0000219,,F,,,9606.0,791T cell line,N
5342,Intermediate,,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),80641,Homo sapiens,11831,BAO_0000219,,F,,,9606.0,791T cell line,N
5343,Intermediate,,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,80641,Homo sapiens,11831,BAO_0000219,,F,,,9606.0,791T cell line,N
5344,Intermediate,,,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,80640,Homo sapiens,12782,BAO_0000219,,F,,,9606.0,786-0,N
5345,Intermediate,,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,22226,,1229,BAO_0000019,,F,,,,,U
5346,Expert,,,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,80433,Homo sapiens,15313,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5347,Expert,,,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,80433,Homo sapiens,15313,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5348,Intermediate,,,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,80433,Homo sapiens,11544,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5349,Intermediate,,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5350,Intermediate,,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5351,Intermediate,,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5352,Intermediate,,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5353,Intermediate,,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5354,Intermediate,,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5355,Intermediate,,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5356,Intermediate,,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5357,Intermediate,,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5358,Intermediate,,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),80021,Homo sapiens,14769,BAO_0000219,,F,,,9606.0,A498,N
5359,Intermediate,,,,Compound was tested for the growth inhibition of A498 renal tumor cell line,80021,Homo sapiens,15354,BAO_0000219,,F,,,9606.0,A498,N
5360,Intermediate,,,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),80021,Homo sapiens,17445,BAO_0000219,,F,,,9606.0,A498,N
5361,Intermediate,,,,In vitro inhibitory concentration against renal cancer cell line A498,80021,Homo sapiens,4337,BAO_0000219,,F,,,9606.0,A498,N
5362,Intermediate,,,,Cytotoxicity against A 498 tumor cell line,80021,Homo sapiens,15277,BAO_0000219,,F,,,9606.0,A498,N
5363,Intermediate,,,,In vitro antitumor activity against A498 human cancer cell line,80021,Homo sapiens,4812,BAO_0000219,,F,,,9606.0,A498,N
5364,Intermediate,,,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),80021,Homo sapiens,4812,BAO_0000219,,F,,,9606.0,A498,N
5365,Intermediate,,,,Inhibitory dose required against A498 human tumor cell lines,80021,Homo sapiens,4995,BAO_0000219,,F,,,9606.0,A498,N
5366,Intermediate,,,,Anticancer activity against one renal cancer (A498 cell line),80021,Homo sapiens,5847,BAO_0000219,,F,,,9606.0,A498,N
5367,Intermediate,,,,In vitro cytotoxicity against melanoma A498 cell line,80021,Homo sapiens,6557,BAO_0000219,,F,,,9606.0,A498,N
5368,Intermediate,,,,Compound was tested for growth inhibitory activity against A498 cell line,80021,Homo sapiens,2597,BAO_0000219,,F,,,9606.0,A498,N
5369,Intermediate,,,,Compound tested for growth inhibition of renal cancer cell line A498,80021,Homo sapiens,6058,BAO_0000219,,F,,,9606.0,A498,N
5370,Intermediate,,,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,80021,Homo sapiens,17708,BAO_0000219,,F,,,9606.0,A498,N
5371,Intermediate,,,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,80021,Homo sapiens,15176,BAO_0000219,,F,,,9606.0,A498,N
5372,Intermediate,,,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,80021,Homo sapiens,15300,BAO_0000219,,F,,,9606.0,A498,N
5373,Intermediate,,,,Tested for cytotoxicity against A498 cell lines in renal cancer,80021,Homo sapiens,11970,BAO_0000219,,F,,,9606.0,A498,N
5374,Intermediate,,,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,80021,Homo sapiens,12400,BAO_0000219,,F,,,9606.0,A498,N
5375,Expert,,,,Cytotoxic effect on renal cancer lines A498,80021,Homo sapiens,12888,BAO_0000219,,F,,,9606.0,A498,N
5376,Intermediate,,,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,80021,Homo sapiens,3030,BAO_0000219,,F,,,9606.0,A498,N
5377,Intermediate,,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),80021,Homo sapiens,14769,BAO_0000219,,F,,,9606.0,A498,N
5378,Intermediate,,,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,80021,Homo sapiens,17376,BAO_0000219,,F,,,9606.0,A498,N
5379,Intermediate,,,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,80021,Homo sapiens,16558,BAO_0000219,,F,,,9606.0,A498,N
5380,Intermediate,,,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,80021,Homo sapiens,5194,BAO_0000219,,F,,,9606.0,A498,N
5381,Intermediate,,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,80021,Homo sapiens,10708,BAO_0000219,,F,,,9606.0,A498,N
5382,Expert,,,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,80682,Homo sapiens,16880,BAO_0000219,,F,,,9606.0,A549,N
5383,Intermediate,,,,Antitumor activity against A549 human lung carcinoma cell line,80682,Homo sapiens,10196,BAO_0000219,,F,,,9606.0,A549,N
5384,Intermediate,,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,80682,Homo sapiens,10196,BAO_0000219,,F,,,9606.0,A549,N
5385,Intermediate,,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,80682,Homo sapiens,10196,BAO_0000219,,F,,,9606.0,A549,N
5386,Intermediate,,,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",80682,Homo sapiens,12083,BAO_0000219,,F,,,9606.0,A549,N
5387,Expert,,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,80682,Homo sapiens,16464,BAO_0000219,,F,,,9606.0,A549,N
5388,Intermediate,,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80682,Homo sapiens,16464,BAO_0000219,,F,,,9606.0,A549,N
5389,Expert,,,,In vitro cytotoxic activity against human lung A549 cell line,80682,Homo sapiens,16470,BAO_0000219,,F,,,9606.0,A549,N
5390,Intermediate,,,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),80682,Homo sapiens,16470,BAO_0000219,,F,,,9606.0,A549,N
5391,Intermediate,,,,In vitro cytotoxic activity against human lung A549 cell line),80682,Homo sapiens,16470,BAO_0000219,,F,,,9606.0,A549,N
5392,Intermediate,,,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,80682,Homo sapiens,16470,BAO_0000219,,F,,,9606.0,A549,N
5393,Expert,,,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,80682,Homo sapiens,16582,BAO_0000219,,F,,,9606.0,A549,N
5394,Intermediate,,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",80682,Homo sapiens,15935,BAO_0000219,,F,,,9606.0,A549,N
5395,Intermediate,,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",80682,Homo sapiens,15935,BAO_0000219,,F,,,9606.0,A549,N
5396,Expert,,,,Inhibition of A549 human lung carcinoma cell proliferation,80682,Homo sapiens,16597,BAO_0000219,,F,,,9606.0,A549,N
5397,Intermediate,,,,Inhibitory activity against A549 lung adenocarcinoma cell line,80682,Homo sapiens,17376,BAO_0000219,,F,,,9606.0,A549,N
5398,Intermediate,,,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,80682,Homo sapiens,16496,BAO_0000219,,F,,,9606.0,A549,N
5399,Intermediate,,,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,80682,Homo sapiens,16152,BAO_0000219,,F,,,9606.0,A549,N
5400,Intermediate,,,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,80682,Homo sapiens,16152,BAO_0000219,,F,,,9606.0,A549,N
5401,Intermediate,,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80682,Homo sapiens,16464,BAO_0000219,,F,,,9606.0,A549,N
5402,Intermediate,,,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,80682,Homo sapiens,2288,BAO_0000219,,F,,,9606.0,A549,N
5403,Intermediate,,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,80682,Homo sapiens,17350,BAO_0000219,,F,,,9606.0,A549,N
5404,Expert,,,,Inhibition of A549 cancer cell proliferation,80682,Homo sapiens,4090,BAO_0000219,,F,,,9606.0,A549,N
5405,Expert,,,,Inhibition of A549 cancer cell proliferation (Not tested),80682,Homo sapiens,4090,BAO_0000219,,F,,,9606.0,A549,N
5406,Intermediate,,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,80682,Homo sapiens,17350,BAO_0000219,,F,,,9606.0,A549,N
5407,Intermediate,,,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,80682,Homo sapiens,4197,BAO_0000219,,F,,,9606.0,A549,N
5408,Intermediate,,,,Antiproliferative potency determined as inhibitory concentration against A549 cells,80682,Homo sapiens,17072,BAO_0000219,,F,,,9606.0,A549,N
5409,Intermediate,,,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,80682,Homo sapiens,17072,BAO_0000219,,F,,,9606.0,A549,N
5410,Intermediate,,,,Cytotoxicity against Renal cell lines A549 was determined,80682,Homo sapiens,5194,BAO_0000219,,F,,,9606.0,A549,N
5411,Intermediate,,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,50588,Canis lupus familiaris,4257,BAO_0000218,,A,,,9615.0,,N
5412,Intermediate,,,,Area under curve was determined in dog after oral administration at 1 mg/kg,50588,Canis lupus familiaris,6123,BAO_0000218,,A,,,9615.0,,N
5413,Intermediate,,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,Canis lupus familiaris,1337,BAO_0000218,,A,,,9615.0,,N
5414,Intermediate,,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,Canis lupus familiaris,1337,BAO_0000218,,A,,,9615.0,,N
5415,Intermediate,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),50588,Canis lupus familiaris,8833,BAO_0000218,,A,,,9615.0,,N
5416,Intermediate,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),50588,Canis lupus familiaris,8833,BAO_0000218,,A,,,9615.0,,N
5417,Intermediate,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),50588,Canis lupus familiaris,8833,BAO_0000218,,A,,,9615.0,,N
5418,Intermediate,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),50588,Canis lupus familiaris,8833,BAO_0000218,,A,,,9615.0,,N
5419,Intermediate,,Plasma,1969.0,Area under plasma concentration time curve in dog upon oral administration,50588,Canis lupus familiaris,17657,BAO_0000218,,A,,,9615.0,,N
5420,Intermediate,,Plasma,1969.0,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,50588,Canis lupus familiaris,17650,BAO_0000218,,A,,,9615.0,,N
5421,Intermediate,,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,50588,Canis lupus familiaris,1977,BAO_0000218,,A,,,9615.0,,N
5422,Intermediate,,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,50588,Canis lupus familiaris,1977,BAO_0000218,,A,,,9615.0,,N
5423,Intermediate,,,,Area under the curve for the compound was obtained when tested in dog,50588,Canis lupus familiaris,3132,BAO_0000218,,A,,,9615.0,,N
5424,Intermediate,,,,Area under the curve at a dose of 1 mg/kg,50588,Canis lupus familiaris,5473,BAO_0000218,,A,,,9615.0,,N
5425,Intermediate,,,,Area under the curve at a dose of 1 mg/kg (oral),50588,Canis lupus familiaris,5474,BAO_0000218,,A,,,9615.0,,N
5426,Intermediate,,,,Area under the curve at i.v. dose of 0.2 mg/kg,50588,Canis lupus familiaris,5474,BAO_0000218,,A,,,9615.0,,N
5427,Intermediate,,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,50588,Canis lupus familiaris,6062,BAO_0000218,,A,,,9615.0,,N
5428,Intermediate,,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,50588,Canis lupus familiaris,4709,BAO_0000218,,A,,,9615.0,,N
5429,Intermediate,,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,50588,Canis lupus familiaris,2652,BAO_0000218,,A,,,9615.0,,N
5430,Intermediate,,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,50588,Canis lupus familiaris,2652,BAO_0000218,,A,,,9615.0,,N
5431,Intermediate,,,,Compound was evaluated for area under the curve in dog blood.,50588,Canis lupus familiaris,2877,BAO_0000218,,A,,,9615.0,,N
5432,Intermediate,,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,50588,Canis lupus familiaris,5444,BAO_0000218,,A,,,9615.0,,N
5433,Intermediate,,Plasma,1969.0,AUC in dog after oral dose (1 mg/kg),50588,Canis lupus familiaris,5130,BAO_0000218,,A,,,9615.0,,N
5434,Intermediate,,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,50588,Canis lupus familiaris,6265,BAO_0000218,,A,,,9615.0,,N
5435,Intermediate,,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",50588,Canis lupus familiaris,4657,BAO_0000218,,A,,,9615.0,,N
5436,Intermediate,,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,50588,Canis lupus familiaris,16367,BAO_0000218,,A,,,9615.0,,N
5437,Intermediate,,,,Pharmacokinetic parameter AUC after oral administration to dogs,50588,Canis lupus familiaris,16367,BAO_0000218,,A,,,9615.0,,N
5438,Intermediate,,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,50588,Canis lupus familiaris,9579,BAO_0000218,,A,,,9615.0,,N
5439,Intermediate,,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,50588,Canis lupus familiaris,9579,BAO_0000218,,A,,,9615.0,,N
5440,Intermediate,,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,50588,Canis lupus familiaris,5983,BAO_0000218,,A,,,9615.0,,N
5441,Intermediate,,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,50588,Canis lupus familiaris,6241,BAO_0000218,,A,,,9615.0,,N
5442,Intermediate,,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",50588,Canis lupus familiaris,5313,BAO_0000218,,A,,,9615.0,,N
5443,Intermediate,,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",50588,Canis lupus familiaris,5313,BAO_0000218,,A,,,9615.0,,N
5444,Intermediate,,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,Canis lupus familiaris,6642,BAO_0000218,,A,,,9615.0,,N
5445,Intermediate,,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,Canis lupus familiaris,6642,BAO_0000218,,A,,,9615.0,,N
5446,Intermediate,,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),50588,Canis lupus familiaris,6641,BAO_0000218,,A,,,9615.0,,N
5447,Intermediate,,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),50588,Canis lupus familiaris,6642,BAO_0000218,,A,,,9615.0,,N
5448,Intermediate,,,,Compound was evaluated for oral bioavailability in dog; 90-100,50588,Canis lupus familiaris,17791,BAO_0000218,,A,,,9615.0,,N
5449,Intermediate,,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,50588,Canis lupus familiaris,17655,BAO_0000218,,A,,,9615.0,,N
5450,Intermediate,,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,50588,Canis lupus familiaris,17655,BAO_0000218,,A,,,9615.0,,N
5451,Intermediate,,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,50588,Canis lupus familiaris,6596,BAO_0000218,,A,,,9615.0,,N
5452,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,3880,BAO_0000218,,A,,,9615.0,,N
5453,Intermediate,,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,50588,Canis lupus familiaris,16367,BAO_0000218,,A,,,9615.0,,N
5454,Intermediate,,Plasma,1969.0,Plasma protein binding towards dog plasma at 10 uM,50588,Canis lupus familiaris,17409,BAO_0000218,,A,,,9615.0,,N
5455,Intermediate,,Plasma,1969.0,Plasma protein binding towards dog plasma at 100 uM,50588,Canis lupus familiaris,17409,BAO_0000218,,A,,,9615.0,,N
5456,Intermediate,,,,Bioavailability in dog (dose 4 mg/kg p.o.),50588,Canis lupus familiaris,2959,BAO_0000218,,A,In vivo,,9615.0,,N
5457,Intermediate,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,50588,Canis lupus familiaris,13501,BAO_0000218,,A,In vivo,,9615.0,,N
5458,Intermediate,,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,50588,Canis lupus familiaris,4527,BAO_0000218,,A,In vivo,,9615.0,,N
5459,Intermediate,,,,Bioavailability in dogs,50588,Canis lupus familiaris,15145,BAO_0000218,,A,In vivo,,9615.0,,N
5460,Intermediate,,,,Bioavailability,50588,Canis lupus familiaris,4219,BAO_0000218,,A,In vivo,,9615.0,,N
5461,Intermediate,,,,Oral bioavailability in dog (dose 10 mg/kg),50588,Canis lupus familiaris,17538,BAO_0000218,,A,In vivo,,9615.0,,N
5462,Intermediate,,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,50588,Canis lupus familiaris,17538,BAO_0000218,,A,In vivo,,9615.0,,N
5463,Intermediate,,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),50588,Canis lupus familiaris,1466,BAO_0000218,,A,In vivo,,9615.0,,N
5464,Intermediate,,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,50588,Canis lupus familiaris,17650,BAO_0000218,,A,In vivo,,9615.0,,N
5465,Intermediate,,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,50588,Canis lupus familiaris,3132,BAO_0000218,,A,In vivo,,9615.0,,N
5466,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5467,Autocuration,,Liver,2107.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5468,Autocuration,,Liver,2107.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5469,Autocuration,,Liver,2107.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5470,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5471,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5472,Autocuration,,Muscle tissue,2385.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5473,Autocuration,,Muscle tissue,2385.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5474,Autocuration,,Muscle tissue,2385.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5475,Autocuration,,Spleen,2106.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5476,Autocuration,,Spleen,2106.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5477,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5478,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5479,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5480,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5481,Autocuration,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,Mus sp.,2413,BAO_0000218,,A,,,10095.0,,U
5482,Autocuration,,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),22224,Cercopithecidae,17827,BAO_0000019,,A,,,9527.0,,U
5483,Autocuration,,Cerebellum,2037.0,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),22224,Cercopithecidae,17827,BAO_0000019,,A,,,9527.0,,U
5484,Autocuration,,Frontal cortex,1870.0,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),22224,Cercopithecidae,17827,BAO_0000019,,A,,,9527.0,,U
5485,Autocuration,,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),22224,Cercopithecidae,17827,BAO_0000019,,A,,,9527.0,,U
5486,Autocuration,,Striatum,2435.0,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),22224,Cercopithecidae,17827,BAO_0000019,,A,,,9527.0,,U
5487,Autocuration,,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),22224,Cercopithecidae,17827,BAO_0000019,,A,,,9527.0,,U
5488,Autocuration,,Cerebellum,2037.0,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),22224,Cercopithecidae,17827,BAO_0000019,,A,,,9527.0,,U
5489,Autocuration,,Frontal cortex,1870.0,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),22224,Cercopithecidae,17827,BAO_0000019,,A,,,9527.0,,U
5490,Autocuration,,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),22224,Cercopithecidae,17827,BAO_0000019,,A,,,9527.0,,U
5491,Autocuration,,Striatum,2435.0,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),22224,Cercopithecidae,17827,BAO_0000019,,A,,,9527.0,,U
5492,Autocuration,,,,Compound was evaluated for oral bioavailability in rats,22224,Cercopithecidae,17791,BAO_0000218,,A,,,9527.0,,U
5493,Autocuration,,Plasma,1969.0,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,22224,Cercopithecidae,17667,BAO_0000218,,A,In vivo,,9527.0,,U
5494,Autocuration,,,,Half life period was evaluated in monkey,22224,Cercopithecidae,17791,BAO_0000019,,A,,,9527.0,,U
5495,Autocuration,,,,Half-life in rhesus monkeys by intravenous administration of dose,22224,Cercopithecidae,110,BAO_0000218,,A,In vivo,,9527.0,,U
5496,Intermediate,,Plasma,1969.0,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,50594,Mus musculus,5781,BAO_0000218,,A,,,10090.0,,N
5497,Intermediate,,Plasma,1969.0,AUC after intraperitoneal administration of 100 mg/kg in mice,50594,Mus musculus,17734,BAO_0000218,,A,,,10090.0,,N
5498,Intermediate,,Plasma,1969.0,AUC value was determined after oral administration,50594,Mus musculus,17718,BAO_0000218,,A,,,10090.0,,N
5499,Intermediate,,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,Mus musculus,4573,BAO_0000218,,A,,,10090.0,,N
5500,Intermediate,,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,Mus musculus,3277,BAO_0000218,,A,,,10090.0,,N
5501,Intermediate,,,,Area under curve by ioral administration in mouse,50594,Mus musculus,2862,BAO_0000218,,A,,,10090.0,,N
5502,Intermediate,,,,Area under curve by iv administration in mouse,50594,Mus musculus,2862,BAO_0000218,,A,,,10090.0,,N
5503,Intermediate,,,,Area under curve at 0-8 hr in IRC mice after peroral administration,50594,Mus musculus,5951,BAO_0000218,,A,,,10090.0,,N
5504,Intermediate,,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,50594,Mus musculus,17729,BAO_0000218,,A,,,10090.0,,N
5505,Intermediate,,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,50594,Mus musculus,17728,BAO_0000218,,A,,,10090.0,,N
5506,Intermediate,,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,50594,Mus musculus,17728,BAO_0000218,,A,,,10090.0,,N
5507,Intermediate,,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,50594,Mus musculus,17729,BAO_0000218,,A,,,10090.0,,N
5508,Intermediate,,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5509,Intermediate,,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5510,Intermediate,,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5511,Intermediate,,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5512,Intermediate,,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5513,Intermediate,,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5514,Intermediate,,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5515,Intermediate,,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5516,Intermediate,,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5517,Intermediate,,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5518,Intermediate,,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5519,Intermediate,,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5520,Intermediate,,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5521,Intermediate,,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5522,Intermediate,,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5523,Intermediate,,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5524,Expert,,,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,80433,Homo sapiens,9424,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5525,Intermediate,,,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,80433,Homo sapiens,11544,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5526,Intermediate,,,,Cytotoxicity of compound against 8226/DOX1V cells,80433,Homo sapiens,17378,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5527,Intermediate,,,,Cytotoxicity of compound against 8226/S cells,80433,Homo sapiens,17378,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5528,Intermediate,,,,Inhibitory concentration against 8226 myeloma cancer cell line,80433,Homo sapiens,17079,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5529,Intermediate,,,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,80433,Homo sapiens,17079,BAO_0000219,,F,,,9606.0,RPMI-8226,N
5530,Intermediate,,,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,80647,Homo sapiens,13466,BAO_0000219,,F,,,9606.0,833K,N
5531,Intermediate,,,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',80647,Homo sapiens,13466,BAO_0000219,,F,,,9606.0,833K,N
5532,Expert,,,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,80647,Homo sapiens,2392,BAO_0000219,,F,,,9606.0,833K,N
5533,Intermediate,,,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,80647,Homo sapiens,2392,BAO_0000219,,F,,,9606.0,833K,N
5534,Autocuration,,,,Inhibitory activity against caspase-1,22226,,6608,BAO_0000019,,B,,,,,U
5535,Autocuration,,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,45,Enterococcus faecalis,10199,BAO_0000357,,B,,,1351.0,,H
5536,Intermediate,,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,80648,Homo sapiens,17749,BAO_0000219,,F,,,9606.0,8701-BC,N
5537,Intermediate,,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,80648,Homo sapiens,17749,BAO_0000219,,F,,,9606.0,8701-BC,N
5538,Intermediate,,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,22226,,1229,BAO_0000019,,F,,,,,U
5539,Intermediate,,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,22226,,1229,BAO_0000019,,F,,,,,U
5540,Intermediate,,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,22226,,1229,BAO_0000019,,F,,,,,U
5541,Autocuration,,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,22226,,6390,BAO_0000019,,B,,,,,U
5542,Autocuration,,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,22226,Streptococcus pyogenes,16219,BAO_0000019,,F,,,1314.0,,U
5543,Autocuration,,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,22226,Streptococcus pyogenes,16219,BAO_0000019,,F,,,1314.0,,U
5544,Autocuration,,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,11922,,17043,BAO_0000357,,B,,,,,H
5545,Intermediate,,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,81115,Homo sapiens,6929,BAO_0000219,,F,,,9606.0,KB ,N
5546,Intermediate,,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,81115,Homo sapiens,6929,BAO_0000219,,A,,,9606.0,KB ,N
5547,Autocuration,,,,In vitro cytotoxicity of compound was tested against 9KB cells.,22226,Homo sapiens,7083,BAO_0000219,,F,,,9606.0,,U
5548,Intermediate,,,,Cytotoxic concentration against 9L cells was determined on day 3,80653,Rattus norvegicus,12446,BAO_0000219,,F,,,10116.0,9L,N
5549,Expert,,,,Tested in vitro for anticancer activity against 9L cells,80653,Rattus norvegicus,15345,BAO_0000219,,F,,,10116.0,9L,N
5550,Expert,,,,Tested in vitro for anticancer activity against 9L cells; Not determined,80653,Rattus norvegicus,15345,BAO_0000219,,F,,,10116.0,9L,N
5551,Intermediate,,,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,80682,Homo sapiens,6301,BAO_0000219,,F,,,9606.0,A549,N
5552,Intermediate,,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,80682,Homo sapiens,4833,BAO_0000219,,F,,,9606.0,A549,N
5553,Intermediate,,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,80682,Homo sapiens,4833,BAO_0000219,,F,,,9606.0,A549,N
5554,Intermediate,,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,80682,Homo sapiens,4833,BAO_0000219,,F,,,9606.0,A549,N
5555,Expert,,,,Cytotoxicity against human lung carcinoma A549 cell line,80682,Homo sapiens,13330,BAO_0000219,,F,,,9606.0,A549,N
5556,Expert,,,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,25,Homo sapiens,17517,BAO_0000219,,F,,,9606.0,A549,D
5557,Expert,,,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",25,Homo sapiens,17517,BAO_0000219,,F,,,9606.0,A549,D
5558,Intermediate,,,,"In vitro growth inhibition of A549, lung carcinoma",80682,Homo sapiens,14425,BAO_0000219,,F,,,9606.0,A549,N
5559,Intermediate,,,,"In vitro growth inhibition of A549, lung carcinoma.",80682,Homo sapiens,14425,BAO_0000219,,F,,,9606.0,A549,N
5560,Expert,,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,Homo sapiens,5228,BAO_0000219,,F,,,9606.0,A549,N
5561,Intermediate,,,,Cytotoxic activity against human lung cancer A549 cell line was determined,80682,Homo sapiens,5351,BAO_0000219,,F,,,9606.0,A549,N
5562,Expert,,,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,80682,Homo sapiens,12198,BAO_0000219,,F,,,9606.0,A549,N
5563,Intermediate,,,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,80682,Homo sapiens,13891,BAO_0000219,,F,,,9606.0,A549,N
5564,Expert,,,,Cytotoxicity in A549 (human carcinoma) cell line.,80682,Homo sapiens,5677,BAO_0000219,,F,,,9606.0,A549,N
5565,Intermediate,,,,Cytotoxicity on lung carcinoma (A-549) cell line,80682,Homo sapiens,13788,BAO_0000219,,F,,,9606.0,A549,N
5566,Expert,,,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,80682,Homo sapiens,13384,BAO_0000219,,F,,,9606.0,A549,N
5567,Intermediate,,,,Effective dose of compound against replication of A549 cell line was evaluated,80682,Homo sapiens,6726,BAO_0000219,,F,,,9606.0,A549,N
5568,Expert,,,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,80682,Homo sapiens,3455,BAO_0000219,,F,,,9606.0,A549,N
5569,Intermediate,,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),80682,Homo sapiens,5726,BAO_0000219,,F,,,9606.0,A549,N
5570,Intermediate,,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,80682,Homo sapiens,5726,BAO_0000219,,F,,,9606.0,A549,N
5571,Intermediate,,,,The compound was evaluated for antiproliferative activity against A549 cell line,80682,Homo sapiens,3936,BAO_0000219,,F,,,9606.0,A549,N
5572,Intermediate,,,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,80682,Homo sapiens,14991,BAO_0000219,,F,,,9606.0,A549,N
5573,Intermediate,,,,Concentration required for growth inhibition of human lung carcinoma cell line A549,80682,Homo sapiens,5243,BAO_0000219,,F,,,9606.0,A549,N
5574,Intermediate,,,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,80682,Homo sapiens,12858,BAO_0000219,,F,,,9606.0,A549,N
5575,Intermediate,,,,Growth inhibition against A549 cell line was evaluated,80682,Homo sapiens,6776,BAO_0000219,,F,,,9606.0,A549,N
5576,Intermediate,,,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,80682,Homo sapiens,16558,BAO_0000219,,F,,,9606.0,A549,N
5577,Expert,,,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,80682,Homo sapiens,4583,BAO_0000219,,F,,,9606.0,A549,N
5578,Intermediate,,,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,80682,Homo sapiens,13514,BAO_0000219,,F,,,9606.0,A549,N
5579,Expert,,,,Chemosensitivity against DT-diaphorase rich A549 cell lines,80682,Homo sapiens,15166,BAO_0000219,,F,,,9606.0,A549,N
5580,Intermediate,,,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,80682,Homo sapiens,13873,BAO_0000219,,F,,,9606.0,A549,N
5581,Expert,,,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,80682,Homo sapiens,6447,BAO_0000219,,F,,,9606.0,A549,N
5582,Intermediate,,,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,80682,Homo sapiens,2068,BAO_0000219,,F,,,9606.0,A549,N
5583,Expert,,,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,80682,Homo sapiens,1863,BAO_0000219,,F,,,9606.0,A549,N
5584,Intermediate,,,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,80682,Homo sapiens,13873,BAO_0000219,,F,,,9606.0,A549,N
5585,Intermediate,,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,80682,Homo sapiens,13873,BAO_0000219,,F,,,9606.0,A549,N
5586,Expert,,,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,80682,Homo sapiens,13873,BAO_0000219,,F,,,9606.0,A549,N
5587,Intermediate,,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),80682,Homo sapiens,579,BAO_0000219,,F,,,9606.0,A549,N
5588,Intermediate,,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,80682,Homo sapiens,579,BAO_0000219,,F,,,9606.0,A549,N
5589,Intermediate,,,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,80682,Homo sapiens,4584,BAO_0000219,,F,,,9606.0,A549,N
5590,Expert,,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,80682,Homo sapiens,5421,BAO_0000219,,F,,,9606.0,A549,N
5591,Intermediate,,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,80682,Homo sapiens,5421,BAO_0000219,,F,,,9606.0,A549,N
5592,Intermediate,,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,80682,Homo sapiens,5421,BAO_0000219,,F,,,9606.0,A549,N
5593,Intermediate,,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,80682,Homo sapiens,5421,BAO_0000219,,F,,,9606.0,A549,N
5594,Intermediate,,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,80682,Homo sapiens,14188,BAO_0000219,,F,,,9606.0,A549,N
5595,Intermediate,,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,80682,Homo sapiens,14188,BAO_0000219,,F,,,9606.0,A549,N
5596,Intermediate,,,,Compound was tested for the growth inhibition of A549 lung tumor cell line,80682,Homo sapiens,15354,BAO_0000219,,F,,,9606.0,A549,N
5597,Expert,,,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,80682,Homo sapiens,14253,BAO_0000219,,F,,,9606.0,A549,N
5598,Intermediate,,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,80682,Homo sapiens,13873,BAO_0000219,,F,,,9606.0,A549,N
5599,Intermediate,,,,Oral bioavailability in dog (conscious),50588,Canis lupus familiaris,3043,BAO_0000218,,A,In vivo,,9615.0,,N
5600,Intermediate,,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,50588,Canis lupus familiaris,3045,BAO_0000218,,A,In vivo,,9615.0,,N
5601,Intermediate,,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,50588,Canis lupus familiaris,3022,BAO_0000218,,A,In vivo,,9615.0,,N
5602,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,4453,BAO_0000218,,A,In vivo,,9615.0,,N
5603,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,1696,BAO_0000218,,A,In vivo,,9615.0,,N
5604,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,5045,BAO_0000218,,A,In vivo,,9615.0,,N
5605,Intermediate,,,,Oral bioavailability in dog (fasted),50588,Canis lupus familiaris,5356,BAO_0000218,,A,In vivo,,9615.0,,N
5606,Intermediate,,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,50588,Canis lupus familiaris,17764,BAO_0000218,,A,In vivo,,9615.0,,N
5607,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,6448,BAO_0000218,,A,In vivo,,9615.0,,N
5608,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,1475,BAO_0000218,,A,In vivo,,9615.0,,N
5609,Intermediate,,,,Percent bioavailability in dog,50588,Canis lupus familiaris,3788,BAO_0000218,,A,In vivo,,9615.0,,N
5610,Intermediate,,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,50588,Canis lupus familiaris,3639,BAO_0000218,,A,In vivo,,9615.0,,N
5611,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,13397,BAO_0000218,,A,In vivo,,9615.0,,N
5612,Intermediate,,,,The compound was evaluated for bioavailability in dogs; 34-44,50588,Canis lupus familiaris,2137,BAO_0000218,,A,In vivo,,9615.0,,N
5613,Intermediate,,,,Bioavailability in dog (dose 4 mg/kg p.o.),50588,Canis lupus familiaris,2959,BAO_0000218,,A,In vivo,,9615.0,,N
5614,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,6448,BAO_0000218,,A,In vivo,,9615.0,,N
5615,Intermediate,,,,8 hour trough Blood level in dog was measured after administration of compound,50588,Canis lupus familiaris,6084,BAO_0000218,,A,,,9615.0,,N
5616,Intermediate,,Plasma,1969.0,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,50588,Canis lupus familiaris,3639,BAO_0000218,,A,In vivo,,9615.0,,N
5617,Intermediate,,,,C24 after oral administration at 5 mg/kg,50588,Canis lupus familiaris,6316,BAO_0000218,,A,,,9615.0,,N
5618,Intermediate,,,,Clearance after oral and iv dosing in dogs,50588,Canis lupus familiaris,5238,BAO_0000218,,A,,,9615.0,,N
5619,Intermediate,,Plasma,1969.0,Clearance of the drug was measured in the plasma of dog,50588,Canis lupus familiaris,17796,BAO_0000218,,A,,,9615.0,,N
5620,Intermediate,,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,50588,Canis lupus familiaris,2652,BAO_0000218,,A,,,9615.0,,N
5621,Intermediate,,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,Canis lupus familiaris,5654,BAO_0000218,,A,In vivo,,9615.0,,N
5622,Intermediate,,,,Clearance of compound was determined in dogs,50588,Canis lupus familiaris,6621,BAO_0000218,,A,In vivo,,9615.0,,N
5623,Intermediate,,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,50588,Canis lupus familiaris,6505,BAO_0000218,,A,In vivo,,9615.0,,N
5624,Intermediate,,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,Canis lupus familiaris,5802,BAO_0000218,,A,In vivo,,9615.0,,N
5625,Intermediate,,,,Plasma clearance in dog was determined,50588,Canis lupus familiaris,17267,BAO_0000218,,A,In vivo,,9615.0,,N
5626,Intermediate,,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,Canis lupus familiaris,4521,BAO_0000218,,A,In vivo,,9615.0,,N
5627,Intermediate,,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,50588,Canis lupus familiaris,6535,BAO_0000218,,A,In vivo,,9615.0,,N
5628,Intermediate,,,,Plasma clearance in dog after administration of 1 mg/kg iv,50588,Canis lupus familiaris,6535,BAO_0000218,,A,In vivo,,9615.0,,N
5629,Intermediate,,,,Plasma clearance in dogs,50588,Canis lupus familiaris,6535,BAO_0000218,,A,In vivo,,9615.0,,N
5630,Intermediate,,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,50588,Canis lupus familiaris,5542,BAO_0000218,,A,In vivo,,9615.0,,N
5631,Intermediate,,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,50588,Canis lupus familiaris,5199,BAO_0000218,,A,In vivo,,9615.0,,N
5632,Intermediate,,,,Plasma clearance after 15 mg/kg iv dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,In vivo,,9615.0,,N
5633,Intermediate,,,,Plasma clearance after 30 mg/kg po dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,In vivo,,9615.0,,N
5634,Intermediate,,,,Plasma administration to dogs,50588,Canis lupus familiaris,16367,BAO_0000218,,A,In vivo,,9615.0,,N
5635,Intermediate,,,,Plasma clearance was determined,50588,Canis lupus familiaris,5505,BAO_0000218,,A,In vivo,,9615.0,,N
5636,Intermediate,,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,50588,Canis lupus familiaris,6215,BAO_0000218,,A,In vivo,,9615.0,,N
5637,Intermediate,,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,50588,Canis lupus familiaris,1466,BAO_0000218,,A,In vivo,,9615.0,,N
5638,Intermediate,Microsomes,Liver,2107.0,Intrinsic clearance in human liver microsomes,102164,Homo sapiens,5007,BAO_0000251,,A,In vitro,,9606.0,,S
5639,Intermediate,Microsomes,Liver,2107.0,Intrinsic clearance in human liver microsomes,102164,Homo sapiens,5007,BAO_0000251,,A,In vitro,,9606.0,,S
5640,Intermediate,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,Canis lupus familiaris,16452,BAO_0000218,,A,In vivo,,9615.0,,N
5641,Intermediate,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,Canis lupus familiaris,16452,BAO_0000218,,A,In vivo,,9615.0,,N
5642,Intermediate,,,,Clearance in dog (dose 1 mg/kg i.v.),50588,Canis lupus familiaris,16452,BAO_0000218,,A,In vivo,,9615.0,,N
5643,Intermediate,,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,50588,Canis lupus familiaris,6221,BAO_0000218,,A,In vivo,,9615.0,,N
5644,Intermediate,,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,Canis lupus familiaris,5007,BAO_0000218,,A,In vivo,,9615.0,,N
5645,Intermediate,,,,Plasma clearance after peroral administration at 10 mpk in dog,50588,Canis lupus familiaris,5668,BAO_0000218,,A,In vivo,,9615.0,,N
5646,Intermediate,,,,Plasma clearance after peroral administration at 5 mpk in dog,50588,Canis lupus familiaris,5668,BAO_0000218,,A,In vivo,,9615.0,,N
5647,Intermediate,,,,Plasma clearance after peroral administration at 5 mg/kg in dog,50588,Canis lupus familiaris,5668,BAO_0000218,,A,In vivo,,9615.0,,N
5648,Intermediate,,,,Plasma clearance was measured in dog,50588,Canis lupus familiaris,15660,BAO_0000218,,A,In vivo,,9615.0,,N
5649,Intermediate,,,,Plasma clearance was measured in dog,50588,Canis lupus familiaris,15660,BAO_0000218,,A,In vivo,,9615.0,,N
5650,Intermediate,,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,50588,Canis lupus familiaris,5983,BAO_0000218,,A,In vivo,,9615.0,,N
5651,Intermediate,,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,50588,Canis lupus familiaris,5600,BAO_0000218,,A,In vivo,,9615.0,,N
5652,Intermediate,,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,50588,Canis lupus familiaris,17764,BAO_0000218,,A,In vivo,,9615.0,,N
5653,Intermediate,,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,50588,Canis lupus familiaris,6039,BAO_0000218,,A,In vivo,,9615.0,,N
5654,Intermediate,,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,50588,Canis lupus familiaris,6039,BAO_0000218,,A,In vivo,,9615.0,,N
5655,Intermediate,,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,50588,Canis lupus familiaris,6039,BAO_0000218,,A,In vivo,,9615.0,,N
5656,Intermediate,,,,Clearance by intravenous administration of 1.2 mg/kg in dog,50588,Canis lupus familiaris,4368,BAO_0000218,,A,In vivo,,9615.0,,N
5657,Intermediate,,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,50588,Canis lupus familiaris,4305,BAO_0000218,,A,In vivo,,9615.0,,N
5658,Intermediate,,Plasma,1969.0,Clearance value was evaluated in dog plasma,50588,Canis lupus familiaris,1918,BAO_0000218,,A,In vivo,,9615.0,,N
5659,Intermediate,,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,50588,Canis lupus familiaris,6005,BAO_0000218,,A,In vivo,,9615.0,,N
5660,Intermediate,,Plasma,1969.0,Compound was tested for plasma clearance in dog,50588,Canis lupus familiaris,4839,BAO_0000218,,A,In vivo,,9615.0,,N
5661,Intermediate,,,,Pharmacokinetic property (Plasma clearance) was measured in dog,50588,Canis lupus familiaris,4239,BAO_0000218,,A,In vivo,,9615.0,,N
5662,Intermediate,,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,50594,Mus musculus,17729,BAO_0000218,,A,,,10090.0,,N
5663,Intermediate,,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,50594,Mus musculus,17728,BAO_0000218,,A,,,10090.0,,N
5664,Intermediate,,,,Area under curve value in mouse at a dose of 10 mg/kg,50594,Mus musculus,5302,BAO_0000218,,A,,,10090.0,,N
5665,Intermediate,,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,Mus musculus,5506,BAO_0000218,,A,,,10090.0,,N
5666,Intermediate,,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,Mus musculus,5506,BAO_0000218,,A,,,10090.0,,N
5667,Intermediate,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,,,10090.0,,N
5668,Intermediate,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,,,10090.0,,N
5669,Intermediate,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,,,10090.0,,N
5670,Intermediate,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,50594,Mus musculus,17764,BAO_0000218,,F,,,10090.0,,N
5671,Intermediate,,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,50594,Mus musculus,17764,BAO_0000218,,A,,,10090.0,,N
5672,Intermediate,,,,Area under curve was determined for the compound at 24 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,,,10090.0,,N
5673,Intermediate,,,,Area under curve was determined for the compound at 40 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,,,10090.0,,N
5674,Intermediate,,,,Area under curve was determined for the compound at 5 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,,,10090.0,,N
5675,Intermediate,,,,Area under the curve for the compound is obtained at dose 25 mg/kg,50594,Mus musculus,3132,BAO_0000218,,A,,,10090.0,,N
5676,Intermediate,,,,Area under the curve for the compound was obtained when tested in mouse,50594,Mus musculus,3132,BAO_0000218,,A,,,10090.0,,N
5677,Intermediate,,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,50594,Mus musculus,17837,BAO_0000218,,A,,,10090.0,,N
5678,Intermediate,,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,50594,Mus musculus,17837,BAO_0000218,,A,,,10090.0,,N
5679,Intermediate,,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,50594,Mus musculus,6062,BAO_0000218,,A,,,10090.0,,N
5680,Intermediate,,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,50594,Mus musculus,4066,BAO_0000218,,A,,,10090.0,,N
5681,Intermediate,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),50594,Mus musculus,16597,BAO_0000218,,A,,,10090.0,,N
5682,Intermediate,,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,50594,Mus musculus,14239,BAO_0000218,,A,,,10090.0,,N
5683,Intermediate,,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,50594,Mus musculus,14239,BAO_0000218,,A,,,10090.0,,N
5684,Intermediate,,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",50594,Mus musculus,4890,BAO_0000218,,A,,,10090.0,,N
5685,Intermediate,,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),50594,Mus musculus,429,BAO_0000218,,A,,,10090.0,,N
5686,Intermediate,,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),50594,Mus musculus,429,BAO_0000218,,A,,,10090.0,,N
5687,Intermediate,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,50594,Mus musculus,5969,BAO_0000218,,A,,,10090.0,,N
5688,Intermediate,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,50594,Mus musculus,5969,BAO_0000218,,A,,,10090.0,,N
5689,Intermediate,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,Mus musculus,5969,BAO_0000218,,A,,,10090.0,,N
5690,Intermediate,,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,50594,Mus musculus,6091,BAO_0000218,,A,,,10090.0,,N
5691,Intermediate,,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,50594,Mus musculus,6091,BAO_0000218,,A,,,10090.0,,N
5692,Intermediate,,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,50594,Mus musculus,6091,BAO_0000218,,A,,,10090.0,,N
5693,Intermediate,,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,50594,Mus musculus,6091,BAO_0000218,,A,,,10090.0,,N
5694,Intermediate,,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,50594,Mus musculus,6178,BAO_0000218,,A,,,10090.0,,N
5695,Intermediate,,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,50594,Mus musculus,6178,BAO_0000218,,A,,,10090.0,,N
5696,Intermediate,,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",50594,Mus musculus,6619,BAO_0000218,,A,,,10090.0,,N
5697,Intermediate,,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",50594,Mus musculus,6619,BAO_0000218,,A,,,10090.0,,N
5698,Intermediate,,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",50594,Mus musculus,3760,BAO_0000218,,A,,,10090.0,,N
5699,Intermediate,,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",50594,Mus musculus,3760,BAO_0000218,,A,,,10090.0,,N
5700,Intermediate,,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",50594,Mus musculus,3760,BAO_0000218,,A,,,10090.0,,N
5701,Intermediate,,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",50594,Mus musculus,3760,BAO_0000218,,A,,,10090.0,,N
5702,Intermediate,,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,50594,Mus musculus,3192,BAO_0000218,,A,,,10090.0,,N
5703,Intermediate,,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,50594,Mus musculus,3192,BAO_0000218,,A,,,10090.0,,N
5704,Intermediate,,,,Area under the curve was evaluated in mice after intravenous administration,50594,Mus musculus,2675,BAO_0000218,,A,,,10090.0,,N
5705,Intermediate,,,,Area under the curve was evaluated in mice after oral administration,50594,Mus musculus,2675,BAO_0000218,,A,,,10090.0,,N
5706,Intermediate,,Plasma,1969.0,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,,,10090.0,,N
5707,Intermediate,,Plasma,1969.0,AUC total value at a dose of 10 mg/kg peroral administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,,,10090.0,,N
5708,Intermediate,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),50594,Mus musculus,16597,BAO_0000218,,A,,,10090.0,,N
5709,Intermediate,,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,50594,Mus musculus,17734,BAO_0000218,,A,,,10090.0,,N
5710,Intermediate,,Blood,178.0,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5711,Intermediate,,,,The compound was tested in vitro for anticancer activity against 9L cells,80653,,15345,BAO_0000219,,F,,,,9L,N
5712,Autocuration,,,,Anti proliferation activity determined; Weak effect,22226,Rattus norvegicus,2181,BAO_0000019,,F,,,10116.0,,U
5713,Autocuration,,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,22226,Rattus norvegicus,2181,BAO_0000219,,F,,,10116.0,,U
5714,Autocuration,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,22226,Rattus norvegicus,2181,BAO_0000219,,F,,,10116.0,,U
5715,Autocuration,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,22226,Rattus norvegicus,2181,BAO_0000219,,F,,,10116.0,,U
5716,Autocuration,,,,The cytotoxic activity was in vitro tested by 9PS assay method,22226,Mus musculus,10486,BAO_0000019,,F,,,10090.0,,U
5717,Autocuration,,,,The cytotoxic activity was in vitro tested by 9PS assay method.,22226,Mus musculus,10486,BAO_0000019,,F,,,10090.0,,U
5718,Autocuration,,,,Partition coefficient (logD6.5),22224,,15508,BAO_0000019,,A,,,,,U
5719,Expert,,,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,81034,Homo sapiens,5242,BAO_0000219,,F,,,9606.0,A2780,N
5720,Intermediate,,,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),80018,Homo sapiens,16167,BAO_0000219,,F,,,9606.0,A-375,N
5721,Expert,,,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,80852,Homo sapiens,4782,BAO_0000219,,F,,,9606.0,A-431,N
5722,Expert,,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,Homo sapiens,16093,BAO_0000219,,F,,,9606.0,A-431,D
5723,Intermediate,,,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,80021,Homo sapiens,2596,BAO_0000219,,F,,,9606.0,A498,N
5724,Intermediate,,,,in vitro cytotoxicity against A 498 cancer cell line,80021,Homo sapiens,2596,BAO_0000219,,F,,,9606.0,A498,N
5725,Intermediate,,,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,80021,Homo sapiens,3239,BAO_0000219,,F,,,9606.0,A498,N
5726,Intermediate,,,,Cytotoxic activity against A 498 renal cancer cell lines.,80021,Homo sapiens,1847,BAO_0000219,,F,,,9606.0,A498,N
5727,Intermediate,,,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,80021,Homo sapiens,10553,BAO_0000219,,F,,,9606.0,A498,N
5728,Autocuration,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,22226,Staphylococcus aureus,16219,BAO_0000019,,F,,,1280.0,,U
5729,Autocuration,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,22226,Staphylococcus aureus,16219,BAO_0000019,,F,,,1280.0,,U
5730,Autocuration,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,22226,Staphylococcus aureus,16219,BAO_0000019,,F,,,1280.0,,U
5731,Autocuration,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,22226,Staphylococcus aureus,16219,BAO_0000019,,F,,,1280.0,,U
5732,Intermediate,,,,Inhibitory concentration required against A 549 lung cancer cell line,80682,Homo sapiens,4782,BAO_0000219,,F,,,9606.0,A549,N
5733,Intermediate,,,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,80682,Homo sapiens,11805,BAO_0000219,,F,,,9606.0,A549,N
5734,Intermediate,,,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,80682,Homo sapiens,11805,BAO_0000219,,F,,,9606.0,A549,N
5735,Intermediate,,,,In vitro cytotoxicity against lung cancer A 549 cell lines,80682,Homo sapiens,2007,BAO_0000219,,F,,,9606.0,A549,N
5736,Intermediate,,,,Compound was tested for its cytotoxicity against A 549 cell line,80682,Homo sapiens,4594,BAO_0000219,,F,,,9606.0,A549,N
5737,Expert,,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",80682,Homo sapiens,6018,BAO_0000219,,F,,,9606.0,A549,N
5738,Intermediate,,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",80682,Homo sapiens,6018,BAO_0000219,,F,,,9606.0,A549,N
5739,Expert,,,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,80682,Homo sapiens,3599,BAO_0000219,,F,,,9606.0,A549,N
5740,Intermediate,,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,80682,Homo sapiens,2551,BAO_0000219,,F,,,9606.0,A549,N
5741,Expert,,,,In vitro inhibition of A549 (human lung cancer) cell growth.,80682,Homo sapiens,16132,BAO_0000219,,F,,,9606.0,A549,N
5742,Intermediate,,,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,80682,Homo sapiens,16132,BAO_0000219,,F,,,9606.0,A549,N
5743,Expert,,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,80682,Homo sapiens,2551,BAO_0000219,,F,,,9606.0,A549,N
5744,Expert,,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),80682,Homo sapiens,2551,BAO_0000219,,F,,,9606.0,A549,N
5745,Autocuration,,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,22226,,11913,BAO_0000218,,F,,,,,U
5746,Autocuration,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,104694,,12621,BAO_0000218,,F,In vivo,,,,H
5747,Autocuration,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,104694,,12621,BAO_0000218,,F,In vivo,,,,H
5748,Autocuration,,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,104694,,12621,BAO_0000218,,F,In vivo,,,,H
5749,Autocuration,,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,104694,,12621,BAO_0000218,,F,In vivo,,,,H
5750,Autocuration,,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,104694,,12621,BAO_0000218,,F,In vivo,,,,H
5751,Expert,,,,Inhibition of A-498 human Renal cell proliferation,80021,Homo sapiens,3600,BAO_0000219,,F,,,9606.0,A498,N
5752,Autocuration,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",22226,Rattus norvegicus,1796,BAO_0000019,,F,,,10116.0,,U
5753,Autocuration,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",22226,Rattus norvegicus,1796,BAO_0000019,,F,,,10116.0,,U
5754,Autocuration,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",22226,Rattus norvegicus,1796,BAO_0000019,,F,,,10116.0,,U
5755,Expert,,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,80012,Homo sapiens,16464,BAO_0000219,,F,,,9606.0,A 172,N
5756,Intermediate,,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80012,Homo sapiens,16464,BAO_0000219,,F,,,9606.0,A 172,N
5757,Intermediate,,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80012,Homo sapiens,16464,BAO_0000219,,F,,,9606.0,A 172,N
5758,Expert,,,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,80682,Homo sapiens,13617,BAO_0000219,,F,,,9606.0,A549,N
5759,Intermediate,,,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,80682,Homo sapiens,4584,BAO_0000219,,F,,,9606.0,A549,N
5760,Expert,,,,Cytotoxic activity evaluated against A549 tumor cells,80682,Homo sapiens,13799,BAO_0000219,,F,,,9606.0,A549,N
5761,Intermediate,,,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,80682,Homo sapiens,16726,BAO_0000219,,F,,,9606.0,A549,N
5762,Intermediate,,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,80682,Homo sapiens,16109,BAO_0000219,,F,,,9606.0,A549,N
5763,Intermediate,,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,80682,Homo sapiens,16109,BAO_0000219,,F,,,9606.0,A549,N
5764,Intermediate,,,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,80682,Homo sapiens,15474,BAO_0000219,,F,,,9606.0,A549,N
5765,Intermediate,,,,Cytotoxicity of compound against A549 cell line,80682,Homo sapiens,6851,BAO_0000219,,F,,,9606.0,A549,N
5766,Expert,,,,Cytotoxicity against human lung cell carcinoma A549 cell line,80682,Homo sapiens,17534,BAO_0000219,,F,,,9606.0,A549,N
5767,Intermediate,,,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,80682,Homo sapiens,2621,BAO_0000219,,F,,,9606.0,A549,N
5768,Intermediate,,,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,80682,Homo sapiens,830,BAO_0000219,,F,,,9606.0,A549,N
5769,Intermediate,,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,80682,Homo sapiens,14255,BAO_0000219,,F,,,9606.0,A549,N
5770,Intermediate,,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,80682,Homo sapiens,14255,BAO_0000219,,F,,,9606.0,A549,N
5771,Intermediate,,,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,80682,Homo sapiens,1590,BAO_0000219,,F,,,9606.0,A549,N
5772,Expert,,,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,80682,Homo sapiens,6146,BAO_0000219,,F,,,9606.0,A549,N
5773,Expert,,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,Homo sapiens,17427,BAO_0000219,,F,,,9606.0,A549,N
5774,Intermediate,,,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,80682,Homo sapiens,5280,BAO_0000219,,F,,,9606.0,A549,N
5775,Intermediate,,,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,80682,Homo sapiens,16786,BAO_0000219,,F,,,9606.0,A549,N
5776,Intermediate,,,,In vitro cytotoxicity against A549 (human lung cancer),80682,Homo sapiens,5895,BAO_0000219,,F,,,9606.0,A549,N
5777,Expert,,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,80682,Homo sapiens,14297,BAO_0000219,,F,,,9606.0,A549,N
5778,Intermediate,,,,In vivo antiproliferative activity against A549 cell line,80682,Homo sapiens,17824,BAO_0000218,,F,,,9606.0,A549,N
5779,Intermediate,,,,Inhibition of non-small-cell lung adenocarcinoma (A549),80682,Homo sapiens,14368,BAO_0000219,,F,,,9606.0,A549,N
5780,Intermediate,,,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,80682,Homo sapiens,14368,BAO_0000219,,F,,,9606.0,A549,N
5781,Intermediate,,,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,80682,Homo sapiens,14254,BAO_0000219,,F,,,9606.0,A549,N
5782,Intermediate,,,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),80682,Homo sapiens,15897,BAO_0000219,,F,,,9606.0,A549,N
5783,Intermediate,,,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,80682,Homo sapiens,13866,BAO_0000219,,F,,,9606.0,A549,N
5784,Intermediate,,,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,80682,Homo sapiens,13370,BAO_0000219,,F,,,9606.0,A549,N
5785,Intermediate,,,,Inhibitory activity against A549 lung cancer cell line,80682,Homo sapiens,4862,BAO_0000219,,F,,,9606.0,A549,N
5786,Intermediate,,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,80682,Homo sapiens,4862,BAO_0000219,,F,,,9606.0,A549,N
5787,Intermediate,,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,80682,Homo sapiens,4862,BAO_0000219,,F,,,9606.0,A549,N
5788,Intermediate,,,,Inhibitory concentration against A549 (lung cancer) cell line,80682,Homo sapiens,15970,BAO_0000219,,F,,,9606.0,A549,N
5789,Expert,,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,80682,Homo sapiens,17713,BAO_0000219,,F,,,9606.0,A549,N
5790,Intermediate,,,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,80682,Homo sapiens,4833,BAO_0000219,,F,,,9606.0,A549,N
5791,Expert,,,,Activity against A549 cancer cell line.,80682,Homo sapiens,13736,BAO_0000219,,F,,,9606.0,A549,N
5792,Intermediate,,,,The compound was evaluated for cytotoxicity against A549 cell line,80682,Homo sapiens,4312,BAO_0000219,,F,,,9606.0,A549,N
5793,Intermediate,,,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,80682,Homo sapiens,5421,BAO_0000219,,F,,,9606.0,A549,N
5794,Intermediate,,,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,80682,Homo sapiens,5421,BAO_0000219,,F,,,9606.0,A549,N
5795,Intermediate,,,,Growth inhibitory activity was measured for human A549 tumor cell line.,80682,Homo sapiens,14717,BAO_0000219,,F,,,9606.0,A549,N
5796,Intermediate,,,,Inhibitory activity against A549 lung cancer cell line,80682,Homo sapiens,4634,BAO_0000219,,F,,,9606.0,A549,N
5797,Intermediate,,,,Inhibitory activity against A549 cell line; inactive,80682,Homo sapiens,1149,BAO_0000219,,F,,,9606.0,A549,N
5798,Expert,,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,80682,Homo sapiens,5421,BAO_0000219,,F,,,9606.0,A549,N
5799,Expert,,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,80682,Homo sapiens,5421,BAO_0000219,,F,,,9606.0,A549,N
5800,Intermediate,,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,80682,Homo sapiens,5421,BAO_0000219,,F,,,9606.0,A549,N
5801,Intermediate,,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),80682,Homo sapiens,3320,BAO_0000219,,F,,,9606.0,A549,N
5802,Intermediate,,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),80682,Homo sapiens,3320,BAO_0000219,,F,,,9606.0,A549,N
5803,Intermediate,,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),80682,Homo sapiens,3320,BAO_0000219,,F,,,9606.0,A549,N
5804,Intermediate,,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),80682,Homo sapiens,3320,BAO_0000219,,F,,,9606.0,A549,N
5805,Intermediate,,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),80682,Homo sapiens,3320,BAO_0000219,,F,,,9606.0,A549,N
5806,Intermediate,,,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,80682,Homo sapiens,5726,BAO_0000219,,F,,,9606.0,A549,N
5807,Intermediate,,,,Plasma clearance (in vivo) in mongrel dogs was determined,50588,Canis lupus familiaris,17800,BAO_0000218,,A,In vivo,,9615.0,,N
5808,Intermediate,,,,Plasma clearance was measured in dog,50588,Canis lupus familiaris,5985,BAO_0000218,,A,In vivo,,9615.0,,N
5809,Intermediate,,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,50588,Canis lupus familiaris,5530,BAO_0000218,,A,In vivo,,9615.0,,N
5810,Intermediate,,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,50588,Canis lupus familiaris,5530,BAO_0000218,,A,In vivo,,9615.0,,N
5811,Intermediate,,Plasma,1969.0,Tested for plasma clearance in dog,50588,Canis lupus familiaris,4839,BAO_0000218,,A,In vivo,,9615.0,,N
5812,Intermediate,,,,The compound was tested for clearance in dog plasma.,50588,Canis lupus familiaris,3639,BAO_0000218,,A,In vivo,,9615.0,,N
5813,Intermediate,,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",50588,Canis lupus familiaris,4838,BAO_0000218,,A,In vivo,,9615.0,,N
5814,Intermediate,,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,50588,Canis lupus familiaris,4137,BAO_0000218,,A,In vivo,,9615.0,,N
5815,Intermediate,,Plasma,1969.0,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),50588,Canis lupus familiaris,5017,BAO_0000218,,A,In vivo,,9615.0,,N
5816,Intermediate,Microsomes,Liver,2107.0,In vitro clearance in dog liver microsomes,50588,Canis lupus familiaris,17538,BAO_0000218,,A,In vitro,,9615.0,,N
5817,Intermediate,,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,50588,Canis lupus familiaris,6161,BAO_0000218,,A,In vivo,,9615.0,,N
5818,Intermediate,,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,50588,Canis lupus familiaris,6161,BAO_0000218,,A,In vivo,,9615.0,,N
5819,Intermediate,,,,Plasma clearance in dog,50588,Canis lupus familiaris,1696,BAO_0000218,,A,In vivo,,9615.0,,N
5820,Intermediate,,,,Clearance rate in dog,50588,Canis lupus familiaris,6762,BAO_0000218,,A,In vivo,,9615.0,,N
5821,Intermediate,,Plasma,1969.0,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,50588,Canis lupus familiaris,5932,BAO_0000218,,A,In vivo,,9615.0,,N
5822,Intermediate,,,,Clearance in dogs,50588,Canis lupus familiaris,6305,BAO_0000218,,A,In vivo,,9615.0,,N
5823,Intermediate,,,,Plasma clearance in dogs,50588,Canis lupus familiaris,4942,BAO_0000218,,A,In vivo,,9615.0,,N
5824,Intermediate,,,,Plasma clearance was determined,50588,Canis lupus familiaris,4219,BAO_0000218,,A,In vivo,,9615.0,,N
5825,Intermediate,,,,Lower clearance in dog (i.v.) at 0.5 mpk,50588,Canis lupus familiaris,17853,BAO_0000218,,A,In vivo,,9615.0,,N
5826,Intermediate,,,,Plasma clearance in Beagle dogs,50588,Canis lupus familiaris,4514,BAO_0000218,,A,In vivo,,9615.0,,N
5827,Intermediate,,,,Plasma clearance (Clp) in dog,50588,Canis lupus familiaris,6448,BAO_0000218,,A,In vivo,,9615.0,,N
5828,Intermediate,,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,50588,Canis lupus familiaris,6227,BAO_0000218,,A,In vivo,,9615.0,,N
5829,Intermediate,,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,50588,Canis lupus familiaris,6227,BAO_0000218,,A,In vivo,,9615.0,,N
5830,Intermediate,,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,50588,Canis lupus familiaris,6062,BAO_0000218,,A,In vivo,,9615.0,,N
5831,Intermediate,,,,Plasma clearance of compound was determined in dog,50588,Canis lupus familiaris,6821,BAO_0000218,,A,In vivo,,9615.0,,N
5832,Intermediate,,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,50588,Canis lupus familiaris,4709,BAO_0000218,,A,In vivo,,9615.0,,N
5833,Intermediate,,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,Canis lupus familiaris,4521,BAO_0000218,,A,In vivo,,9615.0,,N
5834,Intermediate,,,,Plasma clearance in dog was determined,50588,Canis lupus familiaris,5374,BAO_0000218,,A,In vivo,,9615.0,,N
5835,Intermediate,,,,Plasma clearance was calculated in dog,50588,Canis lupus familiaris,6057,BAO_0000218,,A,In vivo,,9615.0,,N
5836,Intermediate,,,,Plasma clearance at the dose of 2 mg/kg in dog,50588,Canis lupus familiaris,4727,BAO_0000218,,A,In vivo,,9615.0,,N
5837,Intermediate,,,,Plasma clearance in dog,50588,Canis lupus familiaris,5145,BAO_0000218,,A,In vivo,,9615.0,,N
5838,Intermediate,,,,Plasma clearance in dog,50588,Canis lupus familiaris,17657,BAO_0000218,,A,In vivo,,9615.0,,N
5839,Intermediate,,,,Plasma clearance in dog; Unable to calculate,50588,Canis lupus familiaris,17657,BAO_0000218,,A,In vivo,,9615.0,,N
5840,Intermediate,,,,Plasma clearance in rhesus monkey,50588,Canis lupus familiaris,5145,BAO_0000218,,A,In vivo,,9615.0,,N
5841,Intermediate,,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,Canis lupus familiaris,6642,BAO_0000218,,A,In vivo,,9615.0,,N
5842,Intermediate,,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,Canis lupus familiaris,6641,BAO_0000218,,A,In vivo,,9615.0,,N
5843,Intermediate,,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,Canis lupus familiaris,6642,BAO_0000218,,A,In vivo,,9615.0,,N
5844,Intermediate,,,,Plasma clearance was evaluated in dog,50588,Canis lupus familiaris,5472,BAO_0000218,,A,In vivo,,9615.0,,N
5845,Intermediate,,,,Plasma clearance was evaluated in dog; Not tested,50588,Canis lupus familiaris,5472,BAO_0000218,,A,In vivo,,9615.0,,N
5846,Intermediate,,,,Plasma clearance was evaluated in rhesus,50588,Canis lupus familiaris,5472,BAO_0000218,,A,In vivo,,9615.0,,N
5847,Intermediate,,,,Plasma clearance was evaluated in rhesus; Not tested,50588,Canis lupus familiaris,5472,BAO_0000218,,A,In vivo,,9615.0,,N
5848,Intermediate,,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,50588,Canis lupus familiaris,4257,BAO_0000218,,A,In vivo,,9615.0,,N
5849,Intermediate,,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,Canis lupus familiaris,6679,BAO_0000218,,A,In vivo,,9615.0,,N
5850,Intermediate,,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,Canis lupus familiaris,5546,BAO_0000218,,A,In vivo,,9615.0,,N
5851,Intermediate,,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,Canis lupus familiaris,6348,BAO_0000218,,A,In vivo,,9615.0,,N
5852,Intermediate,,,,Clearance value at a dose of 0.2 mg/kg i.v.,50588,Canis lupus familiaris,5474,BAO_0000218,,A,In vivo,,9615.0,,N
5853,Intermediate,,Plasma,1969.0,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,50588,Canis lupus familiaris,6316,BAO_0000218,,A,In vivo,,9615.0,,N
5854,Intermediate,,,,Cmax after oral dose of compound at 3 mg/kg in dogs,50588,Canis lupus familiaris,17594,BAO_0000218,,A,In vivo,,9615.0,,N
5855,Intermediate,,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,50588,Canis lupus familiaris,17594,BAO_0000218,,A,In vivo,,9615.0,,N
5856,Intermediate,,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,Canis lupus familiaris,5802,BAO_0000218,,A,In vivo,,9615.0,,N
5857,Intermediate,,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,50588,Canis lupus familiaris,6535,BAO_0000218,,A,In vivo,,9615.0,,N
5858,Intermediate,,,,Cmax in dog after administration of 1 mg/kg iv,50588,Canis lupus familiaris,6535,BAO_0000218,,A,In vivo,,9615.0,,N
5859,Intermediate,,Plasma,1969.0,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,50588,Canis lupus familiaris,1466,BAO_0000218,,A,In vivo,,9615.0,,N
5860,Intermediate,,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,50588,Canis lupus familiaris,6505,BAO_0000218,,A,In vivo,,9615.0,,N
5861,Intermediate,,,,Cmax was determine after peroral administration at 10 mpk in dog,50588,Canis lupus familiaris,5668,BAO_0000218,,A,In vivo,,9615.0,,N
5862,Intermediate,,,,Cmax was determine after peroral administration at 5 mpk in dog,50588,Canis lupus familiaris,5668,BAO_0000218,,A,In vivo,,9615.0,,N
5863,Intermediate,,,,Cmax was determine after peroral administration at 5 mg/kg in dog,50588,Canis lupus familiaris,5668,BAO_0000218,,A,In vivo,,9615.0,,N
5864,Intermediate,,,,Cmax after 0.3 mg/kg po administration in dog,50588,Canis lupus familiaris,5600,BAO_0000218,,A,In vivo,,9615.0,,N
5865,Intermediate,,,,Cmax after peroral administration in dogs at 2.4 uM/kg,50588,Canis lupus familiaris,17764,BAO_0000218,,A,In vivo,,9615.0,,N
5866,Intermediate,,,,Cmax in dog after oral administration at 1 mg/kg,50588,Canis lupus familiaris,6123,BAO_0000218,,A,In vivo,,9615.0,,N
5867,Intermediate,,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,50588,Canis lupus familiaris,6123,BAO_0000218,,A,In vivo,,9615.0,,N
5868,Intermediate,,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,50588,Canis lupus familiaris,6757,BAO_0000218,,A,In vivo,,9615.0,,N
5869,Intermediate,,,,Cmax value after 15 mg/kg iv dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,In vivo,,9615.0,,N
5870,Intermediate,,Blood,178.0,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5871,Intermediate,,Blood,178.0,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5872,Intermediate,,Bone,10000001.0,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5873,Intermediate,,Bone,10000001.0,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5874,Intermediate,,Bone,10000001.0,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5875,Intermediate,,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5876,Intermediate,,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5877,Intermediate,,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5878,Intermediate,,Heart,948.0,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5879,Intermediate,,Heart,948.0,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5880,Intermediate,,Heart,948.0,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5881,Intermediate,,Kidney,2113.0,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5882,Intermediate,,Kidney,2113.0,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5883,Intermediate,,Kidney,2113.0,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5884,Intermediate,,Intestine,160.0,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5885,Intermediate,,Intestine,160.0,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5886,Intermediate,,Intestine,160.0,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5887,Intermediate,,Liver,2107.0,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5888,Intermediate,,Liver,2107.0,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5889,Intermediate,,Liver,2107.0,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5890,Intermediate,,Lung,2048.0,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5891,Intermediate,,Lung,2048.0,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5892,Intermediate,,Lung,2048.0,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5893,Intermediate,,Muscle tissue,2385.0,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5894,Intermediate,,Muscle tissue,2385.0,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5895,Intermediate,,Muscle tissue,2385.0,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5896,Intermediate,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5897,Intermediate,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5898,Intermediate,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5899,Intermediate,,Intestine,160.0,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5900,Intermediate,,Intestine,160.0,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5901,Intermediate,,Intestine,160.0,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5902,Intermediate,,Spleen,2106.0,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5903,Intermediate,,Spleen,2106.0,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5904,Intermediate,,Spleen,2106.0,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5905,Intermediate,,Stomach,945.0,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5906,Intermediate,,Stomach,945.0,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
5907,Expert,,,,Cytotoxicity against A-172 human tumor cell lines,80012,Homo sapiens,2036,BAO_0000219,,F,,,9606.0,A 172,N
5908,Intermediate,,,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,80012,Homo sapiens,2357,BAO_0000219,,F,,,9606.0,A 172,N
5909,Intermediate,,,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,80014,Homo sapiens,1457,BAO_0000219,,F,,,9606.0,A204,N
5910,Intermediate,,,,Tested for antiproliferative activity against A-2780 tumoral cell line,81034,Homo sapiens,4379,BAO_0000219,,F,,,9606.0,A2780,N
5911,Intermediate,,,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,80018,Homo sapiens,1093,BAO_0000219,,F,,,9606.0,A-375,N
5912,Intermediate,,,,Tested in vitro against A-375 cell line human melanoma,80018,Homo sapiens,12152,BAO_0000219,,F,,,9606.0,A-375,N
5913,Expert,,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,80019,Homo sapiens,16464,BAO_0000219,,F,,,9606.0,A-427,N
5914,Intermediate,,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80019,Homo sapiens,16464,BAO_0000219,,F,,,9606.0,A-427,N
5915,Expert,,,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,80019,Homo sapiens,16582,BAO_0000219,,F,,,9606.0,A-427,N
5916,Intermediate,,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80019,Homo sapiens,16464,BAO_0000219,,F,,,9606.0,A-427,N
5917,Intermediate,,,,Antitumor activity on A-427 lung carcinoma cell lines,80019,Homo sapiens,10413,BAO_0000219,,F,,,9606.0,A-427,N
5918,Intermediate,,,,Cytotoxic activity against human A-427 lung tumor cell line,80019,Homo sapiens,6418,BAO_0000219,,F,,,9606.0,A-427,N
5919,Expert,,,,In vitro antitumor effects against human A-427 cell lines.,80019,Homo sapiens,17134,BAO_0000219,,F,,,9606.0,A-427,N
5920,Expert,,,,In vitro inhibition of A-427 (human lung cancer) cell growth.,80019,Homo sapiens,16132,BAO_0000219,,F,,,9606.0,A-427,N
5921,Intermediate,,,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,80019,Homo sapiens,16132,BAO_0000219,,F,,,9606.0,A-427,N
5922,Intermediate,,,,Cytotoxic activity of compound against A-427 lung human tumor cell line,80019,Homo sapiens,16780,BAO_0000219,,F,,,9606.0,A-427,N
5923,Expert,,,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,80852,Homo sapiens,4085,BAO_0000219,,F,,,9606.0,A-431,N
5924,Intermediate,,,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,80021,Homo sapiens,1276,BAO_0000219,,F,,,9606.0,A498,N
5925,Expert,,,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,80021,Homo sapiens,3498,BAO_0000219,,F,,,9606.0,A498,N
5926,Intermediate,,,,Cytotoxicity against human kidney carcinoma A-498cell lines,80021,Homo sapiens,1169,BAO_0000219,,F,,,9606.0,A498,N
5927,Intermediate,,,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,80021,Homo sapiens,4450,BAO_0000219,,F,,,9606.0,A498,N
5928,Intermediate,,,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,80021,Homo sapiens,3311,BAO_0000219,,F,,,9606.0,A498,N
5929,Intermediate,,,,Antitumor cytotoxic activity against A-498 cell line was determined,80021,Homo sapiens,4461,BAO_0000219,,F,,,9606.0,A498,N
5930,Intermediate,,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,80021,Homo sapiens,3311,BAO_0000219,,F,,,9606.0,A498,N
5931,Intermediate,,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,80021,Homo sapiens,3311,BAO_0000219,,F,,,9606.0,A498,N
5932,Intermediate,,,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,80021,Homo sapiens,1457,BAO_0000219,,F,,,9606.0,A498,N
5933,Intermediate,,,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,80021,Homo sapiens,3664,BAO_0000219,,F,,,9606.0,A498,N
5934,Intermediate,,,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",80021,Homo sapiens,15895,BAO_0000219,,F,,,9606.0,A498,N
5935,Intermediate,,,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,80682,Homo sapiens,11843,BAO_0000219,,F,,,9606.0,A549,N
5936,Intermediate,,,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,80682,Homo sapiens,11843,BAO_0000219,,F,,,9606.0,A549,N
5937,Intermediate,,,,In vitro antiproliferative activity against human A-549 NSCL cell line,80682,Homo sapiens,17705,BAO_0000219,,F,,,9606.0,A549,N
5938,Intermediate,,,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,80682,Homo sapiens,17705,BAO_0000219,,F,,,9606.0,A549,N
5939,Intermediate,,,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,80682,Homo sapiens,4369,BAO_0000219,,F,,,9606.0,A549,N
5940,Intermediate,,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,80682,Homo sapiens,4369,BAO_0000219,,F,,,9606.0,A549,N
5941,Intermediate,,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,80682,Homo sapiens,4369,BAO_0000219,,F,,,9606.0,A549,N
5942,Intermediate,,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,80682,Homo sapiens,4369,BAO_0000219,,F,,,9606.0,A549,N
5943,Intermediate,,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,80682,Homo sapiens,4369,BAO_0000219,,F,,,9606.0,A549,N
5944,Intermediate,,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,80682,Homo sapiens,4369,BAO_0000219,,F,,,9606.0,A549,N
5945,Intermediate,,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,80682,Homo sapiens,4369,BAO_0000219,,F,,,9606.0,A549,N
5946,Expert,,,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,80682,Homo sapiens,4787,BAO_0000219,,F,,,9606.0,A549,N
5947,Intermediate,,,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,80682,Homo sapiens,4787,BAO_0000219,,F,,,9606.0,A549,N
5948,Intermediate,,,,Cytotoxic activity against A-549 cell line,80682,Homo sapiens,6513,BAO_0000219,,F,,,9606.0,A549,N
5949,Intermediate,,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,80682,Homo sapiens,6690,BAO_0000219,,F,,,9606.0,A549,N
5950,Intermediate,,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,80682,Homo sapiens,6690,BAO_0000219,,F,,,9606.0,A549,N
5951,Expert,,,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",80682,Homo sapiens,12263,BAO_0000219,,F,,,9606.0,A549,N
5952,Intermediate,,,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),80682,Homo sapiens,1054,BAO_0000219,,F,,,9606.0,A549,N
5953,Intermediate,,,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),80682,Homo sapiens,1359,BAO_0000219,,F,,,9606.0,A549,N
5954,Intermediate,,,,Cytotoxic activity against human lung carcinoma (A-549) cell line,80682,Homo sapiens,3547,BAO_0000219,,F,,,9606.0,A549,N
5955,Expert,,,,Cytotoxic activity towards A-549 cells,80682,Homo sapiens,5771,BAO_0000219,,F,,,9606.0,A549,N
5956,Intermediate,,,,"In vitro percent inhibition of A549, lung carcinoma.",80682,Homo sapiens,14425,BAO_0000219,,F,,,9606.0,A549,N
5957,Intermediate,,,,"In vitro percent inhibition of A549, lung carcinoma",80682,Homo sapiens,14425,BAO_0000219,,F,,,9606.0,A549,N
5958,Intermediate,,,,"In vitro percent inhibition of A549, lung carcinoma.",80682,Homo sapiens,14425,BAO_0000219,,F,,,9606.0,A549,N
5959,Intermediate,,,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",80682,Homo sapiens,14425,BAO_0000219,,F,,,9606.0,A549,N
5960,Intermediate,,,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,80682,Homo sapiens,5280,BAO_0000219,,F,,,9606.0,A549,N
5961,Intermediate,,,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,80682,Homo sapiens,15176,BAO_0000219,,F,,,9606.0,A549,N
5962,Intermediate,,,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,80682,Homo sapiens,15300,BAO_0000219,,F,,,9606.0,A549,N
5963,Intermediate,,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,Homo sapiens,17824,BAO_0000218,,F,,,9606.0,A549,N
5964,Intermediate,,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,Homo sapiens,17824,BAO_0000218,,F,,,9606.0,A549,N
5965,Intermediate,,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,Homo sapiens,17824,BAO_0000218,,F,,,9606.0,A549,N
5966,Intermediate,,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,Homo sapiens,17824,BAO_0000218,,F,,,9606.0,A549,N
5967,Intermediate,,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,Homo sapiens,17824,BAO_0000218,,F,,,9606.0,A549,N
5968,Intermediate,,,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",80682,Homo sapiens,17824,BAO_0000219,,F,,,9606.0,A549,N
5969,Intermediate,,,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),80682,Homo sapiens,17528,BAO_0000218,,F,,,9606.0,A549,N
5970,Expert,,,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,80682,Homo sapiens,6870,BAO_0000219,,F,,,9606.0,A549,N
5971,Intermediate,,,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,80682,Homo sapiens,6870,BAO_0000219,,F,,,9606.0,A549,N
5972,Intermediate,,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,80682,Homo sapiens,6870,BAO_0000219,,F,,,9606.0,A549,N
5973,Intermediate,,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,80682,Homo sapiens,6870,BAO_0000219,,F,,,9606.0,A549,N
5974,Intermediate,,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,80682,Homo sapiens,16726,BAO_0000219,,F,,,9606.0,A549,N
5975,Intermediate,,,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",80682,Homo sapiens,6170,BAO_0000219,,F,,,9606.0,A549,N
5976,Expert,,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,80682,Homo sapiens,6583,BAO_0000219,,F,,,9606.0,A549,N
5977,Expert,,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,80682,Homo sapiens,6583,BAO_0000219,,F,,,9606.0,A549,N
5978,Expert,,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,80682,Homo sapiens,6583,BAO_0000219,,F,,,9606.0,A549,N
5979,Expert,,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,80682,Homo sapiens,6583,BAO_0000219,,F,,,9606.0,A549,N
5980,Expert,,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,80682,Homo sapiens,6583,BAO_0000219,,F,,,9606.0,A549,N
5981,Intermediate,,,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,80682,Homo sapiens,17321,BAO_0000219,,F,,,9606.0,A549,N
5982,Expert,,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,80682,Homo sapiens,17528,BAO_0000219,,F,,,9606.0,A549,N
5983,Expert,,,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,80682,Homo sapiens,12888,BAO_0000219,,F,,,9606.0,A549,N
5984,Intermediate,,,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,80682,Homo sapiens,4312,BAO_0000219,,F,,,9606.0,A549,N
5985,Intermediate,,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,80682,Homo sapiens,4312,BAO_0000219,,F,,,9606.0,A549,N
5986,Intermediate,,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,80682,Homo sapiens,4312,BAO_0000219,,F,,,9606.0,A549,N
5987,Intermediate,,,,In vitro antiproliferative activity against A549 cell line,80682,Mus musculus,17737,BAO_0000219,,F,,,10090.0,A549,N
5988,Intermediate,,,,Synergism with indomethacin in A549 cells,80682,,6630,BAO_0000219,,F,,,,A549,N
5989,Intermediate,,,,Synergism with tolmetin in A549 cells,80682,,6630,BAO_0000219,,F,,,,A549,N
5990,Intermediate,,,,Synergism with sulindac in A549 cells,80682,,6630,BAO_0000219,,F,,,,A549,N
5991,Intermediate,,,,Antagonism of indomethacin in A549 cells,80682,,6630,BAO_0000219,,F,,,,A549,N
5992,Intermediate,,,,Antagonism of sulindac in A549 cells,80682,,6630,BAO_0000219,,F,,,,A549,N
5993,Intermediate,,,,Antagonism of tolmetin in A549 cells,80682,,6630,BAO_0000219,,F,,,,A549,N
5994,Intermediate,,,,Synergism with indomethacin in A549 cells,80682,,6630,BAO_0000219,,F,,,,A549,N
5995,Intermediate,,,,Synergism with sulindac in A549 cells,80682,,6630,BAO_0000219,,F,,,,A549,N
5996,Intermediate,,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,80682,,6630,BAO_0000219,,F,,,,A549,N
5997,Intermediate,,,,Cmax value after 30 mg/kg po dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,In vivo,,9615.0,,N
5998,Intermediate,,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),50588,Canis lupus familiaris,5944,BAO_0000218,,A,In vivo,,9615.0,,N
5999,Intermediate,,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,50588,Canis lupus familiaris,5944,BAO_0000218,,A,In vivo,,9615.0,,N
6000,Intermediate,,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),50588,Canis lupus familiaris,5944,BAO_0000218,,A,In vivo,,9615.0,,N
6001,Intermediate,,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,50588,Canis lupus familiaris,5944,BAO_0000218,,A,In vivo,,9615.0,,N
6002,Intermediate,,,,Cmax value after administration of 4 mg/Kg oral dose in dog,50588,Canis lupus familiaris,2959,BAO_0000218,,A,In vivo,,9615.0,,N
6003,Intermediate,,,,Cmax value in dog,50588,Canis lupus familiaris,6241,BAO_0000218,,A,In vivo,,9615.0,,N
6004,Intermediate,,,,Cmax value in dogs after oral administration at 1 mg/kg,50588,Canis lupus familiaris,6241,BAO_0000218,,A,In vivo,,9615.0,,N
6005,Intermediate,,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,50588,Canis lupus familiaris,2652,BAO_0000218,,A,In vivo,,9615.0,,N
6006,Intermediate,,Plasma,1969.0,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,50588,Canis lupus familiaris,1806,BAO_0000218,,A,In vivo,,9615.0,,N
6007,Intermediate,,Plasma,1969.0,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,50588,Canis lupus familiaris,1806,BAO_0000218,,A,In vivo,,9615.0,,N
6008,Intermediate,,,,Concentration maxima after oral dosing in dogs,50588,Canis lupus familiaris,1021,BAO_0000218,,A,In vivo,,9615.0,,N
6009,Intermediate,,,,Concentration maxima after oral dosing in dogs; not available,50588,Canis lupus familiaris,1021,BAO_0000218,,A,In vivo,,9615.0,,N
6010,Intermediate,,,,Concentration maxima after oral dosing in dogs; not available,50588,Canis lupus familiaris,1021,BAO_0000218,,A,In vivo,,9615.0,,N
6011,Intermediate,,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,50588,Canis lupus familiaris,5444,BAO_0000218,,A,In vivo,,9615.0,,N
6012,Intermediate,,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,50588,Canis lupus familiaris,5444,BAO_0000218,,A,In vivo,,9615.0,,N
6013,Intermediate,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,50588,Canis lupus familiaris,5444,BAO_0000218,,A,In vivo,,9615.0,,N
6014,Intermediate,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,50588,Canis lupus familiaris,5444,BAO_0000218,,A,In vivo,,9615.0,,N
6015,Intermediate,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,50588,Canis lupus familiaris,5444,BAO_0000218,,A,In vivo,,9615.0,,N
6016,Intermediate,,Plasma,1969.0,Cmax in dog plasma after oral dose (1 mg/kg),50588,Canis lupus familiaris,5130,BAO_0000218,,A,In vivo,,9615.0,,N
6017,Intermediate,,Plasma,1969.0,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,50588,Canis lupus familiaris,3249,BAO_0000218,,A,In vivo,,9615.0,,N
6018,Intermediate,,Plasma,1969.0,Maximal plasma concentration at a dose of 1 mg/kg,50588,Canis lupus familiaris,5473,BAO_0000218,,A,In vivo,,9615.0,,N
6019,Intermediate,,Plasma,1969.0,Maximal plasma concentration at a dose of 1 mg/kg (oral),50588,Canis lupus familiaris,5474,BAO_0000218,,A,In vivo,,9615.0,,N
6020,Intermediate,,Plasma,1969.0,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,50588,Canis lupus familiaris,4657,BAO_0000218,,A,In vivo,,9615.0,,N
6021,Intermediate,,,,Maximum concentration of compound in dog was evaluated.,50588,Canis lupus familiaris,3031,BAO_0000218,,A,In vivo,,9615.0,,N
6022,Intermediate,,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,50588,Canis lupus familiaris,4527,BAO_0000218,,A,In vivo,,9615.0,,N
6023,Intermediate,,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,50588,Canis lupus familiaris,4186,BAO_0000218,,A,In vivo,,9615.0,,N
6024,Intermediate,,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,Canis lupus familiaris,5007,BAO_0000218,,A,In vivo,,9615.0,,N
6025,Intermediate,,Plasma,1969.0,Maximum concentration obtained in dog plasma was determined,50588,Canis lupus familiaris,3132,BAO_0000218,,A,In vivo,,9615.0,,N
6026,Intermediate,,,,Maximum concentration was determined,50588,Canis lupus familiaris,5006,BAO_0000218,,A,In vivo,,9615.0,,N
6027,Intermediate,,,,Maximum concentration at the dose of 2 mg/kg in dog,50588,Canis lupus familiaris,4727,BAO_0000218,,A,In vivo,,9615.0,,N
6028,Intermediate,,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,Canis lupus familiaris,1916,BAO_0000218,,A,In vivo,,9615.0,,N
6029,Intermediate,,Plasma,1969.0,Maximum concentration was evaluated in dog plasma,50588,Canis lupus familiaris,1918,BAO_0000218,,A,In vivo,,9615.0,,N
6030,Intermediate,,,,Maximum concentration was evaluated after 75 min after administration in dog,50588,Canis lupus familiaris,3045,BAO_0000218,,A,In vivo,,9615.0,,N
6031,Intermediate,,Plasma,1969.0,Maximum plasma concentration determined in dog after oral administration of 17b,50588,Canis lupus familiaris,9579,BAO_0000218,,A,In vivo,,9615.0,,N
6032,Intermediate,,Plasma,1969.0,Maximum plasma concentration determined in dog after oral administration of 2b,50588,Canis lupus familiaris,9579,BAO_0000218,,A,In vivo,,9615.0,,N
6033,Intermediate,,Plasma,1969.0,Maximum plasma concentration in dog,50588,Canis lupus familiaris,933,BAO_0000218,,A,In vivo,,9615.0,,N
6034,Intermediate,,Plasma,1969.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,50588,Canis lupus familiaris,17839,BAO_0000218,,A,In vivo,,9615.0,,N
6035,Intermediate,,Plasma,1969.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,50588,Canis lupus familiaris,17839,BAO_0000218,,A,In vivo,,9615.0,,N
6036,Intermediate,,Plasma,1969.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,50588,Canis lupus familiaris,17839,BAO_0000218,,A,In vivo,,9615.0,,N
6037,Intermediate,,Plasma,1969.0,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,50588,Canis lupus familiaris,17839,BAO_0000218,,A,In vivo,,9615.0,,N
6038,Intermediate,,Plasma,1969.0,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,Canis lupus familiaris,6348,BAO_0000218,,A,In vivo,,9615.0,,N
6039,Intermediate,,Plasma,1969.0,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,50588,Canis lupus familiaris,16367,BAO_0000218,,A,In vivo,,9615.0,,N
6040,Intermediate,,Plasma,1969.0,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,Canis lupus familiaris,1337,BAO_0000218,,A,In vivo,,9615.0,,N
6041,Intermediate,,Plasma,1969.0,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,Canis lupus familiaris,1337,BAO_0000218,,A,In vivo,,9615.0,,N
6042,Intermediate,,Plasma,1969.0,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,50588,Canis lupus familiaris,5199,BAO_0000218,,A,In vivo,,9615.0,,N
6043,Intermediate,,Plasma,1969.0,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,50588,Canis lupus familiaris,17650,BAO_0000218,,A,In vivo,,9615.0,,N
6044,Intermediate,,Plasma,1969.0,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,50588,Canis lupus familiaris,6679,BAO_0000218,,A,In vivo,,9615.0,,N
6045,Intermediate,,Plasma,1969.0,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,50588,Canis lupus familiaris,5356,BAO_0000218,,A,In vivo,,9615.0,,N
6046,Intermediate,,Plasma,1969.0,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,50588,Canis lupus familiaris,5356,BAO_0000218,,A,In vivo,,9615.0,,N
6047,Intermediate,,Plasma,1969.0,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,50588,Canis lupus familiaris,6227,BAO_0000218,,A,In vivo,,9615.0,,N
6048,Intermediate,,Plasma,1969.0,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,50588,Canis lupus familiaris,6227,BAO_0000218,,A,In vivo,,9615.0,,N
6049,Intermediate,,Plasma,1969.0,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,50588,Canis lupus familiaris,6227,BAO_0000218,,A,In vivo,,9615.0,,N
6050,Intermediate,,Plasma,1969.0,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,50588,Canis lupus familiaris,6227,BAO_0000218,,A,In vivo,,9615.0,,N
6051,Expert,,Plasma,1969.0,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,Canis lupus familiaris,3598,BAO_0000218,,A,In vivo,,9615.0,,N
6052,Intermediate,,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,50588,Canis lupus familiaris,4368,BAO_0000218,,A,In vivo,,9615.0,,N
6053,Intermediate,,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,50588,Canis lupus familiaris,6265,BAO_0000218,,A,In vivo,,9615.0,,N
6054,Intermediate,,Stomach,945.0,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
6055,Intermediate,,Urine,1088.0,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
6056,Intermediate,,Urine,1088.0,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
6057,Intermediate,,Urine,1088.0,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,50594,Mus musculus,7767,BAO_0000218,,A,In vivo,,10090.0,,N
6058,Intermediate,,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,50594,Mus musculus,17811,BAO_0000218,,A,,,10090.0,,N
6059,Intermediate,,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,50594,Mus musculus,17811,BAO_0000218,,A,,,10090.0,,N
6060,Intermediate,,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6061,Intermediate,,Blood,178.0,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6062,Intermediate,,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6063,Intermediate,,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6064,Intermediate,,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6065,Intermediate,,Blood,178.0,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6066,Intermediate,,Blood,178.0,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6067,Intermediate,,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6068,Intermediate,,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6069,Intermediate,,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6070,Intermediate,,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6071,Intermediate,,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6072,Intermediate,,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,50594,Mus musculus,17257,BAO_0000218,,A,,,10090.0,,N
6073,Intermediate,,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,50594,Mus musculus,17257,BAO_0000218,,A,,,10090.0,,N
6074,Intermediate,,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,50594,Mus musculus,17257,BAO_0000218,,A,,,10090.0,,N
6075,Intermediate,,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,50594,Mus musculus,17257,BAO_0000218,,A,,,10090.0,,N
6076,Intermediate,,,,Time at maximum activity in mice (Radiolabeled compound),50594,Mus musculus,17827,BAO_0000218,,A,,,10090.0,,N
6077,Intermediate,,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,50594,Mus musculus,3760,BAO_0000218,,A,,,10090.0,,N
6078,Intermediate,,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,50594,Mus musculus,3760,BAO_0000218,,A,,,10090.0,,N
6079,Intermediate,,,,Binding towards mouse plasma protein at 10 uM,50594,Mus musculus,17409,BAO_0000218,,A,,,10090.0,,N
6080,Intermediate,,,,Binding towards mouse plasma protein at 100 uM,50594,Mus musculus,17409,BAO_0000218,,A,,,10090.0,,N
6081,Intermediate,,,,Bioavailability was evaluated in mice after intravenous administration,50594,Mus musculus,2675,BAO_0000218,,A,In vivo,,10090.0,,N
6082,Intermediate,,,,Bioavailability was evaluated in mice after oral administration,50594,Mus musculus,2675,BAO_0000218,,A,In vivo,,10090.0,,N
6083,Intermediate,,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,50594,Mus musculus,3132,BAO_0000218,,A,In vivo,,10090.0,,N
6084,Intermediate,,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,50594,Mus musculus,3132,BAO_0000218,,A,In vivo,,10090.0,,N
6085,Intermediate,,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
6086,Intermediate,,,,Oral bioavailability in mouse,50594,Mus musculus,2862,BAO_0000218,,A,In vivo,,10090.0,,N
6087,Intermediate,,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,50594,Mus musculus,17764,BAO_0000218,,A,In vivo,,10090.0,,N
6088,Intermediate,,Brain,955.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6089,Intermediate,,Brain,955.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6090,Intermediate,,Brain,955.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6091,Intermediate,,Brain,955.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6092,Intermediate,,Brain,955.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6093,Intermediate,,Brain,955.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6094,Intermediate,,Heart,948.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6095,Intermediate,,Heart,948.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6096,Intermediate,,Heart,948.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6097,Intermediate,,Heart,948.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6098,Intermediate,,,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),80682,Homo sapiens,1276,BAO_0000219,,F,,,9606.0,A549,N
6099,Expert,,,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,80682,Homo sapiens,3498,BAO_0000219,,F,,,9606.0,A549,N
6100,Intermediate,,,,Cytotoxicity against human lung carcinoma A-549 cell lines,80682,Homo sapiens,1169,BAO_0000219,,F,,,9606.0,A549,N
6101,Intermediate,,,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,80682,Homo sapiens,4450,BAO_0000219,,F,,,9606.0,A549,N
6102,Intermediate,,,,In vitro cytotoxicity against human lung carcinoma cell line A-549,80682,Homo sapiens,358,BAO_0000219,,F,,,9606.0,A549,N
6103,Intermediate,,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,80682,Homo sapiens,358,BAO_0000219,,F,,,9606.0,A549,N
6104,Intermediate,,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,80682,Homo sapiens,358,BAO_0000219,,F,,,9606.0,A549,N
6105,Intermediate,,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,80682,Homo sapiens,358,BAO_0000219,,F,,,9606.0,A549,N
6106,Intermediate,,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,80682,Homo sapiens,358,BAO_0000219,,F,,,9606.0,A549,N
6107,Intermediate,,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,80682,Homo sapiens,358,BAO_0000219,,F,,,9606.0,A549,N
6108,Intermediate,,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,80682,Homo sapiens,358,BAO_0000219,,F,,,9606.0,A549,N
6109,Intermediate,,,,In vitro cytotoxicity against A-549 human lung cancer cells,80682,Homo sapiens,15167,BAO_0000219,,F,,,9606.0,A549,N
6110,Intermediate,,,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,80682,Homo sapiens,4139,BAO_0000219,,F,,,9606.0,A549,N
6111,Intermediate,,,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,80682,Homo sapiens,833,BAO_0000219,,F,,,9606.0,A549,N
6112,Expert,,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,80682,Homo sapiens,15718,BAO_0000219,,F,,,9606.0,A549,N
6113,Intermediate,,,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,80682,Homo sapiens,12373,BAO_0000219,,F,,,9606.0,A549,N
6114,Intermediate,,,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,80682,Homo sapiens,637,BAO_0000219,,F,,,9606.0,A549,N
6115,Expert,,,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,80682,Homo sapiens,14867,BAO_0000219,,F,,,9606.0,A549,N
6116,Intermediate,,,,Antitumor cytotoxic activity against A-549 cell line was determined,80682,Homo sapiens,4461,BAO_0000219,,F,,,9606.0,A549,N
6117,Intermediate,,,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",80682,Homo sapiens,5406,BAO_0000219,,F,,,9606.0,A549,N
6118,Intermediate,,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,80682,Homo sapiens,4457,BAO_0000219,,F,,,9606.0,A549,N
6119,Expert,,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,80682,Homo sapiens,1386,BAO_0000219,,F,,,9606.0,A549,N
6120,Intermediate,,,,Antitumoral activity was assayed against A-549 cell line,80682,Homo sapiens,3265,BAO_0000219,,F,,,9606.0,A549,N
6121,Intermediate,,,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,80682,Homo sapiens,2359,BAO_0000219,,F,,,9606.0,A549,N
6122,Intermediate,,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,80682,Homo sapiens,4457,BAO_0000219,,F,,,9606.0,A549,N
6123,Expert,,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,Homo sapiens,12454,BAO_0000219,,F,,,9606.0,A549,N
6124,Intermediate,,,,Compound was tested for inhibition of cell growth of A-549 cells,80682,Homo sapiens,1481,BAO_0000219,,F,,,9606.0,A549,N
6125,Intermediate,,,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,80682,Homo sapiens,1750,BAO_0000219,,F,,,9606.0,A549,N
6126,Intermediate,,,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,80682,Homo sapiens,5065,BAO_0000219,,F,,,9606.0,A549,N
6127,Expert,,,,In vitro cytotoxicity against A549-human lung carcinoma cells.,80682,Homo sapiens,808,BAO_0000219,,F,,,9606.0,A549,N
6128,Expert,,,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,80682,Homo sapiens,16364,BAO_0000219,,F,,,9606.0,A549,N
6129,Intermediate,,,,Cytotoxic activity against A-549 cell lines.,80682,Homo sapiens,1847,BAO_0000219,,F,,,9606.0,A549,N
6130,Expert,,,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,80682,Homo sapiens,1747,BAO_0000219,,F,,,9606.0,A549,N
6131,Intermediate,,,,Cytotoxicity against human A549 non small cell lung cell lines,80682,Homo sapiens,1003,BAO_0000219,,F,,,9606.0,A549,N
6132,Expert,,,,Inhibition of cell growth in (A-549) lung cell line,80682,Homo sapiens,15313,BAO_0000219,,F,,,9606.0,A549,N
6133,Intermediate,,,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,80682,Homo sapiens,3122,BAO_0000219,,F,,,9606.0,A549,N
6134,Intermediate,,,,In vitro antitumor activity against A-549 tumor cells.,80682,Homo sapiens,16049,BAO_0000219,,F,,,9606.0,A549,N
6135,Expert,,,,In vitro antitumor effects against human A-549 cell lines.,80682,Homo sapiens,17134,BAO_0000219,,F,,,9606.0,A549,N
6136,Intermediate,,,,In vitro cytotoxic activity of compound against A-549 cell line,80682,Homo sapiens,6406,BAO_0000219,,F,,,9606.0,A549,N
6137,Intermediate,,,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,80682,Homo sapiens,627,BAO_0000219,,F,,,9606.0,A549,N
6138,Intermediate,,,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,80682,Homo sapiens,12307,BAO_0000219,,F,,,9606.0,A549,N
6139,Intermediate,,,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,80682,Homo sapiens,17861,BAO_0000219,,F,,,9606.0,A549,N
6140,Expert,,,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,80682,Homo sapiens,6682,BAO_0000219,,F,,,9606.0,A549,N
6141,Intermediate,,,,Inhibitory concentration of compound against A-549 cell line,80682,Homo sapiens,6663,BAO_0000219,,F,,,9606.0,A549,N
6142,Intermediate,,,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,80682,Homo sapiens,2454,BAO_0000219,,F,,,9606.0,A549,N
6143,Intermediate,,,,cytotoxic activity against leukemia (A-549) cancer cell line,80682,Homo sapiens,14709,BAO_0000219,,F,,,9606.0,A549,N
6144,Expert,,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,80682,Homo sapiens,15718,BAO_0000219,,F,,,9606.0,A549,N
6145,Intermediate,,,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,80682,Homo sapiens,15718,BAO_0000219,,F,,,9606.0,A549,N
6146,Intermediate,,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),80682,Homo sapiens,17130,BAO_0000219,,F,,,9606.0,A549,N
6147,Intermediate,,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),80682,Homo sapiens,17130,BAO_0000219,,F,,,9606.0,A549,N
6148,Intermediate,,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),80682,Homo sapiens,17130,BAO_0000219,,F,,,9606.0,A549,N
6149,Intermediate,,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),80682,Homo sapiens,17130,BAO_0000219,,F,,,9606.0,A549,N
6150,Intermediate,,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,80682,,6630,BAO_0000219,,F,,,,A549,N
6151,Intermediate,,,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,80682,Homo sapiens,16726,BAO_0000219,,F,,,9606.0,A549,N
6152,Intermediate,,,,Cytotoxicity against A549 cells; No cytotoxicity,80682,Homo sapiens,17846,BAO_0000219,,F,,,9606.0,A549,N
6153,Expert,,,,Cytotoxicity against human lung carcinoma (A549) cell lines,80682,Homo sapiens,3415,BAO_0000219,,F,,,9606.0,A549,N
6154,Expert,,,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,80682,Homo sapiens,3415,BAO_0000219,,F,,,9606.0,A549,N
6155,Intermediate,,,,In vitro anticancer activity against human lung (A549) cell line,80682,Homo sapiens,5609,BAO_0000219,,F,,,9606.0,A549,N
6156,Intermediate,,,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6157,Intermediate,,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6158,Intermediate,,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6159,Intermediate,,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6160,Intermediate,,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6161,Intermediate,,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6162,Expert,,,,Inhibition of A549 human lung tumor cell proliferation,80682,Homo sapiens,16295,BAO_0000219,,F,,,9606.0,A549,N
6163,Intermediate,,,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",80682,Homo sapiens,16825,BAO_0000219,,F,,,9606.0,A549,N
6164,Expert,,,,In vitro cytotoxicity against human tumor cell line A549,80682,Homo sapiens,3439,BAO_0000219,,F,,,9606.0,A549,N
6165,Intermediate,,,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,80682,Homo sapiens,10870,BAO_0000219,,F,,,9606.0,A549,N
6166,Intermediate,,,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,80682,Homo sapiens,4845,BAO_0000219,,F,,,9606.0,A549,N
6167,Intermediate,,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,80682,Homo sapiens,5822,BAO_0000219,,F,,,9606.0,A549,N
6168,Intermediate,,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,80682,Homo sapiens,5822,BAO_0000219,,F,,,9606.0,A549,N
6169,Intermediate,,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,80682,Homo sapiens,5822,BAO_0000219,,F,,,9606.0,A549,N
6170,Intermediate,,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,80682,Homo sapiens,16381,BAO_0000219,,F,,,9606.0,A549,N
6171,Intermediate,,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,80682,Homo sapiens,16381,BAO_0000219,,F,,,9606.0,A549,N
6172,Intermediate,,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,80682,Homo sapiens,16381,BAO_0000219,,F,,,9606.0,A549,N
6173,Intermediate,,,,In vitro anticancer activity against human lung (A549) cell line,80682,Homo sapiens,5609,BAO_0000219,,F,,,9606.0,A549,N
6174,Intermediate,,,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,80682,Homo sapiens,4644,BAO_0000219,,F,,,9606.0,A549,N
6175,Intermediate,,,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,80682,Homo sapiens,4644,BAO_0000219,,F,,,9606.0,A549,N
6176,Intermediate,,,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,80682,Homo sapiens,4644,BAO_0000219,,F,,,9606.0,A549,N
6177,Intermediate,,,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,80682,Homo sapiens,4644,BAO_0000219,,F,,,9606.0,A549,N
6178,Intermediate,,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,80682,Homo sapiens,5822,BAO_0000219,,F,,,9606.0,A549,N
6179,Expert,,,,Percentage inhibition of human lung carcinoma (A549) cell lines,80682,Homo sapiens,3415,BAO_0000219,,F,,,9606.0,A549,N
6180,Intermediate,,,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,80682,Homo sapiens,16726,BAO_0000219,,F,,,9606.0,A549,N
6181,Intermediate,,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6182,Intermediate,,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6183,Intermediate,,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6184,Intermediate,,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6185,Intermediate,,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6186,Intermediate,,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6187,Intermediate,,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6188,Intermediate,,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6189,Intermediate,,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6190,Intermediate,,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6191,Intermediate,,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,80682,Homo sapiens,16726,BAO_0000219,,F,,,9606.0,A549,N
6192,Intermediate,,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6193,Intermediate,,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6194,Intermediate,,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6195,Intermediate,,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6196,Intermediate,,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,50588,Canis lupus familiaris,6084,BAO_0000218,,A,In vivo,,9615.0,,N
6197,Intermediate,,,,Pharmacokinetic activity (Cmax) in dog,50588,Canis lupus familiaris,6084,BAO_0000218,,A,In vivo,,9615.0,,N
6198,Intermediate,,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,Canis lupus familiaris,4809,BAO_0000218,,A,In vivo,,9615.0,,N
6199,Intermediate,,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,50588,Canis lupus familiaris,5983,BAO_0000218,,A,In vivo,,9615.0,,N
6200,Intermediate,,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,50588,Canis lupus familiaris,6251,BAO_0000218,,A,In vivo,,9615.0,,N
6201,Intermediate,,Plasma,1969.0,Cmax in dog plasma after 30mg/kg oral dose,50588,Canis lupus familiaris,5932,BAO_0000218,,A,In vivo,,9615.0,,N
6202,Intermediate,,Blood,178.0,Tested for the peak blood level in dog,50588,Canis lupus familiaris,4273,BAO_0000218,,A,In vivo,,9615.0,,N
6203,Intermediate,,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",50588,Canis lupus familiaris,5313,BAO_0000218,,A,In vivo,,9615.0,,N
6204,Intermediate,,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",50588,Canis lupus familiaris,5313,BAO_0000218,,A,In vivo,,9615.0,,N
6205,Intermediate,,Blood,178.0,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,50588,Canis lupus familiaris,6221,BAO_0000218,,A,In vivo,,9615.0,,N
6206,Intermediate,,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,50588,Canis lupus familiaris,4709,BAO_0000218,,A,,,9615.0,,N
6207,Intermediate,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,50588,Canis lupus familiaris,167,BAO_0000218,,A,,,9615.0,,N
6208,Intermediate,,Plasma,1969.0,Final plasma concentration in dogs after oral administration at 1 mg/kg,50588,Canis lupus familiaris,6241,BAO_0000218,,A,,,9615.0,,N
6209,Intermediate,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,50588,Canis lupus familiaris,344,BAO_0000218,,A,,,9615.0,,N
6210,Intermediate,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,50588,Canis lupus familiaris,344,BAO_0000218,,A,,,9615.0,,N
6211,Intermediate,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,50588,Canis lupus familiaris,344,BAO_0000218,,A,,,9615.0,,N
6212,Intermediate,,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,50588,Canis lupus familiaris,2189,BAO_0000218,,A,,,9615.0,,N
6213,Intermediate,,Urine,1088.0,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,50588,Canis lupus familiaris,2189,BAO_0000218,,A,,,9615.0,,N
6214,Intermediate,,Urine,1088.0,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,50588,Canis lupus familiaris,2189,BAO_0000218,,A,,,9615.0,,N
6215,Intermediate,,Urine,1088.0,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,50588,Canis lupus familiaris,2189,BAO_0000218,,A,,,9615.0,,N
6216,Intermediate,,,,Absolute bioavailability was evaluated in dog,50588,Canis lupus familiaris,4257,BAO_0000218,,A,In vivo,,9615.0,,N
6217,Intermediate,,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,50588,Canis lupus familiaris,6221,BAO_0000218,,A,In vivo,,9615.0,,N
6218,Intermediate,,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,50588,Canis lupus familiaris,6215,BAO_0000218,,A,In vivo,,9615.0,,N
6219,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,17267,BAO_0000218,,A,In vivo,,9615.0,,N
6220,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,6621,BAO_0000218,,A,In vivo,,9615.0,,N
6221,Intermediate,,,,Bioavailability after intravenous administration in dogs,50588,Canis lupus familiaris,3854,BAO_0000218,,A,In vivo,,9615.0,,N
6222,Intermediate,,,,Bioavailability after peroral administration in dogs,50588,Canis lupus familiaris,3854,BAO_0000218,,A,In vivo,,9615.0,,N
6223,Intermediate,,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),50588,Canis lupus familiaris,5007,BAO_0000218,,A,In vivo,,9615.0,,N
6224,Intermediate,,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,50588,Canis lupus familiaris,4333,BAO_0000218,,A,In vivo,,9615.0,,N
6225,Intermediate,,Plasma,1969.0,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,50588,Canis lupus familiaris,4333,BAO_0000218,,A,In vivo,,9615.0,,N
6226,Intermediate,,,,Bioavailability,50588,Canis lupus familiaris,5006,BAO_0000218,,A,In vivo,,9615.0,,N
6227,Intermediate,,,,Bioavailability,50588,Canis lupus familiaris,5199,BAO_0000218,,A,In vivo,,9615.0,,N
6228,Intermediate,,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,50588,Canis lupus familiaris,4368,BAO_0000218,,A,In vivo,,9615.0,,N
6229,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,3771,BAO_0000218,,A,In vivo,,9615.0,,N
6230,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,4953,BAO_0000218,,A,In vivo,,9615.0,,N
6231,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,5064,BAO_0000218,,A,In vivo,,9615.0,,N
6232,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,17657,BAO_0000218,,A,In vivo,,9615.0,,N
6233,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,17796,BAO_0000218,,A,In vivo,,9615.0,,N
6234,Intermediate,,,,Bioavailability in dog (p.o.) at 2.0 mpk,50588,Canis lupus familiaris,17853,BAO_0000218,,A,In vivo,,9615.0,,N
6235,Intermediate,,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),50588,Canis lupus familiaris,4521,BAO_0000218,,A,In vivo,,9615.0,,N
6236,Intermediate,,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,Canis lupus familiaris,4521,BAO_0000218,,A,In vivo,,9615.0,,N
6237,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,5006,BAO_0000218,,A,In vivo,,9615.0,,N
6238,Intermediate,,,,Bioavailability was evaluated after oral administration in dog,50588,Canis lupus familiaris,16365,BAO_0000218,,A,In vivo,,9615.0,,N
6239,Intermediate,,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,Canis lupus familiaris,1916,BAO_0000218,,A,In vivo,,9615.0,,N
6240,Intermediate,,,,Bioavailability was evaluated in dog,50588,Canis lupus familiaris,1918,BAO_0000218,,A,In vivo,,9615.0,,N
6241,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,4239,BAO_0000218,,A,In vivo,,9615.0,,N
6242,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,6505,BAO_0000218,,A,In vivo,,9615.0,,N
6243,Intermediate,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,Canis lupus familiaris,5334,BAO_0000218,,A,In vivo,,9615.0,,N
6244,Intermediate,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),50588,Canis lupus familiaris,5334,BAO_0000218,,A,In vivo,,9615.0,,N
6245,Intermediate,,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,Canis lupus familiaris,4809,BAO_0000218,,A,In vivo,,9615.0,,N
6246,Intermediate,,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,Canis lupus familiaris,6348,BAO_0000218,,A,In vivo,,9615.0,,N
6247,Intermediate,,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,50588,Canis lupus familiaris,6005,BAO_0000218,,A,In vivo,,9615.0,,N
6248,Intermediate,,,,Bioavailability of compound in dog was determined after peroral administration,50588,Canis lupus familiaris,17804,BAO_0000218,,A,In vivo,,9615.0,,N
6249,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,3184,BAO_0000218,,A,In vivo,,9615.0,,N
6250,Intermediate,,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,50588,Canis lupus familiaris,1806,BAO_0000218,,A,In vivo,,9615.0,,N
6251,Intermediate,,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,50588,Canis lupus familiaris,1806,BAO_0000218,,A,In vivo,,9615.0,,N
6252,Intermediate,,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,50588,Canis lupus familiaris,1806,BAO_0000218,,A,In vivo,,9615.0,,N
6253,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,4839,BAO_0000218,,A,In vivo,,9615.0,,N
6254,Intermediate,,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),50588,Canis lupus familiaris,5017,BAO_0000218,,A,In vivo,,9615.0,,N
6255,Intermediate,,Heart,948.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6256,Intermediate,,Heart,948.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6257,Intermediate,,Kidney,2113.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6258,Intermediate,,Kidney,2113.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6259,Intermediate,,Kidney,2113.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6260,Intermediate,,Kidney,2113.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6261,Intermediate,,Kidney,2113.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6262,Intermediate,,Kidney,2113.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6263,Intermediate,,Liver,2107.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6264,Intermediate,,Liver,2107.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6265,Intermediate,,Liver,2107.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6266,Intermediate,,Liver,2107.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6267,Intermediate,,Liver,2107.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6268,Intermediate,,Liver,2107.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6269,Intermediate,,Lung,2048.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6270,Intermediate,,Lung,2048.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6271,Intermediate,,Lung,2048.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6272,Intermediate,,Lung,2048.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6273,Intermediate,,Lung,2048.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6274,Intermediate,,Lung,2048.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,Mus musculus,846,BAO_0000218,,A,In vivo,,10090.0,,N
6275,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6276,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6277,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6278,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6279,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6280,Intermediate,,Brain,955.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6281,Intermediate,,Brain,955.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6282,Intermediate,,Brain,955.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6283,Intermediate,,Brain,955.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6284,Intermediate,,Brain,955.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6285,Intermediate,,Heart,948.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6286,Intermediate,,Heart,948.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6287,Intermediate,,Heart,948.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6288,Intermediate,,Heart,948.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6289,Intermediate,,Heart,948.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6290,Intermediate,,Kidney,2113.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6291,Intermediate,,Kidney,2113.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6292,Intermediate,,Kidney,2113.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6293,Intermediate,,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,80682,Homo sapiens,17130,BAO_0000219,,F,,,9606.0,A549,N
6294,Intermediate,,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,80682,Homo sapiens,17130,BAO_0000219,,F,,,9606.0,A549,N
6295,Intermediate,,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),80682,Homo sapiens,17130,BAO_0000219,,F,,,9606.0,A549,N
6296,Intermediate,,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),80682,Homo sapiens,17130,BAO_0000219,,F,,,9606.0,A549,N
6297,Expert,,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,80682,Homo sapiens,3263,BAO_0000219,,F,,,9606.0,A549,N
6298,Expert,,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,80682,Homo sapiens,6663,BAO_0000219,,F,,,9606.0,A549,N
6299,Expert,,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,80682,Homo sapiens,6663,BAO_0000219,,F,,,9606.0,A549,N
6300,Expert,,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,80682,Homo sapiens,6663,BAO_0000219,,F,,,9606.0,A549,N
6301,Expert,,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,80682,Homo sapiens,6663,BAO_0000219,,F,,,9606.0,A549,N
6302,Expert,,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,80682,Homo sapiens,6663,BAO_0000219,,F,,,9606.0,A549,N
6303,Intermediate,,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,80682,Homo sapiens,6663,BAO_0000219,,F,,,9606.0,A549,N
6304,Intermediate,,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,80682,Homo sapiens,6663,BAO_0000219,,F,,,9606.0,A549,N
6305,Intermediate,,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,80682,Homo sapiens,6663,BAO_0000219,,F,,,9606.0,A549,N
6306,Intermediate,,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,80682,Homo sapiens,6663,BAO_0000219,,F,,,9606.0,A549,N
6307,Intermediate,,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,80682,Homo sapiens,6663,BAO_0000219,,F,,,9606.0,A549,N
6308,Intermediate,,,,The compound was evaluated for its cytotoxic potency against A-549 cell line,80682,Homo sapiens,3983,BAO_0000219,,F,,,9606.0,A549,N
6309,Expert,,,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,80682,Homo sapiens,11141,BAO_0000219,,F,,,9606.0,A549,N
6310,Intermediate,,,,Cytotoxic activity of compound against A-549 tumor cell line.,80682,Homo sapiens,5076,BAO_0000219,,F,,,9606.0,A549,N
6311,Intermediate,,,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,80682,Homo sapiens,3311,BAO_0000219,,F,,,9606.0,A549,N
6312,Intermediate,,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,80682,Homo sapiens,3311,BAO_0000219,,F,,,9606.0,A549,N
6313,Intermediate,,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,80682,Homo sapiens,3311,BAO_0000219,,F,,,9606.0,A549,N
6314,Intermediate,,,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,80682,Homo sapiens,5076,BAO_0000219,,F,,,9606.0,A549,N
6315,Intermediate,,,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),80682,Homo sapiens,4150,BAO_0000219,,F,,,9606.0,A549,N
6316,Expert,,,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,80682,Homo sapiens,2150,BAO_0000219,,F,,,9606.0,A549,N
6317,Intermediate,,,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,80682,Homo sapiens,4644,BAO_0000219,,F,,,9606.0,A549,N
6318,Intermediate,,,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,80682,Homo sapiens,263,BAO_0000219,,F,,,9606.0,A549,N
6319,Intermediate,,,,Cytotoxic concentration against A-549 tumor cells.,80682,Homo sapiens,11333,BAO_0000219,,F,,,9606.0,A549,N
6320,Intermediate,,,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,80682,Homo sapiens,11333,BAO_0000219,,F,,,9606.0,A549,N
6321,Intermediate,,,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",80682,Homo sapiens,15895,BAO_0000219,,F,,,9606.0,A549,N
6322,Expert,,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,50191,Acinetobacter baumannii,16677,BAO_0000218,,F,,,470.0,,N
6323,Intermediate,,,,Activity against Acinetobacter calcoaceticus (AC54),50192,Acinetobacter calcoaceticus,10624,BAO_0000218,,F,,,471.0,,N
6324,Expert,,,,In vitro antifungal activity against Aspergillus flavus CM74,50274,Aspergillus flavus,16717,BAO_0000218,,F,,,5059.0,,N
6325,Expert,,,,In vitro antifungal activity against Aspergillus flavus CM74,50274,Aspergillus flavus,16717,BAO_0000218,,F,,,5059.0,,N
6326,Intermediate,,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,50416,Aspergillus fumigatus,5513,BAO_0000218,,F,,,746128.0,,N
6327,Intermediate,,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),50416,Aspergillus fumigatus,15962,BAO_0000218,,F,,,746128.0,,N
6328,Intermediate,,,,Antimicrobial activity against Aspergillus fumigatus (MIC),50416,Aspergillus fumigatus,15962,BAO_0000218,,F,,,746128.0,,N
6329,Intermediate,,,,Antimicrobial activity against Aspergillus fumigatus (MIC),50416,Aspergillus fumigatus,15962,BAO_0000218,,F,,,746128.0,,N
6330,Intermediate,,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),50416,Aspergillus fumigatus,15962,BAO_0000218,,F,,,746128.0,,N
6331,Expert,,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,50416,Aspergillus fumigatus,16717,BAO_0000218,,F,,,746128.0,,N
6332,Expert,,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,50416,Aspergillus fumigatus,16717,BAO_0000218,,F,,,746128.0,,N
6333,Intermediate,,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,50296,Actinomyces naeslundii,8117,BAO_0000218,,F,,,1655.0,,N
6334,Intermediate,,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,50366,Actinomyces viscosus,8117,BAO_0000218,,F,,,1656.0,,N
6335,Intermediate,,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),50535,Acanthocheilonema viteae,15472,BAO_0000218,,F,,,6277.0,,N
6336,Intermediate,,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),50535,Acanthocheilonema viteae,15472,BAO_0000218,,F,,,6277.0,,N
6337,Intermediate,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,50169,Aggregatibacter actinomycetemcomitans,16443,BAO_0000218,,F,,,714.0,,N
6338,Intermediate,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,50169,Aggregatibacter actinomycetemcomitans,16443,BAO_0000218,,F,,,714.0,,N
6339,Intermediate,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,50169,Aggregatibacter actinomycetemcomitans,16443,BAO_0000218,,F,,,714.0,,N
6340,Intermediate,,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6341,Intermediate,,,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6342,Intermediate,,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,80682,Homo sapiens,16381,BAO_0000219,,F,,,9606.0,A549,N
6343,Intermediate,,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,80682,Homo sapiens,16381,BAO_0000219,,F,,,9606.0,A549,N
6344,Intermediate,,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,80682,Homo sapiens,16381,BAO_0000219,,F,,,9606.0,A549,N
6345,Intermediate,,,,GI values against A549 cells (lung cancer),80682,Homo sapiens,16381,BAO_0000219,,F,,,9606.0,A549,N
6346,Intermediate,,,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,80682,Homo sapiens,17206,BAO_0000219,,F,,,9606.0,A549,N
6347,Intermediate,,,,Inhibitory activity against A549 human adenocarcinoma,80682,Homo sapiens,16325,BAO_0000219,,F,,,9606.0,A549,N
6348,Intermediate,,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,80682,Homo sapiens,10708,BAO_0000218,,F,,,9606.0,A549,N
6349,Intermediate,,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,80682,Homo sapiens,10708,BAO_0000218,,F,,,9606.0,A549,N
6350,Intermediate,,,,Inhibitory activity against A549 lung adenocarcinoma cell line,80682,Homo sapiens,17376,BAO_0000219,,F,,,9606.0,A549,N
6351,Intermediate,,,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,80682,Homo sapiens,17376,BAO_0000219,,F,,,9606.0,A549,N
6352,Intermediate,,,,Cytotoxicity against human A549 lung cells,80682,Homo sapiens,17488,BAO_0000219,,F,,,9606.0,A549,N
6353,Intermediate,,,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,80682,Homo sapiens,17404,BAO_0000218,,F,,,9606.0,A549,N
6354,Expert,,,,Growth inhibition of A549 (human lung carcinoma) cell line.,80682,Homo sapiens,10958,BAO_0000219,,F,,,9606.0,A549,N
6355,Expert,,,,Effective dose required for inhibitory activity against A549 human tumor cell line.,80682,Homo sapiens,17099,BAO_0000219,,F,,,9606.0,A549,N
6356,Intermediate,,,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,80682,Homo sapiens,17099,BAO_0000219,,F,,,9606.0,A549,N
6357,Intermediate,,,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,80682,Homo sapiens,4096,BAO_0000219,,F,,,9606.0,A549,N
6358,Expert,,,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,80682,Homo sapiens,4096,BAO_0000219,,F,,,9606.0,A549,N
6359,Intermediate,,,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,80682,Homo sapiens,4096,BAO_0000219,,F,,,9606.0,A549,N
6360,Intermediate,,,,In vitro inhibitory activity against A549 tumor cell culture,80682,Homo sapiens,2525,BAO_0000219,,F,,,9606.0,A549,N
6361,Intermediate,,,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,80682,Homo sapiens,2525,BAO_0000219,,F,,,9606.0,A549,N
6362,Intermediate,,,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),80682,Homo sapiens,5302,BAO_0000219,,F,,,9606.0,A549,N
6363,Intermediate,,,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,80682,Homo sapiens,16325,BAO_0000219,,F,,,9606.0,A549,N
6364,Intermediate,,,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,80682,Homo sapiens,16939,BAO_0000219,,F,,,9606.0,A549,N
6365,Intermediate,,,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,80682,Homo sapiens,17229,BAO_0000219,,F,,,9606.0,A549,N
6366,Intermediate,,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,80682,Homo sapiens,17380,BAO_0000219,,F,,,9606.0,A549,N
6367,Intermediate,,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,80682,Homo sapiens,17380,BAO_0000219,,F,,,9606.0,A549,N
6368,Intermediate,,,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,80682,Homo sapiens,1903,BAO_0000219,,F,,,9606.0,A549,N
6369,Intermediate,,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,80682,Homo sapiens,3838,BAO_0000219,,F,,,9606.0,A549,N
6370,Intermediate,,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,80682,Homo sapiens,14696,BAO_0000219,,F,,,9606.0,A549,N
6371,Intermediate,,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,80682,Homo sapiens,3838,BAO_0000219,,F,,,9606.0,A549,N
6372,Intermediate,,,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,80682,Homo sapiens,1522,BAO_0000219,,F,,,9606.0,A549,N
6373,Intermediate,,,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,80682,Homo sapiens,12400,BAO_0000219,,F,,,9606.0,A549,N
6374,Intermediate,,,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,80682,Homo sapiens,14696,BAO_0000219,,F,,,9606.0,A549,N
6375,Intermediate,,,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),80682,Homo sapiens,14769,BAO_0000219,,F,,,9606.0,A549,N
6376,Intermediate,,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,80682,Homo sapiens,14696,BAO_0000219,,F,,,9606.0,A549,N
6377,Intermediate,,,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,80682,Homo sapiens,1888,BAO_0000219,,F,,,9606.0,A549,N
6378,Intermediate,,,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,80682,Homo sapiens,12016,BAO_0000219,,F,,,9606.0,A549,N
6379,Intermediate,,,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,80682,Homo sapiens,6058,BAO_0000219,,F,,,9606.0,A549,N
6380,Intermediate,,,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,80682,Homo sapiens,17708,BAO_0000219,,F,,,9606.0,A549,N
6381,Intermediate,,,,Antitumor activity against A549/ATCC cell line,80682,Homo sapiens,12301,BAO_0000219,,F,,,9606.0,A549,N
6382,Intermediate,,,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,80682,Homo sapiens,11970,BAO_0000219,,F,,,9606.0,A549,N
6383,Expert,,,,In vitro cytotoxicity against A549/ATCC cell line.,80682,Homo sapiens,11818,BAO_0000219,,F,,,9606.0,A549,N
6384,Intermediate,,,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,80682,Homo sapiens,12400,BAO_0000219,,F,,,9606.0,A549,N
6385,Intermediate,,,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,80682,Homo sapiens,3381,BAO_0000219,,F,,,9606.0,A549,N
6386,Intermediate,,,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,80682,Homo sapiens,17376,BAO_0000219,,F,,,9606.0,A549,N
6387,Intermediate,,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,80682,Homo sapiens,10708,BAO_0000219,,F,,,9606.0,A549,N
6388,Autocuration,,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,22226,Homo sapiens,2964,BAO_0000219,,F,,,9606.0,,U
6389,Intermediate,,,,Compound was tested for oral bioavailability in dogs,22224,Canis lupus familiaris,5005,BAO_0000218,,A,In vivo,,9615.0,,U
6390,Intermediate,,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,50588,Canis lupus familiaris,6229,BAO_0000218,,A,In vivo,,9615.0,,N
6391,Intermediate,,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,50588,Canis lupus familiaris,6229,BAO_0000218,,A,In vivo,,9615.0,,N
6392,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,5374,BAO_0000218,,A,In vivo,,9615.0,,N
6393,Intermediate,,,,Compound was tested for the oral bioavailability in dog; No availability,50588,Canis lupus familiaris,5374,BAO_0000218,,A,In vivo,,9615.0,,N
6394,Intermediate,,,,Oral bioavailability in dog (dose 5 mg/kg),50588,Canis lupus familiaris,6265,BAO_0000218,,A,In vivo,,9615.0,,N
6395,Intermediate,,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,50588,Canis lupus familiaris,5654,BAO_0000218,,A,In vivo,,9615.0,,N
6396,Intermediate,,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,50588,Canis lupus familiaris,5654,BAO_0000218,,A,In vivo,,9615.0,,N
6397,Intermediate,,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),50588,Canis lupus familiaris,16456,BAO_0000218,,A,In vivo,,9615.0,,N
6398,Intermediate,,,,Oral bioavailability in dog (dose 5 mg/kg),50588,Canis lupus familiaris,5302,BAO_0000218,,A,In vivo,,9615.0,,N
6399,Intermediate,,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),50588,Canis lupus familiaris,3624,BAO_0000218,,A,In vivo,,9615.0,,N
6400,Intermediate,,,,Oral bioavailability of active FTIs in dogs,50588,Canis lupus familiaris,16452,BAO_0000218,,A,In vivo,,9615.0,,N
6401,Intermediate,,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),50588,Canis lupus familiaris,5802,BAO_0000218,,A,In vivo,,9615.0,,N
6402,Expert,,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,Canis lupus familiaris,3598,BAO_0000218,,A,In vivo,,9615.0,,N
6403,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,17839,BAO_0000218,,A,In vivo,,9615.0,,N
6404,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,6762,BAO_0000218,,A,In vivo,,9615.0,,N
6405,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,6821,BAO_0000218,,A,In vivo,,9615.0,,N
6406,Intermediate,,,,Oral bioavailability of compound was determined in dog; Not tested,50588,Canis lupus familiaris,6821,BAO_0000218,,A,In vivo,,9615.0,,N
6407,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,5210,BAO_0000218,,A,In vivo,,9615.0,,N
6408,Intermediate,,,,Oral bioavailability (10 mg/kg) was determined in dog,50588,Canis lupus familiaris,6227,BAO_0000218,,A,In vivo,,9615.0,,N
6409,Intermediate,,,,Oral bioavailability,50588,Canis lupus familiaris,761,BAO_0000218,,A,In vivo,,9615.0,,N
6410,Intermediate,,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),50588,Canis lupus familiaris,761,BAO_0000218,,A,In vivo,,9615.0,,N
6411,Intermediate,,,,Oral bioavailability administered in solution in rats,50588,Canis lupus familiaris,761,BAO_0000218,,A,In vivo,,9615.0,,N
6412,Intermediate,,,,Oral bioavailability after 30 mg/kg po dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,In vivo,,9615.0,,N
6413,Intermediate,,,,Oral bioavailability at a dose of 1 mg/kg in dogs,50588,Canis lupus familiaris,5474,BAO_0000218,,A,In vivo,,9615.0,,N
6414,Intermediate,,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),50588,Canis lupus familiaris,6535,BAO_0000218,,A,In vivo,,9615.0,,N
6415,Intermediate,,,,Oral bioavailability in Dog; ND = not determined,50588,Canis lupus familiaris,6535,BAO_0000218,,A,In vivo,,9615.0,,N
6416,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,3352,BAO_0000218,,A,In vivo,,9615.0,,N
6417,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,6168,BAO_0000218,,A,In vivo,,9615.0,,N
6418,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,5988,BAO_0000218,,A,In vivo,,9615.0,,N
6419,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,4942,BAO_0000218,,A,In vivo,,9615.0,,N
6420,Intermediate,,,,Oral bioavailability in dogs; No data,50588,Canis lupus familiaris,4942,BAO_0000218,,A,In vivo,,9615.0,,N
6421,Intermediate,,,,Oral bioavailability measured in dogs,50588,Canis lupus familiaris,14541,BAO_0000218,,A,In vivo,,9615.0,,N
6422,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,4449,BAO_0000218,,A,In vivo,,9615.0,,N
6423,Intermediate,,,,Oral bioavailability was calculated in dog,50588,Canis lupus familiaris,6057,BAO_0000218,,A,In vivo,,9615.0,,N
6424,Intermediate,,,,Oral bioavailability after 0.3 mg/kg po administration in dog,50588,Canis lupus familiaris,5600,BAO_0000218,,A,In vivo,,9615.0,,N
6425,Intermediate,,,,Oral bioavailability in dog (i.v. dosing),50588,Canis lupus familiaris,5542,BAO_0000218,,A,In vivo,,9615.0,,N
6426,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,5542,BAO_0000218,,A,In vivo,,9615.0,,N
6427,Intermediate,,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,50588,Canis lupus familiaris,5546,BAO_0000218,,A,In vivo,,9615.0,,N
6428,Intermediate,,,,Oral bioavailability in Beagle dogs,50588,Canis lupus familiaris,4514,BAO_0000218,,A,In vivo,,9615.0,,N
6429,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,3624,BAO_0000218,,A,In vivo,,9615.0,,N
6430,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,3854,BAO_0000218,,A,In vivo,,9615.0,,N
6431,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,5836,BAO_0000218,,A,In vivo,,9615.0,,N
6432,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,5940,BAO_0000218,,A,In vivo,,9615.0,,N
6433,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,6168,BAO_0000218,,A,In vivo,,9615.0,,N
6434,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,6227,BAO_0000218,,A,In vivo,,9615.0,,N
6435,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,6251,BAO_0000218,,A,In vivo,,9615.0,,N
6436,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,6448,BAO_0000218,,A,In vivo,,9615.0,,N
6437,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,6647,BAO_0000218,,A,In vivo,,9615.0,,N
6438,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,5940,BAO_0000218,,A,In vivo,,9615.0,,N
6439,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,933,BAO_0000218,,A,In vivo,,9615.0,,N
6440,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,5210,BAO_0000218,,A,In vivo,,9615.0,,N
6441,Intermediate,,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),50588,Canis lupus familiaris,6642,BAO_0000218,,A,In vivo,,9615.0,,N
6442,Intermediate,,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),50588,Canis lupus familiaris,6641,BAO_0000218,,A,In vivo,,9615.0,,N
6443,Intermediate,,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),50588,Canis lupus familiaris,6642,BAO_0000218,,A,In vivo,,9615.0,,N
6444,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,5472,BAO_0000218,,A,In vivo,,9615.0,,N
6445,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,5985,BAO_0000218,,A,In vivo,,9615.0,,N
6446,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,15660,BAO_0000218,,A,In vivo,,9615.0,,N
6447,Intermediate,,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),50588,Canis lupus familiaris,5530,BAO_0000218,,A,In vivo,,9615.0,,N
6448,Intermediate,,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),50588,Canis lupus familiaris,5530,BAO_0000218,,A,In vivo,,9615.0,,N
6449,Intermediate,,,,Oral bioavailability (F) in dogs,50588,Canis lupus familiaris,6305,BAO_0000218,,A,In vivo,,9615.0,,N
6450,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,5210,BAO_0000218,,A,In vivo,,9615.0,,N
6451,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,5238,BAO_0000218,,A,In vivo,,9615.0,,N
6452,Intermediate,,,,Oral bioavailability in dog (dose 10 mg/kg),50588,Canis lupus familiaris,5668,BAO_0000218,,A,In vivo,,9615.0,,N
6453,Intermediate,,,,Oral bioavailability after peroral administration at 5 mpk in Dog,50588,Canis lupus familiaris,5668,BAO_0000218,,A,In vivo,,9615.0,,N
6454,Intermediate,,,,Oral bioavailability in dog (dose 5 mg/kg),50588,Canis lupus familiaris,5668,BAO_0000218,,A,In vivo,,9615.0,,N
6455,Intermediate,,,,Oral bioavailability in dog (dose 10 mg/kg),50588,Canis lupus familiaris,6084,BAO_0000218,,A,In vivo,,9615.0,,N
6456,Intermediate,,Kidney,2113.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6457,Intermediate,,Kidney,2113.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6458,Intermediate,,Liver,2107.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6459,Intermediate,,Liver,2107.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6460,Intermediate,,Liver,2107.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6461,Intermediate,,Liver,2107.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6462,Intermediate,,Liver,2107.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6463,Intermediate,,Lung,2048.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6464,Intermediate,,Lung,2048.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6465,Intermediate,,Lung,2048.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6466,Intermediate,,Lung,2048.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6467,Intermediate,,Lung,2048.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6468,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6469,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6470,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6471,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6472,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6473,Intermediate,,Spleen,2106.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6474,Intermediate,,Spleen,2106.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6475,Intermediate,,Spleen,2106.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6476,Intermediate,,Spleen,2106.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6477,Intermediate,,Spleen,2106.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6478,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6479,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6480,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6481,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6482,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6483,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6484,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6485,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6486,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6487,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6488,Intermediate,,Heart,948.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6489,Intermediate,,Heart,948.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6490,Intermediate,,Heart,948.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6491,Intermediate,,Heart,948.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6492,Intermediate,,Heart,948.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6493,Intermediate,,Liver,2107.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6494,Intermediate,,Liver,2107.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6495,Intermediate,,Liver,2107.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6496,Intermediate,,Liver,2107.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6497,Intermediate,,Liver,2107.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6498,Intermediate,,Lung,2048.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6499,Intermediate,,Lung,2048.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6500,Intermediate,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,aeinetobacter anitrotap,12269,BAO_0000218,,F,,,107673.0,,N
6501,Intermediate,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,Acinetobacter calcoaceticus subsp. anitratus,12269,BAO_0000218,,F,,,107673.0,,N
6502,Intermediate,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,Acinetobacter calcoaceticus subsp. anitratus,12269,BAO_0000218,,F,,,107673.0,,N
6503,Intermediate,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,aeinetobacter anitrotap,12269,BAO_0000218,,F,,,107673.0,,N
6504,Intermediate,,,,Activity against Acinetobacter calcoaceticus (AC54),50192,Acinetobacter calcoaceticus,10624,BAO_0000218,,F,,,471.0,,N
6505,Intermediate,,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,50714,Anolis carolinensis,17216,BAO_0000218,,F,,,28377.0,,N
6506,Intermediate,,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,50714,Anolis carolinensis,17216,BAO_0000218,,F,,,28377.0,,N
6507,Intermediate,,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,50296,Actinomyces naeslundii,9560,BAO_0000218,,F,,,1655.0,,N
6508,Intermediate,,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,50296,Actinomyces naeslundii,9560,BAO_0000218,,F,,,1655.0,,N
6509,Intermediate,,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,50296,Actinomyces naeslundii,9560,BAO_0000218,,F,,,1655.0,,N
6510,Intermediate,,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,50296,Actinomyces naeslundii,9560,BAO_0000218,,F,,,1655.0,,N
6511,Intermediate,,,,Plaque bactericidal index against Actinomyces naeslundii 631,50296,Actinomyces naeslundii,9560,BAO_0000218,,F,,,1655.0,,N
6512,Intermediate,,,,Plaque bactericidal index against Actinomyces naeslundii N/9,50296,Actinomyces naeslundii,9560,BAO_0000218,,F,,,1655.0,,N
6513,Intermediate,,,,Plaque bactericidal index against Actinomyces naeslundii B74,50296,Actinomyces naeslundii,9560,BAO_0000218,,F,,,1655.0,,N
6514,Intermediate,,,,Plaque bactericidal index against Actinomyces naeslundii N/3,50296,Actinomyces naeslundii,9560,BAO_0000218,,F,,,1655.0,,N
6515,Intermediate,,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,50056,Artemia salina,114,BAO_0000218,,F,,,85549.0,,N
6516,Intermediate,,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",50056,Artemia salina,114,BAO_0000218,,F,,,85549.0,,N
6517,Intermediate,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,50532,Ascaris suum,10841,BAO_0000218,,F,,,6253.0,,N
6518,Intermediate,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,50532,Ascaris suum,10841,BAO_0000218,,F,,,6253.0,,N
6519,Intermediate,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,50532,Ascaris suum,10841,BAO_0000218,,F,,,6253.0,,N
6520,Intermediate,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,50532,Ascaris suum,10841,BAO_0000218,,F,,,6253.0,,N
6521,Intermediate,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,50532,Ascaris suum,10841,BAO_0000218,,F,,,6253.0,,N
6522,Intermediate,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,50532,Ascaris suum,10841,BAO_0000218,,F,,,6253.0,,N
6523,Intermediate,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,50532,Ascaris suum,10841,BAO_0000218,,F,,,6253.0,,N
6524,Intermediate,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,50532,Ascaris suum,10841,BAO_0000218,,F,,,6253.0,,N
6525,Intermediate,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,50532,Ascaris suum,10841,BAO_0000218,,F,,,6253.0,,N
6526,Intermediate,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,50532,Ascaris suum,10841,BAO_0000218,,F,,,6253.0,,N
6527,Intermediate,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,50532,Ascaris suum,10841,BAO_0000218,,F,,,6253.0,,N
6528,Intermediate,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,50532,Ascaris suum,10841,BAO_0000218,,F,,,6253.0,,N
6529,Intermediate,,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,50366,Actinomyces viscosus,8117,BAO_0000218,,F,,,1656.0,,N
6530,Intermediate,,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,50366,Actinomyces viscosus,8117,BAO_0000218,,F,,,1656.0,,N
6531,Intermediate,,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,50366,Actinomyces viscosus,9560,BAO_0000218,,F,,,1656.0,,N
6532,Expert,,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,50366,Actinomyces viscosus,9560,BAO_0000218,,F,,,1656.0,,N
6533,Intermediate,,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,50366,Actinomyces viscosus,9560,BAO_0000218,,F,,,1656.0,,N
6534,Intermediate,,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,50366,Actinomyces viscosus,9560,BAO_0000218,,F,,,1656.0,,N
6535,Intermediate,,,,Plaque bactericidal index against Actinomyces viscosus 8A06,50366,Actinomyces viscosus,9560,BAO_0000218,,F,,,1656.0,,N
6536,Intermediate,,,,Plaque bactericidal index against Actinomyces viscosus M-100,50366,Actinomyces viscosus,9560,BAO_0000218,,F,,,1656.0,,N
6537,Expert,,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,50366,Actinomyces viscosus,9560,BAO_0000218,,F,,,1656.0,,N
6538,Intermediate,,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",50366,Actinomyces viscosus,9560,BAO_0000218,,F,,,1656.0,,N
6539,Intermediate,,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",50366,Actinomyces viscosus,9560,BAO_0000218,,F,,,1656.0,,N
6540,Intermediate,,,,Plaque bactericidal index against Actinomyces viscosus 626,50366,Actinomyces viscosus,9560,BAO_0000218,,F,,,1656.0,,N
6541,Intermediate,,,,Plaque bactericidal index against Actinomyces viscosus T14V,50366,Actinomyces viscosus,9560,BAO_0000218,,F,,,1656.0,,N
6542,Intermediate,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,50535,Acanthocheilonema viteae,10986,BAO_0000218,,F,,,6277.0,,N
6543,Intermediate,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,50535,Acanthocheilonema viteae,10986,BAO_0000218,,F,,,6277.0,,N
6544,Intermediate,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,50535,Acanthocheilonema viteae,10986,BAO_0000218,,F,,,6277.0,,N
6545,Intermediate,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,50535,Acanthocheilonema viteae,10986,BAO_0000218,,F,,,6277.0,,N
6546,Intermediate,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,50535,Acanthocheilonema viteae,10986,BAO_0000218,,F,,,6277.0,,N
6547,Intermediate,,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,80023,Homo sapiens,10708,BAO_0000219,,F,,,9606.0,A673,N
6548,Intermediate,,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,80661,Homo sapiens,10708,BAO_0000219,,F,,,9606.0,A704,N
6549,Autocuration,,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,22226,Rattus norvegicus,416,BAO_0000219,,F,,,10116.0,,U
6550,Intermediate,,,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,80024,Mus musculus,14354,BAO_0000219,,F,,,10090.0,A9,N
6551,Intermediate,,,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,80024,Mus musculus,14354,BAO_0000219,,F,,,10090.0,A9,N
6552,Intermediate,,,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,80024,Homo sapiens,5116,BAO_0000219,,F,,,9606.0,A9,N
6553,Intermediate,,,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,80024,Homo sapiens,5116,BAO_0000219,,F,,,9606.0,A9,N
6554,Expert,,,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,81037,Homo sapiens,15694,BAO_0000219,,F,,,9606.0,Human ovarian carcinoma cell line,N
6555,Expert,,,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",80024,Mus musculus,13038,BAO_0000219,,F,,,10090.0,A9,N
6556,Expert,,,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,80024,Mus musculus,13038,BAO_0000219,,F,,,10090.0,A9,N
6557,Expert,,,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,80024,Mus musculus,10923,BAO_0000219,,F,,,10090.0,A9,N
6558,Intermediate,,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,80024,Mus musculus,10923,BAO_0000219,,F,,,10090.0,A9,N
6559,Intermediate,,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,80024,Mus musculus,10923,BAO_0000219,,F,,,10090.0,A9,N
6560,Expert,,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",10649,,10923,BAO_0000019,,F,,,,,H
6561,Intermediate,,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,80024,Mus musculus,10923,BAO_0000219,,F,,,10090.0,A9,N
6562,Intermediate,,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,80024,Mus musculus,10923,BAO_0000219,,F,,,10090.0,A9,N
6563,Intermediate,,,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,80663,Cricetulus griseus,8158,BAO_0000219,,F,,,10029.0,AA6,N
6564,Autocuration,,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,22226,Homo sapiens,15494,BAO_0000219,,F,,,9606.0,,U
6565,Autocuration,,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",22226,Homo sapiens,15494,BAO_0000219,,F,,,9606.0,,U
6566,Intermediate,,,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),80662,Homo sapiens,12348,BAO_0000219,,F,,,9606.0,AA5,N
6567,Intermediate,,,,Cytotoxicity was measured against AA5/HIV-1(IIIB),80662,Homo sapiens,12348,BAO_0000219,,F,,,9606.0,AA5,N
6568,Intermediate,,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,80662,Homo sapiens,2726,BAO_0000219,,F,,,9606.0,AA5,N
6569,Intermediate,,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,80566,Homo sapiens,2726,BAO_0000219,,F,,,9606.0,U-937,N
6570,Intermediate,,,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,80578,Cricetulus griseus,10747,BAO_0000219,,F,,,10029.0,UV4,N
6571,Expert,,,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",80089,Cricetulus griseus,11005,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6572,Intermediate,,,,Average intracellular compound concentration when the hypoxic SER=1.6,80089,Cricetulus griseus,12687,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6573,Intermediate,,,,Average intracellular compound concentration when the hypoxic SER=1.6.,80089,Cricetulus griseus,12687,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6574,Intermediate,,,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,80089,Cricetulus griseus,12687,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6575,Intermediate,,,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,80089,Cricetulus griseus,12687,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6576,Intermediate,,,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,80089,Cricetulus griseus,12687,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6577,Intermediate,,,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",80089,Cricetulus griseus,13436,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6578,Intermediate,,,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",80089,Cricetulus griseus,13435,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6579,Intermediate,,,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,80089,Cricetulus griseus,13302,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6580,Intermediate,,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,80089,Cricetulus griseus,12687,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6581,Intermediate,,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,80089,Cricetulus griseus,12687,BAO_0000219,,A,,,10029.0,CHO-AA8,N
6582,Intermediate,,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,80089,Cricetulus griseus,12687,BAO_0000219,,A,,,10029.0,CHO-AA8,N
6583,Expert,,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,80089,Cricetulus griseus,12878,BAO_0000219,,A,,,10029.0,CHO-AA8,N
6584,Intermediate,,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,80089,Cricetulus griseus,12878,BAO_0000219,,A,,,10029.0,CHO-AA8,N
6585,Expert,,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,80089,Cricetulus griseus,14367,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6586,Intermediate,,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,80089,Cricetulus griseus,14367,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6587,Expert,,,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,80089,hampster,12398,BAO_0000219,,F,,,36483.0,CHO-AA8,N
6588,Expert,,,,Aerobic growth inhibition in Chinese hamster cell line AA8,80089,Cricetulus griseus,12878,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6589,Expert,,,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,80089,Cricetulus griseus,13820,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6590,Expert,,,,Inhibition of growth under aerobic conditions in AA8 cells,80089,Cricetulus griseus,13436,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6591,Intermediate,,,,Oral bioavailability in dog (dose 10 mg/kg),50588,Canis lupus familiaris,6084,BAO_0000218,,A,In vivo,,9615.0,,N
6592,Intermediate,,,,Oral bioavailability in dog at 10 mg/kg of the compound,50588,Canis lupus familiaris,5711,BAO_0000218,,A,In vivo,,9615.0,,N
6593,Intermediate,,,,Oral bioavailability in dog (dose 5 uM/kg),50588,Canis lupus familiaris,4353,BAO_0000218,,A,In vivo,,9615.0,,N
6594,Intermediate,,,,Oral bioavailability in dog (dose 5 uM/kg),50588,Canis lupus familiaris,4353,BAO_0000218,,A,In vivo,,9615.0,,N
6595,Intermediate,,,,Oral bioavailability in dog (mongrel),50588,Canis lupus familiaris,17800,BAO_0000218,,A,In vivo,,9615.0,,N
6596,Intermediate,,,,Oral bioavailability in dog (dose 10 mg/kg),50588,Canis lupus familiaris,3994,BAO_0000218,,A,In vivo,,9615.0,,N
6597,Intermediate,,,,Oral bioavailability in dog (dose 10 mg/kg),50588,Canis lupus familiaris,3994,BAO_0000218,,F,In vivo,,9615.0,,N
6598,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,5145,BAO_0000218,,A,In vivo,,9615.0,,N
6599,Intermediate,,,,Bioavailability in dog (dose 1 mg/kg i.v.),50588,Canis lupus familiaris,16452,BAO_0000218,,A,In vivo,,9615.0,,N
6600,Intermediate,,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),50588,Canis lupus familiaris,16452,BAO_0000218,,A,In vivo,,9615.0,,N
6601,Intermediate,,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,50588,Canis lupus familiaris,5983,BAO_0000218,,A,In vivo,,9615.0,,N
6602,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,4273,BAO_0000218,,A,In vivo,,9615.0,,N
6603,Intermediate,,,,Bioavailability in dog (dose 3-10 mg/kg),50588,Canis lupus familiaris,12500,BAO_0000218,,A,In vivo,,9615.0,,N
6604,Intermediate,,Plasma,1969.0,The compound was tested for bioavailability of compound in plasma of dog; Complete,50588,Canis lupus familiaris,12500,BAO_0000218,,A,In vivo,,9615.0,,N
6605,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,3639,BAO_0000218,,A,In vivo,,9615.0,,N
6606,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,3880,BAO_0000218,,A,In vivo,,9615.0,,N
6607,Intermediate,,,,Bioavailability in dog,50588,Canis lupus familiaris,4838,BAO_0000218,,A,In vivo,,9615.0,,N
6608,Intermediate,,,,oral bioavailability was measured in dogs,50588,Canis lupus familiaris,15600,BAO_0000218,,A,In vivo,,9615.0,,N
6609,Intermediate,,,,Compound was tested for plasma protein binding in dog; Not determined,50588,Canis lupus familiaris,17248,BAO_0000218,,A,,,9615.0,,N
6610,Intermediate,,,,Compound was tested for plasma protein binding of dog,50588,Canis lupus familiaris,17248,BAO_0000218,,A,,,9615.0,,N
6611,Intermediate,,,,Compound was tested for plasma protein binding of dog; Not determined,50588,Canis lupus familiaris,17248,BAO_0000218,,A,,,9615.0,,N
6612,Intermediate,,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,50588,Canis lupus familiaris,17443,BAO_0000218,,A,,,9615.0,,N
6613,Intermediate,,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,50588,Canis lupus familiaris,4186,BAO_0000218,,A,In vivo,,9615.0,,N
6614,Intermediate,,,,Half life was determined,50588,Canis lupus familiaris,3749,BAO_0000218,,A,,,9615.0,,N
6615,Intermediate,,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,50588,Canis lupus familiaris,3249,BAO_0000218,,A,In vivo,,9615.0,,N
6616,Intermediate,,,,Half life was evaluated in dog,50588,Canis lupus familiaris,3022,BAO_0000218,,A,,,9615.0,,N
6617,Intermediate,,,,Half life was determined,50588,Canis lupus familiaris,3749,BAO_0000218,,A,,,9615.0,,N
6618,Intermediate,,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,Canis lupus familiaris,2517,BAO_0000218,,A,In vivo,,9615.0,,N
6619,Intermediate,,Heart,948.0,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,Canis lupus familiaris,2517,BAO_0000218,,A,In vivo,,9615.0,,N
6620,Intermediate,,Kidney,2113.0,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,Canis lupus familiaris,2517,BAO_0000218,,A,In vivo,,9615.0,,N
6621,Intermediate,,Liver,2107.0,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,Canis lupus familiaris,2517,BAO_0000218,,A,In vivo,,9615.0,,N
6622,Intermediate,,Lung,2048.0,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,Canis lupus familiaris,2517,BAO_0000218,,A,In vivo,,9615.0,,N
6623,Intermediate,,Spleen,2106.0,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,Canis lupus familiaris,2517,BAO_0000218,,A,In vivo,,9615.0,,N
6624,Intermediate,,,,LogP in dog,50588,Canis lupus familiaris,3639,BAO_0000218,,A,,,9615.0,,N
6625,Intermediate,,,,Partition coefficient (logP),50588,Canis lupus familiaris,6227,BAO_0000218,,A,,,9615.0,,N
6626,Intermediate,,,,Partition coefficient in dog,50588,Canis lupus familiaris,6227,BAO_0000218,,A,,,9615.0,,N
6627,Intermediate,,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,50588,Canis lupus familiaris,17764,BAO_0000218,,A,In vivo,,9615.0,,N
6628,Intermediate,,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),50588,Canis lupus familiaris,4809,BAO_0000218,,A,In vivo,,9615.0,,N
6629,Intermediate,,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,50588,Canis lupus familiaris,5600,BAO_0000218,,A,,,9615.0,,N
6630,Intermediate,,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),50588,Canis lupus familiaris,14294,BAO_0000218,,A,,,9615.0,,N
6631,Intermediate,,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),50588,Canis lupus familiaris,14294,BAO_0000218,,A,,,9615.0,,N
6632,Intermediate,,,,Metabolism of compound in dog S9 microsomes; Trace,50588,Canis lupus familiaris,14294,BAO_0000218,,A,,,9615.0,,N
6633,Intermediate,,Liver,2107.0,In vitro metabolic potential in dog liver microsomes,50588,Canis lupus familiaris,6251,BAO_0000218,,A,,,9615.0,,N
6634,Intermediate,,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,50588,Canis lupus familiaris,3748,BAO_0000218,,A,In vivo,,9615.0,,N
6635,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,2713,BAO_0000218,,A,In vivo,,9615.0,,N
6636,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,6512,BAO_0000218,,A,In vivo,,9615.0,,N
6637,Intermediate,,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,Canis lupus familiaris,6679,BAO_0000218,,A,In vivo,,9615.0,,N
6638,Intermediate,,,,The compound was tested for bioavailability in dogs,50588,Canis lupus familiaris,3749,BAO_0000218,,A,In vivo,,9615.0,,N
6639,Intermediate,,,,The compound was tested for oral bioavailability in dogs,50588,Canis lupus familiaris,3749,BAO_0000218,,A,In vivo,,9615.0,,N
6640,Intermediate,,,,Oral bioavailability in dog,50588,Canis lupus familiaris,6742,BAO_0000218,,A,In vivo,,9615.0,,N
6641,Intermediate,,,,Compound was tested for percent protein binding (PB) in dog,50588,Canis lupus familiaris,6227,BAO_0000218,,A,,,9615.0,,N
6642,Intermediate,,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,50588,Canis lupus familiaris,6874,BAO_0000218,,A,,,9615.0,,N
6643,Intermediate,,Plasma,1969.0,Compound was evaluated for plasma clearance.,50588,Canis lupus familiaris,2877,BAO_0000218,,A,In vivo,,9615.0,,N
6644,Intermediate,,Plasma,1969.0,The compound was tested for plasma clearance in dog,50588,Canis lupus familiaris,12500,BAO_0000218,,A,In vivo,,9615.0,,N
6645,Intermediate,,Plasma,1969.0,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,50588,Canis lupus familiaris,12500,BAO_0000218,,A,In vivo,,9615.0,,N
6646,Intermediate,,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,50588,Canis lupus familiaris,4709,BAO_0000218,,A,,,9615.0,,N
6647,Intermediate,,Liver,2107.0,In vitro relative rate of metabolism was determined in dog liver microsomes,50588,Canis lupus familiaris,5542,BAO_0000218,,A,,,9615.0,,N
6648,Intermediate,,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,50588,Canis lupus familiaris,17594,BAO_0000218,,A,In vivo,,9615.0,,N
6649,Intermediate,,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,50588,Canis lupus familiaris,2652,BAO_0000218,,A,In vivo,,9615.0,,N
6650,Intermediate,,,,Half life after intravenous administration in dogs at 1.2 uM/kg,50588,Canis lupus familiaris,17764,BAO_0000218,,A,In vivo,,9615.0,,N
6651,Intermediate,,Lung,2048.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6652,Intermediate,,Lung,2048.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6653,Intermediate,,Lung,2048.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6654,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6655,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6656,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6657,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6658,Intermediate,,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,50594,Mus musculus,6599,BAO_0000218,,A,,,10090.0,CCRF S-180,N
6659,Intermediate,,Brain,955.0,C2 in brain of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,,,10090.0,,N
6660,Intermediate,,Kidney,2113.0,C2 in kidney of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,,,10090.0,,N
6661,Intermediate,,Liver,2107.0,C2 in liver of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,,,10090.0,,N
6662,Intermediate,,Lung,2048.0,C2 in lungs of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,,,10090.0,,N
6663,Intermediate,,Spleen,2106.0,C2 in spleen of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,,,10090.0,,N
6664,Intermediate,,,,Plasma clearance in mouse,50594,Mus musculus,17852,BAO_0000218,,A,In vivo,,10090.0,,N
6665,Intermediate,,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,50594,Mus musculus,17764,BAO_0000218,,A,In vivo,,10090.0,,N
6666,Intermediate,,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,50594,Mus musculus,17837,BAO_0000218,,A,In vivo,,10090.0,,N
6667,Intermediate,,,,Clearance was evaluated in mice after intravenous administration,50594,Mus musculus,2675,BAO_0000218,,A,In vivo,,10090.0,,N
6668,Intermediate,,,,Clearance was evaluated in mice after oral administration,50594,Mus musculus,2675,BAO_0000218,,A,In vivo,,10090.0,,N
6669,Intermediate,,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,50594,Mus musculus,4239,BAO_0000218,,A,In vivo,,10090.0,,N
6670,Intermediate,,,,Plasma clearance of compound was determined at 40 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,In vivo,,10090.0,,N
6671,Intermediate,,,,Plasma clearance of at 24 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,In vivo,,10090.0,,N
6672,Intermediate,,,,Plasma clearance at 24 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,In vivo,,10090.0,,N
6673,Intermediate,,,,Plasma clearance at 5 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,In vivo,,10090.0,,N
6674,Intermediate,,,,Plasma clearance in mice,50594,Mus musculus,5727,BAO_0000218,,A,In vivo,,10090.0,,N
6675,Intermediate,,,,Plasma clearance value upon iv administration in mouse,50594,Mus musculus,2862,BAO_0000218,,A,In vivo,,10090.0,,N
6676,Intermediate,,Plasma,1969.0,Total plasma clearance in mice,50594,Mus musculus,5980,BAO_0000218,,A,In vivo,,10090.0,,N
6677,Intermediate,,,,Clearance in mouse,50594,Mus musculus,17592,BAO_0000218,,A,In vivo,,10090.0,,N
6678,Intermediate,,,,Clearance value was determined,50594,Mus musculus,17718,BAO_0000218,,A,In vivo,,10090.0,,N
6679,Intermediate,,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
6680,Intermediate,,,,Calculated partition coefficient (clogP),22229,,17384,BAO_0000100,,P,,,,,U
6681,Intermediate,,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,50594,Mus musculus,6062,BAO_0000218,,A,In vivo,,10090.0,,N
6682,Intermediate,,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,50594,Mus musculus,17734,BAO_0000218,,A,In vivo,,10090.0,,N
6683,Intermediate,,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,Mus musculus,6348,BAO_0000218,,A,In vivo,,10090.0,,N
6684,Intermediate,,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,50594,Mus musculus,5969,BAO_0000218,,A,In vivo,,10090.0,,N
6685,Intermediate,,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,50594,Mus musculus,5969,BAO_0000218,,A,In vivo,,10090.0,,N
6686,Intermediate,,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,Mus musculus,5969,BAO_0000218,,A,In vivo,,10090.0,,N
6687,Intermediate,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
6688,Intermediate,,,,Cmax after oral administration at 30 mg/kg in ICR mouse,50594,Mus musculus,5781,BAO_0000218,,A,In vivo,,10090.0,,N
6689,Intermediate,,,,Cmax after peroral administration in mice at 2.4 uM/kg,50594,Mus musculus,17764,BAO_0000218,,A,In vivo,,10090.0,,N
6690,Intermediate,,Brain,955.0,Cmax in brain of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,In vivo,,10090.0,,N
6691,Intermediate,,Kidney,2113.0,Cmax in kidney of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,In vivo,,10090.0,,N
6692,Intermediate,,Liver,2107.0,Cmax in liver of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,In vivo,,10090.0,,N
6693,Intermediate,,Lung,2048.0,Cmax in lungs of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,In vivo,,10090.0,,N
6694,Intermediate,,,,Cmax in mice at 18 uM/kg i.p. administration,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
6695,Intermediate,,,,Cmax in mice at 23 uM/kg i.v. administration,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
6696,Intermediate,,,,Cmax in mice at 24 uM/kg i.p. administration,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
6697,Intermediate,,,,Cmax in mice at 25 uM/kg i.p. administration,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
6698,Intermediate,,,,Cmax in mice at 26 uM/kg i.p. administration,50594,Mus musculus,17764,BAO_0000218,,F,In vivo,,10090.0,,N
6699,Intermediate,,Spleen,2106.0,Cmax in spleen of mice at the oral dose of 50 mg/kg,50594,Mus musculus,17641,BAO_0000218,,A,In vivo,,10090.0,,N
6700,Intermediate,,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
6701,Intermediate,,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,50594,Mus musculus,16597,BAO_0000218,,A,In vivo,,10090.0,,N
6702,Intermediate,,,,Cmax value was determined,50594,Mus musculus,5727,BAO_0000218,,A,In vivo,,10090.0,,N
6703,Intermediate,,,,Cmax value in IRC mice,50594,Mus musculus,5951,BAO_0000218,,A,In vivo,,10090.0,,N
6704,Intermediate,,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,Mus musculus,5506,BAO_0000218,,A,In vivo,,10090.0,,N
6705,Intermediate,,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,Mus musculus,5506,BAO_0000218,,A,In vivo,,10090.0,,N
6706,Intermediate,,Plasma,1969.0,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,50594,Mus musculus,14239,BAO_0000218,,A,In vivo,,10090.0,,N
6707,Intermediate,,Plasma,1969.0,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",50594,Mus musculus,4890,BAO_0000218,,A,In vivo,,10090.0,,N
6708,Intermediate,,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,50594,Mus musculus,429,BAO_0000218,,A,In vivo,,10090.0,,N
6709,Intermediate,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,50535,Acanthocheilonema viteae,10986,BAO_0000218,,F,,,6277.0,,N
6710,Intermediate,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,50535,Acanthocheilonema viteae,10986,BAO_0000218,,F,,,6277.0,,N
6711,Intermediate,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,50535,Acanthocheilonema viteae,10986,BAO_0000218,,F,,,6277.0,,N
6712,Intermediate,,,,Inhibitory activity against human tumor cell line A0375 melanoma.,80018,Homo sapiens,13227,BAO_0000219,,F,,,9606.0,A-375,N
6713,Expert,Brain membranes,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,12512,Rattus norvegicus,4481,BAO_0000249,,B,,,10116.0,,D
6714,Expert,,,,Forskolin-induced cAMP production at human A1 adenosine receptor,114,Homo sapiens,16931,BAO_0000019,,F,,,9606.0,,D
6715,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,114,,3850,BAO_0000219,,F,,,,CHO,H
6716,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,114,,3850,BAO_0000219,,F,,,,CHO,H
6717,Expert,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,114,,3850,BAO_0000219,,F,,,,CHO,H
6718,Expert,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,114,,3850,BAO_0000219,,F,,,,CHO,H
6719,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,114,,3850,BAO_0000219,,F,,,,CHO,H
6720,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,114,,3850,BAO_0000219,,F,,,,CHO,H
6721,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,114,,3850,BAO_0000219,,F,,,,CHO,H
6722,Expert,,,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,114,Homo sapiens,3850,BAO_0000219,,F,,,9606.0,CHO,D
6723,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,114,,3850,BAO_0000219,,F,,,,CHO,H
6724,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,114,,3850,BAO_0000219,,F,,,,CHO,H
6725,Expert,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,114,,3850,BAO_0000219,,F,,,,CHO,H
6726,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,114,,3850,BAO_0000219,,F,,,,CHO,H
6727,Expert,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,114,,3850,BAO_0000219,,F,,,,CHO,H
6728,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,114,,3850,BAO_0000219,,F,,,,CHO,H
6729,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,114,,3850,BAO_0000219,,F,,,,CHO,H
6730,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,114,,3850,BAO_0000219,,F,,,,CHO,H
6731,Expert,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,114,,3850,BAO_0000219,,F,,,,CHO,H
6732,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,114,,3850,BAO_0000219,,F,,,,CHO,H
6733,Autocuration,,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,114,,3850,BAO_0000219,,F,,,,CHO,H
6734,Expert,,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,114,,3850,BAO_0000219,,F,,,,CHO,H
6735,Intermediate,,,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,80013,Oryctolagus cuniculus,12680,BAO_0000219,,F,,,9986.0,A10,N
6736,Autocuration,,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,22226,Rattus norvegicus,1313,BAO_0000219,,F,,,10116.0,A10,U
6737,Autocuration,,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,22226,Rattus norvegicus,1313,BAO_0000219,,F,,,10116.0,A10,U
6738,Intermediate,,,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,80013,Rattus norvegicus,17567,BAO_0000219,,F,,,10116.0,A10,N
6739,Intermediate,,,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,80013,Rattus norvegicus,17567,BAO_0000219,,F,,,10116.0,A10,N
6740,Intermediate,,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,80013,Rattus norvegicus,11819,BAO_0000219,,F,,,10116.0,A10,N
6741,Intermediate,,,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,80089,Cricetulus griseus,13436,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6742,Intermediate,,,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,80089,Cricetulus griseus,12687,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6743,Intermediate,,,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,80089,Cricetulus griseus,12651,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6744,Intermediate,,,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,80089,Cricetulus griseus,13300,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6745,Intermediate,,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,80089,Cricetulus griseus,15296,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6746,Intermediate,,,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",80089,Cricetulus griseus,15328,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6747,Intermediate,,,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),80089,Cricetulus griseus,13302,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6748,Expert,,,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",80089,Cricetulus griseus,14367,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6749,Expert,,,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,80089,Cricetulus griseus,17002,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6750,Intermediate,,,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,80089,Cricetulus griseus,13436,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6751,Intermediate,,,,Inhibitory activity against aerobic growth of AA8 cells.,80089,Cricetulus griseus,13435,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6752,Intermediate,,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,Cricetulus griseus,10503,BAO_0000219,,A,,,10029.0,CHO-AA8,N
6753,Expert,,,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,Cricetulus griseus,10503,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6754,Intermediate,,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,Cricetulus griseus,10503,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6755,Expert,,,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,80089,Cricetulus griseus,15090,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6756,Expert,,,,Cytotoxicity against AA8 cell line,80089,Cricetulus griseus,10368,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6757,Intermediate,,,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),80089,Cricetulus griseus,12651,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6758,Intermediate,,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,Cricetulus griseus,12687,BAO_0000219,,A,,,10029.0,CHO-AA8,N
6759,Intermediate,,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,Cricetulus griseus,12687,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6760,Intermediate,,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,Cricetulus griseus,12687,BAO_0000219,,A,,,10029.0,CHO-AA8,N
6761,Intermediate,,,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,80089,Cricetulus griseus,1890,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6762,Intermediate,,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,80089,Cricetulus griseus,10747,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6763,Intermediate,,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,80089,Cricetulus griseus,10747,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6764,Autocuration,,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),22224,Cricetulus griseus,11616,BAO_0000218,,F,,,10029.0,,U
6765,Expert,,,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,80089,Cricetulus griseus,11616,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6766,Autocuration,,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,22224,Cricetulus griseus,3471,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6767,Autocuration,,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,22224,Cricetulus griseus,3471,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6768,Autocuration,,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,22224,Cricetulus griseus,3471,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6769,Autocuration,,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,22224,Cricetulus griseus,3471,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6770,Autocuration,,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,22224,Cricetulus griseus,3471,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6771,Autocuration,,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,22224,Cricetulus griseus,3471,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6772,Autocuration,,,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,22224,Cricetulus griseus,3471,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6773,Expert,,,,Concentration required to reduce AA8 cell survival by 10%,80089,Cricetulus griseus,11616,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6774,Autocuration,,,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",22224,Cricetulus griseus,2656,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6775,Autocuration,,,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,22224,Cricetulus griseus,10518,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6776,Autocuration,,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,22224,Cricetulus griseus,10518,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6777,Autocuration,,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,22224,Cricetulus griseus,10518,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6778,Autocuration,,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,22224,Cricetulus griseus,10518,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6779,Autocuration,,,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,22224,Cricetulus griseus,16156,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6780,Autocuration,,,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,22224,Cricetulus griseus,2656,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6781,Autocuration,,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",22224,Cricetulus griseus,11005,BAO_0000019,,F,,,10029.0,,U
6782,Autocuration,,,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,22224,Cricetulus griseus,11942,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6783,Autocuration,,,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,22224,Cricetulus griseus,2128,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6784,Intermediate,,,,Half life period after 15 mg/kg iv dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,In vivo,,9615.0,,N
6785,Intermediate,,,,Half life period after 30 mg/kg po dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,In vivo,,9615.0,,N
6786,Intermediate,,,,Half life was measured after oral 2b administration (tested in 6 dogs),50588,Canis lupus familiaris,9579,BAO_0000218,,A,In vivo,,9615.0,,N
6787,Intermediate,,,,Half life was measured in dog after oral 17b administration,50588,Canis lupus familiaris,9579,BAO_0000218,,A,In vivo,,9615.0,,N
6788,Intermediate,,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,50588,Canis lupus familiaris,9579,BAO_0000218,,A,In vivo,,9615.0,,N
6789,Intermediate,,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,50588,Canis lupus familiaris,9579,BAO_0000218,,A,In vivo,,9615.0,,N
6790,Intermediate,,,,Tmax value after 15 mg/kg iv dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,In vivo,,9615.0,,N
6791,Intermediate,,,,Tmax value after 30 mg/kg po dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,In vivo,,9615.0,,N
6792,Intermediate,,,,Compound was evaluated for its half life when administered intravenously in dog,50588,Canis lupus familiaris,3184,BAO_0000218,,A,In vivo,,9615.0,,N
6793,Intermediate,,Plasma,1969.0,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),50588,Canis lupus familiaris,5017,BAO_0000218,,A,In vivo,,9615.0,,N
6794,Intermediate,,,,Elimination Half-life of compound was determined in dog,50588,Canis lupus familiaris,6821,BAO_0000218,,A,,,9615.0,,N
6795,Intermediate,,,,Half life of compound in dog following oral administration,50588,Canis lupus familiaris,17839,BAO_0000218,,A,In vivo,,9615.0,,N
6796,Intermediate,,,,Half life of compound was determined in dog,50588,Canis lupus familiaris,17267,BAO_0000218,,A,,,9615.0,,N
6797,Intermediate,,Blood,178.0,Half life of compound was determined in dog blood,50588,Canis lupus familiaris,4727,BAO_0000218,,A,,,9615.0,,N
6798,Intermediate,,,,Half life after oral and iv dosing in dogs,50588,Canis lupus familiaris,5238,BAO_0000218,,A,In vivo,,9615.0,,N
6799,Intermediate,,,,Half life in dogs in hours,50588,Canis lupus familiaris,4942,BAO_0000218,,A,,,9615.0,,N
6800,Intermediate,,,,Half life on i.v. administration of 2 mg/kg was measured in dog,50588,Canis lupus familiaris,6505,BAO_0000218,,A,In vivo,,9615.0,,N
6801,Intermediate,,,,t1/2 in dog after oral dose (1 mg/kg),50588,Canis lupus familiaris,5130,BAO_0000218,,A,In vivo,,9615.0,,N
6802,Intermediate,,,,Half life was evaluated in dog,50588,Canis lupus familiaris,1475,BAO_0000218,,A,,,9615.0,,N
6803,Intermediate,,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,50588,Canis lupus familiaris,17804,BAO_0000218,,A,In vivo,,9615.0,,N
6804,Intermediate,,,,Half life period of compound was determined after peroral administration at 2 mg/kg,50588,Canis lupus familiaris,17804,BAO_0000218,,A,In vivo,,9615.0,,N
6805,Intermediate,,,,Half life period (10 mg/kg) was determined in dog,50588,Canis lupus familiaris,6084,BAO_0000218,,A,In vivo,,9615.0,,N
6806,Intermediate,,,,Half life period (10 mg/kg) was determined in dog,50588,Canis lupus familiaris,6084,BAO_0000218,,A,In vivo,,9615.0,,N
6807,Intermediate,,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,50588,Canis lupus familiaris,5542,BAO_0000218,,A,In vivo,,9615.0,,N
6808,Intermediate,,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,50588,Canis lupus familiaris,5542,BAO_0000218,,A,In vivo,,9615.0,,N
6809,Intermediate,,,,Half life period in dog,50588,Canis lupus familiaris,6084,BAO_0000218,,A,,,9615.0,,N
6810,Intermediate,,,,Half life period in dogs after oral administration at 1 mg/kg,50588,Canis lupus familiaris,6241,BAO_0000218,,A,In vivo,,9615.0,,N
6811,Intermediate,,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,Canis lupus familiaris,1916,BAO_0000218,,A,In vivo,,9615.0,,N
6812,Intermediate,,,,Half-life of compound was determined in dogs,50588,Canis lupus familiaris,6621,BAO_0000218,,A,,,9615.0,,N
6813,Intermediate,,Plasma,1969.0,Half-life in dog plasma,50588,Canis lupus familiaris,1696,BAO_0000218,,A,,,9615.0,,N
6814,Intermediate,,,,Half-life in mongrel dogs was determined,50588,Canis lupus familiaris,17800,BAO_0000218,,A,,,9615.0,,N
6815,Intermediate,,,,Half-life in dog upon oral administration,50588,Canis lupus familiaris,17657,BAO_0000218,,A,In vivo,,9615.0,,N
6816,Intermediate,,,,Half-life in dog upon oral administration; Unable to calculate,50588,Canis lupus familiaris,17657,BAO_0000218,,A,In vivo,,9615.0,,N
6817,Intermediate,,,,Half-life was measured in dog,50588,Canis lupus familiaris,4239,BAO_0000218,,A,,,9615.0,,N
6818,Intermediate,,,,Half-life was measured in dog,50588,Canis lupus familiaris,5985,BAO_0000218,,A,,,9615.0,,N
6819,Intermediate,,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,50588,Canis lupus familiaris,9932,BAO_0000218,,A,,,9615.0,,N
6820,Intermediate,,,,Oral half life was determined,50588,Canis lupus familiaris,5199,BAO_0000218,,A,In vivo,,9615.0,,N
6821,Intermediate,,Plasma,1969.0,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,50588,Canis lupus familiaris,5199,BAO_0000218,,A,In vivo,,9615.0,,N
6822,Intermediate,,Plasma,1969.0,Plasma half life was evaluated,50588,Canis lupus familiaris,1475,BAO_0000218,,A,,,9615.0,,N
6823,Intermediate,,Plasma,1969.0,Plasma half life was evaluated in Dog,50588,Canis lupus familiaris,1475,BAO_0000218,,A,,,9615.0,,N
6824,Intermediate,,Plasma,1969.0,Plasma half life was evaluated in dog,50588,Canis lupus familiaris,1475,BAO_0000218,,A,,,9615.0,,N
6825,Intermediate,,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,50588,Canis lupus familiaris,6316,BAO_0000218,,A,In vivo,,9615.0,,N
6826,Intermediate,,,,Tested for the half life value in dog,50588,Canis lupus familiaris,4883,BAO_0000218,,A,,,9615.0,,N
6827,Intermediate,,,,Maximum time at the dose of 2 mg/kg in dog,50588,Canis lupus familiaris,4727,BAO_0000218,,A,In vivo,,9615.0,,N
6828,Intermediate,,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,Canis lupus familiaris,1916,BAO_0000218,,A,In vivo,,9615.0,,N
6829,Intermediate,,Blood,178.0,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,Canis lupus familiaris,1337,BAO_0000218,,A,In vivo,,9615.0,,N
6830,Intermediate,,Blood,178.0,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,Canis lupus familiaris,1337,BAO_0000218,,A,In vivo,,9615.0,,N
6831,Intermediate,,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,50588,Canis lupus familiaris,6265,BAO_0000218,,A,In vivo,,9615.0,,N
6832,Intermediate,,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,Canis lupus familiaris,4809,BAO_0000218,,A,In vivo,,9615.0,,N
6833,Intermediate,,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,50588,Canis lupus familiaris,5983,BAO_0000218,,A,In vivo,,9615.0,,N
6834,Intermediate,,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",50588,Canis lupus familiaris,5313,BAO_0000218,,A,,,9615.0,,N
6835,Intermediate,,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",50588,Canis lupus familiaris,5313,BAO_0000218,,A,In vivo,,9615.0,,N
6836,Intermediate,,Plasma,1969.0,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,50588,Canis lupus familiaris,17650,BAO_0000218,,A,In vivo,,9615.0,,N
6837,Intermediate,,Plasma,1969.0,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,50588,Canis lupus familiaris,5199,BAO_0000218,,A,In vivo,,9615.0,,N
6838,Intermediate,,Plasma,1969.0,Time taken for maximum plasma concentration in dog,50588,Canis lupus familiaris,933,BAO_0000218,,A,,,9615.0,,N
6839,Intermediate,,,,Time to reach Cmax after oral administration to dogs,50588,Canis lupus familiaris,16367,BAO_0000218,,A,In vivo,,9615.0,,N
6840,Intermediate,,Plasma,1969.0,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,Canis lupus familiaris,6348,BAO_0000218,,A,In vivo,,9615.0,,N
6841,Intermediate,,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,50588,Canis lupus familiaris,6316,BAO_0000218,,A,In vivo,,9615.0,,N
6842,Intermediate,,,,Tmax after peroral administration (1 mg/kg) was determined in dog,50588,Canis lupus familiaris,6215,BAO_0000218,,A,In vivo,,9615.0,,N
6843,Expert,,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,Canis lupus familiaris,3598,BAO_0000218,,A,In vivo,,9615.0,,N
6844,Intermediate,,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,50588,Canis lupus familiaris,4527,BAO_0000218,,A,In vivo,,9615.0,,N
6845,Intermediate,,,,Tmax after peroral administration in dogs at 2.4 uM/kg,50588,Canis lupus familiaris,17764,BAO_0000218,,A,In vivo,,9615.0,,N
6846,Intermediate,,,,In vivo Cmax in mice at dose of 100 mg/kg,50594,Mus musculus,5969,BAO_0000218,,A,In vivo,,10090.0,,N
6847,Intermediate,,,,In vivo Cmax in mice at dose of 50 mg/kg,50594,Mus musculus,5969,BAO_0000218,,A,In vivo,,10090.0,,N
6848,Intermediate,,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,Mus musculus,4573,BAO_0000218,,A,In vivo,,10090.0,,N
6849,Intermediate,,Plasma,1969.0,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,Mus musculus,3277,BAO_0000218,,A,In vivo,,10090.0,,N
6850,Intermediate,,Plasma,1969.0,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,50594,Mus musculus,17734,BAO_0000218,,A,In vivo,,10090.0,,N
6851,Intermediate,,Plasma,1969.0,Maximum concentration obtained in mouse plasma was determined,50594,Mus musculus,3132,BAO_0000218,,A,In vivo,,10090.0,,N
6852,Intermediate,,Plasma,1969.0,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,50594,Mus musculus,3132,BAO_0000218,,A,In vivo,,10090.0,,N
6853,Intermediate,,Plasma,1969.0,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,Mus musculus,6348,BAO_0000218,,A,In vivo,,10090.0,,N
6854,Intermediate,,Plasma,1969.0,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,50594,Mus musculus,17729,BAO_0000218,,A,In vivo,,10090.0,,N
6855,Intermediate,,Plasma,1969.0,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,50594,Mus musculus,17729,BAO_0000218,,A,In vivo,,10090.0,,N
6856,Intermediate,,Plasma,1969.0,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,50594,Mus musculus,17729,BAO_0000218,,A,In vivo,,10090.0,,N
6857,Intermediate,,Plasma,1969.0,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,50594,Mus musculus,17728,BAO_0000218,,A,In vivo,,10090.0,,N
6858,Intermediate,,Plasma,1969.0,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,50594,Mus musculus,17728,BAO_0000218,,A,In vivo,,10090.0,,N
6859,Intermediate,,Plasma,1969.0,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,50594,Mus musculus,17728,BAO_0000218,,A,In vivo,,10090.0,,N
6860,Intermediate,,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,50594,Mus musculus,4066,BAO_0000218,,A,In vivo,,10090.0,,N
6861,Intermediate,,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,50594,Mus musculus,6178,BAO_0000218,,A,In vivo,,10090.0,,N
6862,Intermediate,,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,50594,Mus musculus,6178,BAO_0000218,,A,In vivo,,10090.0,,N
6863,Intermediate,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,50594,Mus musculus,3760,BAO_0000218,,A,In vivo,,10090.0,,N
6864,Intermediate,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,50594,Mus musculus,3760,BAO_0000218,,A,In vivo,,10090.0,,N
6865,Intermediate,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,50594,Mus musculus,3760,BAO_0000218,,A,In vivo,,10090.0,,N
6866,Intermediate,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,50594,Mus musculus,3760,BAO_0000218,,A,In vivo,,10090.0,,N
6868,Intermediate,,,,Cmax in male mice after 2 mg/kg oral dose,50594,Mus musculus,5961,BAO_0000218,,A,In vivo,,10090.0,,N
6869,Intermediate,,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,50594,Mus musculus,6137,BAO_0000218,,A,In vivo,,10090.0,,N
6870,Intermediate,,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,50594,Mus musculus,3802,BAO_0000218,,A,In vivo,,10090.0,,N
6871,Intermediate,,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,50594,Mus musculus,3535,BAO_0000218,,A,,,10090.0,,N
6872,Intermediate,,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,50594,Mus musculus,3535,BAO_0000218,,A,,,10090.0,,N
6873,Intermediate,,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,50594,Mus musculus,3535,BAO_0000218,,A,,,10090.0,,N
6874,Intermediate,,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,50594,Mus musculus,3535,BAO_0000218,,A,,,10090.0,,N
6875,Intermediate,,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,50594,Mus musculus,3535,BAO_0000218,,A,,,10090.0,,N
6876,Intermediate,,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,50594,Mus musculus,3535,BAO_0000218,,A,,,10090.0,,N
6877,Intermediate,,Plasma,1969.0,Maximum concentration in plasma upon oral administration in mouse,50594,Mus musculus,2862,BAO_0000218,,A,,,10090.0,,N
6878,Intermediate,,Plasma,1969.0,Maximum plasma concentration was evaluated in mice after oral administration,50594,Mus musculus,2675,BAO_0000218,,A,,,10090.0,,N
6879,Intermediate,,Plasma,1969.0,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,50594,Mus musculus,2675,BAO_0000218,,A,In vivo,,10090.0,,N
6880,Intermediate,,,,Dose at which the compound induced fecal excretion in mice,50594,Mus musculus,5399,BAO_0000218,,A,,,10090.0,,N
6893,Expert,,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,80013,Rattus norvegicus,11819,BAO_0000219,,F,,,10116.0,A10,N
6894,Expert,,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,80013,Rattus norvegicus,11819,BAO_0000219,,F,,,10116.0,A10,N
6895,Expert,,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,80013,Rattus norvegicus,11819,BAO_0000219,,F,,,10116.0,A10,N
6896,Expert,,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,80013,Rattus norvegicus,11819,BAO_0000219,,F,,,10116.0,A10,N
6897,Intermediate,,,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),80013,Rattus norvegicus,16361,BAO_0000219,,F,,,10116.0,A10,N
6898,Intermediate,,,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,80655,Homo sapiens,2288,BAO_0000219,,F,,,9606.0,A121,N
6899,Intermediate,,,,Anticancer activity against human ovarian carcinoma A121 cells,80655,Homo sapiens,10404,BAO_0000219,,F,,,9606.0,A121,N
6900,Intermediate,,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,80655,Homo sapiens,14790,BAO_0000219,,F,,,9606.0,A121,N
6901,Intermediate,,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,80655,Homo sapiens,14790,BAO_0000219,,F,,,9606.0,A121,N
6902,Expert,,,,Growth inhibition of human ovarian carcinoma (A121) cell line,80655,Homo sapiens,14253,BAO_0000219,,F,,,9606.0,A121,N
6903,Expert,,,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,80655,Homo sapiens,13617,BAO_0000219,,F,,,9606.0,A121,N
6904,Intermediate,,,,Cytotoxicity against human A121 ovarian cells,80655,Homo sapiens,1003,BAO_0000219,,F,,,9606.0,A121,N
6905,Intermediate,,,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,80655,Homo sapiens,830,BAO_0000219,,F,,,9606.0,A121,N
6906,Intermediate,,,,In vitro cytotoxicity against human ovarian carcinoma A21,80655,Homo sapiens,12307,BAO_0000219,,F,,,9606.0,A121,N
6907,Intermediate,,,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,80655,Homo sapiens,14254,BAO_0000219,,F,,,9606.0,A121,N
6908,Intermediate,,,,Inhibitory activity of compound against human A121 ovarian cell line.,80655,Homo sapiens,13370,BAO_0000219,,F,,,9606.0,A121,N
6909,Intermediate,,,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,80655,Homo sapiens,14790,BAO_0000219,,F,,,9606.0,A121,N
6910,Intermediate,,,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,80655,Homo sapiens,3614,BAO_0000219,,F,,,9606.0,A121,N
6911,Intermediate,,,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,80012,Homo sapiens,2664,BAO_0000219,,F,,,9606.0,A 172,N
6912,Expert,,,,In vitro cytotoxicity against A172 human tumor cell lines.,80012,Homo sapiens,2037,BAO_0000219,,F,,,9606.0,A 172,N
6913,Intermediate,,,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,80012,Homo sapiens,14539,BAO_0000219,,F,,,9606.0,A 172,N
6914,Intermediate,,,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,80012,Homo sapiens,2836,BAO_0000219,,F,,,9606.0,A 172,N
6915,Intermediate,,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,80012,Homo sapiens,10708,BAO_0000219,,F,,,9606.0,A 172,N
6916,Autocuration,,,,Association constant against A2 adenosine receptor,104729,Canis lupus familiaris,8975,BAO_0000224,,B,,,9615.0,,H
6917,Intermediate,,,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,80656,fish,7645,BAO_0000219,,F,,,,A2,N
6918,Autocuration,,,,Ratio of Ki for adenosine A2 and A1 receptor binding,104713,Rattus norvegicus,11377,BAO_0000224,,B,,,10116.0,,D
6919,Expert,,,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,80014,Homo sapiens,13528,BAO_0000219,,F,,,9606.0,A204,N
6920,Expert,,,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,80014,Homo sapiens,10160,BAO_0000219,,F,,,9606.0,A204,N
6921,Intermediate,,,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,80015,Homo sapiens,15144,BAO_0000219,,F,,,9606.0,A2058,N
6922,Intermediate,,,,Growth inhibition against Human squamous cell line(A 253),80657,Homo sapiens,13160,BAO_0000219,,F,,,9606.0,A253 cell line,N
6923,Intermediate,,,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,80657,Homo sapiens,12898,BAO_0000219,,F,,,9606.0,A253 cell line,N
6924,Intermediate,,,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,80657,Homo sapiens,13069,BAO_0000219,,F,,,9606.0,A253 cell line,N
6925,Intermediate,,,,Growth inhibition of A253 cell lines.,80657,Homo sapiens,15984,BAO_0000219,,F,,,9606.0,A253 cell line,N
6926,Intermediate,,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),80657,Homo sapiens,15564,BAO_0000219,,F,,,9606.0,A253 cell line,N
6927,Intermediate,,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,80657,Homo sapiens,15564,BAO_0000219,,F,,,9606.0,A253 cell line,N
6928,Intermediate,,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,80657,Homo sapiens,15564,BAO_0000219,,F,,,9606.0,A253 cell line,N
6929,Intermediate,,,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,81034,Homo sapiens,4720,BAO_0000219,,F,,,9606.0,A2780,N
6930,Intermediate,,,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,81034,Homo sapiens,16112,BAO_0000219,,F,,,9606.0,A2780,N
6931,Expert,,,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,81034,Homo sapiens,16597,BAO_0000219,,F,,,9606.0,A2780,N
6932,Intermediate,,,,Cytotoxicity against human cancer cell lines A2780 (ovarian),81034,Homo sapiens,16378,BAO_0000219,,F,,,9606.0,A2780,N
6933,Expert,,,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,81034,Homo sapiens,16085,BAO_0000219,,F,,,9606.0,A2780,N
6934,Intermediate,,,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,81034,Homo sapiens,16317,BAO_0000219,,F,,,9606.0,A2780,N
6935,Intermediate,,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),81034,Homo sapiens,15748,BAO_0000219,,F,,,9606.0,A2780,N
6936,Expert,,,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,81034,Homo sapiens,16597,BAO_0000219,,F,,,9606.0,A2780,N
6937,Expert,,,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,81034,Homo sapiens,16597,BAO_0000219,,F,,,9606.0,A2780,N
6938,Expert,,,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,81034,Homo sapiens,16597,BAO_0000219,,F,,,9606.0,A2780,N
6939,Intermediate,,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,81034,Homo sapiens,15608,BAO_0000219,,F,,,9606.0,A2780,N
6940,Intermediate,,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,81034,Homo sapiens,15608,BAO_0000219,,F,,,9606.0,A2780,N
6941,Intermediate,,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,81034,Homo sapiens,15608,BAO_0000219,,F,,,9606.0,A2780,N
6942,Autocuration,,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,22224,Cricetulus griseus,15296,BAO_0000019,,F,,,10029.0,,U
6943,Autocuration,,,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,22224,Cricetulus griseus,10251,BAO_0000219,,A,,,10029.0,CHO-AA8,U
6944,Autocuration,,,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,22224,Cricetulus griseus,10251,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6945,Autocuration,,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,22224,Cricetulus griseus,10251,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6946,Autocuration,,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),22224,Cricetulus griseus,10251,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6947,Autocuration,,,,Growth inhibition against CHO-derived cell line AA8,22224,Cricetulus griseus,11858,BAO_0000019,,F,,,10029.0,,U
6948,Autocuration,,,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],22224,Cricetulus griseus,11858,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6949,Expert,,,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,80089,hampster,11616,BAO_0000219,,F,,,36483.0,CHO-AA8,N
6950,Expert,,,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,80089,Cricetulus griseus,11616,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6951,Autocuration,,,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,22224,Cricetulus griseus,10518,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6952,Autocuration,,,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,22224,Cricetulus griseus,11396,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6953,Autocuration,,,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,22224,Cricetulus griseus,10518,BAO_0000219,,F,,,10029.0,CHO-AA8,U
6954,Expert,,,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,80089,Cricetulus griseus,11616,BAO_0000219,,F,,,10029.0,CHO-AA8,N
6955,Autocuration,,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,12675,,14837,BAO_0000019,,F,,,,,H
6956,Autocuration,,,,Number of binding sites (n) of isolated serum protein AAG,12675,,14837,BAO_0000019,,F,,,,,H
6957,Intermediate,,,,Association constant for binding to AATT duplex,22222,,16037,BAO_0000225,,B,,,,,M
6958,Expert,,,,Inhibition of ABAE human fibroblast cell proliferation,100090,Homo sapiens,16597,BAO_0000219,,F,,,9606.0,ABAE,N
6959,Intermediate,,,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",80668,Mus musculus,8831,BAO_0000218,,F,,,10090.0,AC755,N
6960,Expert,,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,102444,Oryctolagus cuniculus,13419,BAO_0000218,,F,,,9986.0,,D
6961,Expert,,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,102444,Oryctolagus cuniculus,13419,BAO_0000218,,F,In vivo,,9986.0,,D
6962,Autocuration,,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,69,,15778,BAO_0000357,,B,,,,,H
6963,Autocuration,,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,69,,15778,BAO_0000357,,B,,,,,H
6964,Intermediate,,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,80669,Homo sapiens,12988,BAO_0000219,,F,,,9606.0,ACH-2 cell line,N
6965,Intermediate,,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),80669,Homo sapiens,12988,BAO_0000219,,F,,,9606.0,ACH-2 cell line,N
6966,Autocuration,,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,22224,Human immunodeficiency virus 1,12988,BAO_0000219,,F,,,11676.0,T cell line,U
6967,Autocuration,,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),22224,Human immunodeficiency virus 1,12988,BAO_0000219,,F,,,11676.0,T cell line,U
6968,Autocuration,,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),22224,Human immunodeficiency virus 1,12988,BAO_0000219,,F,,,11676.0,T cell line,U
6969,Intermediate,,,,Inhibition of growth of renal cancer ACHN cell line,80025,Homo sapiens,11843,BAO_0000219,,F,,,9606.0,ACHN,N
6970,Intermediate,,,,Inhibition of growth of ACHN renal cancer cell line,80025,Homo sapiens,16939,BAO_0000219,,F,,,9606.0,ACHN,N
6971,Intermediate,,,,Inhibitory concentration required against ACHN renal cancer cell line,80025,Homo sapiens,4782,BAO_0000219,,F,,,9606.0,ACHN,N
6972,Expert,,,,Concentration required to inhibit growth of human renal (ACHN) cell line,80025,Homo sapiens,6310,BAO_0000219,,F,,,9606.0,ACHN,N
6973,Intermediate,,,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,80025,Homo sapiens,6310,BAO_0000219,,F,,,9606.0,ACHN,N
6974,Intermediate,,,,Cytotoxic activity against ACHN Renal cancer cell line,80025,Homo sapiens,12858,BAO_0000219,,F,,,9606.0,ACHN,N
6975,Intermediate,,,,Cytotoxicity evaluation against ACHN renal cancer cells,80025,Homo sapiens,17380,BAO_0000219,,F,,,9606.0,ACHN,N
6976,Intermediate,,,,In vitro antitumor activity against human renal ACHN cell line,80025,Homo sapiens,5858,BAO_0000219,,F,,,9606.0,ACHN,N
6977,Intermediate,,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,80025,Homo sapiens,3838,BAO_0000219,,F,,,9606.0,ACHN,N
6978,Intermediate,,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,80025,Homo sapiens,3838,BAO_0000219,,F,,,9606.0,ACHN,N
6979,Intermediate,,,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",80025,Homo sapiens,5406,BAO_0000219,,F,,,9606.0,ACHN,N
6980,Intermediate,,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,80025,Homo sapiens,4071,BAO_0000219,,F,,,9606.0,ACHN,N
6981,Expert,,,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,80025,Homo sapiens,4071,BAO_0000219,,F,,,9606.0,ACHN,N
6982,Intermediate,,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,80025,Homo sapiens,4071,BAO_0000219,,F,,,9606.0,ACHN,N
6983,Intermediate,,,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,80025,Homo sapiens,15002,BAO_0000219,,F,,,9606.0,ACHN,N
6984,Intermediate,,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),80025,Homo sapiens,14769,BAO_0000219,,F,,,9606.0,ACHN,N
6985,Intermediate,,,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",80025,Homo sapiens,13958,BAO_0000219,,F,,,9606.0,ACHN,N
6986,Intermediate,,,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,80025,Homo sapiens,1665,BAO_0000219,,F,,,9606.0,ACHN,N
6987,Intermediate,,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,80025,Homo sapiens,15354,BAO_0000219,,F,,,9606.0,ACHN,N
6988,Intermediate,,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,80025,Homo sapiens,15354,BAO_0000219,,F,,,9606.0,ACHN,N
6989,Intermediate,,,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,80025,Homo sapiens,13978,BAO_0000219,,F,,,9606.0,ACHN,N
6990,Intermediate,,,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,80025,Homo sapiens,6798,BAO_0000219,,F,,,9606.0,ACHN,N
6991,Intermediate,,,,Tmax value after administration of 4 mg/Kg oral dose in dog,50588,Canis lupus familiaris,2959,BAO_0000218,,A,In vivo,,9615.0,,N
6992,Intermediate,,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",50588,Canis lupus familiaris,9932,BAO_0000218,,A,,,9615.0,,N
6993,Intermediate,,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,Canis lupus familiaris,5546,BAO_0000218,,A,,,9615.0,,N
6994,Intermediate,,,,Volume distribution after 15 mg/kg iv dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,In vivo,,9615.0,,N
6995,Intermediate,,,,Volume distribution after 30 mg/kg po dose in Dogs,50588,Canis lupus familiaris,16907,BAO_0000218,,A,In vivo,,9615.0,,N
6996,Intermediate,,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,50588,Canis lupus familiaris,4257,BAO_0000218,,A,In vivo,,9615.0,,N
6997,Intermediate,,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,50588,Canis lupus familiaris,4305,BAO_0000218,,A,In vivo,,9615.0,,N
6998,Intermediate,,,,Volume of distribution was evaluated in dog,50588,Canis lupus familiaris,5472,BAO_0000218,,A,In vivo,,9615.0,,N
6999,Intermediate,,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,50588,Canis lupus familiaris,6062,BAO_0000218,,A,In vivo,,9615.0,,N
7000,Expert,,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,Canis lupus familiaris,3598,BAO_0000218,,A,,,9615.0,,N
7001,Intermediate,,,,The compound was tested for volume of distribution in dog,50588,Canis lupus familiaris,12500,BAO_0000218,,A,In vivo,,9615.0,,N
7002,Intermediate,,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,50588,Canis lupus familiaris,12500,BAO_0000218,,A,In vivo,,9615.0,,N
7003,Intermediate,,,,Vd (1 mg/kg) was determined in dog (in vivo),50588,Canis lupus familiaris,6227,BAO_0000218,,A,In vivo,,9615.0,,N
7004,Intermediate,,,,Vd in dog,50588,Canis lupus familiaris,6227,BAO_0000218,,A,In vivo,,9615.0,,N
7005,Intermediate,,,,Volume distribution was determined,50588,Canis lupus familiaris,4219,BAO_0000218,,A,In vivo,,9615.0,,N
7006,Intermediate,,,,Volume of distribution in dog,50588,Canis lupus familiaris,1696,BAO_0000218,,A,In vivo,,9615.0,,N
7007,Intermediate,,,,Volume of distribution by as 4 fold increase by iv administration in dogs,50588,Canis lupus familiaris,5542,BAO_0000218,,A,In vivo,,9615.0,,N
7008,Intermediate,,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,50588,Canis lupus familiaris,5199,BAO_0000218,,A,In vivo,,9615.0,,N
7009,Intermediate,,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,Canis lupus familiaris,6348,BAO_0000218,,A,In vivo,,9615.0,,N
7010,Intermediate,,,,Volume distribution at the dose of 2 mg/kg in dog,50588,Canis lupus familiaris,4727,BAO_0000218,,A,In vivo,,9615.0,,N
7011,Intermediate,,,,Steady state volume of distribution was determined,50588,Canis lupus familiaris,16367,BAO_0000218,,A,In vivo,,9615.0,,N
7012,Intermediate,,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,50588,Canis lupus familiaris,2652,BAO_0000218,,A,In vivo,,9615.0,,N
7013,Intermediate,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,Canis lupus familiaris,16452,BAO_0000218,,A,In vivo,,9615.0,,N
7014,Intermediate,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,Canis lupus familiaris,16452,BAO_0000218,,A,In vivo,,9615.0,,N
7015,Intermediate,,,,Bioavailability in dog (dose 1 mg/kg i.v.),50588,Canis lupus familiaris,16452,BAO_0000218,,A,In vivo,,9615.0,,N
7016,Intermediate,,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,Canis lupus familiaris,5334,BAO_0000218,,A,In vivo,,9615.0,,N
7017,Intermediate,,,,Pharmacokinetic property (vdss) was measured in dog,50588,Canis lupus familiaris,4239,BAO_0000218,,A,In vivo,,9615.0,,N
7018,Intermediate,,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,50588,Canis lupus familiaris,4709,BAO_0000218,,A,In vivo,,9615.0,,N
7019,Intermediate,,,,Vdss was determined after iv 0.1 mg/kg administration in dog,50588,Canis lupus familiaris,5600,BAO_0000218,,A,In vivo,,9615.0,,N
7020,Intermediate,,,,Volume displacement was calculated in dog,50588,Canis lupus familiaris,6057,BAO_0000218,,A,In vivo,,9615.0,,N
7021,Intermediate,,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,Canis lupus familiaris,5654,BAO_0000218,,A,In vivo,,9615.0,,N
7022,Intermediate,,,,Volume distribution constant was determined,50588,Canis lupus familiaris,5505,BAO_0000218,,A,In vivo,,9615.0,,N
7023,Intermediate,,,,Volume distribution at a dose of 1 uM/kg in dog was determined,50588,Canis lupus familiaris,4527,BAO_0000218,,A,In vivo,,9615.0,,N
7024,Intermediate,,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,Canis lupus familiaris,4521,BAO_0000218,,A,In vivo,,9615.0,,N
7025,Intermediate,,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,Canis lupus familiaris,4521,BAO_0000218,,A,In vivo,,9615.0,,N
7026,Intermediate,,,,Volume distribution (Vdss) was measured in dog,50588,Canis lupus familiaris,15660,BAO_0000218,,A,In vivo,,9615.0,,N
7027,Intermediate,,,,Volume distribution (Vdss) was measured in dog,50588,Canis lupus familiaris,15660,BAO_0000218,,A,In vivo,,9615.0,,N
7028,Intermediate,,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,Canis lupus familiaris,6679,BAO_0000218,,A,In vivo,,9615.0,,N
7029,Intermediate,,,,Volume of distribution in steady state was determined in dog,50588,Canis lupus familiaris,5145,BAO_0000218,,A,In vivo,,9615.0,,N
7030,Intermediate,,,,Volume of distribution of compound was determined in dog,50588,Canis lupus familiaris,6821,BAO_0000218,,A,In vivo,,9615.0,,N
7031,Intermediate,,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,50588,Canis lupus familiaris,4137,BAO_0000218,,A,In vivo,,9615.0,,N
7032,Intermediate,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),50588,Canis lupus familiaris,5334,BAO_0000218,,A,In vivo,,9615.0,,N
7033,Intermediate,,,,Volume of distribution (Vdss) was measured in dog,50588,Canis lupus familiaris,15660,BAO_0000218,,A,In vivo,,9615.0,,N
7034,Intermediate,,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,Canis lupus familiaris,6642,BAO_0000218,,A,In vivo,,9615.0,,N
7035,Intermediate,,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,Canis lupus familiaris,6641,BAO_0000218,,A,In vivo,,9615.0,,N
7036,Intermediate,,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,Canis lupus familiaris,6642,BAO_0000218,,A,In vivo,,9615.0,,N
7037,Intermediate,,,,Maximum rate of depolarization of the upstroke of the action potential,50588,Canis lupus familiaris,11659,BAO_0000218,,A,,,9615.0,,N
7038,Intermediate,,,,Steady state volume distribution in dog,50588,Canis lupus familiaris,6448,BAO_0000218,,A,In vivo,,9615.0,,N
7039,Intermediate,,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,50588,Canis lupus familiaris,5474,BAO_0000218,,A,In vivo,,9615.0,,N
7040,Intermediate,,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,50588,Canis lupus familiaris,1466,BAO_0000218,,A,In vivo,,9615.0,,N
7041,Intermediate,,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,50588,Canis lupus familiaris,6535,BAO_0000218,,A,In vivo,,9615.0,,N
7042,Intermediate,,,,Volume distribution in dog after administration of 1 mg/kg iv,50588,Canis lupus familiaris,6535,BAO_0000218,,A,In vivo,,9615.0,,N
7043,Intermediate,,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,50588,Canis lupus familiaris,17764,BAO_0000218,,A,In vivo,,9615.0,,N
7044,Intermediate,,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,50588,Canis lupus familiaris,6215,BAO_0000218,,A,In vivo,,9615.0,,N
7045,Intermediate,,,,Vss on i.v. administration of 2 mg/kg was measured in dog,50588,Canis lupus familiaris,6505,BAO_0000218,,A,In vivo,,9615.0,,N
7046,Intermediate,,,,Vss was determined,50588,Canis lupus familiaris,3639,BAO_0000218,,A,,,9615.0,,N
7047,Intermediate,,,,Vss in dog,50588,Canis lupus familiaris,3639,BAO_0000218,,A,,,9615.0,,N
7048,Intermediate,,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,50588,Canis lupus familiaris,6062,BAO_0000218,,A,In vivo,,9615.0,,N
7049,Intermediate,,,,Volume distribution in dogs,50588,Canis lupus familiaris,4942,BAO_0000218,,A,In vivo,,9615.0,,N
7050,Intermediate,,,,Volume of distribution in dog,50588,Canis lupus familiaris,17796,BAO_0000218,,A,In vivo,,9615.0,,N
7051,Intermediate,,,,Tested for the oral bioavailability in dog,50588,Canis lupus familiaris,4883,BAO_0000218,,A,In vivo,,9615.0,,N
7060,Intermediate,,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,50594,Mus musculus,17837,BAO_0000218,,A,In vivo,,10090.0,,N
7061,Intermediate,,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,50594,Mus musculus,17729,BAO_0000218,,A,In vivo,,10090.0,,N
7062,Intermediate,,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,50594,Mus musculus,17729,BAO_0000218,,A,In vivo,,10090.0,,N
7063,Intermediate,,,,Bioavailability was measured in mouse,50594,Mus musculus,4239,BAO_0000218,,A,In vivo,,10090.0,,N
7064,Intermediate,,,,Bioavailability in mouse,50594,Mus musculus,17592,BAO_0000218,,A,In vivo,,10090.0,,N
7065,Intermediate,,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,Mus musculus,6348,BAO_0000218,,A,In vivo,,10090.0,,N
7066,Intermediate,,,,Bioavailability in mouse,50594,Mus musculus,2801,BAO_0000218,,A,In vivo,,10090.0,,N
7067,Intermediate,,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,50594,Mus musculus,2801,BAO_0000218,,A,In vivo,,10090.0,,N
7068,Intermediate,,,,Oral bioavailability in mouse,50594,Mus musculus,17718,BAO_0000218,,A,In vivo,,10090.0,,N
7069,Intermediate,,,,Oral availability at 50 mg/kg po in male mice,50594,Mus musculus,5727,BAO_0000218,,A,In vivo,,10090.0,,N
7070,Intermediate,,,,Oral bioavailability in mouse (dose 10 mg/kg),50594,Mus musculus,5302,BAO_0000218,,A,In vivo,,10090.0,,N
7071,Expert,,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,50594,Mus musculus,3598,BAO_0000218,,A,In vivo,,10090.0,,N
7072,Intermediate,,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",50594,Mus musculus,5961,BAO_0000218,,A,In vivo,,10090.0,,N
7074,Intermediate,,,,Oral bioavailability in mouse,50594,Mus musculus,6091,BAO_0000218,,A,In vivo,,10090.0,,N
7075,Intermediate,,,,Oral bioavailability in vivo in mice;ND=Not determined,50594,Mus musculus,6091,BAO_0000218,,A,In vivo,,10090.0,,N
7076,Intermediate,,,,Oral bioavailability in mouse at 10 mg/kg of the compound,50594,Mus musculus,5711,BAO_0000218,,A,In vivo,,10090.0,,N
7077,Intermediate,,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),50594,Mus musculus,17728,BAO_0000218,,A,In vivo,,10090.0,,N
7078,Intermediate,,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),50594,Mus musculus,17728,BAO_0000218,,A,In vivo,,10090.0,,N
7079,Intermediate,,,,Tested for bioavailability of the compound,50594,Mus musculus,3802,BAO_0000218,,A,In vivo,,10090.0,,N
7080,Intermediate,,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,50594,Mus musculus,3802,BAO_0000218,,A,In vivo,,10090.0,,N
7081,Intermediate,,Plasma,1969.0,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,50594,Mus musculus,14029,BAO_0000218,,A,,,10090.0,,N
7082,Intermediate,,Plasma,1969.0,The plasma half life of compound was determined on heparin prepared by human plasma. ,50594,Mus musculus,14029,BAO_0000218,,A,,,10090.0,,N
7083,Intermediate,,Plasma,1969.0,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,50594,Mus musculus,14029,BAO_0000218,,A,,,10090.0,,N
7084,Intermediate,,Plasma,1969.0,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,50594,Mus musculus,14029,BAO_0000218,,A,,,10090.0,,N
7085,Intermediate,,Plasma,1969.0,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,50594,Mus musculus,14029,BAO_0000218,,A,,,10090.0,,N
7086,Intermediate,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,F,,,10090.0,,N
7087,Intermediate,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,,,10090.0,,N
7088,Intermediate,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,50594,Mus musculus,17753,BAO_0000218,,A,,,10090.0,,N
7089,Intermediate,,Blood,178.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7090,Intermediate,,Blood,178.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7091,Intermediate,,Blood,178.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7092,Intermediate,,Blood,178.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7093,Intermediate,,Blood,178.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7094,Intermediate,,Blood,178.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7095,Intermediate,,Blood,178.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7096,Intermediate,,Bone,10000001.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7097,Intermediate,,Bone,10000001.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7098,Intermediate,,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,81034,Homo sapiens,15608,BAO_0000219,,F,,,9606.0,A2780,N
7099,Expert,,,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,81034,Homo sapiens,3290,BAO_0000219,,F,,,9606.0,A2780,N
7100,Intermediate,,,,Compound was evaluated for cytotoxicity against A2780 cell line,81034,Homo sapiens,2859,BAO_0000219,,F,,,9606.0,A2780,N
7101,Expert,,,,Inhibition of A2780 cell clonogenic assay,81034,Homo sapiens,15688,BAO_0000219,,F,,,9606.0,A2780,N
7102,Expert,,,,Cytotoxic effect on ovarian cancer cell line (A2780),81034,Homo sapiens,5642,BAO_0000219,,F,,,9606.0,A2780,N
7103,Intermediate,,,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,81034,Homo sapiens,6633,BAO_0000219,,F,,,9606.0,A2780,N
7104,Intermediate,,,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",81034,Homo sapiens,3906,BAO_0000219,,F,,,9606.0,A2780,N
7105,Expert,,,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,81034,Homo sapiens,6788,BAO_0000219,,F,,,9606.0,A2780,N
7106,Expert,,,,Antiproliferative activity against human A2780 cells,81034,Homo sapiens,17582,BAO_0000219,,F,,,9606.0,A2780,N
7107,Expert,,,,Inhibition of human A2780 cell proliferation,81034,Homo sapiens,17764,BAO_0000219,,F,,,9606.0,A2780,N
7108,Expert,,,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,81034,Homo sapiens,17764,BAO_0000219,,F,,,9606.0,A2780,N
7109,Expert,,,,Inhibition of human A2780 cell proliferation (No data),81034,Homo sapiens,17764,BAO_0000219,,F,,,9606.0,A2780,N
7110,Intermediate,,,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,81034,Homo sapiens,2815,BAO_0000219,,F,,,9606.0,A2780,N
7111,Intermediate,,,,Compound was evaluated against human Ovarian carcinoma cell line A2780,81034,Homo sapiens,16930,BAO_0000219,,F,,,9606.0,A2780,N
7112,Expert,,,,Growth inhibition against A2780 wild-type ovarian cell lines,81034,Homo sapiens,17777,BAO_0000219,,F,,,9606.0,A2780,N
7113,Intermediate,,,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,81034,Homo sapiens,17777,BAO_0000219,,F,,,9606.0,A2780,N
7114,Autocuration,,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,104766,Homo sapiens,16936,BAO_0000019,,F,,,9606.0,,D
7115,Intermediate,,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,81034,Homo sapiens,13759,BAO_0000219,,F,,,9606.0,A2780,N
7116,Intermediate,,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,81034,Homo sapiens,13759,BAO_0000219,,F,,,9606.0,A2780,N
7117,Intermediate,,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,81034,Homo sapiens,13759,BAO_0000219,,F,,,9606.0,A2780,N
7118,Intermediate,,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,81034,Homo sapiens,13759,BAO_0000219,,F,,,9606.0,A2780,N
7119,Intermediate,,,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,81034,Homo sapiens,15292,BAO_0000219,,F,,,9606.0,A2780,N
7120,Intermediate,,,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,81034,Homo sapiens,15292,BAO_0000219,,F,,,9606.0,A2780,N
7121,Expert,,,,In vitro inhibition of human ovarian cell line A2780,81034,Homo sapiens,15069,BAO_0000219,,F,,,9606.0,A2780,N
7122,Expert,,,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",81034,Homo sapiens,15069,BAO_0000219,,F,,,9606.0,A2780,N
7123,Intermediate,,,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),81034,Homo sapiens,14073,BAO_0000219,,F,,,9606.0,A2780,N
7124,Expert,,,,Concentration required to inhibit A2780-cell growth by 50%,81034,Homo sapiens,14553,BAO_0000219,,F,,,9606.0,A2780,N
7125,Expert,,,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,81034,Homo sapiens,13040,BAO_0000219,,F,,,9606.0,A2780,N
7126,Expert,,,,Cytotoxic effect on human ovarian (A2780) cancer cell line,81034,Homo sapiens,6891,BAO_0000219,,F,,,9606.0,A2780,N
7127,Intermediate,,,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,81034,Homo sapiens,15569,BAO_0000219,,F,,,9606.0,A2780,N
7128,Expert,,,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,81034,Homo sapiens,14190,BAO_0000219,,F,,,9606.0,A2780,N
7129,Expert,,,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,81034,Homo sapiens,15014,BAO_0000219,,F,,,9606.0,A2780,N
7130,Intermediate,,,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,81034,Homo sapiens,15014,BAO_0000219,,F,,,9606.0,A2780,N
7131,Intermediate,,,,Cytotoxicity against human ovarian carcinoma A2780 cell line,81034,Homo sapiens,17496,BAO_0000219,,F,,,9606.0,A2780,N
7132,Intermediate,,,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",81034,Homo sapiens,13617,BAO_0000219,,F,,,9606.0,A2780,N
7133,Intermediate,,,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",81034,Homo sapiens,13617,BAO_0000219,,F,,,9606.0,A2780,N
7134,Intermediate,,,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",81034,Homo sapiens,13617,BAO_0000219,,F,,,9606.0,A2780,N
7135,Intermediate,,,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",81034,Homo sapiens,13617,BAO_0000219,,F,,,9606.0,A2780,N
7136,Intermediate,,,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,81034,Homo sapiens,17672,BAO_0000219,,F,,,9606.0,A2780,N
7137,Intermediate,,,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,81034,Homo sapiens,4544,BAO_0000219,,F,,,9606.0,A2780,N
7138,Intermediate,,,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,81034,Homo sapiens,4544,BAO_0000219,,F,,,9606.0,A2780,N
7139,Intermediate,,,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",81034,Homo sapiens,16317,BAO_0000219,,F,,,9606.0,A2780,N
7140,Intermediate,,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,81034,Homo sapiens,15099,BAO_0000219,,F,,,9606.0,A2780,N
7141,Intermediate,,,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,81034,Homo sapiens,13978,BAO_0000219,,F,,,9606.0,A2780,N
7142,Expert,,,,In vitro antitumor activity against A2780 cell line.,81034,Homo sapiens,12989,BAO_0000219,,F,,,9606.0,A2780,N
7143,Intermediate,,,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,81034,Homo sapiens,5574,BAO_0000219,,F,,,9606.0,A2780,N
7144,Expert,,,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,81034,Homo sapiens,13528,BAO_0000219,,F,,,9606.0,A2780,N
7145,Intermediate,,,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,80025,Homo sapiens,12782,BAO_0000219,,F,,,9606.0,ACHN,N
7146,Intermediate,,,,The IC50 value was measured on ACHN cell line in renal tumor type.,80025,Homo sapiens,14255,BAO_0000219,,F,,,9606.0,ACHN,N
7147,Intermediate,,,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,80025,Homo sapiens,16364,BAO_0000219,,F,,,9606.0,ACHN,N
7148,Expert,,,,In vitro lethal concentration against most sensitive ACHN cell line,80025,Homo sapiens,17376,BAO_0000219,,F,,,9606.0,ACHN,N
7149,Intermediate,,,,Tested for cytotoxic activity against renal cancer ACHN cell line,80025,Homo sapiens,12016,BAO_0000219,,F,,,9606.0,ACHN,N
7150,Intermediate,,,,Compound tested for growth inhibition of renal cancer cell line ACHN,80025,Homo sapiens,6058,BAO_0000219,,F,,,9606.0,ACHN,N
7151,Intermediate,,,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,80025,Homo sapiens,17708,BAO_0000219,,F,,,9606.0,ACHN,N
7152,Intermediate,,,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,80025,Homo sapiens,15176,BAO_0000219,,F,,,9606.0,ACHN,N
7153,Intermediate,,,,In vitro anticancer activity against ACHN renal cancer cell line,80025,Homo sapiens,2806,BAO_0000219,,F,,,9606.0,ACHN,N
7154,Intermediate,,,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,80025,Homo sapiens,15300,BAO_0000219,,F,,,9606.0,ACHN,N
7155,Intermediate,,,,Percent selectivity was evaluated in renal ACHN cell lines,80025,Homo sapiens,16364,BAO_0000219,,F,,,9606.0,ACHN,N
7156,Intermediate,,,,In vitro inhibitory activity against renal ACHN cancer cell line,80025,Homo sapiens,13859,BAO_0000219,,F,,,9606.0,ACHN,N
7157,Intermediate,,,,Tested for cytotoxicity against ACHN cell lines in renal cancer,80025,Homo sapiens,11970,BAO_0000219,,F,,,9606.0,ACHN,N
7158,Intermediate,,,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,80025,Homo sapiens,2450,BAO_0000219,,F,,,9606.0,ACHN,N
7159,Intermediate,,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,80025,Homo sapiens,12696,BAO_0000219,,F,,,9606.0,ACHN,N
7160,Intermediate,,,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,80025,Homo sapiens,12400,BAO_0000219,,F,,,9606.0,ACHN,N
7161,Expert,,,,Cytotoxic effect on renal cancer line ACHN,80025,Homo sapiens,12888,BAO_0000219,,F,,,9606.0,ACHN,N
7162,Intermediate,,,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,80025,Homo sapiens,3156,BAO_0000219,,F,,,9606.0,ACHN,N
7163,Intermediate,,,,In vitro inhibition of Renal Cancer ACHN cell lines,80025,Homo sapiens,3381,BAO_0000219,,F,,,9606.0,ACHN,N
7164,Intermediate,,,,Antitumor activity against human renal adenocarcinoma ACHN cells,80025,Homo sapiens,16747,BAO_0000219,,F,,,9606.0,ACHN,N
7165,Expert,,,,Antitumor activity against human renal adenocarcinoma ACHN cells.,80025,Homo sapiens,16748,BAO_0000219,,F,,,9606.0,ACHN,N
7166,Intermediate,,,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,80025,Homo sapiens,12062,BAO_0000219,,F,,,9606.0,ACHN,N
7167,Intermediate,,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),80025,Homo sapiens,14769,BAO_0000219,,F,,,9606.0,ACHN,N
7168,Intermediate,,,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",80025,Homo sapiens,15895,BAO_0000219,,F,,,9606.0,ACHN,N
7169,Intermediate,,,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,80025,Homo sapiens,17376,BAO_0000219,,F,,,9606.0,ACHN,N
7170,Intermediate,,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,80025,Homo sapiens,14882,BAO_0000219,,F,,,9606.0,ACHN,N
7171,Intermediate,,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,80025,Homo sapiens,14882,BAO_0000219,,F,,,9606.0,ACHN,N
7172,Intermediate,,,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,80025,Homo sapiens,15661,BAO_0000219,,F,,,9606.0,ACHN,N
7173,Autocuration,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,22224,,9680,BAO_0000019,,A,,,,,U
7174,Autocuration,,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,10647,,14579,BAO_0000019,,F,,,,,H
7175,Expert,,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,50529,Cytomegalovirus,17290,BAO_0000218,,F,,,10358.0,HEL,N
7176,Intermediate,,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,50529,Cytomegalovirus,17290,BAO_0000218,,F,,,10358.0,,N
7177,Autocuration,,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),12159,,15891,BAO_0000357,,B,,,,,H
7178,Autocuration,,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),12159,,15890,BAO_0000357,,B,,,,,H
7179,Intermediate,,,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,80670,Bos taurus,3801,BAO_0000219,,F,,,9913.0,ADDP cell line,N
7180,Intermediate,,,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,80671,Mus musculus,9222,BAO_0000219,,F,,,10090.0,ADJ/PC6,N
7181,Intermediate,,,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,80671,Mus musculus,9222,BAO_0000219,,F,,,10090.0,ADJ/PC6,N
7182,Intermediate,,,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",80671,Mus musculus,7257,BAO_0000219,,F,,,10090.0,ADJ/PC6,N
7183,Intermediate,,,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,80671,Mus musculus,7257,BAO_0000219,,F,,,10090.0,ADJ/PC6,N
7184,Intermediate,,,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,80671,Mus musculus,7257,BAO_0000219,,A,,,10090.0,ADJ/PC6,N
7185,Intermediate,,,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,80671,Mus musculus,8084,BAO_0000219,,F,,,10090.0,ADJ/PC6,N
7186,Autocuration,,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,22224,Mus musculus,14943,BAO_0000019,,F,,,10090.0,,U
7187,Autocuration,,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,22224,Mus musculus,14943,BAO_0000019,,F,,,10090.0,,U
7188,Autocuration,,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,22224,Mus musculus,14943,BAO_0000019,,F,,,10090.0,,U
7189,Autocuration,,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),22224,Bacillus subtilis,10524,BAO_0000218,,A,In vivo,,1423.0,,U
7190,Intermediate,,Plasma,1969.0,AUC value in dog after IV administration at a dose of 5 mg/kg,50588,Canis lupus familiaris,3546,BAO_0000218,,A,,,9615.0,,N
7191,Intermediate,,Plasma,1969.0,AUC value in dog after oral administration at a dose of 5 mg/kg,50588,Canis lupus familiaris,3546,BAO_0000218,,A,,,9615.0,,N
7192,Intermediate,,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,50588,Canis lupus familiaris,3546,BAO_0000218,,A,In vivo,,9615.0,,N
7193,Intermediate,,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,50588,Canis lupus familiaris,3546,BAO_0000218,,A,In vivo,,9615.0,,N
7194,Intermediate,,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,50588,Canis lupus familiaris,3546,BAO_0000218,,A,In vivo,,9615.0,,N
7195,Intermediate,,,,Compound was evaluated for its clearance when administered intravenously in dog,50588,Canis lupus familiaris,3184,BAO_0000218,,A,In vivo,,9615.0,,N
7196,Intermediate,,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,Canis lupus familiaris,16456,BAO_0000218,,A,In vivo,,9615.0,,N
7197,Intermediate,,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),50588,Canis lupus familiaris,4809,BAO_0000218,,A,In vivo,,9615.0,,N
7198,Intermediate,,,,Calculated partition coefficient (clogP),22229,,4219,BAO_0000100,,P,,,,,U
7199,Intermediate,,,,Half life in dog,50588,Canis lupus familiaris,3748,BAO_0000218,,A,,,9615.0,,N
7200,Intermediate,,,,Time taken for EC90 was determined when tested in dog,50588,Canis lupus familiaris,3132,BAO_0000218,,A,,,9615.0,,N
7201,Intermediate,,,,Half life (iv) was determined,50588,Canis lupus familiaris,4219,BAO_0000218,,A,,,9615.0,,N
7202,Intermediate,,Liver,2107.0,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,50588,Canis lupus familiaris,16907,BAO_0000218,,A,,,9615.0,,N
7203,Intermediate,,,,Area under the curve was calculated in dog after iv administration,50588,Canis lupus familiaris,6057,BAO_0000218,,A,,,9615.0,,N
7204,Intermediate,,,,Area under the curve was calculated in dog after peroral administration,50588,Canis lupus familiaris,6057,BAO_0000218,,A,,,9615.0,,N
7205,Intermediate,,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,50588,Canis lupus familiaris,17853,BAO_0000218,,A,,,9615.0,,N
7206,Intermediate,,,,pKa was evaluated in dog,50588,Canis lupus familiaris,3639,BAO_0000218,,A,,,9615.0,,N
7207,Intermediate,,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,50588,Canis lupus familiaris,14541,BAO_0000218,,A,,,9615.0,,N
7208,Intermediate,,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,Canis lupus familiaris,16456,BAO_0000218,,A,In vivo,,9615.0,,N
7209,Intermediate,,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,Canis lupus familiaris,16456,BAO_0000218,,A,In vivo,,9615.0,,N
7210,Intermediate,,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,50588,Canis lupus familiaris,2652,BAO_0000218,,A,In vivo,,9615.0,,N
7211,Intermediate,,,,Compound was evaluated for the half-life (t 1/2) in hours,50588,Canis lupus familiaris,3624,BAO_0000218,,A,,,9615.0,,N
7212,Intermediate,,Blood,178.0,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,Canis lupus familiaris,1337,BAO_0000218,,A,In vivo,,9615.0,,N
7213,Intermediate,,Blood,178.0,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,Canis lupus familiaris,1337,BAO_0000218,,A,In vivo,,9615.0,,N
7214,Intermediate,,,,Half life after intravenous administration of 1 mg/kg in dog,50588,Canis lupus familiaris,4709,BAO_0000218,,A,In vivo,,9615.0,,N
7215,Intermediate,,,,Half life was measured in dog,50588,Canis lupus familiaris,15660,BAO_0000218,,A,,,9615.0,,N
7216,Intermediate,,,,Half life period in dog after 5 mg/kg dose,50588,Canis lupus familiaris,5302,BAO_0000218,,A,In vivo,,9615.0,,N
7217,Intermediate,,,,Half life period was evaluated in dog; 4-4.8,50588,Canis lupus familiaris,17791,BAO_0000218,,A,,,9615.0,,N
7218,Intermediate,,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,Canis lupus familiaris,6348,BAO_0000218,,A,In vivo,,9615.0,,N
7219,Intermediate,,,,Half-life was determined in dog after a3 mg/kg of iv dose,50588,Canis lupus familiaris,4257,BAO_0000218,,A,In vivo,,9615.0,,N
7220,Intermediate,,,,Half-life was determined,50588,Canis lupus familiaris,3771,BAO_0000218,,A,,,9615.0,,N
7221,Intermediate,,,,Half life in dogs,50588,Canis lupus familiaris,6305,BAO_0000218,,A,,,9615.0,,N
7222,Intermediate,,Plasma,1969.0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,50588,Canis lupus familiaris,13501,BAO_0000218,,A,In vivo,,9615.0,,N
7223,Intermediate,,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,50588,Canis lupus familiaris,17594,BAO_0000218,,A,In vivo,,9615.0,,N
7224,Intermediate,,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,50588,Canis lupus familiaris,3045,BAO_0000218,,A,In vivo,,9615.0,,N
7225,Intermediate,,,,Compound was evaluated for the half life period after oral administration in conscious dog.,50588,Canis lupus familiaris,3043,BAO_0000218,,A,In vivo,,9615.0,,N
7226,Intermediate,,,,Compound was tested for half life in dog,50588,Canis lupus familiaris,4839,BAO_0000218,,A,,,9615.0,,N
7227,Intermediate,,,,Compound was tested for its half life in dog,50588,Canis lupus familiaris,4839,BAO_0000218,,A,,,9615.0,,N
7228,Intermediate,,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,Canis lupus familiaris,5802,BAO_0000218,,A,In vivo,,9615.0,,N
7229,Intermediate,,,,Half life of compound in dog was determined,50588,Canis lupus familiaris,17839,BAO_0000218,,A,,,9615.0,,N
7230,Intermediate,,,,Half life (iv) was determined,50588,Canis lupus familiaris,4219,BAO_0000218,,A,In vivo,,9615.0,,N
7231,Intermediate,,Blood,178.0,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),50588,Canis lupus familiaris,13966,BAO_0000218,,A,,,9615.0,,N
7232,Intermediate,,Plasma,1969.0,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,50588,Canis lupus familiaris,3994,BAO_0000218,,A,In vivo,,9615.0,,N
7233,Intermediate,,Plasma,1969.0,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,50588,Canis lupus familiaris,3994,BAO_0000218,,F,In vivo,,9615.0,,N
7234,Intermediate,,,,Half life in dog,50588,Canis lupus familiaris,4453,BAO_0000218,,A,,,9615.0,,N
7235,Intermediate,,Plasma,1969.0,Half life in dog plasma,50588,Canis lupus familiaris,6535,BAO_0000218,,A,,,9615.0,,N
7236,Intermediate,,Plasma,1969.0,Half life in dog plasma after administration of 0.25 mg/kg iv,50588,Canis lupus familiaris,6535,BAO_0000218,,A,In vivo,,9615.0,,N
7237,Intermediate,,Plasma,1969.0,Half life in dog plasma after administration of 1 mg/kg iv,50588,Canis lupus familiaris,6535,BAO_0000218,,A,In vivo,,9615.0,,N
7238,Intermediate,,Plasma,1969.0,Half life in dog plasma was determined at dose 10 mg/kg,50588,Canis lupus familiaris,3132,BAO_0000218,,A,In vivo,,9615.0,,N
7239,Intermediate,,,,Half life in dog was determined,50588,Canis lupus familiaris,5374,BAO_0000218,,A,,,9615.0,,N
7240,Intermediate,,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,Canis lupus familiaris,5007,BAO_0000218,,A,In vivo,,9615.0,,N
7241,Intermediate,,Plasma,1969.0,Half life upon exposure to human plasma,50588,Canis lupus familiaris,16907,BAO_0000218,,A,,,9615.0,,N
7242,Intermediate,,,,Half life was calculated in dog,50588,Canis lupus familiaris,6057,BAO_0000218,,A,,,9615.0,,N
7243,Intermediate,,,,Half life was determined,50588,Canis lupus familiaris,5006,BAO_0000218,,A,,,9615.0,,N
7244,Intermediate,,,,Half life was determined,50588,Canis lupus familiaris,5473,BAO_0000218,,A,,,9615.0,,N
7245,Intermediate,,,,Half life by intravenous administration of 1.2 mg/kg in dog,50588,Canis lupus familiaris,4368,BAO_0000218,,A,In vivo,,9615.0,,N
7246,Intermediate,,,,Half life in dog,50588,Canis lupus familiaris,6448,BAO_0000218,,A,,,9615.0,,N
7247,Intermediate,,,,Half life in dog after intra venous administration of the compound,50588,Canis lupus familiaris,4353,BAO_0000218,,A,,,9615.0,,N
7248,Intermediate,,,,Half life in dog after intra venous administration of the compound; ND means Not determined,50588,Canis lupus familiaris,4353,BAO_0000218,,A,,,9615.0,,N
7249,Intermediate,,,,Half life in dog after po administration of the compound,50588,Canis lupus familiaris,4353,BAO_0000218,,A,In vivo,,9615.0,,N
7250,Intermediate,,,,Half life in dog after po administration of the compound; ND means Not determined,50588,Canis lupus familiaris,4353,BAO_0000218,,A,In vivo,,9615.0,,N
7251,Intermediate,,,,Half life in dog at the single oral dose of 1 mg/kg,50588,Canis lupus familiaris,6265,BAO_0000218,,A,In vivo,,9615.0,,N
7252,Intermediate,,,,Half life in dogs,50588,Canis lupus familiaris,5006,BAO_0000218,,A,,,9615.0,,N
7253,Intermediate,,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,50588,Canis lupus familiaris,5356,BAO_0000218,,A,In vivo,,9615.0,,N
7254,Intermediate,,,,Half life in rat,50588,Canis lupus familiaris,405,BAO_0000218,,A,,,9615.0,,N
7255,Intermediate,,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,Canis lupus familiaris,6642,BAO_0000218,,A,In vivo,,9615.0,,N
7256,Intermediate,,Bone,10000001.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7257,Intermediate,,Bone,10000001.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7258,Intermediate,,Bone,10000001.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7259,Intermediate,,Bone,10000001.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7260,Intermediate,,Bone,10000001.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7261,Intermediate,,Gut,10000004.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7262,Intermediate,,Gut,10000004.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7263,Intermediate,,Gut,10000004.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7264,Intermediate,,Gut,10000004.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7265,Intermediate,,Gut,10000004.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7266,Intermediate,,Gut,10000004.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7267,Intermediate,,Gut,10000004.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7268,Intermediate,,Heart,948.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7269,Intermediate,,Heart,948.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7270,Intermediate,,Heart,948.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7271,Intermediate,,Heart,948.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7272,Intermediate,,Heart,948.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7273,Intermediate,,Heart,948.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7274,Intermediate,,Heart,948.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7275,Intermediate,,Kidney,2113.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7276,Intermediate,,Kidney,2113.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7277,Intermediate,,Kidney,2113.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7278,Intermediate,,Kidney,2113.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7279,Intermediate,,Kidney,2113.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7280,Intermediate,,Kidney,2113.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7281,Intermediate,,Kidney,2113.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7282,Intermediate,,Liver,2107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7283,Intermediate,,Liver,2107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7284,Intermediate,,Liver,2107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7285,Intermediate,,Liver,2107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7286,Intermediate,,Liver,2107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7287,Intermediate,,Liver,2107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7288,Intermediate,,Liver,2107.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7289,Intermediate,,Lung,2048.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7290,Intermediate,,,,In vitro cytotoxicity against A2780 (human ovarian cancer),81034,Homo sapiens,5895,BAO_0000219,,F,,,9606.0,A2780,N
7291,Intermediate,,,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,81034,Homo sapiens,6338,BAO_0000219,,F,,,9606.0,A2780,N
7292,Intermediate,,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,81034,Homo sapiens,15163,BAO_0000219,,F,,,9606.0,A2780,N
7293,Intermediate,,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,81034,Homo sapiens,15163,BAO_0000219,,F,,,9606.0,A2780,N
7294,Expert,,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,81034,Homo sapiens,15000,BAO_0000219,,F,,,9606.0,A2780,N
7295,Expert,,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,81034,Homo sapiens,15000,BAO_0000219,,F,,,9606.0,A2780,N
7296,Expert,,,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,81034,Homo sapiens,14729,BAO_0000219,,F,,,9606.0,A2780,N
7297,Intermediate,,,,In vitro cytotoxicity against A2780 cell line,81034,Homo sapiens,17270,BAO_0000219,,F,,,9606.0,A2780,N
7298,Intermediate,,,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,81034,Homo sapiens,5685,BAO_0000219,,F,,,9606.0,A2780,N
7299,Intermediate,,,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,81034,Homo sapiens,3563,BAO_0000219,,F,,,9606.0,A2780,N
7300,Intermediate,,,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,81034,Homo sapiens,17753,BAO_0000218,,F,,,9606.0,A2780,N
7301,Intermediate,,,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",81034,Homo sapiens,16317,BAO_0000219,,F,,,9606.0,A2780,N
7302,Intermediate,,,,Inhibition of tubulin polymerization in analogy of ca.,81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7303,Intermediate,,,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,81034,Homo sapiens,3801,BAO_0000219,,F,,,9606.0,A2780,N
7304,Expert,,,,Cytotoxic effect in ovarian cancer cell line (A2780),81034,Homo sapiens,6181,BAO_0000219,,F,,,9606.0,A2780,N
7305,Intermediate,,,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,81034,Homo sapiens,5318,BAO_0000219,,F,,,9606.0,A2780,N
7306,Intermediate,,,,Tested for the cytotoxicity in A2780 ovarian cell line,81034,Homo sapiens,4840,BAO_0000219,,F,,,9606.0,A2780,N
7307,Intermediate,,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),81034,Homo sapiens,15748,BAO_0000219,,F,,,9606.0,A2780,N
7308,Intermediate,,,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,81034,Homo sapiens,15748,BAO_0000219,,F,,,9606.0,A2780,N
7309,Intermediate,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,80017,,15748,BAO_0000219,,F,,,,A2780cisR,N
7310,Intermediate,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),80017,,15748,BAO_0000219,,F,,,,A2780cisR,N
7311,Intermediate,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,80017,,15748,BAO_0000219,,F,,,,A2780cisR,N
7312,Intermediate,,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),80017,,15748,BAO_0000219,,F,,,,A2780cisR,N
7313,Intermediate,,,,In vivo log of cells killed after administration of compound in A2780 cell line,81034,Homo sapiens,17753,BAO_0000218,,F,,,9606.0,A2780,N
7314,Intermediate,,,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,81034,Homo sapiens,17753,BAO_0000218,,F,In vivo,,9606.0,A2780,N
7315,Intermediate,,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7316,Intermediate,,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7317,Intermediate,,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7318,Intermediate,,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7319,Intermediate,,,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),81034,Homo sapiens,17528,BAO_0000218,,F,,,9606.0,A2780,N
7320,Intermediate,,,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,81034,Homo sapiens,6633,BAO_0000219,,F,,,9606.0,A2780,N
7321,Expert,,,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,81034,Homo sapiens,15000,BAO_0000219,,F,,,9606.0,A2780,N
7322,Expert,,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,81034,Homo sapiens,17528,BAO_0000219,,F,,,9606.0,A2780,N
7323,Intermediate,,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7324,Intermediate,,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7325,Intermediate,,,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7326,Intermediate,,,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7327,Intermediate,,,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7328,Expert,,,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7329,Intermediate,,,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7330,Intermediate,,,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7331,Intermediate,,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,Homo sapiens,16936,BAO_0000219,,F,,,9606.0,A2780,N
7332,Intermediate,,,,In vitro antiproliferative activity against A2780 cell line,81034,Mus musculus,17737,BAO_0000219,,F,,,10090.0,A2780,N
7333,Expert,,,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,81034,Mus musculus,17764,BAO_0000219,,F,,,10090.0,A2780,N
7334,Intermediate,,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,81034,Homo sapiens,3830,BAO_0000219,,F,,,9606.0,A2780,N
7335,Intermediate,,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,81034,Homo sapiens,3829,BAO_0000219,,F,,,9606.0,A2780,N
7336,Intermediate,,,,Vc value in dog after IV administration at a dose of 5 mg/kg,50588,Canis lupus familiaris,3546,BAO_0000218,,A,,,9615.0,,N
7337,Intermediate,,,,Half life period in dog after IV administration at a dose of 5 mg/kg,50588,Canis lupus familiaris,3546,BAO_0000218,,A,In vivo,,9615.0,,N
7338,Autocuration,,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,22224,Cercopithecidae,5668,BAO_0000019,,A,,,9527.0,,U
7339,Autocuration,,Plasma,1969.0,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,,,9527.0,,U
7340,Autocuration,,Plasma,1969.0,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,,,9527.0,,U
7341,Autocuration,,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,22224,Macaca fascicularis,4256,BAO_0000218,,A,In vivo,,9541.0,,U
7342,Autocuration,,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,22224,Macaca fascicularis,4256,BAO_0000218,,A,In vivo,,9541.0,,U
7343,Autocuration,,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,22224,Macaca fascicularis,4256,BAO_0000218,,A,In vivo,,9541.0,,U
7344,Autocuration,,,,Oral Bioavailability in rat,22224,Rattus norvegicus,4256,BAO_0000218,,A,In vivo,,10116.0,,U
7345,Autocuration,,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,Cercopithecidae,1916,BAO_0000218,,A,,,9527.0,,U
7346,Autocuration,,,,Area under curve value in monkey at a dose of 5 mg/kg,22224,Cercopithecidae,5302,BAO_0000218,,A,,,9527.0,,U
7347,Autocuration,,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,22224,Cercopithecidae,4257,BAO_0000218,,A,,,9527.0,,U
7348,Autocuration,,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,22224,Cercopithecidae,5355,BAO_0000019,,A,,,9527.0,,U
7349,Autocuration,,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,22224,Cercopithecidae,5355,BAO_0000019,,A,,,9527.0,,U
7350,Autocuration,,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,22224,Cercopithecidae,5355,BAO_0000019,,A,,,9527.0,,U
7351,Autocuration,,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,22224,Cercopithecidae,6078,BAO_0000218,,A,,,9527.0,,U
7352,Autocuration,,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,22224,Cercopithecidae,6078,BAO_0000218,,A,,,9527.0,,U
7353,Autocuration,,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,22224,Cercopithecidae,6062,BAO_0000218,,A,,,9527.0,,U
7354,Autocuration,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,Cercopithecidae,2661,BAO_0000218,,A,,,9527.0,,U
7355,Autocuration,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,Cercopithecidae,2661,BAO_0000019,,A,,,9527.0,,U
7356,Autocuration,,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,22224,Cercopithecidae,5394,BAO_0000218,,A,,,9527.0,,U
7357,Autocuration,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,22224,Cercopithecidae,4397,BAO_0000218,,A,,,9527.0,,U
7358,Autocuration,,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,22224,Cercopithecidae,17509,BAO_0000218,,A,,,9527.0,,U
7359,Autocuration,,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,22224,Cercopithecidae,17509,BAO_0000218,,A,,,9527.0,,U
7360,Autocuration,,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),22224,Cercopithecidae,6641,BAO_0000218,,A,In vivo,,9527.0,,U
7361,Autocuration,,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),22224,Cercopithecidae,5355,BAO_0000218,,A,,,9527.0,,U
7362,Autocuration,,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,In vivo,,9527.0,,U
7363,Autocuration,,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,Cercopithecidae,3443,BAO_0000218,,A,In vivo,,9527.0,,U
7364,Autocuration,,,,Binding towards monkey plasma protein at 10 uM,22224,Cercopithecidae,17409,BAO_0000019,,A,,,9527.0,,U
7365,Autocuration,,,,Binding towards monkey plasma protein at 100 uM,22224,Cercopithecidae,17409,BAO_0000019,,A,,,9527.0,,U
7366,Autocuration,,,,Apparent bioavailability in squirrel monkey was determined,22224,Cercopithecidae,1052,BAO_0000218,,A,In vivo,,9527.0,,U
7367,Autocuration,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,22224,Cercopithecidae,13501,BAO_0000218,,A,In vivo,,9527.0,,U
7368,Autocuration,,,,Bioavailability in monkey (dose 2 mg/kg),22224,monkey,17509,BAO_0000218,,A,In vivo,,9443.0,,U
7369,Autocuration,,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,22224,Cercopithecidae,5394,BAO_0000218,,A,In vivo,,9527.0,,U
7370,Autocuration,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,Cercopithecidae,2661,BAO_0000218,,A,In vivo,,9527.0,,U
7371,Autocuration,,,,Bioavailability in monkey (i.d. dosing),22224,monkey,11219,BAO_0000218,,A,In vivo,,9443.0,,U
7372,Autocuration,,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,22224,Cercopithecidae,3045,BAO_0000218,,A,In vivo,,9527.0,,U
7373,Autocuration,,,,Clearance of the drug was measured in cynomolgus,22224,Cercopithecidae,17796,BAO_0000019,,A,,,9527.0,,U
7374,Autocuration,,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,22224,Cercopithecidae,1399,BAO_0000218,,A,In vivo,,9527.0,,U
7375,Autocuration,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,Cercopithecidae,2661,BAO_0000218,,A,In vivo,,9527.0,,U
7376,Autocuration,,Plasma,1969.0,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,Macaca mulatta,5005,BAO_0000218,,A,In vivo,,9544.0,,U
7377,Autocuration,,,,Plasma clearance in rhesus monkey was determined,22224,Cercopithecidae,17267,BAO_0000218,,A,In vivo,,9527.0,,U
7378,Autocuration,,,,Plasma clearance in monkey after administration of 1 mg/kg iv,22224,Cercopithecidae,6535,BAO_0000218,,A,In vivo,,9527.0,,U
7379,Autocuration,,,,Plasma clearance in cynomolgus monkey,22224,Cercopithecidae,5922,BAO_0000218,,A,In vivo,,9527.0,,U
7380,Autocuration,,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,22224,Cercopithecidae,6221,BAO_0000218,,A,In vivo,,9527.0,,U
7381,Autocuration,,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,22224,Cercopithecidae,5668,BAO_0000218,,A,In vivo,,9527.0,,U
7382,Autocuration,,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
7383,Autocuration,,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
7384,Autocuration,,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,22224,Cercopithecidae,5355,BAO_0000218,,A,In vivo,,9527.0,,U
7385,Autocuration,,,,Tested for Clearance upon iv administration to african green monkey,22224,Cercopithecidae,4578,BAO_0000218,,A,In vivo,,9527.0,,U
7386,Autocuration,,,,Clearance in monkey,22224,Cercopithecidae,17592,BAO_0000218,,A,In vivo,,9527.0,,U
7387,Intermediate,,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,Canis lupus familiaris,6641,BAO_0000218,,A,In vivo,,9615.0,,N
7388,Intermediate,,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,Canis lupus familiaris,6642,BAO_0000218,,A,In vivo,,9615.0,,N
7389,Intermediate,,,,Half life was evaluated after intravenous administration to dogs,50588,Canis lupus familiaris,16367,BAO_0000218,,A,In vivo,,9615.0,,N
7390,Intermediate,,,,Half life was evaluated in dog,50588,Canis lupus familiaris,5472,BAO_0000218,,A,,,9615.0,,N
7391,Intermediate,,,,Half life was evaluated in dog,50588,Canis lupus familiaris,5474,BAO_0000218,,A,,,9615.0,,N
7392,Intermediate,,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,Canis lupus familiaris,5654,BAO_0000218,,A,In vivo,,9615.0,,N
7393,Intermediate,,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),50588,Canis lupus familiaris,6227,BAO_0000218,,A,In vivo,,9615.0,,N
7394,Intermediate,,,,Half life period after intravenous administration in dog,50588,Canis lupus familiaris,6227,BAO_0000218,,A,In vivo,,9615.0,,N
7395,Intermediate,,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,50588,Canis lupus familiaris,6221,BAO_0000218,,A,In vivo,,9615.0,,N
7396,Intermediate,,,,Half life period at a dose of 1 uM/kg in dog was determined,50588,Canis lupus familiaris,4527,BAO_0000218,,A,,,9615.0,,N
7397,Intermediate,,,,Half life period was determine after peroral administration at 10 mpk in dog,50588,Canis lupus familiaris,5668,BAO_0000218,,A,In vivo,,9615.0,,N
7398,Intermediate,,,,Half life period was determine after peroral administration at 5 mpk in dog,50588,Canis lupus familiaris,5668,BAO_0000218,,A,In vivo,,9615.0,,N
7399,Intermediate,,,,Half life period was determined,50588,Canis lupus familiaris,3854,BAO_0000218,,A,,,9615.0,,N
7400,Intermediate,,,,Half life period was determined,50588,Canis lupus familiaris,5505,BAO_0000218,,A,,,9615.0,,N
7401,Intermediate,,,,Half life period by iv administration in dog at a dose of 6 mg/kg,50588,Canis lupus familiaris,6251,BAO_0000218,,A,In vivo,,9615.0,,N
7402,Intermediate,,,,Half life period was evaluated in dog,50588,Canis lupus familiaris,1918,BAO_0000218,,A,,,9615.0,,N
7403,Intermediate,,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,Canis lupus familiaris,5546,BAO_0000218,,A,In vivo,,9615.0,,N
7404,Intermediate,,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),50588,Canis lupus familiaris,4809,BAO_0000218,,A,In vivo,,9615.0,,N
7405,Intermediate,,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,50588,Canis lupus familiaris,6215,BAO_0000218,,A,In vivo,,9615.0,,N
7406,Intermediate,,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,50588,Canis lupus familiaris,4527,BAO_0000218,,A,In vivo,,9615.0,,N
7407,Intermediate,,,,Half-life after oral dose of compound at 3 mg/kg in dogs,50588,Canis lupus familiaris,17594,BAO_0000218,,A,In vivo,,9615.0,,N
7408,Intermediate,,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,50588,Canis lupus familiaris,17839,BAO_0000218,,A,In vivo,,9615.0,,N
7409,Intermediate,,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,50588,Canis lupus familiaris,17839,BAO_0000218,,A,In vivo,,9615.0,,N
7410,Intermediate,,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,50588,Canis lupus familiaris,17839,BAO_0000218,,A,In vivo,,9615.0,,N
7411,Intermediate,,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,50588,Canis lupus familiaris,17839,BAO_0000218,,A,In vivo,,9615.0,,N
7412,Intermediate,,Plasma,1969.0,Half-life of compound in plasma of dog was determined,50588,Canis lupus familiaris,5210,BAO_0000218,,A,,,9615.0,,N
7413,Intermediate,,,,Half-life of compound was determined in dogs,50588,Canis lupus familiaris,5210,BAO_0000218,,A,,,9615.0,,N
7414,Intermediate,,,,Half-life after administration of 4 mg/Kg oral dose in dog,50588,Canis lupus familiaris,2959,BAO_0000218,,A,In vivo,,9615.0,,N
7415,Intermediate,,,,Half-life after intravenous administration of 1 mg/kg/h in dog,50588,Canis lupus familiaris,4137,BAO_0000218,,A,In vivo,,9615.0,,N
7416,Intermediate,,,,Half-life in Dog,50588,Canis lupus familiaris,5064,BAO_0000218,,A,,,9615.0,,N
7417,Intermediate,,,,Half-life in Dog,50588,Canis lupus familiaris,5147,BAO_0000218,,A,,,9615.0,,N
7418,Intermediate,,,,Half-life in dog,50588,Canis lupus familiaris,5145,BAO_0000218,,A,,,9615.0,,N
7419,Intermediate,,,,Half-life in dog after oral administration at 1 mg/kg,50588,Canis lupus familiaris,6123,BAO_0000218,,A,In vivo,,9615.0,,N
7420,Intermediate,,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,50588,Canis lupus familiaris,6123,BAO_0000218,,A,In vivo,,9615.0,,N
7421,Intermediate,,,,Half-life in dogs,50588,Canis lupus familiaris,4333,BAO_0000218,,A,,,9615.0,,N
7422,Intermediate,,,,Half-life in dogs; ND indicates not determined,50588,Canis lupus familiaris,4333,BAO_0000218,,A,,,9615.0,,N
7423,Intermediate,,Plasma,1969.0,Half-life in plasma of dog,50588,Canis lupus familiaris,12500,BAO_0000218,,A,,,9615.0,,N
7424,Intermediate,,Plasma,1969.0,Half-life in plasma of dog at dose of 3-10 mgkg,50588,Canis lupus familiaris,12500,BAO_0000218,,A,,,9615.0,,N
7425,Intermediate,,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,50588,Canis lupus familiaris,6005,BAO_0000218,,A,In vivo,,9615.0,,N
7426,Intermediate,,,,Half-life was measured in dog after an iv dose of 1 mg/kg,50588,Canis lupus familiaris,6062,BAO_0000218,,A,In vivo,,9615.0,,N
7427,Intermediate,,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,50588,Canis lupus familiaris,17650,BAO_0000218,,A,In vivo,,9615.0,,N
7428,Intermediate,,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,50588,Canis lupus familiaris,5530,BAO_0000218,,A,In vivo,,9615.0,,N
7429,Intermediate,,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,50588,Canis lupus familiaris,5530,BAO_0000218,,A,In vivo,,9615.0,,N
7430,Intermediate,,,,Half-life of the compound after 0.3 mg/kg po administration in dog,50588,Canis lupus familiaris,5600,BAO_0000218,,A,In vivo,,9615.0,,N
7431,Intermediate,,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,50588,Canis lupus familiaris,6039,BAO_0000218,,A,In vivo,,9615.0,,N
7432,Intermediate,,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,50588,Canis lupus familiaris,6039,BAO_0000218,,A,In vivo,,9615.0,,N
7433,Intermediate,,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,50588,Canis lupus familiaris,6039,BAO_0000218,,A,In vivo,,9615.0,,N
7434,Intermediate,,,,t1/2 in dog,50588,Canis lupus familiaris,6227,BAO_0000218,,A,,,9615.0,,N
7435,Intermediate,,,,Half-life period measured in dogs,50588,Canis lupus familiaris,14541,BAO_0000218,,A,,,9615.0,,N
7436,Intermediate,,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,Canis lupus familiaris,4521,BAO_0000218,,A,In vivo,,9615.0,,N
7437,Intermediate,,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,Canis lupus familiaris,4521,BAO_0000218,,A,In vivo,,9615.0,,N
7438,Intermediate,,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,Canis lupus familiaris,6679,BAO_0000218,,A,In vivo,,9615.0,,N
7439,Intermediate,,Plasma,1969.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",50588,Canis lupus familiaris,1116,BAO_0000218,,A,In vitro,,9615.0,,N
7440,Intermediate,,,,In vivo half life period was calculated at 1 mg/kg in dog,50588,Canis lupus familiaris,5444,BAO_0000218,,A,In vivo,,9615.0,,N
7441,Intermediate,,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,50588,Canis lupus familiaris,5444,BAO_0000218,,A,In vivo,,9615.0,,N
7442,Intermediate,,,,Longer half-life in dog (i.v.) at 0.5 mpk,50588,Canis lupus familiaris,17853,BAO_0000218,,A,In vivo,,9615.0,,N
7443,Intermediate,,,,Oral bioavailability in dog (dose 5 uM/kg),50588,Canis lupus familiaris,4353,BAO_0000218,,A,In vivo,,9615.0,,N
7444,Intermediate,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,Canis lupus familiaris,16452,BAO_0000218,,A,In vivo,,9615.0,,N
7445,Intermediate,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,Canis lupus familiaris,16452,BAO_0000218,,A,In vivo,,9615.0,,N
7446,Intermediate,,,,Bioavailability in dog (dose 1 mg/kg i.v.),50588,Canis lupus familiaris,16452,BAO_0000218,,A,In vivo,,9615.0,,N
7447,Intermediate,,Lung,2048.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7448,Intermediate,,Lung,2048.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7449,Intermediate,,Lung,2048.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7450,Intermediate,,Lung,2048.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7451,Intermediate,,Lung,2048.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7452,Intermediate,,Lung,2048.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7453,Intermediate,,Muscle tissue,2385.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7454,Intermediate,,Muscle tissue,2385.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7455,Intermediate,,Muscle tissue,2385.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7456,Intermediate,,Muscle tissue,2385.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7457,Intermediate,,Muscle tissue,2385.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7458,Intermediate,,Muscle tissue,2385.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7459,Intermediate,,Muscle tissue,2385.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7460,Intermediate,,Zone of skin,14.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7461,Intermediate,,Zone of skin,14.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7462,Intermediate,,Zone of skin,14.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7463,Intermediate,,Zone of skin,14.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7464,Intermediate,,Zone of skin,14.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7465,Intermediate,,Zone of skin,14.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7466,Intermediate,,Zone of skin,14.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7467,Intermediate,,Spleen,2106.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7468,Intermediate,,Spleen,2106.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7469,Intermediate,,Spleen,2106.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7470,Intermediate,,Spleen,2106.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7471,Intermediate,,Spleen,2106.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7472,Intermediate,,Spleen,2106.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7473,Intermediate,,Spleen,2106.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7474,Intermediate,,Stomach,945.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7475,Intermediate,,Stomach,945.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7476,Intermediate,,Stomach,945.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7477,Intermediate,,Stomach,945.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7478,Intermediate,,Stomach,945.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7479,Intermediate,,Stomach,945.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7480,Intermediate,,Stomach,945.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,Mus musculus,10107,BAO_0000218,,A,In vivo,,10090.0,,N
7481,Intermediate,,,,Oral bioavailability in rat,50597,Rattus norvegicus,4689,BAO_0000218,,A,In vivo,,10116.0,,N
7482,Intermediate,,,,Tested for the bioavailability in rat,50597,Rattus norvegicus,4950,BAO_0000218,,A,In vivo,,10116.0,,N
7483,Intermediate,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,Rattus norvegicus,5328,BAO_0000218,,A,In vivo,,10116.0,,N
7484,Intermediate,,,,Bioavailability in rat,50597,Rattus norvegicus,406,BAO_0000218,,A,In vivo,,10116.0,,N
7485,Intermediate,,,,Bioavailability in rat,50597,Rattus norvegicus,12500,BAO_0000218,,A,In vivo,,10116.0,,N
7486,Intermediate,,,,Bioavailability in rat (dose 3-10 mg/kg),50597,Rattus norvegicus,12500,BAO_0000218,,A,In vivo,,10116.0,,N
7487,Intermediate,,,,Bioavailability in rat,50597,Rattus norvegicus,5247,BAO_0000218,,A,In vivo,,10116.0,,N
7488,Intermediate,,Plasma,1969.0,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,Rattus norvegicus,4186,BAO_0000218,,A,In vivo,,10116.0,,N
7489,Intermediate,,Plasma,1969.0,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,50597,Rattus norvegicus,4186,BAO_0000218,,A,In vivo,,10116.0,,N
7490,Intermediate,,,,Half life after oral administration was determined in rats at 6 mg/kg,50597,Rattus norvegicus,6647,BAO_0000218,,A,In vivo,,10116.0,,N
7491,Intermediate,,,,Half life was determined,50597,Rattus norvegicus,6484,BAO_0000218,,A,,,10116.0,,N
7492,Intermediate,,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,50597,Rattus norvegicus,3249,BAO_0000218,,A,In vivo,,10116.0,,N
7493,Intermediate,,Plasma,1969.0,Plasma half life in rat at oral dose 2.8 mg/mk body weight,50597,Rattus norvegicus,6281,BAO_0000218,,A,In vivo,,10116.0,,N
7494,Intermediate,,,,Half life in rats,50597,Rattus norvegicus,3307,BAO_0000218,,A,,,10116.0,,N
7495,Intermediate,,Blood,178.0,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,50597,Rattus norvegicus,12058,BAO_0000218,,A,In vivo,,10116.0,,N
7496,Intermediate,,,,Hill coefficient of the compound,50597,Rattus norvegicus,8833,BAO_0000218,,A,,,10116.0,,N
7497,Intermediate,,Blood,178.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,50597,Rattus norvegicus,3193,BAO_0000218,,A,,,10116.0,,N
7498,Intermediate,,Blood,178.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,50597,Rattus norvegicus,3193,BAO_0000218,,A,,,10116.0,,N
7499,Intermediate,,Blood,178.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,50597,Rattus norvegicus,3193,BAO_0000218,,A,,,10116.0,,N
7500,Intermediate,,Blood,178.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,50597,Rattus norvegicus,3193,BAO_0000218,,A,,,10116.0,,N
7501,Intermediate,,Blood,178.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,50597,Rattus norvegicus,3193,BAO_0000218,,A,,,10116.0,,N
7502,Intermediate,,Blood,178.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,50597,Rattus norvegicus,3193,BAO_0000218,,A,,,10116.0,,N
7503,Intermediate,,Blood,178.0,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",50597,Rattus norvegicus,3193,BAO_0000218,,A,,,10116.0,,N
7504,Intermediate,,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,50597,Rattus norvegicus,5960,BAO_0000218,,A,,,10116.0,,N
7505,Intermediate,,Brain,955.0,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,50597,Rattus norvegicus,13950,BAO_0000218,,A,In vivo,,10116.0,,N
7506,Intermediate,,Brain,955.0,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,50597,Rattus norvegicus,13950,BAO_0000218,,A,In vivo,,10116.0,,N
7507,Intermediate,,Brain,955.0,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,50597,Rattus norvegicus,13950,BAO_0000218,,A,In vivo,,10116.0,,N
7508,Intermediate,,Brain,955.0,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,50597,Rattus norvegicus,13950,BAO_0000218,,A,In vivo,,10116.0,,N
7509,Intermediate,,Brain,955.0,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,50597,Rattus norvegicus,13950,BAO_0000218,,A,In vivo,,10116.0,,N
7510,Intermediate,,Thyroid gland,2046.0,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,50597,Rattus norvegicus,13950,BAO_0000218,,A,In vivo,,10116.0,,N
7511,Intermediate,,Thyroid gland,2046.0,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,50597,Rattus norvegicus,13950,BAO_0000218,,A,In vivo,,10116.0,,N
7512,Intermediate,,Thyroid gland,2046.0,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,50597,Rattus norvegicus,13950,BAO_0000218,,A,In vivo,,10116.0,,N
7513,Intermediate,,Thyroid gland,2046.0,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,50597,Rattus norvegicus,13950,BAO_0000218,,A,In vivo,,10116.0,,N
7514,Intermediate,,Thyroid gland,2046.0,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,50597,Rattus norvegicus,13950,BAO_0000218,,A,In vivo,,10116.0,,N
7515,Intermediate,,Blood,178.0,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,Rattus norvegicus,9866,BAO_0000218,,A,In vivo,,10116.0,,N
7516,Intermediate,,Blood,178.0,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,50597,Rattus norvegicus,9866,BAO_0000218,,A,In vivo,,10116.0,,N
7517,Intermediate,,Blood,178.0,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,50597,Rattus norvegicus,9866,BAO_0000218,,A,In vivo,,10116.0,,N
7518,Intermediate,,Bone,10000001.0,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,Rattus norvegicus,9866,BAO_0000218,,A,In vivo,,10116.0,,N
7519,Intermediate,,Bone,10000001.0,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,50597,Rattus norvegicus,9866,BAO_0000218,,A,In vivo,,10116.0,,N
7520,Intermediate,,Bone,10000001.0,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,50597,Rattus norvegicus,9866,BAO_0000218,,A,In vivo,,10116.0,,N
7521,Intermediate,,Heart,948.0,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,Rattus norvegicus,9866,BAO_0000218,,A,In vivo,,10116.0,,N
7522,Intermediate,,Heart,948.0,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,50597,Rattus norvegicus,9866,BAO_0000218,,A,In vivo,,10116.0,,N
7523,Intermediate,,Heart,948.0,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,50597,Rattus norvegicus,9866,BAO_0000218,,A,In vivo,,10116.0,,N
